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NF Nuclear factor 
NF-κB Nuclear factor-kappa B 
NHAdV Non-human adenovirus 
NHEJ Non-homologous end joining 
NK Natural killer 
NLRP3 NOD-like receptor family pyrin domain containing 3 
NLS Nuclear localization signal 
NPC Nuclear pore complex 
NPM1 Nucleophosmin 
NTA Nanoparticle Tracking Analysis 
NXF1 Nuclear RNA export factor 1 
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O.C.T Optimal cutting temperature compound 
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PKA Protein kinase A 
PKC Protein kinase C 
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PP2A Protein phosphatase IIA 
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PRR Pattern recognition receptors 
PSGL-1 P-selectin glycoprotein ligand-1 
PSMB Immunoproteasome subunit beta 
PTPRC Protein tyrosine phosphatase receptor type C 
PUROR Puromycin resistance gene 
PVDF Polyvinylidene difluoride 
pDC Plasmacytoid dendritic cell 
pDNA Plasmid DNA 
pHPMA Poly[N-(2-hydroxypropyl)methacrylamide] 
pRb Retinoblastoma tumor suppressor 
pTP Pre-terminal protein 
pVI Pre-protein VI 
pVIn Pre-protein VI cleaved N-terminal 
pVII Pre-protein VII 
qPCR Quantitative real-time polymerase chain reaction 
RAAS Renin-angiotensin-aldosterone system 
RCA Replication-competent adenoviruses 
REC Renal epithelium-derived cells  
RFP Red fluorescent protein 
RFU Relative fluorescence units 
RGD Arginine-glycine-aspartic acid 
RGE Arginine-glycine-glutamic acid 
RID Receptor internalization and degradation 
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RISC RNA-induced silencing complex 
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SR-A Scavenger receptor A 
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TP Terminal protein 
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VA-I Virus-associated RNA I 
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Abstract 
Human adenovirus serotype 5 (HAdV-5)-based gene delivery vectors are an attractive 
option for gene therapy applications because they can deliver large transgenes to a broad 
range of tissues, allow high level transgene expression, have negligible risk of insertional 
mutagenesis and are easily produced at high titers. Unfortunately, their high 
immunogenicity and liver and spleen-associated toxicity when intravascularly administered 
and high prevalence of neutralizing antibodies in patients remain challenges to be 
overcome for the generation of safe HAdV-5-based vectors for systemic gene therapy. The 
discovery that coagulation factor X (FX), a zymogen of a vitamin K-dependent serine 
protease that circulates in the bloodstream, simultaneously binds HAdV-5 hexon and 
heparan sulphate proteoglycans (HSPGs) to mediate hepatic transduction enabled the 
generation of HAdV-5 vectors with substantially reduced liver transduction via the 
manipulation of key amino acid residues in the adenoviral hexon protein. However, FX 
was also recently shown to protect HAdV-5 from neutralization by preventing binding of 
natural IgM antibodies to HAdV-5 capsids and it was reported that, in the absence of FX-
binding and neutralization, HAdV-5 vectors can use alternative FX-independent 
transduction pathways for hepatocyte transduction. These findings highlight the complex 
interactions between adenoviruses and host blood factors and cells as well as the need for 
further research on these processes. Here, the interactions that mediate hepatic and splenic 
tropism of HAdV-5-based vectors and activation of the anti-viral immune response 
following intravascular delivery were investigated and targeted HAdV-5 delivery to the 
kidney was assessed. 
Liver and spleen transduction was assessed in immunocompetent C57BL/6 and 
immunocompromised Rag 2-/- or NSG mice lacking different components of the immune 
response, following intravascular administration of wild type or FX-binding deficient 
HAdV-5 vectors. HAdV-5 virions were neutralized in C57BL/6 mice in the absence of FX-
binding, confirming a role for FX in protecting HAdV-5 from in vivo neutralization. 
However, NSG mice, which lack both innate and adaptive immunity, failed to neutralize 
FX-binding deficient HAdV-5 virions. Interestingly, administration of FX-binding 
deficient HAdV-5 vectors to IgM antibody-deficient Rag 2-/- mice revealed that IgM 
antibodies might not be required for in vivo neutralization of HAdV-5, indicating that 
innate immunity alone might be sufficient. In agreement with previous reports, exposure of 
FX-binding deficient HAdV-5 vectors to C57BL/6 serum or wild type HAdV-5 vectors to 
C57BL/6 serum pre-incubated with the FX inhibitor X-bp led to HAdV-5 neutralization in 
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vitro. In contrast, Rag 2-/- and NSG serum failed to neutralize HAdV-5 in vitro in the 
absence of FX-binding, indicating that IgM antibodies are essential for in vitro HAdV-5 
neutralization. This suggests in vitro and in vivo adenovirus neutralization is mediated by 
different mechanisms.  
Importantly, administration of FX-binding deficient HAdV-5 vectors to NSG mice, which 
were unable to neutralize HAdV-5, confirmed the existence of alternative FX-independent 
pathways for liver and spleen transduction in the absence of neutralization. CAR and αvβ3,5 
integrins were assessed as possible host cell receptors for HAdV-5 transduction of these 
tissues in immunocompetent and immunocompromised mice. The use of CAR or αvβ3,5 
integrin-binding ablated HAdV-5 vectors revealed that CAR and αvβ3,5 integrins might 
serve as receptors for HAdV-5 liver transduction in immunocompetent C57BL/6 mice in 
contrast to immunocompromised Rag 2-/- mice. Neither CAR nor αvβ3,5 integrins mediated 
HAdV-5 spleen transduction in either mouse strain. Furthermore, administration of HAdV-
5 vectors simultaneously ablated for FX and αvβ3,5 integrin-binding to NSG mice showed 
that αvβ3,5 integrins play no role in liver or spleen transduction in the absence of 
neutralization. With the aim to define novel FX-independent pathways of HAdV-5 
transduction in vitro that might be relevant in vivo, cell transduction was assessed for wild 
type or FX-binding deficient HAdV-5 vectors in the presence of immunocompromised Rag 
2-/- serum or serum that had been pre-incubated with X-bp. These studies confirmed the 
existence of FX-independent mechanisms able to enhance HAdV-5 cell transduction in 
vitro in the presence of mouse serum and absence of neutralization. To identify the 
receptor(s) involved in in vitro HAdV-5 transduction in the presence of mouse serum, 
soluble recombinant HAdV-5 fiber knob was used to block access of virions to CAR and 
wild type or FX-binding deficient HAdV-5 cell transduction was assessed in high and low 
CAR-expressing cell lines in the presence of C57BL/6 or Rag 2-/- serum with or without X-
bp. HAdV-5 predominantly used a FX-independent pathway for cell transduction of high 
CAR-expressing cell lines in the presence of Rag 2-/- serum and soluble fiber knob 
substantially reduced both C57BL/6 and Rag 2-/- serum-enhanced transduction in such cell 
lines, suggesting a role for CAR, Conversely, HAdV-5 used the FX-mediated pathway or 
other FX and CAR-independent pathways for low CAR-expressing cell line transduction. 
Importantly, the use of CAR-binding deficient HAdV-5 vectors demonstrated that CAR 
usage in this setting does not rely on direct interactions of HAdV-5 with CAR, thus 
implicating a role for a mouse serum protein(s) in this process. To investigate these 
different pathways further, virions were fluorescently labelled with Alexa Fluor 488 dye 
and HAdV-5 cell binding, uptake and endosomal membrane penetration were 
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characterized in the presence of FX by microscopic assessment of individual virions at the 
single cell level. FX substantially enhanced virion cell binding but had minimal effect on 
virion uptake and it was suggested to decrease efficiency of endosomal membrane 
penetration, limiting escape of virions from endosomes into the cytosol. 
Finally, FX and CAR-binding deficient HAdV-5 vectors were engineered to incorporate 
renal-targeting peptides found by in vitro phage display into the HI loop of the fiber knob 
domain for kidney-specific gene therapy. The resultant mutant HAdV-5 vectors were 
tested for their specificity in mediating gene delivery to ligand-expressing cells in vitro but 
failed to achieve specific targeting.  
Together, these findings contribute to a deeper understanding of the interactions between 
HAdV-5 vectors and host blood components and cell receptors, and their implications for 
liver and spleen transduction and neutralization of virions. The studies presented in this 
thesis highlight the limitations of current re-targeting strategies and the need for further 
research to successfully develop efficient HAdV-5-based vectors for systemic gene 
therapy.
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1.1 Gene therapy and gene therapy vectors 
Currently, one of the most promising fields in biomedicine is gene therapy, a set of 
techniques that allows the treatment of diseases with no effective current medication, 
through the manipulation of the genome of the affected individual (Miller, 1992). The 
concept originated with a focus on inherited and acquired diseases where a particular gene 
encodes a mutation/s that results in a loss of function and thus needs to be replaced with a 
functional copy of the gene (replacement gene therapy) (e.g: replacement of coagulation 
factor IX gene in hemophilia). The concept soon broadened to include suicide gene 
therapy, which is aimed at inducing death in mutated cells (e.g: oncolytic adenoviruses to 
kill cancer cells), suppressive gene therapy to inhibit the expression of deleterious gene 
products (e.g: shRNA to silence huntingtin mRNA in Huntington), and immune gene 
therapy to modulate the immune response to infections or mutated self-cells (e.g: chimeric 
antigen receptor (CAR) T cell technology to stimulate an immune response against 
cancer). However, it was not until the emergence of new technologies such as sequencing 
platforms and advances in the field of recombinant DNA along with a deeper knowledge in 
cell biology driven by the sequencing of the human genome (Lander et al., 2001), which 
widened the scope of genetic targets, that gene therapy became a feasible option. 
Importantly, thanks to the remarkable progress made in the last three decades in the 
development of gene transfer vehicles able to deliver therapeutic transgenes to target cells 
with relatively high efficiency, viral vectors became the key players and gene therapy 
finally reached the clinic in 1990 for the treatment of the rare autosomal recessive severe 
combined immunodeficiency (SCID) disorder (Blaese et al., 1995). Subsequently, the 
number of clinical trials increased exponentially, mainly focused on cancer (64.4%) but 
also to treat monogenic diseases (10%), infectious diseases (7.6%), cardiovascular diseases 
(7.5%), neurological diseases (1.8%), ocular diseases (1.8%), inflammatory diseases 
(0.6%), etc. (The Journal of Gene Medicine: Clinical Trial, 2016) (Figure 1-1). Despite the 
large number of clinical trials starting each year, only a few progress through phases 
towards reaching the market. For instance, of all clinical trials to date, 57.6% reached 
phase I, 20.3% phase I/II, 17.1% phase II, 1% phase II/III, 3.7% phase III and only 0.1% 
reached phase IV (The Journal of Gene Medicine: Clinical Trial, 2016). Indeed, it is a 
significant challenge to successfully pass pharmacodynamics, pharmacokinetics and safety 
tests and, in fact, only a few gene therapy products have been approved so far in China, 
Philippines, Russia and the EU (e.g: Gendicine employing an adenoviral vector encoding 
p53 for the treatment of head and neck squamous cell carcinoma [reviewed by (Peng, 
2005, Chen et al., 2014)], alipogene tiparvovec (Glybera) employing an adeno-associated 
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vector (AAV) encoding the human lipoprotein lipase (LPL) complementary DNA (cDNA) 
for the treatment of lipoprotein lipase deficiency (Gaudet et al., 2010), Neovasculgen 
employing a plasmid DNA encoding the vascular endothelial growth factor (VEGF) for the 
treatment of peripheral arterial disease (PAD) (Burleva and Babushkina, 2016), or 
Strimvelis employing a retroviral vector encoding the human adenosine deaminase (ADA) 
cDNA sequence for the treatment of ADA-SCID (Hoggatt, 2016)) (see below and section 
1.3.2). 
 
Figure 1-1. Gene therapy clinical trials. A) Number of gene therapy clinical trials approved by years to 
date. A total of 142 gene therapy clinical trials have not been assigned to any particular year and thus have 
been omitted from display on the chart. Numbers are indicated in the figure. B) Gene therapy clinical trials 
by indication to date. Numbers and percentages are indicated in the figure. Figure in (B) reproduced with 
permission from (The Journal of Gene Medicine: Clinical Trial, 2016). Copyright® 2016 by John Wiley and 
Sons Ltd. 
Viral vectors are based on the virus’ capacity to deliver the viral genome to the cytoplasm 
or nucleus of eukaryotic cells. There is a short list of viral vectors that can be safely used in 
in vivo protocols, which includes retroviral, lentiviral, adeno-associated and adenoviral 
vectors (Lukashev and Zamyatnin, 2016, Kotterman et al., 2015) (Figure 1-2). Alternative 
viral vectors such as those based on herpes simplex virus, poxvirus and vaccinia virus as 
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well as non-viral vectors, are also currently being developed (Figure 1-2). Retroviral 
vectors are able to transduce dividing cells with high efficiency and integrate their genome 
into the host cell, are easy to manipulate for cloning and have a broad cell tropism and low 
immunogenicity. Despite the retroviral vectors’ capability to integrate their genome into 
the host cell was commonly thought to be a desirable feature for gene therapy viral vectors 
because it allows long-term therapeutic gene expression, integration events were shown to 
occur more frequently into actively transcribed genome loci, thus increasing the risk of 
insertional mutagenesis (Cattoglio et al., 2010, Wu et al., 2003, Hacein-Bey-Abina et al., 
2008). Also, the fact that retroviral vectors cannot transduce non-dividing cells is yet 
another limitation. To overcome these problems, lentiviral vectors emerged as a safer 
alternative to γ-retrovirus-based retroviral vectors, allowing transduction of non-dividing 
cells, production at higher titers and, importantly, a lower risk of insertional mutagenesis 
(Zhou et al., 2016), making them particularly attractive for certain diseases where long-
term therapeutic gene expression is required [reviewed by (Quinonez and Sutton, 2002)]. 
However, they do not allow high levels of transgene expression and their transgene 
capacity is relatively low (~9 kb). As for lentiviral vectors, adeno-associated vectors can 
also transduce dividing and non-dividing cells. Also, their low immunogenicity compared 
to lentiviral vectors (Vandendriessche et al., 2007) together with the episomal nature of 
their genome (Duan et al., 1998, Nakai et al., 2001) allows safer long-term transgene 
expression. However, more recent studies reported that adeno-associated vectors are also 
able to integrate into the host genome, albeit at low frequencies, highlighting a potential 
risk of insertional mutagenesis [reviewed by (Deyle and Russell, 2009, McCarty et al., 
2004)]. Nevertheless, adeno-associated vectors have shown great success in clinical trials 
for the treatment of ocular disease (Maguire et al., 2009, Jacobson et al., 2012), 
haemophilia B (Nathwani et al., 2011) and Parkinson’s disease (PD) (LeWitt et al., 2011, 
Muramatsu et al., 2010) among others. Importantly, in November 2012, the European 
Medicines Agency approved the first gene therapy product in the Western countries: 
Glybera, an AAV1-based vector to deliver human LPL cDNA to muscle cells via 
intramuscular injection for the treatment of lipoprotein lipase deficiency that shows safety 
and persistent transgene expression (Gaudet et al., 2010). Unfortunately, adeno-associated 
vectors do not allow high levels of transgene expression, their production is relatively 
complex, and their low transgene capacity (~4 kb) renders them suitable for only certain 
pathologies [(Clement and Grieger, 2016) and reviewed by (Lu, 2004)]. Adenoviral 
vectors, which also transduce dividing and non-dividing cells, bypassed these limitations 
allowing high levels of transgene expression, long-term transgene expression, higher 
transgene capacity of up to ~37 kb, production at higher titers, and very low to absent risk 
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of insertional mutagenesis since they very rarely integrate (Harui et al., 1999, Stephen et 
al., 2008, Stephen et al., 2010). Conversely, they exhibit high immunogenicity in 
comparison to other vectors (Stilwell and Samulski, 2004) and toxicity at high doses and 
can be neutralized by the host pre-existing immunity. Despite some challenges have yet to 
be overcome, adenoviruses are among the most promising gene transfer vectors of all 
available vectors, have been used in clinical trials mainly for the treatment of cancer as 
oncolytic vectors and as vaccines, and are also being tested for a wide range of human 
diseases such as cardiovascular, ocular, neurologic or inflammatory disease (The Journal 
of Gene Medicine: Clinical Trial, 2016). Furthermore, the world’s first gene therapy 
product approved was based on an adenoviral vector to treat head and neck squamous cell 
carcinoma [reviewed by (Peng, 2005, Chen et al., 2014)], highlighting their success as 
vectors. For their characteristics and their potential, adenoviral vectors are currently on the 
top choice of vectors for gene therapy clinical trials. 
 
Figure 1-2. Gene transfer vectors used in gene therapy clinical trials. Numbers and percentages for each 
gene transfer vector are indicated in the figure. Figure reproduced with permission from (The Journal of 
Gene Medicine: Clinical Trial, 2016). 
1.2 Adenovirus 
Adenoviruses were first discovered in 1953 during a study attempting to grow human 
adenoid tissue in the laboratory, when Rowe and colleagues described a cytopathogenic 
agent that could induce cellular transmittable degeneration (ROWE et al., 1953). 
Adenovirus belongs to the Adenoviridae family of viruses characterized by having a non-
enveloped icosahedral capsid that contains a linear double-stranded DNA genome. 
Adenovirus have been classified into five genera (Mastadenovirus, Aviadenovirus, 
Atadenovirus, Siadenovirus and Ichtadenovirus) based on the host from where they were 
first isolated (Adenovirus taxonomy, 2016). Mastadenovirus (mammalian adenoviruses) 
were classified into subtypes such as canine, murine or human adenovirus. Human 
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adenovirus, which originated from human and simian samples, were classified into species 
A-G and further subclassified into 54 different human serotypes and 33 simian serotypes 
according to phylogenetic sequence similarity, ability to agglutinate erythrocytes and 
oncogenic properties and serologic profiles [(Adenovirus taxonomy, 2016, Bailey and 
Mautner, 1994) and reviewed by (Davison et al., 2003)]. Serotypes belonging to the same 
species share tropism and clinical properties. Species B, C, D and E have ocular tropism, 
species A, D, F and G enteric tropism, species A, B, C and E respiratory tropism, and 
species B and D renal tropism [reviewed by (Arnberg, 2012)] (Table 1-1). Regarding their 
clinical properties, adenovirus can cause infections in humans that in most cases present 
with mild symptoms and self-resolve within a few days. Species D can cause epidemic 
keratoconjunctivitis, species F have been associated with gastroenteritis, species A, B, C 
and E cause respiratory disease, and species B are responsible for kidney disease [reviewed 
by (White et al., 2007)]. Unfortunately, some infections can have more severe outcomes 
such as pneumonia, which has been associated with acute respiratory distress syndrome 
[reviewed by (Brkic et al., 2002)]. Moreover, adenoviruses can worsen symptoms of 
established pathologies such as asthma or cystic fibrosis (CF), cause epidemic infections in 
closed communities, and even be lethal in immunosuppressed individuals [(Gern et al., 
2012) and reviewed by (Frickmann et al., 2012, Schaller et al., 2006, Echavarria, 2008, 
Lion, 2014, Lion et al., 2003, de Mezerville et al., 2006, Chakrabarti et al., 2002)]. Among 
human adenovirus serotypes, serotype 5 of species C (HAdV-5) is by far the best 
characterized serotype, with detailed description of its genetic and capsid structure 
characteristics, tropism in vitro and in vivo, potential toxicity and associated immune 
responses when used as a vector in vivo, and has shown broad potential in the development 
of therapeutic vectors in the clinic. For these reasons, HAdV-5 is the serotype of choice in 
the studies presented in this thesis.  
Table 1-1. Classification of human adenovirus serotypes.  
Adenovirus 
species 
Adenovirus 
serotype Tropism Receptors 
1
  
Adapter 
molecules 1, 5 
A 12, 18, 31 Enteric, 
respiratory CAR   FIX
6
, FX 
B1 3, 7, 16, 21, 50 
Ocular, 
respiratory, 
renal 
CD462, DSG22, 
CD80, CD86, 
HSPG3 
FX 
B2 11, 14, 34, 35 
Ocular, 
respiratory, 
renal 
CD462, DSG22, 
CD80, CD86, 
HSPG3 
FX 
C 1, 2, 5, 6 Ocular, 
respiratory 
CAR, integrins, 
HSPG, VCAM-1, 
DPPC, 
lactoferrin, 
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MHC-I-α2, SR, 
LRP, CR1,  
C4BP, FVII, 
FIX, FX, PC 
D 
8, 9, 10, 13, 15, 
17, 19, 20, 22, 
23, 24, 25, 26, 
27, 28, 29, 30, 
32, 33, 36, 37, 
38, 39, 42, 43, 
44, 45, 46, 47, 
48, 49, 51, 53, 54 
Ocular, 
enteric, renal SA, CD46
4
, CAR FX 
E 4 Ocular, 
respiratory CAR 
 
F 40, 41 Enteric CAR  
G 52 Enteric SA7, CAR7  
1Both confirmed and postulated receptors and adapter molecules have been included. Some are not confirmed 
for all serotypes belonging to the same adenovirus species. 
2Serotypes 11, 21, 35, and 50 use CD46 (Gaggar et al., 2005, Trinh et al., 2012) and CD46 is a low-affinity 
receptor for serotypes 3 and 7 and might not be a receptor for serotype 14 (Marttila et al., 2005, Tuve et al., 
2006, Trinh et al., 2012). Serotypes 3, 7, 11 and 14 can use DSG2 (Wang et al., 2011c, Trinh et al., 2012).  
3Serotypes 3 and 35 can bind to HSPG but with low affinity (Tuve et al., 2008). 
4Only serotypes 26, 37 and 49 from species D have been suggested to use CD46 (Lemckert et al., 2006, Wu 
et al., 2004, Li et al., 2012). 
5Refer to (Waddington et al., 2008, Balakireva et al., 2003, Adams et al., 2009, Johansson et al., 2007, Martin 
et al., 2003, Shayakhmetov et al., 2005b). 
6Coagulation factor IX (FIX) enhances cell binding and infection of serotypes 18 and 31 but not 12 (Lenman 
et al., 2011, Jonsson et al., 2009).  
Reviewed by (Arnberg, 2012, Zhang and Bergelson, 2005, Arnberg, 2009, Sharma et al., 2009b, Excoffon et 
al., 2014).  
7(Lenman et al., 2015). 
ND; not determined, CAR; coxsackie and adenovirus receptor, HSPG; heparan sulphate proteoglycan, 
VCAM-1; vascular cell adhesion molecule-1, MHC-I-α2; α2 domain of the major histocompatibility 
complex-I, LRP; low-density lipoprotein receptor-related protein, SR; scavenger receptor, CR1; complement 
receptor 1, DPPC; dipalmitoyl phosphatidylcholine, C4BP; C4b-binding protein, DSG2; desmoglein 2, SA; 
sialic acid-containing glycoproteins, FVII; coagulation factor VII, FX; coagulation factor X. 
1.2.1 Human adenovirus structure 
1.2.1.1 Adenovirus genome 
The human adenovirus genome is a ~34-37 kb linear dsDNA genome that encodes early, 
intermediate and late genes and contains inverted terminal repeats (ITRs) at each 5’ and 3’ 
end as well as the packaging signal, a sequence adjacent to the left ITR that allows genome 
packaging into the viral capsid (Flint, 1982) (Figure 1-3). Early genes (E1-E4) are 
implicated in the expression, transcription and replication of viral DNA and the 
suppression of the host anti-viral immune response and are transcribed from E1A, E1B, 
E2A, E2B, E3 and E4 transcriptional units. Intermediate genes include protein IX/Mu/μ 
and IVa2, which are transcribed from separate transcriptional units (Persson et al., 1979). 
Late genes (L1-L5) encode structural proteins of the capsid or proteins involved in capsid 
assembly and are transcribed from the major late promoter (MLP) in the major late 
transcriptional unit (MLTU) [reviewed by (Akusjarvi, 2008)]. Importantly, L4-33K and 
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L4-22K proteins are expressed from the L4 specific promoter (L4P) at intermediate times 
of infection and activate the MLP (Morris et al., 2010). A novel open reading frame 
(ORF), the U exon-24K, is expressed at late times of infection from a unique promoter 
within the UXP transcriptional unit (located between L5 and E3) (Tollefson et al., 2007, 
Ying et al., 2010). The adenoviral genome also encodes two viral RNAs: virus-associated 
RNA I (VA-I) and VA-II, which are involved in the suppression of the host immune 
response and are expressed from a polymerase III promoter [reviewed by (Mathews, 
1995)]. Furthermore, multiple mRNAs can be transcribed from a single gene, which can be 
subsequently subjected to alternative splicing and differential polyadenylation resulting in 
viral proteins with different functions [reviewed by (Biasiotto and Akusjarvi, 2015)]. 
Interestingly, DNA sequence corresponding to protein regions with a key function in 
maintaining virion structure or completion of viral cycle tend to be conserved among 
species and serotypes, while sequences corresponding to exposed protein regions 
associated with immune recognition or without an essential role in stabilsing virion 
structure exhibit a higher degree of divergence (Chroboczek and Jacrot, 1987, Bailey and 
Mautner, 1994, Tarassishin et al., 2000). This phenomenon can be also observed in the 
conservation of genes across genera, thus defining 16 genus-common genes with key 
functions in DNA replication, encapsidation and virion structure such as the adenoviral 
DNA polymerase, pre-terminal protein (pTP), ssDNA-binding protein (DBP)/E2A, IVa2, 
fiber, hexon or pre-protein VI (pVI), and genus-specific genes that were created later in 
evolution such as the Mastadenovirus E4 Orf1 (Davison et al., 2003). Importantly, despite 
divergence in adenoviral genome sequence and gene content, the organization of common 
genes in the adenoviral genome has been highly conserved in the course of viral evolution 
(Tibbetts, 1977, Davison et al., 2003). 
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Figure 1-3. Adenoviral genome map. Early genes are shown as orange arrows, intermediate genes as black 
arrows and late genes as blue arrows. Viral-associated RNAs are shown as thick black arrows. The arrows’s 
tip indicates the orientation of adenoviral genes. Internal terminal repeats (ITR) in green and adenoviral DNA 
packaging signal (Ψ) in purple. Certain transcripts for each adenoviral gene are indicated. Viral genes have 
been mapped by superimposing an arbitrary scale of 100 map units. “p” preceding protein names refers to 
their precursor forms. MLTU; major late transcriptional unit; VA-I and II; virus-associated RNA I and II, 
respectively, L4P; L4 specific promoter, Orf; open reading frame. 
1.2.1.2 Adenovirus capsid composition 
The adenoviral capsid is a 90-100 nm non-enveloped capsid of ~150MDa with pseudo 
triangulation number (T) = 25 icosahedral symmetry formed by 20 facets, 30 edges and 12 
vertices (World WSM and Horwitz MS, 2007) (Figure 1-4). The main components of the 
capsid are protein II/hexon (240 homotrimers) and protein IV/fiber (12 homotrimers), 
which is anchored into protein III/penton base (12 homopentamers) at each of the 12 
apexes (van Oostrum and Burnett, 1985). This structure is further stabilized by the cement 
proteins IIIa, VI, VIII and IX with copy number 60, ~350, 120 and 240, respectively 
[(Benevento et al., 2014, Reddy and Nemerow, 2014, Reddy et al., 2010) and reviewed by 
(Russell, 2009) and (Vellinga et al., 2005)]. The capsid also contains DNA-associated 
proteins V (~157 copies), VII (833 copies), X (100 copies), IVa2 (only a few copies), 
terminal protein (TP) (2 copies) and the viral cysteine protease L3-23K/AVP (~7 copies) 
[(Benevento et al., 2014, van Oostrum and Burnett, 1985, Anderson, 1990) and reviewed 
by (Russell, 2009)] (Figure 1-4A). In particular, each facet of the icosahedral capsid is 
formed by 9 hexons stabilized by protein IX, which has been termed the Group of Nine 
(GON), bound to 3 peripentonal hexons (PPHs) that are associated with protein IIIa 
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(Figure 1-4C left panel and Figure 1-4D left two panels). This gives a total of 12 hexons 
that are in turn associated with 1 penton base, forming a group of 13 independent 
polypeptides. A total of 5 PPHs (one from each structure of 13 polypeptides) associate 
with one penton base, forming what has been termed the Group of Six (GOS) (Figure 1-4C 
right panel) [(Stewart et al., 1991) and reviewed by (San Martin, 2012)]. Furthermore, four 
hexons together with one penton base monomer conform the asymmetric unit (AU) (Figure 
1-4B-C). Importantly, protein VI and VIII together with V form a complex that associates 
with PPHs and hexons from the GON to increase capsid stability (Figure 1-4D right two 
panels) (Reddy et al., 2010, Reddy and Nemerow, 2014).  
 
Figure 1-4. Adenoviral capsid structure and organization of capsid proteins. A) Schematic illustration of 
the organization of dsDNA and major, cement and core proteins in the adenoviral capsid. B) Overall 
organization of the adenoviral capsid. Hexons within the asymmetric unit (AU) of one facet are indicated 
with numbers. The outline of the triangular icosahedral facet is indicated as a grey triangle and the Group of 
Nine (GON), which is formed by 9 hexons in each facet plus three adjacent penton base, with a yellow line. 
Penton base represented in magenta, outer cement protein IIIa and IX in purple and blue, respectively, and 
hexons in light blue, light yellow, light green and tan. Fiber is not shown. C) GON (left panel). Group of Six 
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(GOS) formed by one penton and the five adjacent peripentonal hexons (PPHs) (right panel). Hexon trimers 
are depicted as hexagons with an overlaid triangle and penton base as pentagons. PPHs are highlighted in 
yellow. Hexons within the AU of one facet are indicated with numbers. D) Arrangement of cement proteins 
in the adenoviral capsid. The capsid exterior (left two panels) and interior (right two panels) are shown. The 
outline of hexons within one facet in the capsid exterior (farthest left panel) is highlighted by black lines. The 
GON is indicated with a yellow line. Protein IIIa represented in purple, IX in blue, VI in red, VIII in orange, 
V in green, penton base in magenta and hexons in light blue, light yellow, light green and tan. Figures in (A-
B and D) adapted from (Reddy and Nemerow, 2014). Figures in (C) adapted from (San Martin, 2012). 
The fiber protein protrudes outwards from the capsid vertex and is composed of 3 
monomers, each containing an N-terminal tail, a rod-like shaft region with triple β-spiral 
repeat motifs, and a C-terminal globular knob domain with three eight-stranded antiparallel 
β sandwich and exposed loops (Ruigrok et al., 1990, Xia et al., 1994, van Raaij et al., 
1999, Stewart et al., 1993) (Figure 1-5C). In the trimeric conformation, the fiber knob 
domain has a three-bladed propeller structure and contains a central depression (Xia et al., 
1994). The fiber protein inserts the fiber shaft and N-terminal domain into the penton base 
(Liu et al., 2011, Zubieta et al., 2005). The interactions are made via three flexible fiber N-
terminal tails with three penton base grooves and with an arginine-glycine-aspartic acid 
(RGD) motif in the penton base (Figure 1-5J). Also, the fiber shaft interacts with the 
penton base pore at the top surface (Liu et al., 2011, Zubieta et al., 2005) (Figure 1-5M). 
The penton base is composed of 5 subunits where each monomer has a basal β-barrel jelly 
roll domain containing both C and N-terminals facing the inner part of the capsid and a 
distal irregular insertion domain that contains variable loops (Zubieta et al., 2005) (Figure 
1-5B). The penton base N-terminal region interacts with protein IIIa (Liu et al., 2010). The 
penton base also interacts with the fiber N-terminal tail via three penton base grooves 
formed between penton subunits and the RGD motif, which is located in one of the penton 
base monomer variable loops (Zubieta et al., 2005), and also interacts with the fiber shaft 
via the penton base pore top surface (Liu et al., 2011, Zubieta et al., 2005). The interaction 
between penton base and hexon involves loops of the jelly roll motifs of both proteins 
(Fabry et al., 2005) (Figure 1-5L). Regarding the hexon, it is composed of 3 subunits each 
containing an eight-stranded β-barrel with jelly roll topology and loops connected by α-
helixes (Roberts et al., 1986, Rux and Burnett, 2000, Liu et al., 2010) (Figure 1-5A). 
Importantly, the hexon has 7 hypervariable regions (HVR), 5 of which are exposed on the 
outer part of the capsid and 2 of which (HVRs 1 and 6) are buried (Crawford-Miksza and 
Schnurr, 1996, Rux and Burnett, 2000). Both the C and N-terminals of hexon face the 
inner part of the capsid (Roberts et al., 1986, Liu et al., 2010). Interactions between hexons 
are made via their C-terminal, the β-barrel structure and the hexon loops (Fabry et al., 
2005, Reddy et al., 2010). Interactions of hexons with protein IIIa are made via the hexon 
N-terminal and with protein VIII via the hexon C or N-terminal (Reddy et al., 2010, Liu et 
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al., 2010) (Figure 1-5N). Also, the hexons within the GON interact with the C-terminal of 
protein IX and the PPHs interact with the N-terminal of protein IX (Reddy and Nemerow, 
2014) (Figure 1-5K).  
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Figure 1-5. Adenoviral capsid structural proteins and their interactions. Ribbon diagram of the ordered 
segments of hexon (A), protein IX triskelion (D), protein IIIa (E), protein VIII (F), protein V (G), protein VI 
(H), VIII-A:VI:V complex (I), peripentonal hexon (PPH) and penton base (L) and fiber N-terminal tail and 
penton base (M). Cryo-Electron Microscopy or X-ray diffraction structure and molecular dynamic flexible 
fitting (MDFF) simulation of penton base (B) and fiber (C) with each monomer coloured uniquely, and 
simulation of the interactions between the fiber N-terminal tail and penton base (J), between hexons and 
protein IX (K) and between hexons, protein IIIa, VIII, VI and V (N). Complex 1 composed of proteins VIII-
A, VI and V, and complex 2 of proteins VIII-B and VI are shown (N). Three molecules of protein IX 
    Chapter 1 | Introduction 
14 
 
(labelled as “A”, “B” and “C”) are shown in (D), and fragment 1 (F1) and 2 (F2) of protein VIII in (F). Black 
arrows in (J) indicate sites of interactions between fiber and penton base. Fiber is represented in magenta in 
(J) and red in (M), penton base in yellow in (J), light pink in (M), multicolored in the right position in (L) and 
magenta in (N), hexons in light blue, light yellow or light tan in (K and N) and multicolored in the left 
position in (L), protein IX in dark blue in (K), protein IIIa in purple in (N), protein V in green (N), protein VI 
in red (N) and protein VIII in orange (N). Certain protein residues are labelled in (D-H, K and N) and two out 
of the three interacting hexon loops with the penton base are indicated in (L). HVR; hypervariable regions, 
RGD; arginine-glycine-glutamic acid residues, pVIn; pre-protein VI cleaved N-terminal, PB; penton base. 
Figures from (A), (D-I), (K) and (N) adapted from (Reddy and Nemerow, 2014). Figure in (B) adapted from 
(Zubieta et al., 2005). Figures in (C) and (J) adapted from (Liu et al., 2011). Figures in (L) adapted from 
(Fabry et al., 2005). Figure in (M) adapted from (Nemerow et al., 2012). 
Protein IIIa and IX are the only cement proteins that stabilize the adenovirus capsid from 
the capsid exterior (Figure 1-4D left two panels). The Protein IIIa structure was shown to 
be predominantly composed of an α-helix with one 3-stranded β-sheet (Liu et al., 2010). 
This structure was later updated to a long extended polypeptide forming the N-terminal 
and an antiparallel very well ordered four-helix bundle structure [originally assigned to 
protein IX (Liu et al., 2010)], composed of two long helix-turn-helix motifs and a 
disordered region (Reddy and Nemerow, 2014) (Figure 1-5E). This protein was initially 
described to be located under the capsid vertices inside the virion (San Martin et al., 2008) 
but later shown to present its C-terminal on the capsid exterior (Reddy and Nemerow, 
2014). Protein IIIa simultaneously interacts via the protein IIIa N-terminal domains with 
the peripentonal hexons (PPH) reaching the penton base and it has been suggested that it 
also interacts with another protein IIIa molecule (Liu et al., 2010, Reddy and Nemerow, 
2014) (Figure 1-5N). Protein IX is located at the facet edges at the outer part of the capsid 
(Reddy and Nemerow, 2014). Initial studies showed an exceptionally extended and flexible 
conformation composed of an N-terminal domain, a rope domain and a long 12-turn helix-
bundle domain (Liu et al., 2010). Importantly, a recently updated structure of protein IX 
reversed the chain direction placing the C-terminal to the capsid exterior and assigned the 
four-helix bundle to protein IIIa (Reddy and Nemerow, 2014). Based on the initial 
structure, this protein was described to interact via the C-terminal α-helix of different 
copies of protein IX with hexon by forming a 4-helix bundle (Fabry et al., 2009, Liu et al., 
2010, Saban et al., 2006, Marsh et al., 2006). However, later studies showed these 
interactions correspond to protein IIIa (Reddy and Nemerow, 2014). Also, different copies 
of protein IX were shown to interact with each other via the N-terminal β-strand forming 
trimeric triskelion-like structures at the GON (Furcinitti et al., 1989, Liu et al., 2010). 
According to the updated model, the triskelion-like structures are formed with the C-
terminal and not the N-terminal of protein IX (Figure 1-5D), and while the triskelion-like 
structures stabilize the hexons within the GON, the N-terminal of each protein IX 
simultaneously interacts with the PPHs (Reddy and Nemerow, 2014) (Figure 1-5K). 
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Protein VI, VIII and V act as cement proteins stabilizing the adenovirus capsid from the 
capsid interior (Figure 1-4D right two panels). Originally, protein VIII was described to be 
a protein located in the inner part of the capsid composed of an ordered helix, an inverted 
U-shaped structure and an extended polypeptide chain (Reddy et al., 2010, Liu et al., 
2010). Later studies showed that pre-protein VIII is cleaved by AVP into three fragments, 
which combine to form two structurally distinct copies of protein VIII: VIII-A containing 
fragments 1 (composed of an ordered helix and an inverted U-shaped structure) and 
fragment 3 (composed of an extended polypeptide chain), and VIII-B only containing 
fragment 1 (Reddy and Nemerow, 2014) (Figure 1-5F). This study showed that while 
protein VIII-A forms a complex with protein VI and V by direct binding (complex 1), 
VIII-B only binds to protein VI (termed VI-B for convenience) (complex 2) (Figure 1-5I 
and N). Thus, complex 1 was reported to stabilize PPHs with the GON from underneath 
the capsid vertex via interactions mediated by protein VIII-A and VI, and complex 2 to 
stabilize the hexons within the same GON at each facet via interactions with both VIII-B 
and VI-B (Figure 1-4D right two panels). Protein VI has unstructured C and N-terminals 
and a helical core and is localized in the inner part of the capsid (Reddy and Nemerow, 
2014) (Figure 1-5H). Reddy et al. showed that after proteolysis by AVP, the cleaved 
peptide corresponding to the first 33 N-terminal residues of pre-protein VI is separated 
from the rest of the molecule but remains bound to the PPH (Reddy and Nemerow, 2014). 
The same study proposed that the next 34-50 residues of the cleaved protein VI, which are 
involved in endosomal membrane penetration, can adopt a helical conformation upon 
contact with endosomal membranes. Also, this region as well as the α-helix and the C-
terminal of protein VI were described to interact with PPHs, joining them to the adjacent 
GON. Interestingly, this study also showed that protein VI can interact with protein V and 
VIII. As described above, protein VI can stabilize the capside via formation of two 
different complexes by associating with protein V and VIII-A (complex 1) or only with 
VIII-B (complex 2) (Figure 1-5I and N). Protein V is a core protein composed of an 
ordered C-terminal with two α-helix, and a disordered and extended N-terminal (Reddy 
and Nemerow, 2014) (Figure 1-5G). Via the C-terminal it associates with protein VI and 
the fragment 3 of VIII-A (Figure 1-5I and N), and via the N-terminal with the viral DNA.  
Despite the general capsid architecture being conserved among genera, there are genus-
specific proteins that confer unique features to the capsid structure. For instance, 
Atadenovirus lacks proteins V and IX from Mastadenovirus, which are replaced by 
proteins p32k and LH3 (Pantelic et al., 2008). In particular, LH3 confers stability to the 
adenoviral capsid by binding to hexons from the outer part of the capsid where it locates on 
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top of hexons (Pantelic et al., 2008). Likewise, non-human adenovirus (NHAdV) canine 
serotype 2 (CAV-2), a member of the Mastadenovirus genera, displays some structural 
differences compared to human adenovirus. CAV-2 exhibits a smooth structure where 
many of the external penton base and hexon loops are shorter or absent in comparison to 
human adenovirus (HAdV) (Schoehn et al., 2008). Conversely, the fiber shows a more 
complex structure with two bends in the shaft at repeats 4 and 10, and the C-terminal of 
protein IX is located on the outer part of the capsid (Schoehn et al., 2008). Furthermore, 
there are also structural differences among HAdV serotypes. One of the clearest 
differences corresponds to the length and the flexibility of the fiber shaft. While species C 
have fibers with 18 or 22 shaft repeats, species A have longer and more flexible fibers with 
23 shaft repeats and species B, D and E have shorter and more rigid fibers with 6, 8 or 12 
fiber shafts, respectively [reviewed by (Arnberg, 2012)]. Interestingly, species F display 
two different fibers on the capsid, a long one with 21 or 22 fiber shafts and a shorter one of 
12 (Kidd et al., 1993, Yeh et al., 1994). Also, two different fibers have been reported in 
species G, which include a long one of 17 fiber shaft repeats and a shorter one of 9 (Jones 
et al., 2007). Importantly, the short and long fibers of species F and G bind different host 
cell receptors (Roelvink et al., 1998, Lenman et al., 2015). Similarly, differences in the 
penton base have been reported, with species F not containing an RGD motif in contrast to 
other HAdV serotypes (Albinsson and Kidd, 1999). Capsid protein structure differences 
might have important implications during host cell receptor recognition, virion 
internalization or capsid disassembly and assembly processes as well as implications for 
virion recognition by the anti-viral host immune response.  
1.2.2 Human adenovirus “life” cycle 
1.2.2.1 Adenovirus internalization 
The classical species C HAdV in vitro cell entry pathway (Figure 1-6) starts with the 
attachment to its primary receptor the coxsackie and adenovirus receptor (CAR) 
(Bergelson et al., 1997, Tomko et al., 1997), which also serves as a receptor for species A, 
D, E, F and G adenoviruses (Roelvink et al., 1998, Lenman et al., 2015). Binding to CAR 
is made via interactions between the extracellular domains of CAR and the lateral interface 
between two adjacent fiber knob domains (Roelvink et al., 1999, Lortat-Jacob et al., 2001, 
Freimuth et al., 1999, Kirby et al., 2000, Bewley et al., 1999, Excoffon et al., 2005), and 
this first interaction induces clustering of multiple CAR proteins (Burckhardt et al., 2011). 
Soon after, the RGD motif in the penton base interacts with αvβ1, α3β1, αMβ2, αvβ3 or αvβ5 
integrins (Salone et al., 2003, Li et al., 2001, Davison et al., 1997, Wickham et al., 1993, 
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Chiu et al., 1999, Mathias et al., 1998, Davison et al., 2001, Huang et al., 1996). In 
particular, binding to CAR gives rise to diffusive and drifting motions that together with 
virus attachment to immobile integrins promotes the release of fiber from virions and thus 
the start of capsid disassembly (Nakano et al., 2000, Burckhardt et al., 2011). Interestingly, 
the released fiber remains associated with the plasma membrane for up to 30 to 60 min 
(Greber et al., 1993). Also, this first capsid disassembly event results in the exposure of 
pVI from the capsid (Burckhardt et al., 2011). αvβ1, αvβ3 and αvβ5 integrins act as 
secondary HAdV-5 receptors to promote viral internalization (Wickham et al., 1993, 
Wickham et al., 1994, Mathias et al., 1998, Shayakhmetov et al., 2005a, Salone et al., 
2003), which takes place 5 min after receptor-recognition (Greber et al., 1993) and is 
mediated via clathrin-mediated endocytosis and involves the cytosolic GTPase dynamin 
(Patterson and Russell, 1983, Meier et al., 2002, Wang et al., 1998, Chardonnet and Dales, 
1970a). In this process, αvβ3 and αvβ5 integrins recruit the adaptor complex AP-2 to 
facilitate viral endocytosis (Honing et al., 2005, Robinson, 2004). Also, binding of HAdV-
5 to integrins leads to integrin clustering, which activates signalling pathways such as 
p85/p110 phosphoinositide-3-OH kinase (PI3K) via the activation of the p85 subunit (Li et 
al., 1998b, Li et al., 1998a). PI(3,4)P2 and PI(3,4,5)P3 [products of PI3K activation 
(Simonsen et al., 2001)] activate Rab5 GTPase that regulates endocytosis and homotypic 
vesicular fusion with early endosomes (Rauma et al., 1999, Zerial and McBride, 2001). 
Also, peripheral trafficking of endocytic vesicles containing virus requires protein kinase C 
(PKC) (Nakano et al., 2000), which is activated by PI(3,4,5)P3 (Nakano et al., 2000). In 
addition, PI3K prepares the host cell for trafficking of endosomes and viral particles along 
the microtubule network by activating Rac1 and CDC42, members of the Rho family of 
GTPases that are involved in the polymerization of monomeric actin and reorganization of 
actin filaments (Li et al., 1998a). Further viral capsid disassembly occurs in the endocytic 
pathway and, between 40 and 150 min after internalization, the hexon is partially degraded 
in a process dependent on endosomal and lysosomal proteases (Greber et al., 1993, Greber 
et al., 1996). Also, protein IIIa and protein VIII detach from the virion in endosomal 
vesicles within 15 min after adenovirus internalization and, 3 to 5 min later, the penton 
base dissociates from hexon (Greber et al., 1993). Interestingly, adenovirus was shown to 
trigger macropinocytosis, coincident with clathrin-mediated viral endocytosis, but its role 
has not been fully defined yet (Meier et al., 2002). Next, internalized adenoviral particles 
escape from early endosomes into the cytosol and only 5% of the incoming viruses are 
degraded in lysosomes (Greber et al., 1993). This process has been associated with protein 
VI, which penetrates the endosomes via the N-terminal amphipathic α-helix (Wiethoff et 
al., 2005, Moyer et al., 2011) introducing positive curvature strain to the membrane that 
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leads to membrane fragmentation (Maier et al., 2010). This process requires cleavage of 
pVI by AVP and is triggered by two separate signals: activation of AVP by acidification of 
endosomes and capsid disassembly via RGD-dependent interaction of penton base with 
integrin receptors (Greber et al., 1996, Shayakhmetov et al., 2005a, Burckhardt et al., 2011, 
Wang et al., 2000). In particular, αvβ5 integrins have been directly associated with the 
promotion of viral penetration from endosomes (Wickham et al., 1994). Also, PKC has 
been associated with adenovirus escape from endosomes (Nakano et al., 2000). When 
adenoviruses access the cytosol, the adenoviral nucleocapsid is mainly composed of hexon 
partially associated with protein VI and protein IX and contains the adenoviral DNA, 
which is condensed with proteins V, VII and X, covalently associated with the TP at each 
5’ DNA end and non-covalently associated with AVP (Wodrich et al., 2010, Xue et al., 
2005). Adenoviral nucleocapsids are transported along the microtubule network via a 
bidirectional movement towards the nucleus (Suomalainen et al., 1999, Mabit et al., 2002, 
Dales and Chardonnet, 1973) in a process facilitated by the cytoplasmic dynein and 
dynactin (Suomalainen et al., 1999, Kelkar et al., 2004, Leopold et al., 2000). Also, it was 
recently reported that a PPxY motif (x being any amino acid) in protein VI recruits Nedd4-
family E3 ubiquitin ligases resulting in protein VI ubiquitylation (Wodrich et al., 2010). 
Via an unknown mechanism, this event mediates the microtubule-dependent transport of 
protein VI, essential for transport of virions towards the nucleus (Wodrich et al., 2010). 
Importantly, upon adenovirus uptake, signalling pathways involved in transport of 
nucleocapsids along the microtubule network are also activated. These include cAMP-
dependent protein kinase A (PKA), p38 mitogen-activated protein kinase (MAPK), and 
MAPKAP kinase 2 (MK2) that depends on MKK6 (Suomalainen et al., 2001, Bhat and 
Fan, 2002, Tibbles et al., 2002). PKA and P38 MAPK stimulate both the frequency and 
velocity of minus-end-directed viral motility along microtubules (towards the microtubule 
organizing centre (MTOC) adjacent to the nucleus), MK2 enhances the frequency of 
minus-end-directed virus transport, and p38 MAPK suppresses lateral viral motilities thus 
enhancing nuclear targeting (Suomalainen et al., 2001). Viral particles can be detected at 
the nuclear membrane by electron microscopy within 45 to 60 min post adenovirus uptake 
(Dales and Chardonnet, 1973, Greber et al., 1993) and adenoviral DNA and proteins V and 
VII within 60 to 120 min (Greber et al., 1997, Matthews and Russell, 1998). The 
mechanism by which adenoviral nucleocapsids dissociate from microtubules to interact 
with the cell nucleus has not been fully defined yet. However, the nuclear export factor 
exportin 1 (XPO1)/CRM1, which binds CAN/Nup214, has been proposed to be part of a 
sensor mechanism that triggers the detachment of nucleocapsids from microtubules 
proximal to the nucleus, allowing them to interact with the nuclear membrane (Strunze et 
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al., 2005). Once the nucleocapsid reaches the nuclear membrane, it interacts with 
CAN/Nup214 at the nuclear pore complex (NPC) (Strunze et al., 2011). Also, despite the 
majority of protein IX is lost from the capsid in the cytosol, with a 30 min half-time 
(Greber et al., 1993), it seems that adenoviral nucleocapsids bind to kinesin-1 light-chain 
(KLC)1 and 2 via protein IX (Strunze et al., 2011). Simultaneously, kinesin-1 heavy-chain 
KIF5c interacts with the nucleoporin Nup358, which is attached to the Nup214:Nup88 
complex, mediating capsid disassembly and displacement of Nup214, Nup358 and Nup62 
from the NPC towards the cell periphery (plus-end-directed motility), which in turn causes 
NPC disruption and thus increases nuclear envelope permeability (Greber et al., 1997, 
Strunze et al., 2011). These interactions recruit nuclear histone H1 via an unknown 
mechanism, and H1 binds to hexon (Trotman et al., 2001). Also, DNA-associated protein 
VII binds to H1 import factors importin α, importin β, importin 7 and transportin via 
nuclear localization signal (NLS)-containing regions present in protein VII (Wodrich et al., 
2006, Hindley et al., 2007). As a result, H1-hexon complexes are imported into the nucleus 
leading to complete capsid disassembly and delivery of viral DNA, protein V, protein VI, 
protein VII and TP into the nucleus where DNA replication occurs (Trotman et al., 2001, 
Strunze et al., 2011, Greber et al., 1997, Xue et al., 2005, Wodrich et al., 2006, Hindley et 
al., 2007, Chatterjee et al., 1986, Matthews and Russell, 1998, Le et al., 2006, Fredman and 
Engler, 1993, Schreiner et al., 2012). Hsc70 has also been associated with import of viral 
DNA in vitro but its role has not been confirmed yet (Saphire et al., 2000). More recently it 
was reported that a significant fraction of the incoming viral genomes (~25%) is 
misdelivered to the cytosol as a consequence of virus docking and disassembly at the NPC 
and only a 6% to 48% is imported into the nucleus, a percentage that increases at higher 
viral multiplicity of infection (MOI) (Wang et al., 2013). Once the viral DNA is 
internalized into the nucleus, the TP forms a complex with the cellular CAD pyrimidine 
synthesis enzyme allowing correct location of adenoviral DNA for replication (Fredman 
and Engler, 1993, Angeletti and Engler, 1998). According to several reports, replication 
and transcription of early genes requires only viral DNA, protein VI and protein VII, and 
protein V may be dispensable (Xue et al., 2005, Haruki et al., 2006, Chatterjee et al., 1986, 
Schreiner et al., 2012), which is in agreement with the observed earlier dissociation of 
protein V from DNA in comparison to that of protein VII (Le et al., 2006, Puntener et al., 
2011, Chatterjee et al., 1986). Replication-deficient adenoviral vectors (E1A-deficient) do 
not replicate their DNA and instead remain episomal in the nucleus of host cells or rarely 
integrated into the host genome (Harui et al., 1999, Stephen et al., 2008, Stephen et al., 
2010). In the case of wild type adenovirus, replication of viral DNA and production of 
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viral proteins gives rise to a new generation of virions ready to lyse host cells and start a 
new viral cycle.  
 
Figure 1-6. Classical species C human adenovirus in vitro transduction pathway. 1. Adenovirus attaches 
to the plasma membrane via CAR and αvβ1, α3β1, αMβ2, αvβ3 and αvβ5 integrins. 2. Adenovirus binding to 
integrins promotes integrin clustering leading to the activation of signalling pathways within the host cell. 3. 
Adenoviral binding to αvβ1, αvβ3 and αvβ5 integrins promotes internalization of viral particles via clathrin-
mediated endocytosis within 5 min after receptor recognition. 4. Protein IIIa and protein VIII dissociate from 
viral capsids in the endosomes 10 min after receptor recognition. 5. Adenoviral capsids escape from early 
endosomes 15 min after receptor recognition in a process mediated by protein VI that results in the partial 
degradation of pre-protein VI (pVI). 6. Viral capsids travel along the microtubule network towards the 
nucleus and the penton dissociates from capsids during this process. 7. A total of 5% of the incoming 
adenoviruses get degraded in the lysosomes. 8. Protein IX dissociates from the viral capsid at the nuclear 
pore complex (NPC) and adenoviral DNA is imported into the nucleus along with proteins V, VI and VII and 
terminal protein (TP). MTOC; microtubule-organizing centre. 
Importantly, other receptors have also been associated with HAdV-5 cell transduction. 
These include vascular cell adhesion molecule-1 (VCAM-1) (Chu et al., 2001), α2 domain 
of the major histocompatibility complex-I (MHC-I-α2) (Hong et al., 1997, Davison et al., 
1999), scavenger receptor (SR) (Khare et al., 2012), low-density lipoprotein receptor-
related protein (LRP) (Shayakhmetov et al., 2005b) and complement receptor (CR)1 
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(Carlisle et al., 2009) (Table 1-1). Moreover, the use of adaptor molecules such as 
dipalmitoyl phosphatidylcholine (DPPC) (Balakireva et al., 2003), lactoferrin (Adams et 
al., 2009, Johansson et al., 2007), C4b-binding protein (C4BP) (Martin et al., 2003, 
Shayakhmetov et al., 2005b) or coagulation factors (see section 1.3.4.2) has also been 
reported (Table 1-1). The diversity of HAdV-5 interactions with host proteins together 
with the existence of other receptors such as desmoglein 2 (DSG2), sialic acid-containing 
glycoproteins, CD46, CD80 or CD86 that can be used by other adenovirus species 
[reviewed by (Arnberg, 2009, Arnberg, 2012, Hall et al., 2010)] (Table 1-1) and with the 
existence of species or serotype-specific endocytic pathways such as macropinocytosis 
(Amstutz et al., 2008, Kalin et al., 2010) and trafficking kinetics (Miyazawa et al., 2001, 
Chardonnet and Dales, 1970b, Shayakhmetov et al., 2003) demonstrates the high 
versatility of adenovirus to infect host cells within different environments. 
1.2.2.2 Adenoviral DNA transcription and replication 
Following delivery of viral DNA, proteins V, VI and VII and TP into the nucleus of the 
host cell, adenoviral genomes associate with promyelocytic leukemia-nuclear bodies 
(PML-NBs) and form viral replication centres (Puvion-Dutilleul and Puvion, 1990, Doucas 
et al., 1996). To repress incoming viral genomes from successful replication, a network of 
cellular processes get activated (see section 1.2.3). In return, early viral genes are 
expressed. Early proteins have two major roles during the infection process: they 
counteract the anti-viral immune response (see section 1.2.4) and induce the infected cell 
into the S-phase of cell cycle (synthesis phase) to support adenoviral DNA replication 
(Spitkovsky et al., 1996). Initiation of viral gene expression is mediated by protein VI, 
which via the PPxY motif activates the adenovirus E1A promoter for E1A expression 
(Schreiner et al., 2012). E1A binds to retinoblastoma tumor suppressor (pRb) (Buchkovich 
et al., 1990, Giordano et al., 1991, Dyson et al., 1989) leading to its dissociation from the 
transcription factor E2F and thus induction of progression into the S-phase (Bagchi et al., 
1990). E1A also enhances the expression of cell division cycle 25A (CDC25A) and cyclin 
E, which are involved in the G1/S-phase transition (Spitkovsky et al., 1996), and regulates 
effectors of cyclin dependent kinase 2 (CDK2) (Alevizopoulos et al., 1998). Moreover, a 
role for E1A in epigenetic reprogramming for induction of the S-phase has been reported 
(Horwitz et al., 2008, Ferrari et al., 2008). In addition, during the early phase, E1A 
activates E1B and E2 early promoters for expression of E1B (Wu et al., 1987) and E2 
(Reichel et al., 1988). E3 and E4 expression is also activated by E1A through its 
interaction with ring finger protein 20 (RNF20), which recruits Paf1/RNA polymerase II 
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complex component (PAF1) to early genes enabling transcription (Jones and Shenk, 1979, 
Fonseca et al., 2013). Also, protein X was shown to bind to viral DNA (Anderson et al., 
1989), and pre-protein X was reported to target the nucleolus and was associated with the 
accumulation of E2 early proteins via modulation of mRNA biogenesis (Lee et al., 2004). 
Mature viral transcripts of early genes are then exported from the nucleus into the 
cytoplasm, where protein synthesis occurs, in a XPO1-dependent manner (Schmid et al., 
2012). Interestingly, E1A promotes expression of viral genes that can cooperate with E1A 
in inducing cells into the S-phase. This is the case of E1B 55K, which has been involved in 
the enhancement of cyclin E expression (Zheng et al., 2008). However, as a result of E1A 
expression, p53 is stabilized and subsequently induces cell cycle arrest at G1 or cell 
apoptosis via the activation of downstream proteins (Lowe and Ruley, 1993, Debbas and 
White, 1993). To prevent death of the infected cell, E1B 19K and E1B 55K antagonize 
E1A-triggered p53-mediated apoptosis (Sabbatini et al., 1995, Teodoro and Branton, 1997, 
Debbas and White, 1993). In particular, E1B 55K interacts with p53 (Kao et al., 1990) and 
represses transcriptional activation of p53-inducible genes (Yew et al., 1994, Martin and 
Berk, 1998, Martin and Berk, 1999). Also, E1B 55K forms a complex with E4 open 
reading frame 6 (E4 Orf6)/E4 34K that acts as an E3 ubiquitin ligase and mediates 
proteasomal degradation of p53 (Harada et al., 2002, Querido et al., 2001). Moreover, 
SUMOylation of E1B 55K allows E1B 55K to be imported into the nucleus, associate with 
PML-NBs and in turn SUMOylate p53 to promote its association with PML-NBs and thus 
its displacement from target sites (Endter et al., 2005, Endter et al., 2001, Muller and 
Dobner, 2008, Pennella et al., 2010, Wimmer et al., 2010). E4 Orf3/E4 11K has also been 
associated with the blockade of p53-dependent transcription of host proteins by inducing 
epigenetic changes on p53 target promoters and thus preventing p53 DNA-binding (Soria 
et al., 2010). Thus, via the action of viral proteins, adenoviruses block the anti-viral 
intracellular immune response and proceed to replicate their genome. 
Adenoviral DNA replication involves adenoviral DNA polymerase, pTP, E2A and cellular 
proteins nuclear factor (NF)I and III [reviewed by (Challberg and Kelly, 1989, Stillman, 
1989)] (Figure 1-7). The process is initiated with the formation of a complex between pTP 
and the adenoviral DNA polymerase (Parker et al., 1998, Brenkman et al., 2002) and the 
binding of pTP to the terminal dCMP of either ITR of the viral DNA, where it serves as a 
viral protein primer (Challberg et al., 1980, Rekosh et al., 1977). This DNA region is 
defined as the origin of replication (Tamanoi and Stillman, 1983, Challberg and Rawlins, 
1984, Rawlins et al., 1984, Lally et al., 1984, Wides et al., 1987). NFI transcription factor 
binds to viral DNA in close proximity to the origins of replication and to the adenoviral 
    Chapter 1 | Introduction 
23 
 
DNA polymerase and stabilizes the adenoviral DNA polymerase:pTP complex (Mul and 
Van der Vliet, 1992, Nagata et al., 1982, Bosher et al., 1990, Chen et al., 1990), 
stimulating initiation of replication (Leegwater et al., 1985, Rosenfeld et al., 1987, Nagata 
et al., 1983b). E2A enhances the rate of initiation of viral DNA replication by facilitating 
binding of NFI to viral DNA and is the primary determinant of the efficiency of DNA 
replication (Cleat and Hay, 1989, Stuiver and van der Vliet, 1990, Jones et al., 1987, 
Caravokyri and Leppard, 1996, Mul and van der Vliet, 1993). Furthermore, NFIII can also 
bind to viral DNA and stimulate DNA replication (Pruijn et al., 1986, Rosenfeld et al., 
1987, O'Neill et al., 1988). The transition from initiation of replication to elongation of 
viral DNA takes place by a jumping back mechanism that is based on the formation of a 
pTP-CAT intermediate following pTP binding to dCMP, that is next coupled with an 
internal GTA triplet that jumps back from three positions forward [reviewed by (King and 
van der Vliet, 1994)]. This process ends with the dissociation of pTP from the adenoviral 
DNA polymerase (King et al., 1997). Next, the adenoviral DNA polymerase elongates the 
nascent DNA chains while E2A binds to and protects the exposed ssDNA (Nass and 
Frenkel, 1980, van der Vliet et al., 1978, Fowlkes et al., 1979, Lindenbaum et al., 1986). 
Of note, the topoisomerase NFII is required for replication of long DNA templates 
(Guggenheimer et al., 1984, Nagata et al., 1983a), and the host cell protein nucleophosmin 
(NPM1), which is relocated from the nucleolus to the nucleoplasm in a protein V-
dependent manner, has also been associated with viral DNA replication (Ugai et al., 2012). 
 
Figure 1-7. Adenovirus dsDNA replication mechanism. DBP; ssDNA-binding protein/E2A, pTP; pre-
terminal protein, pol; adenoviral DNA polymerase. 
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When viral DNA replication is completed, newly synthetized dsDNA is transported to the 
periphery of the viral replication centres to serve as a template for expression of three 
different transcriptional units: protein IX, IVa2 and the MLTU for late gene expression 
(Pombo et al., 1994). Despite the majority of protein VII is removed from viral DNA upon 
entry into the nucleus, some molecules remain bound to DNA during the early phase of 
infection (Ross et al., 2011). These DNA-bound protein VII subsequently dissociate from 
viral DNA as a consequence of the transcription process via a mechanism that involves a 
structural change in the viral chromatin (Schreiner et al., 2013, Chen et al., 2007). IVa2 has 
been associated with the activation of transcription of late genes through the formation of a 
complex with L4-33K (Tribouley et al., 1994, Lutz and Kedinger, 1996, Pardo-Mateos and 
Young, 2004, Ali et al., 2007, Farley et al., 2004). The long primary transcript produced 
from MLTU accumulates in interchromatin granules and Cajal bodies (CBs) rosettes 
together with transcription and splicing factors, where it is processed and spliced for 
production of the viral late mRNAs (Aspegren et al., 1998, James et al., 2010, Bridge et al., 
1995, Gama-Carvalho et al., 2003). The splicing process has been associated with E4 Orf4, 
L4-33K and L4-22K, as well as with cellular proteins PKA, DNA-dependent protein 
kinase (DNA-PK) and protein phosphatase IIA (PP2A) [(Brestovitsky et al., 2011, Morris 
and Leppard, 2009) and reviewed by (Biasiotto and Akusjarvi, 2015)]. The resultant 
transcripts are then exported into the cytoplasm in a process that is selective for viral 
transcripts mediated by the E1B 55K:E4 Orf6 complex and the cellular nuclear RNA 
export factor 1 (NXF1) (Woo and Berk, 2007, Blanchette et al., 2008, Yatherajam et al., 
2011, Bridge and Ketner, 1990). Next, late mRNAs are translated in a process mediated by 
the viral L4-100K protein (Hayes et al., 1990), and newly synthetized late proteins are 
imported into the nucleus for virion assembly.  
1.2.2.3 Adenoviral DNA packaging and capsid maturation 
Adenoviral late proteins are synthetized in the cytoplasm. While the majority of viral 
proteins assemble independently in the cytoplasm, hexon trimers need the assistance of L4-
100K, which binds to hexon monomers via one of the L4-100K globular domains and acts 
as a chaperone for hexon folding and self-assembly (Hong et al., 2005, Oosterom-Dragon 
and Ginsberg, 1981, Cepko and Sharp, 1982). Subsequently, viral proteins are imported 
into the nucleus for virion assembly. Unlike fiber and penton base oligomers, hexon 
trimers require the association with pVI to be imported into the nucleus (Kauffman and 
Ginsberg, 1976, Wodrich et al., 2003). Once in the nucleus, adenoviral structural proteins 
assemble to form a procapsid. Next, the newly synthetized adenoviral dsDNA is inserted 
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into the procapsid in a process dependent on the presence of an adenoviral DNA packaging 
signal and viral proteins IVa2 and L4-22K. The packaging signal is an A/T-rich sequence 
located at nucleotides 194 to 358 in HAdV-5 adjacent to the left ITR (Hearing et al., 1987). 
IVa2 is able to bind to the packaging signal and mediate DNA packaging into capsids via a 
mechanism that requires hydrolysis of ATP (Zhang and Imperiale, 2000, Ostapchuk et al., 
2005, Ostapchuk et al., 2011, Ostapchuk and Hearing, 2008). In this process, L4-22K binds 
to and forms a complex with IVa2 that enhances IVa2 binding to the packaging signal 
(Ewing et al., 2007). Moreover, L1-52/55K, which is located beneath the vertex (Condezo 
et al., 2015), can bind to IVa2 (Perez-Romero et al., 2006) and also to the packaging signal 
in an IVa2 and sequence-independent manner (Perez-Romero et al., 2005, Zhang and 
Arcos, 2005) and play a role in viral DNA packaging (Gustin and Imperiale, 1998, Perez-
Romero et al., 2005, Hasson et al., 1989). Furthermore, protein IIIa can also bind to the 
packaging signal and interact with L1-52/55K (Ma and Hearing, 2011), and protein VII 
and pre-protein VII (pVII) can bind to IVa2 and L1-52/55K as well as to viral DNA in a 
non-specific manner (Zhang and Arcos, 2005). Since protein IIIa is located at the capsid 
vertex, a possible role in signalling the position for viral DNA to be encapsidated has been 
proposed (Ma and Hearing, 2011). L4-33K, which is expressed at the early stages of the 
late phase of infection and localizes to the nucleus, was also shown to have a role in DNA 
packaging and to function as an alternative RNA splicing factor for pIIIa, pVI and fiber 
transcripts (Fessler and Young, 1999, Wu et al., 2013). Final maturation of the procapsid 
into infectious adenoviral particles requires the action of AVP, which moves along the 
viral DNA (McGrath et al., 2001a) until it finds a particular protein consensus sequence 
(Diouri et al., 1996) on the precursor of protein IIIa, VI, VII, VIII, X, TP and L1-52/55K 
and cleaves them to generate mature proteins (Tremblay et al., 1983, Boudin et al., 1980, 
Perez-Berna et al., 2014). Of note, the cleavage sequence is found in residue 570 of protein 
IIIa, residues 33 and 239 of VI, residues 13 and 24 of VII, residues 111, 131 and 157 of 
VIII, residues 27, 32 and 51 of X, residues 36, 66, 124, 275, 300, 351, 382 and 398 of L1-
52/55K and residues 175, 183, 316 and 349 of TP [reviewed by (Mangel and San Martin, 
2014)]. This event was found essential for successful infection of host cells, since viral 
capsids containing the precursor capsid proteins instead of the corresponding mature forms 
exhibit a more ordered and stable structure that impairs capsid disassembly (Silvestry et 
al., 2009, Perez-Berna et al., 2009). Also, the release of L1-52/55K from the capsid via 
proteolytic processing by the AVP was shown to facilitate genome release during capsid 
disassembly (Condezo et al., 2015). Moreover, it was reported that activation of AVP 
requires two events (Gupta et al., 2004, Mangel et al., 1993): first, AVP binds to viral 
DNA in a sequence-independent manner leading to a conformational change in AVP and 
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thus its partial activation (Mangel et al., 1993). Partially activated AVP cleaves pVI at the 
C-terminal and the cleaved peptide covalently binds to AVP resulting in a second 
conformational change that leads to its complete activation (Mangel et al., 1993, McGrath 
et al., 2003, McGrath et al., 2001b). Once mature infectious virions are formed, AVP 
prepares infected cells for viral progeny release by cleaving cytokeratin and thus inducing 
changes in the cell cytoskeleton (Chen et al., 1993b). In this process, actin was shown to 
bind to and activate AVP (Brown et al., 2002). Next, E3-11.6K/adenovirus death protein 
(ADP), which accumulates in infected cells towards the late stages of infection, induces 
lysis of infected cells via an unidentified mechanism involving the cellular protein MAD2 
mitotic arrest deficient-like 2 (MAD2L2)/MAD2B (Tollefson et al., 1996b, Tollefson et 
al., 1996a, Ying and Wold, 2003) and thus allows virions release. Interestingly, fiber, 
penton base and hexon proteins are produced in excess during adenovirus late gene 
expression (Boulanger and Puvion, 1973, Rebetz et al., 2009). The excess protein produced 
was shown to promote the spread of progeny viruses to neighbouring cells by mediating 
disruption of cell-cell junctions in a process involving fiber:penton base:hexon complexes 
binding to basolateral CAR of infected and neighbouring cells (Walters et al., 2002, Zhang 
et al., 2015).  
1.2.3 Anti-viral host immune response against adenovirus 
The immune system is prepared to combat the biological threats that an organism may be 
subjected to. The first line of defence is based on mechanical barriers (e.g: skin or mucous 
membranes), on chemical barriers including anti-microbial substances that inhibit bacteria 
growth (e.g: salivary lysozyme), digestive enzymes, extreme pH or α-defensins secreted by 
Paneth cells, and on microbiological barriers such as the microbial flora, which produces 
bacteriocins and other anti-microbial peptides. The second line of defence is composed of 
the innate immunity, a conjunction of different cells and mechanisms (macrophages, mast 
cells, dendritic cells (DC), natural killer (NK) cells, the complement system, pattern 
recognition receptors (PRRs), etc.) that can trigger a non-specific acute inflammation 
process mediated by pro-inflammatory cytokines and chemokines, upon detection of 
threats. Finally, if the threat persists, phagocytes such as DCs migrate to the lymph nodes 
and activate adaptive immune responses, the third line of defence, which is mainly 
composed of B and T cells. Effector B cells and CD8+ T cells or also called cytotoxic T 
lymphocytes (CTLs) are able to generate antigen-specific receptors (BCR or TCR, 
respectively) upon binding to specific antigens and reception of activation signals in a 
process mediated by Th2 or Th1-type CD4+ T cells, which in turn require the presence of 
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active antigen presenting cells (APCs) or DCs to promote the expression of co-stimulatory 
molecules. As a result, effector B cells generate antigen-specific antibodies to neutralize 
microorganisms and viruses and CD8+ T cells mediate cytolytic killing of infected cells. In 
particular, the anti-viral response is based on mechanisms to prevent infection of host cells 
such as neutralizing antibodies and complement, and on immune cells that eliminate 
infected cells such as NK cells or CTLs, which are driven by the release of interferon 
(IFN) and tumor necrosis factor (TNF)-α (reviewed by (Fensterl and Sen, 2009, Warren 
and Smyth, 1999, Lopez-Gordo et al., 2014a, Andersen et al., 2006) (Figure 1-8). 
Neutralizing IgG antibodies (NAbs) can recognize specific epitopes on adenoviral capsid 
proteins (Sumida et al., 2005, Gall et al., 1996) such as the hexon (Roberts et al., 2006, 
Abe et al., 2009, Shiratsuchi et al., 2010, Bradley et al., 2012b, Hong et al., 2003), the fiber 
(Myhre et al., 2007, Bradley et al., 2012a, Yu et al., 2013, Hong et al., 2003, Gahery-
Segard et al., 1998, Parker et al., 2009) or the penton base (Yu et al., 2013, Hong et al., 
2003, Gahery-Segard et al., 1998), and form immune complexes that can be phagocytosed 
by macrophages via antibody constant fraction receptors (FcR) or recognized by FcR on 
NK cells [reviewed by (Gattoni et al., 2006, Warren and Smyth, 1999)]. These interactions 
also result in the production of type I (α and β) IFN and the maturation of caspase-
dependent interleukin (IL)-1β (Zaiss et al., 2009). Moreover, adenovirus recognition by 
anti-hexon and anti-penton base antibodies results in the accumulation of virions in 
endocytic vesicles (Wohlfart, 1988). Similarly, circulating IgM antibodies negatively 
correlate with liver transduction (Khare et al., 2013). This is partly due to resident 
macrophages in the liver [Kupffer cells (KC)], which have FcR that can bind to IgM 
antibodies on virions (Xu et al., 2008), and partly due to complement component 3 (C3) 
receptor CRIg-dependent KC recognition of virions that have been opsonised by the 
complement system (He et al., 2013). Also, KC can bind to adenoviral capsids via 
scavenger receptors such as scavenger receptor A (SR-A)-II (Xu et al., 2008, Haisma et al., 
2008, Khare et al., 2012) and undergo cell death following phagocytosis in a process 
dependent on adenovirus capsid disassembly and endosomal membrane penetration 
(Manickan et al., 2006, Smith et al., 2008). Another defence mechanisms dependent on the 
Fc portion of IgM or IgG antibodies is the cytosolic tripartite motif-containing protein 21 
(TRIM21), which is a RING finger E3-ubiquitin ligase that depends on the host AAA 
ATPase valosin-containing protein (VCP) and the proteasome to degrade viral capsids 
(Mallery et al., 2010, Hauler et al., 2012). Furthermore, a recent report showed that upon 
IgM binding to virions and subsequent opsonisation of capsids by complement proteins in 
vitro (Cichon et al., 2001), receptor-ligand interactions of virions with host cells gets 
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blocked (Xu et al., 2013). Interestingly, while the classical complement pathway (IgM-
mediated) plays a critical role in opsonizing virions in vitro (Xu et al., 2013), both the 
classical and non-classical pathways are apparent in vivo (Tian et al., 2009, Xu et al., 2008, 
Jiang et al., 2004), indicating that in the absence of IgM antibodies adenoviral capsids can 
activate and be opsonized by the complement system. Also, the complement system is 
involved in other processes such as adenovirus-induced thrombocytopenia, which is 
dependent on factor B and C3 of the alternative complement pathway and results in the 
induction of the nuclear factor-kappa B (NF-κB) upon C3 binding to adenoviral capsids 
(Appledorn et al., 2008a, Kiang et al., 2006). Furthermore, adenoviral DNA can trigger an 
innate immune response. Plasmacytoid DCs (pDCs) can recognize non-methylated viral 
CpG-containing DNA in the endosomes through Toll-like receptor (TLR)9, which via the 
myeloid differentiation primary response 88 (MYD88) results in the expression of pro-
inflammatory genes and secretion of IL-6 and IL-12 (Yamaguchi et al., 2007, Zhu et al., 
2007). Also, the activation of pDC by certain adenovirus serotypes such as HAdV-35 can 
lead to IFN-α production in a TLR9-dependent manner and subsequent NK cell activation 
(Pahl et al., 2012, Zhu et al., 2008), and immune complexes can induce DC maturation via 
TLR9 agonist motifs present in the adenoviral genome (Perreau et al., 2012). Furthermore, 
adenoviral DNA can also trigger TLR-independent responses on conventional DCs (cDCs) 
and macrophages (Basner-Tschakarjan et al., 2006, Zhu et al., 2007). Macrophages can 
detect adenoviral DNA in a TLR9-independent manner leading to the maturation of pro-
IL-1β via a mechanism mediated by NOD-like receptor family pyrin domain containing 3 
(NLRP3) and apoptosis-associated speck-like protein containing a caspase-recruitment 
domain (ASC), components of the innate cytosolic molecular complex called the 
inflammasome (Muruve et al., 2008), and that requires penetration of endosomal 
membranes (Barlan et al., 2011b, Barlan et al., 2011a). Also, binding of macrophage β3 
integrins with the adenovirus RGD motif promotes secretion of IL-1α (Di Paolo et al., 
2009a). TLR2 has also been associated with NF-κB activation and humoral responses to 
adenovirus (Appledorn et al., 2008b). Moreover, the RNA sensor melanoma 
differentiation-associated protein 5 (MDA5) and cytosolic adenoviral DNA sensors such as 
absent in melanoma 2 (AIM2), TRAF family member-associated NF-κB activator 
(TANK)-binding kinase 1 (TBK1), DEAD-box helicase 41 (DDX41), DNA-dependent 
activator of IRFs (DAI), cyclic GMP-AMP synthase (cGAS), or the complex formed by 
NLRP3 with ASC and caspase-1, can lead to cytokine production (mainly type I IFN) upon 
adenovirus infection (Schulte et al., 2013, Stein and Falck-Pedersen, 2012, Steinstraesser et 
al., 2011, Nociari et al., 2007, Muruve et al., 2008, Lam et al., 2014). Interestingly, 
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adenovirus-induced rupture of endosomal membranes activates the NLRP3 inflammasome 
(Barlan et al., 2011b, Barlan et al., 2011a). Other proteins such as DDX58/retinoic acid-
inducible gene I (RIG-I), which recognizes VA-I and II, have also been associated with 
adenoviral-induced innate immune responses (Minamitani et al., 2011). Also, other cell 
types such as erythrocytes or neutrophils contribute to anti-adenoviral immune responses 
through interactions with adenovirus capsids via CAR, CR1 or FcR (Carlisle et al., 2009, 
Cotter et al., 2005). Importantly, the production of type I IFN by infected cells or immune 
cells such as DC or macrophages promotes an anti-viral state in neighbouring non-infected 
cells by triggering the expression of anti-viral enzymes such as MxA, 2’,5’-oligoadenylate 
synthase and eukaryotic translation initiation factor 2 α kinase 2 (EIF2AK2)/protein kinase 
RNA-activated (PKR) via Jak-STAT signalling (Katze et al., 2002). Also, type I IFN leads 
to the maturation of DC by up-regulating the expression of co-stimulatory molecules such 
as CD80, CD86 and CD40 (Vujanovic et al., 2009). The production of type II IFN (IFN-γ) 
by NK cells also contributes to the promotion of an anti-viral state, for instance, by 
inducing the expression of major histocompatibility complex class I (MHC-I) on non-
immune cells as well as MHC-II on professional APC [reviewed by (Gattoni et al., 2006)], 
which use it to present antigens to naive CD4+ T cells TCR and thus initiate an adaptive 
immune response. Furthermore, IFN-γ and TNF-α inhibit early adenovirus transgene 
expression via a transcription-related mechanism (Mestan et al., 1986, Sung et al., 2001). 
TNF-α, which is produced by macrophages and lymphocytes, is also able to induce 
apoptosis of infected cells by binding to its receptors TNF-related apoptosis-inducing 
ligand (TRAIL) 1 and 2 (Wong and Goeddel, 1986, Nagata, 1997). Activated macrophages 
and DC also release IL-12, which leads to the differentiation of naive CD4+ T cells into T 
helper (Th)1-type CD4+ T cells and contributes to IFN-γ secretion by Th1-type CD4+ T 
and CD8+ T cells [(Akira, 2000) and reviewed by (Jankovic et al., 2001)] and thus further 
enhances the overall immune response. However, for complete T CD8+ cells activation, 
both the presence of Th1 or Th2-type CD4+ T cells and antigen presentation by DCs via 
MHC-I are needed (Albert et al., 1998, Ekkens et al., 2007, Schumacher et al., 2004). 
Effector CD8+ T cells can then produce a cytotoxic response towards the infected cell that 
ends with apoptosis. Also, NK cell activation in vitro relies on the contribution of T cells 
(Pahl et al., 2012), suggesting a reciprocal interaction between immune cells for their 
activation. On the other hand, upon interaction of Th2-type CD4+ T cells TCR with MHC-
II:antigen complex from B cells that have previously recognized and internalised an 
antigen via their BCR, Th2-type CD4+ T cell gets activated and produces cytokines that in 
turn initiate a process of BCR isotype switching on the B cell resulting in its maturation 
towards a plasma antibody-producing B cell [reviewed by (Jankovic et al., 2001)]. Also, B 
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cells as well as neutrophils, macrophages, and T cells express α-defensins [reviewed by 
(Selsted and Ouellette, 2005)], which have been postulated to bind to the adenoviral capsid 
in a RGD motif-dependent manner based on cryoEM and molecular dynamic flexible 
fitting (MDFF) simulations (Flatt et al., 2013) and block the disassembly of capsids (Smith 
and Nemerow, 2008, Smith et al., 2010, Snijder et al., 2013).  
Finally, non-immune cells can also activate immune responses upon adenovirus infections. 
For instance, epithelial cells and renal epithelium-derived cells (REC) can activate the 
immune system in a CAR or RGD-dependent manner, respectively (Tamanini et al., 2006, 
Liu et al., 2005), and induce the expression of CXCL10/IFN-inducible protein 10 (IP-10) 
via NF-κB signalling. Also, epithelial cells and mucosal tissue can release β-defensins 
(Pazgier et al., 2006). 
 
Figure 1-8. Innate and adaptive anti-adenoviral immune response. 1. Maturation of interleukin (IL)-1α 
upon binding of macrophage β3 integrins to adenovirus penton base RGD motif. 2. Maturation of IL-1β upon 
recognition of adenoviral dsDNA by macrophages. 3. Binding to adenoviral capsid via scavenger receptor A 
(SR-A)-II. 4. Macrophage maturation upon phagocytosis of immune complexes (ICs) via antibody constant 
fraction receptors (FcR). 5. Adenovirus neutralization via the IgM-mediated classical complement pathway. 
6. Thrombocytopenia resulting from the activation of the alternative complement pathway on adenoviral 
capsids. 7. Production of IL-2 by Th1-type CD4+ T cells upon antigen presentation by antigen presenting 
cells (APCs) via major histocompatibility complex class II (MHC-II), and IL-2-mediated activation of CD8+ 
T cells. 8. Activation of CD8+ T cells as a result of antigen presentation by dendritic cells (DC) via MHC-I. 
9. Secretion of interferon (IFN)-α and β by infected cells and expression of CXCL10 upon adenovirus 
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binding to CAR or αvβ3,5 integrins. 10. Maturation of DCs via phagocytosis of ICs. 11. B cell maturation and 
isotype switching following antigen presentation to Th2-type CD4+ T cells. 12. IFN-γ-mediated induction of 
MHC-II on APCs and antigen presentation to Th2-type CD4+ T cells. 13. Recognition of ICs via FcR on NK 
cells. 14. Secretion of IL-6 and 12 by plasmacytoid dendritic cell (pDC) upon adenoviral dsDNA recognition 
via Toll-like receptor (TLR)9. 15. Secretion of IFN-α upon macrophage or pDC activation leading to the 
induction of an anti-viral state on non-infected cells. 16. Secretion of tumor necrosis factor (TNF)-α upon 
macrophage activation resulting in TNF-related apoptosis-inducing ligand (TRAIL) 1 and 2-mediated 
apoptosis of infected cells. CAR; coxsackie virus and adenovirus receptor, C3b; complement component 3b, 
IFNR; interferon receptor; BCR; B cell receptor, TCR; T cell receptor. Figure adapted from (Lopez-Gordo et 
al., 2014b). 
1.2.4 Adenovirus evasion of host immune response 
Despite the high complexity and efficiency of the immune system to stop viral infections, 
adenoviruses evolved to attenuate the anti-viral innate immune response and even to 
benefit from it to boost infection events. The key players are adenoviral proteins E1, E3 
and E4 together with protein VI, protein VII and adenoviral RNAs (Table 1-2).  
In addition to controlling viral gene expression, the cell cycle and apoptosis, E1A protein 
also has a role in other processes such as immune suppression (Ferrari et al., 2008). Taking 
a focus on the latter, E1A blocks the response to IFN-α by inhibiting the binding of IFN-
stimulated gene factor 3 (ISGF3) transcriptional complex to the interferon-stimulated 
response element (ISRE), which is in turn required for ISGF3 expression (Gutch and 
Reich, 1991, Kalvakolanu et al., 1991). The mechanism by which E1A inhibits ISGF3 
binding to ISRE was found to involve E1A blocking binding of the signal transducer and 
activator of transcription (STAT)2 domain of ISGF3 to acetyltransferase p300 and/or 
CREB-binding protein (CBP) (Bhattacharya et al., 1996). Since p300 and CBP are 
transcription adaptors for ISGF3, the inhibition of their binding to ISGF3 results in the 
repression of STAT2 transactivation (Bhattacharya et al., 1996). Interestingly, the 
conserved region (CR)1 of E1A was found indispensable in this process (Gutch and Reich, 
1991, Kalvakolanu et al., 1991, Ackrill et al., 1991). E1A can also inhibit IFN-stimulated 
gene (ISG) expression by binding to the RNF20 complex, which catalyses histone 2B 
(H2B) monoubiquitination for activation of gene expression as a response to IFN (Fonseca 
et al., 2012). Moreover, E1A was reported to inhibit the induction of MHC-II by IFN-γ as 
well as the production of IFN-β in response to dsRNA (Ackrill et al., 1991). In order to 
block the presentation of peptides to the immunoproteasome, E1A interacts with the 
immunoproteasome subunit beta (PSMB)10/MECL1 and modulates STAT1 
phosphorylation, which results in the downregulation of the IFN-γ-induced PSMB10, 
PSMB9/LMP2 and PSMB8/LMP7 expression (Berhane et al., 2011b). Likewise, E1B is 
also involved in attenuating immune responses. E1B 19K blocks TNF-α-induced apoptosis 
by binding to the apoptosis inducers BAK and BAX and thus preventing them from 
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forming functional oligomers (Chiou et al., 1994, White et al., 1992, Sundararajan and 
White, 2001). E1B 55K represses transcription of ISGs allowing the formation of viral 
replication centres (Chahal et al., 2012, Chahal et al., 2013). E1B 55K also inhibits 
expression of genes that induce synthesis of IFN such as DDX58, MDA5, interferon 
regulatory factor (IRF)7 and MYD88 (Miller et al., 2009). Moreover, it was shown that 
E1B 55K interacts with E4 Orf6 and cellular proteins cullin (CUL)5, RBX1 and elongins B 
and C to assemble an SCF (Skp, CUL, F-box)-like E3-ubiquitin ligase complex (Harada et 
al., 2002, Querido et al., 2001) that triggers proteasome-mediated degradation of p53 
(Harada et al., 2002, Querido et al., 2001), MRE11 (Stracker et al., 2002), DNA ligase IV 
(Baker et al., 2007), Bloom helicase (BLM) (Orazio et al., 2011), integrin α3 (Dallaire et 
al., 2009) and TIP60 (Gupta et al., 2013). Via the degradation of DNA ligase IV, which is 
responsible for non-homologous end joining (NHEJ) (Grawunder et al., 1998), and the 
degradation of MRE11 that is a component of the MRE11-RAD50-NBS1 (MRN) complex 
involved in double strand break (DSB) repair and formation of viral genome concatemers, 
adenovirus prevents the induction of DNA damage signalling during viral replication and 
viral genome concatenation that would otherwise interfere with the packaging of viral 
DNA into virions (Weiden and Ginsberg, 1994). TIP60 is an acetyltransferase involved in 
histone acetylation to regulate gene expression, DNA damage response (DDR), apoptosis 
and cell cycle and it binds to the E1A promoter and acetylates histone 4 (H4) to suppress 
E1A gene expression (Sun et al., 2009, Gupta et al., 2013). Degradation of TIP60 by the 
E1B 55K:E4 Orf6 complex allows viral early gene transcription (Gupta et al., 2013). 
Furthermore, the E1B 55K:E4 Orf6 complex triggers proteasome-mediated degradation of 
SPOC1 (Schreiner et al., 2013), which is involved in chromatin condensation and in the 
DDR to DSBs and leads to the repression of viral gene expression at the level of 
transcription (Schreiner et al., 2013, Mund et al., 2012). Finally, E1B 55K also mediates 
proteasomal degradation of death domain-associated protein (DAXX) by acting as a 
CUL5-dependent E3-ubiquitin-ligase in a process that is independent of E4 Orf6 
(Schreiner et al., 2010). Since DAXX forms a complex with ATP-dependent helicase 
(ATRX) [reviewed by (Salomoni and Khelifi, 2006)] and represses viral replication by 
silencing viral gene expression (Tavalai et al., 2008), degradation of DAXX allows viral 
DNA replication. 
E3 proteins play a key role in the modulation of the anti-viral immune response [reviewed 
by (Lichtenstein et al., 2004)]. E3 19K has two main functions: inhibition of T cell 
recognition of infected cells and inhibition of NK cell activation. To prevent CD8+ T cell 
activation, E3 19K inhibits transport of MHC-I to the plasma membrane by retaining this 
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molecule in the endoplasmic reticulum (ER) (Burgert and Kvist, 1985, Burgert et al., 1987, 
Cox et al., 1991). Via E1A and p300-dependent (Routes et al., 2005) or E1A-independent 
mechanisms (Tomasec et al., 2007), adenovirus transduction results in the upregulation of 
proteins that can bind to the killer cell lectin like receptor C1 (KLRC1)/NKG2D, which is 
a receptor expressed on NK cells and T cells (Bauer et al., 1999). To counteract this 
process, E3 19K sequesters KLRC1 ligands such as the MHC-I chain-related protein A and 
B (MICA and MICB) in the ER and thus prevents their expression on the plasma 
membrane and subsequent recognition by KLRC1 (McSharry et al., 2008). Moreover, a 
complex formed by E3 10.4K/receptor internalization and degradation (RID)-α and E3 
14.5K/RID-β (Stewart et al., 1995, Gooding et al., 1991, Tollefson et al., 1991) induces 
internalization and degradation of death-domain-containing receptors of the TNFR 
superfamily such as Fas cell surface death receptor (FAS) (Burgert et al., 2002, Elsing and 
Burgert, 1998, Hilgendorf et al., 2003, Tollefson et al., 1998, McNees et al., 2002) or the 
epidermal growth factor receptor (EGFR) (Hilgendorf et al., 2003, Carlin et al., 1989, 
Tollefson et al., 1991). Also, E3 10.4K:E3 14.5K complex together with E3 6.7K inhibits 
ligand-induced apoptosis in infected cells by down-regulating TRAIL 1 and 2 (Burgert et 
al., 2002, Benedict et al., 2001, Hilgendorf et al., 2003). Furthermore, E3 14.7K supresses 
the cytolytic and pro-inflammatory functions of TNF-α (Burgert et al., 2002, Horton et al., 
1991). 
In similarity to E4 Orf6, E4 Orf3 can associate with E1B 55K and form a complex that 
prevents concatemer formation (Weiden and Ginsberg, 1994). Also, it was reported that 
both E4 Orf6 and 3 can bind to DNA-PK, which is involved in the DSB repair response 
[reviewed by (Jeggo et al., 1995)], and thus inhibit viral genome concatenation (Boyer et 
al., 1999). The E1B 55K:E4 Orf3 complex also mediates SUMOylation of cellular proteins 
(Sohn and Hearing, 2012). Moreover, E4 Orf3 has been associated with the disruption of 
PML spherical nuclear bodies, which localize adjacent to viral replication centres and 
respond to IFN [(Stadler et al., 1995, Grotzinger et al., 1996) and reviewed by (Regad and 
Chelbi-Alix, 2001)], and their reorganization into track-like structures (Doucas et al., 1996, 
Stracker et al., 2002, Carvalho et al., 1995). In particular, E4 Orf3 was reported to interact 
with PMLII, an isoform of PML protein (Hoppe et al., 2006, Leppard et al., 2009), and this 
interaction was necessary for PML-NB reorganization into track-like structures (Hoppe et 
al., 2006). Simultaneously, E4 Orf3 also interacts and relocates cellular proteins such as 
speckled protein 100kDa (Sp100) (Carvalho et al., 1995), TIF1α (Yondola and Hearing, 
2007), or the MRN complex (Stracker et al., 2002, Evans and Hearing, 2005, Carson et al., 
2009, Stracker et al., 2005) into these structures. Since Sp100 is an IFN-inducible protein 
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with a role in activation and repression of transcription (Grotzinger et al., 1996), re-
localization of Sp100 may prevent its anti-viral action. The role of TIF1α in an anti-viral 
immune response is unclear (Yondola and Hearing, 2007).  
Other viral proteins such as protein VI, protein VII and TP have also been associated with 
the evasion of anti-viral immune responses. Protein VI prevents DAXX-mediated 
repression of viral gene expression by interacting with and displacing DAXX from the 
PML-NB and translocating it into the cytoplasm (Schreiner et al., 2012). Binding of 
protein VII to adenovirus genomes prevents DNA sensing and activation of the MRN 
complex during viral DNA replication, which would otherwise lead to viral genome 
concatenation (Karen and Hearing, 2011), as well as activation of SPOC1 (Schreiner et al., 
2013). Also, a recent study reported that protein VII can associate with cellular histones 
and form complexes with nucleosomes following post-translational modification (Avgousti 
et al., 2016). In particular, this study showed that protein VII binds to high mobility group 
box 1 (HMGB1) and retains it in the chromatin. Since HMGB1 is secreted from immune 
cells (Lotze and Tracey, 2005, Kang et al., 2014), its retention in the chromatin prevents 
HMGB1-associated immune responses (Avgousti et al., 2016). Furthermore, adenoviral 
RNA VA-I blocks activation of the IFN-inducible EIF2AK2, which represses protein 
synthesis in response to dsRNA [(O'Malley et al., 1986) and reviewed by (Mathews and 
Shenk, 1991)], and is involved in selective translation of viral mRNAs over host cell 
protein (O'Malley et al., 1989). VA-I and II are also processed to 5’ and 3’ small viral 
RNAs (svaRNAs) (Andersson et al., 2005), and svaRNAs of VA-I can interact with 
argonaute 2 (AGO2), a member of the RNA-induced silencing complex (RISC), to inhibit 
gene expression (Aparicio et al., 2006). 
Interestingly, not only adenovirus can evade the anti-viral immune response but also use it 
to its benefit. For instance, IL-8 induces expression of adenoviral receptors αvβ3 integrin 
and human CAR (hCAR) to the apical side of polarized cells via the activation of Src-
family tyrosine kinases or the activation of AKT/S6K and inhibition of glycogen synthase 
kinase 3 (GSK3)β, respectively (Lutschg et al., 2011, Kotha et al., 2015). Also, IL-8 
promotes the adhesion of transmigrating neutrophils at the apical surface of polarized 
epithelium and that process has been associated with the enhancement of adenovirus 
transduction via a yet unidentified mechanism (Kotha et al., 2015). Importantly, the 
mechanisms mediating evasion of the anti-viral immune response differ between 
adenovirus serotypes. For instance, HAdV-4 and HAdV-12 E4 Orf3 do not relocate 
MRE11 to track-like structures and thus fail to prevent the accumulation of MRN complex 
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at viral replication centres and subsequent DNA concatenation (Stracker et al., 2005). Also, 
differences on the components forming the E1B 55K:E4 Orf6 complex from different 
serotypes have been reported. While HAdV-34/B2, HAdV-9/D and HAdV-4/E form E1B 
55K:E4 Orf6 complexes composed of CUL5 in similarity to HAdV-5, HAdV-12/A and 
HAdV-40/F associate with CUL2, and HAdV-16/B1 seems to bind both CUL2 and 5 
(Cheng et al., 2011). Moreover, not only they differ in structure but also in their function, 
since only HAdV-5, 12 and 40 E1B 55K:E4 Orf6 complexes are able to degrade p53, 
MRE11 or integrin α3. In contrast, HAdV-9, 16 and 34 E1B 55K:E4 Orf6 complexes are 
unable to degrade p53 or integrin α3, and HAdV-4 E1B 55K:E4 Orf6 complex is unable to 
degrade p53 or MRE11 (Cheng et al., 2011). These data suggest either the existence of 
complementary viral mechanisms to target degradation of cellular proteins or serotype-
specific cellular mechanisms mediating the anti-viral immune response. Also, while 
HAdV-5 E1B 55K:E4 Orf3 complex can mediate SUMOylation of NBS1 and MRE11, 
E1B 55K:E4 Orf3 complexes from other serotypes such as HAdV-3, 4, 9 and 12 are not 
able to do so (Sohn and Hearing, 2012). Furthermore, there are mechanisms of evasion of 
the anti-viral immune response that belong to unique serotypes, as is the case for HAdV-
19a E3 49K protein (Windheim et al., 2013). E3 49K is proteolytically cleaved and the 
large ectodomain sec49K is secreted from infected cells for binding to protein tyrosine 
phosphatase receptor type C (PTPRC)/CD45 on leukocytes, resulting in the inhibition of 
NK cell activation and cytotoxicity as well as T cell activation and cytokine production 
(Windheim et al., 2013). Such mechanisms have not yet been described for other 
serotypes. Serotype-specific differences in the mechanisms dictating evasion of the anti-
viral immune response have direct implications for adenoviral vector development, since 
they may lead researchers towards serotype-directed strategies to increase gene transfer 
efficiency (see section 1.3.5). 
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Table 1-2. Adenovirus evasion of host immune responses by adenoviral proteins. 
Adenoviral 
protein Function Mechanism 
E1A 
Blockade of IFN-α response. Inhibition of ISGF3 transcriptional complex binding to ISRE. Binding of E1A to RNF20 complex. 
Inhibition of MHC-II induction.  
Inhibition of dsRNA-mediated IFN-β production.  
Blockade of peptide presentation to the 
immunoproteasome. 
Interaction of E1A with PSMB10/MECL1 leading to downregulation 
of PSMB10, PSMB9/LMP2 and PSMB8/LMP7. 
E1B and E4 
Blockade of TNF-α-induced apoptosis. Binding of E1B 19K to BAK and BAX to prevent oligomer formation. 
Repression of ISGs transcription. E1B 55K-mediated.  
Relieve of silencing of viral gene expression to allow 
viral DNA replication. 
E1B 55K-mediated degradation of DAXX. 
 
Repression of IFN synthesis. E1B 55K-mediated inhibition of DDX58, MDA5, IRF7, MYD88 
expression. 
Prevention of E1A-triggered apoptosis. 
E1B 19K-mediated modulation of p53-mediated apoptosis. 
E1B 55K-mediated repression of transcriptional activation of p53-
inducible genes and SUMOylation of p53 for its displacement from 
PML-NBs. 
E1B 55K:E4 Orf6 complex-mediated degradation of p53. 
E4 Orf3-mediated epigenetic regulation of p53 target promoters to 
prevent p53 DNA-binding. 
Inhibition of the induction of DNA damage signalling 
during viral replication and of viral DNA concatenation. 
E1B 55K:E4 Orf6 complex-mediated degradation of DNA ligase IV 
and MRE11. 
Prevention of DDR and relieve of E1A gene expression 
repression to allow viral early gene transcription. E1B 55K:E4 Orf6 complex-mediated degradation of TIP60. 
Relieve of viral gene expression repression. E1B 55K:E4 Orf6 complex-mediated degradation of SPOC1. 
Prevention of DSB repair response and thus DNA E1B 55K:E4 Orf3 complex-mediated.  
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concatenation. E4 Orf3 and 6 bind to and inhibit DNA-PK. 
Inhibition of IFN response. E4 Orf3-mediated disruption of IFN-responsive PML-NB and re-localization of Sp100 and MRN complex. 
E3 
Inhibition of T cell activation. E3 19K-mediated inhibition of MHC-I transport to the plasma 
membrane. 
Prevention of T cell and NK cell killing of infected cells 
via KLRC1/NKG2D receptors. 
Sequestration of MICA and MICB in the ER to prevent their plasma 
membrane localizaiton. 
Prevention of CTL and FAS or EGF-R-mediated 
apoptosis. 
E3 10.4K:E3 14.5 K complex-mediated internalization and 
degradation of FAS and EGF-R. 
Inhibition of ligand-induced apoptosis. E3 10.4K:E3 14.5 K complex and E3 6.7K-mediated downregulation 
of TRAIL 1 and 2. 
Suppression of the cytolytic and pro-inflammatory 
functions of TNF-α. E3 14.7K-mediated. 
Protein VI Relieve of silencing of viral gene expression to allow 
viral DNA replication. 
Interaction of protein VI with DAXX and displacement from the 
PML-NB into the cytoplasm. 
Protein VII 
Prevention of DNA sensing and activation of the MRN 
complex during viral DNA replication and thus 
concatenation. 
Binding of protein VII to viral DNA. 
Relieve of viral gene expression repression. Binding of protein VII to SPOC1. 
Prevention of HMGB1-mediated immune responses. Binding of protein VII to HMGB1 for its retention in the chromatin 
and thus inhibition of its secretion from immune cells. 
Adenoviral RNA 
Inhibition of protein synthesis repression in response to 
dsRNA. Blockade of the activation of IFN-inducible EIF2AK2. 
Inhibition of gene expression for certain cellular proteins. Interaction of svaRNAs of VA-I with AGO2. 
ISGF3; IFN-stimulated gene factor 3, ISRE; interferon-stimulated response element, RNF20; ring finger protein 20, PSMB10; immunoproteasome subunit beta 10, TNF; tumor necrosis 
factor, ISG; IFN-stimulated gene, IRF; interferon regulatory factor, DDR; DNA damage response, DAXX; death domain-associated protein, DSB; double strand break, DNA-PK; 
DNA-dependent protein kinase, PML-NB; promyelocytic leukemia-nuclear bodies, Sp100; speckled protein 100kDa, MRN; MRE11-RAD50-NBS1, MHC; major histocompatibility 
complex, KLRC1; killer cell lectin like receptor C1, MICA and MICB; MHC-I chain-related protein A and B, ER; endoplasmic reticulum, FAS; Fas cell surface death receptor, EGF-R; 
epidermal growth factor receptor, TRAIL; TNF-related apoptosis-inducing ligand, HMGB1; high mobility group box 1, svaRNA; small viral RNA, AGO2; argonaute 2. 
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1.3 Adenoviruses as gene therapy vectors 
To date, the use of adenoviral vectors in clinical trials represents 21.7% of all vectors used 
(The Journal of Gene Medicine: Clinical Trial, 2016). Despite the percentage has 
decreased in the last few years due to the optimization of lentiviral and adeno-associated 
vectors and the emergence of novel vectors, overall, adenoviral vectors still hold the 
highest percentage of individual vectors being used. Adenoviral vectors are very attractive 
vectors for several reasons: they can infect dividing and quiescent cells, exhibit very low 
risk of insertional mutagenesis since they remain episomal, have a considerably large 
packaging capacity allowing the insertion of long transgenes, achieve high levels of 
transient transgene expression and long-term transgene expression, have a wide tropism, 
can be easily engineered, can be produced at high titers under Good Manufacturing 
Practice (GMP) and are stable, which allows their manipulation, storage and distribution to 
clinics [reviewed by (Lusky, 2005)]. 
1.3.1 Evolution of adenoviral vectors 
Adenoviruses can be genetically engineered to generate replication-deficient adenoviral 
vectors able to transduce host cells but unable to replicate inside of them, a key feature for 
gene transfer vehicles. Three generations of adenoviral vectors have been developed: first, 
second, and third generation (Figure 1-9). The first generation vectors have the E1 and/or 
E3 genes deleted from the adenoviral genome but retain the ITRs, the packaging signal and 
the remaining viral genes [reviewed by (Danthinne and Imperiale, 2000)]. This particular 
deletion allows the introduction of up to ~8 kb of foreign DNA, which can be expressed 
under the control of a heterologous promoter. Due to the lack of the E1 gene, which is 
involved in the initiation of viral DNA replication by activating the expression of E2 gene 
(Reichel et al., 1988), these vectors can transduce host cells but do not replicate. For this 
reason, they need to be produced in packaging cell lines such as HEK-293 cells (Graham et 
al., 1977) engineered to provide the E1 gene in trans and thus allow vector amplification. 
However, researchers soon observed that replication-competent adenoviruses were 
generated in these packaging cell lines since the adenoviral genome was able to undergo 
homologous recombination with the adenoviral DNA within the cell genome and regain 
the E1 gene (Lochmuller et al., 1994, Hehir et al., 1996). Thus, optimized packaging cell 
lines such as Per.C6® cells with only the exact sequence corresponding to the E1 gene 
with no flanking adenoviral sequences were generated, ensuring the replication-deficient 
nature and safety of adenoviral vectors (Fallaux et al., 1998). Moreover, since the E1 gene 
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also induces the expression of E3 and E4 genes, these vectors exhibit reduced expression 
of viral proteins and thus reduced stimulation of the anti-viral immune response to viral 
antigens in comparison to wild type adenovirus. However, the presence of E1-like proteins 
in host cells able to promote the expression of viral genes can result in antigen-related 
toxicity and allow replication of vectors (Reichel et al., 1987). Also, increasing knowledge 
on the adenovirus biology highlighted additional issues associated with the E1 gene 
deletion. Since E2 and E3 genes are involved in intrinsic defence mechanisms against the 
intracellular immune response, E1 gene deletion results in disarmed vectors that trigger the 
host cell immune response to transduced cells (Poller et al., 1996). These characteristics 
highly limit the duration of transgene expression and cause toxicity. With the aim to 
prevent viral DNA replication in host cells, reduce the anti-viral immune response to viral 
antigens and increase transgene capacity, second generation adenoviral vectors were 
generated by removing the E2 and/or E4 regions in addition to E1 and E3 [(Amalfitano et 
al., 1998) and reviewed by (Wang and Finer, 1996)]. Of note, new packaging cell lines 
expressing E1, viral DNA polymerase and pTP had to be engineered for successful vector 
production (Amalfitano and Chamberlain, 1997). This new generation of vectors increased 
the transgene capacity to ~14 kb, achieved longer transgene expression and decreased 
vector-associated inflammatory responses (Dedieu et al., 1997, Wang et al., 1997). Further 
genetic manipulation of adenoviral vectors gave rise to a further sophisticated version, the 
third generation helper-dependent (HD) or also called gutless vectors [reviewed by (Cots et 
al., 2013, Alba et al., 2005)]. These vectors are devoid of viral genes and only retain the 
ITRs and the packaging signal, thus they allow the insertion of particularly long transgenes 
of up to ~37 kb (Kochanek et al., 1996). Due to the lack of suitable packaging cell lines, 
HD vectors require a first or second generation helper adenoviral vector that complements 
the viral genes involved in viral DNA replication and packaging and capsid assembly in 
trans (Kochanek et al., 1996). Despite allowing long-term transgene expression since the 
lack of viral coding sequences highly diminished immunogenicity (Maione et al., 2001, 
Ehrhardt and Kay, 2002, Dudley et al., 2004, Kim et al., 2001), the presence of helper 
vector contaminants limits their potential. To reduce this contamination, several strategies 
based on the Cre-loxP or Flp-FRT systems were developed to prevent the generation of 
helper virions during the production process [reviewed by (Cots et al., 2013, Alba et al., 
2005, Segura et al., 2008)]. These strategies consist of the addition of locus of X-over P1 
(loxP) or flippase recognition target (FRT) sequences flanking the helper packaging signal. 
The production of these vectors in cell lines expressing the recombinase Cre or Flp, 
respectively, allows the excision of the helper packaging signal and thus prevents 
packaging of helper vector DNA. However, due to the reversible nature of these systems 
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and induced toxicity (Loonstra et al., 2001), other strategies such as the addition of 
attB/attP-φC31 sequences flanking the helper packaging signal are currently being 
developed (Alba et al., 2007, Alba et al., 2011). The presence of attB/attP-φC31 sequences 
retards helper vector DNA packaging, which reduces the amount of helper virions 
generated at collection time-points during the production process. Also, this strategy is 
often combined with the reversion of the orientation of the DNA packaging signal 
sequence of the helper vector to avoid homologous recombination events between helper 
and HD vector genomes (Palmer and Ng, 2003). However, since these vectors are 
composed of stuffer DNA in place of viral gene sequences to maintain optimum vector size 
and thus ensure genetic stability (Bett et al., 1993, Parks and Graham, 1997, Smith et al., 
2009, Shayakhmetov et al., 2004a), the activation of innate immune mechanisms upon 
recognition of dsDNA have been observed (Cerullo et al., 2007). The promotion of 
immune responses to HD capsids upon intravenous administration has also been reported 
(Brunetti-Pierri et al., 2004, Mane et al., 2006). 
 
Figure 1-9. Genome map of first, second and third generation adenoviral vectors. The location of 
deleted viral genes and maximal transgene capacity for each type of vector are indicated. Adenoviral genes 
have been mapped by superimposing an arbitrary scale of 100 map units. Internal terminal repeats (ITR) in 
green, adenoviral DNA packaging signal (Ψ) in purple and genetic engineering in grey. 
1.3.2 Adenoviral vectors in the clinic 
Adenoviral vectors have shown promise as oncolytic vectors, as vaccines and in gene 
therapy. Oncolytic adenoviral vectors are replication-competent adenoviral vectors that 
have particular mutations in their genome to selectively and exclusively replicate in cancer 
cells leading to the lysis and thus death of the transduced cancer cell and the production of 
new virions able to transduce and kill neighbouring cancer cells [reviewed by (Rosewell 
Shaw and Suzuki, 2016, Fukuhara et al., 2016)]. Also, oncolytic adenoviral vectors have 
been employed to deliver transgenes encoding immune modulatory molecules selectively 
to cancer cells and thus modulate the immune response towards cancer cells [reviewed by 
(Rosewell Shaw and Suzuki, 2016, Fukuhara et al., 2016)]. The rationale behind using 
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adenoviruses for vaccine vector development lies on their capability to induce a potent T 
and B cell response to antigens encoded as transgenes and thus provide immunity to a 
particular disease [(Yang et al., 2003) and reviewed by (Majhen et al., 2014)]. As for 
adenoviral oncolytic vectors, adenovirus-based vaccines have reached the clinical stage, 
showing promising results against bacteria, viruses and protozoans in clinical trials (The 
Journal of Gene Medicine: Clinical Trial, 2016, Clinical Trials, 2016). Since these 
approaches differ from the focus of the studies presented in this thesis, oncolytic 
adenoviral vectors and adenovirus-based vaccines will not be further discussed. Regarding 
the use of adenoviral vectors in gene therapy, increasing knowledge of adenovirus biology 
has allowed remarkable progress in their optimization as vectors, which has directly 
translated into a growing interest in adenovirus-based gene therapy. To date, there have 
been over 500 clinical trials based on adenoviral vectors for the treatment of 
cardiovascular, ocular, neurologic or inflammatory disease, as well as cancer with some of 
them reaching phase II and III (The Journal of Gene Medicine: Clinical Trial, 2016). As an 
example, a phase III clinical trial is being conducted in the USA using an adenovirus-based 
approach to deliver a transgene encoding VEGF via a perivascular collagen collar device 
for stenosis prevention in end-stage renal disease (ID#1 US-0854). Another ongoing 
clinical trial is employing an adenoviral vector to deliver a p21 gene via intraocular 
administration to the subconjunctival space prior to trabeculectomy for the treatment of 
glaucoma, currently on phase I (ID# US-0589). A clinical trial in phase I using HAdV-5 
encoding fibroblast growth factor (FGF) for the treatment of peripheral artery occlusive 
disease Fontaine stage III is currently taking place in the UK (ID# UK-0026). Importantly, 
the world’s first gene therapy product approved by a government agency for clinical use 
was an adenoviral vector encoding p53 for the treatment of head and neck squamous cell 
carcinoma (Gendicine), which was licensed in China in October 2003 [reviewed by (Peng, 
2005, Chen et al., 2014)]. The product is also currently been used in a phase II multi-center 
clinical trial for patients with recurrent head and neck squamous cell carcinoma in the USA 
(ID# US-0226), and other adenoviral vectors based on the p53 transgene as a therapeutic 
agent have also been developed and used in clinical trials for hepatocellular carcinoma 
(ID# US-0189), adenocarcinoma of the prostate (ID# US-0192), breast cancer (ID# US-
0216) or metastatic bladder cancer (ID# US-0219) among others (The Journal of Gene 
Medicine: Clinical Trial, 2016).  
                                                 
1Gene therapy clinical Trial identification number as cataloged in The Journal of Gene Medicine: Clinical 
Trial, 2016. 
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1.3.3 Limitations of adenoviral vectors 
Despite the promising results shown, however, there are still pitfalls that need to be further 
addressed to develop safe and efficient adenoviral gene transfer vectors. The main limiting 
factors for the use of HAdV-5 in gene therapy are the liver and spleen-associated toxicity 
induced following intravascular administration of vectors that can lead to systemic 
inflammatory response syndrome and multiorgan failure (see section 1.3.4), the existence 
of pre-existing immunity that neutralizes virions preventing them from reaching the target 
tissue, and the induction of immune responses elicited by transduced cells that leads to 
their elimination and thus the termination of transgene expression (see section 1.2.3). For 
the treatment of certain diseases a finite expression of the therapeutic transgene can be 
sufficient such as in the case of suicide gene therapy for the treatment of prostate cancer 
(Kubo et al., 2015) or even advantageous such as the induction of vasculogenesis for the 
treatment of coronary artery disease (Grines et al., 2003). However, for other diseases such 
as Duchenne muscular dystrophy (DMD) (Kawano et al., 2008) or CF (Potash et al., 2013), 
where replacement gene therapy is needed to restore protein deficiencies, persistent 
expression of transgene is an essential requisite. Also, certain diseases require re-
administration of the gene therapy vector. Thus, even when pre-existing immunity is 
absent when the vector is administered for the first time, new neutralizing antibodies are 
generated against virions following the first administration, precluding future re-
administration of vectors (Ye et al., 2000, Haegel-Kronenberger et al., 2004). In order to 
bypass neutralization of virions by pre-existing immunity, alternative strategies such as ex 
vivo approaches have been developed. For instance, one study reported the success of an 
adenoviral vector-based gene therapy ex vivo approach to deliver the tissue inhibitor of 
metalloproteinases-3 (TIMP-3) to retard intimal thickening in autologous porcine 
arteriovenous interposition grafts in the long-term (3 months) (George et al., 2011). This 
study highlights the translational potential for ex vivo gene therapy. Unfortunately, ex vivo 
approaches are limited to certain pathologies and are not suitable for most diseases. Thus, 
alternative strategies to bypass pre-existing immunity and evade the anti-viral immune 
response are being under study (see section 1.3.5). Finally, one study reported that the 
adenoviral genome is not exempt from recombination events with the host cell genome and 
that this can lead to vector genome integration in vitro and in vivo (Stephen et al., 2010, 
Stephen et al., 2008). Despite such integration events are very rare [homologous 
recombination: ~2x10-5 (in vitro) and ~4x10-7 (in vivo) per vector molecule per cell, 
heterologous recombination: ~3x10-3 (in vitro) and ~7x10-5 (in vivo) per vector molecule 
    Chapter 1 | Introduction 
43 
 
per cell (Stephen et al., 2010, Stephen et al., 2008)], this represents a safety risk and thus it 
is a concern that should be further addressed.   
1.3.4 Liver tropism and detargeting strategies for HAdV-5-based 
vectors 
1.3.4.1 Receptor-mediated HAdV-5 gene transfer 
The treatment of many diseases such as cardiovascular disease or metastatic cancer 
requires administration of the adenoviral vector via the vasculature or with potential 
exposure to the bloodstream. However, upon intravascular delivery, HAdV-5-based 
vectors exhibit high hepatic tropism, which can result in toxicity and the activation of 
immune responses (Lozier et al., 2002, Raper et al., 2002, Atencio et al., 2006, Morral et 
al., 2002). Importantly, these side effects can even lead to fatal consequences, as 
exemplified by a participant in a phase I clinical trial for ornithine transcarbamylase (OTC) 
deficiency with a HAdV-5-based approach, who suffered from severe systemic 
inflammatory response syndrome and died 98 h following intravascular vector 
administration (Raper et al., 2003). The anatomical architecture of liver sinusoids results in 
the sequestration of adenoviral particles in the space of Disse (Di Paolo et al., 2009b, 
Shayakhmetov et al., 2004b), the area beneath and between sinusoidal endothelial cells and 
the hepatocyte surface. Moreover, adenoviral particles are trapped by liver residential 
macrophages (KC) (Alemany et al., 2000, Di Paolo et al., 2009b, Tao et al., 2001). KCs 
can be depleted by the use of clodronate liposomes, which are ingested by KC causing 
their death (van Rooijen and van Kesteren-Hendrikx, 2003). However, even in the absence 
of KCs, intravascular administration of high doses of HAdV-5 still results in efficient liver 
transduction (Wolff et al., 1997, Di Paolo et al., 2009b), indicating that adenovirus 
interacts with cellular receptors to mediate hepatocyte cell transduction.  
In an attempt to identify the receptors that dictate HAdV-5 liver tropism, the receptors 
involved in the classical in vitro transduction pathway (CAR and αvβ3,5 integrins) were 
assessed. Mutations in the fiber or penton base to ablate HAdV-5 interactions with CAR or 
αvβ3,5 integrins, respectively, (Leissner et al., 2001, Alemany and Curiel, 2001, Smith et 
al., 2002, Smith et al., 2003b, Martin et al., 2003, Einfeld et al., 2001, Mizuguchi et al., 
2002, Smith et al., 2003a, Bradshaw et al., 2012) (Figure 1-10) or the combination of both 
ablating mutations (Koizumi et al., 2003, Martin et al., 2003, Smith et al., 2003b) 
successfully impaired adenoviral transduction in vitro but failed to significantly reduce in 
vivo liver transduction. However, there is some controversy with other studies showing 
    Chapter 1 | Introduction 
44 
 
700-fold reduced mouse liver transduction (Einfeld et al., 2001) or 509-fold reduced rat 
liver transduction (Nicol et al., 2004) with HAdV-5 vectors ablated for both CAR and 
αvβ3,5 integrin-binding. Other studies investigated the role of heparan sulphate (HS) in liver 
transduction and reported that HAdV-5 binding to heparan sulphate glycosaminoglycans 
(HS-GAG) is sufficient to mediate liver transduction (Dechecchi et al., 2001, Smith et al., 
2003a). Mutant adenovirus lacking binding to HS (91KKTK942 mutated to 91GAGA94 in 
the fiber shaft) exhibited decreased liver transduction in non-human primates (Smith et al., 
2003a). Another study assessing the 91GAGA94 mutation only resulted in a moderate 
decrease in liver transduction in rats (Nicol et al., 2004). Other mutations were assessed 
such as the replacement of the HAdV-5 fiber shaft (containing the 91KKTK94 motif) with 
the fiber shaft from HAdV-31 or from HAdV-41, which do not contain this motif (Di 
Paolo et al., 2007). However, no liver de-targeting was observed in this study. The 
combination of 91GAGA94 mutation with CAR-binding ablating mutations achieved 
1000-fold decreased liver transduction in mice (Smith et al., 2003b). Ablation of CAR and 
αvβ3,5 integrin-binding together with the replacement of HAdV-5 fiber shaft with the non-
KKTK-containing fiber shaft from HAdV-25 resulted in a >30,000-fold decrease in mouse 
liver transduction (Koizumi et al., 2003). Other studies report that 91GATK94 mutation 
alone or in combination with CAR-ablating point mutation Y477A achieved the same 
extent of liver de-targeting in mice (Bayo-Puxan et al., 2006). However, in the later study, 
they suggest that fiber shaft mutations may alter the fiber structure conferring rigidity and 
thus hampering simultaneous binding of HAdV-5 to CAR and αvβ3,5 integrins. Further 
work reported that the 91GAGA94 mutation does not negatively affect adenovirus binding 
to host cells but instead it interferes with virus trafficking at a post-attachment stage 
blocking cell transduction (Kritz et al., 2007). Studies based on mutating HAdV-5 capsid 
proteins to impair HAdV-5:HS interaction have not succeeded in de-targeting HAdV-5 
from the liver. However, HS has been associated with HAdV-5 transduction in several 
studies that used heparin lyases I, II and III to remove HS from cultured cells (Dechecchi 
et al., 2000, Dechecchi et al., 2001) or HSpositive and HSnegative cell lines (Dechecchi et al., 
2001). 
                                                 
2Numbers refer to amino acid residue position in the protein. 
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Figure 1-10. HAdV-2 fiber and HAdV-5 penton base receptor-binding sites. Ribbon diagram of fiber 
knob and shaft domains (4 last repeats) (A) or penton base (light pink) (B). Contact sites between fiber knob 
and coxsackie and adenovirus receptor (CAR) (Roelvink et al., 1999) or penton base and αvβ3,5 integrins 
(Bradshaw et al., 2012, Smith et al., 2003b) that have been targeted for mutation are indicated. S; serine, P; 
proline; Y; tyrosine, T; threonine, A; alanine. Figure in (A) adapted from (Hall et al., 2010) and figure in (B) 
adapted from (Nemerow et al., 2012). 
1.3.4.2 Interactions of HAdV-5 with blood components: erythrocytes, 
platelets and blood proteins 
Following intravascular administration, HAdV-5-based vectors not only interact with 
components of the immune response (see section 1.2.3), but also with other cells and 
proteins in the bloodstream that can affect vector persistence in blood and biodistribution 
and toxicity profiles. 
Human but not mouse or rhesus macaque erythrocytes were reported to bind HAdV-5 
virions via interactions of CAR with the fiber knob domain (Seiradake et al., 2009) (Figure 
1-11). Also, human but not mouse erythrocytes can interact with HAdV-5 virions via CR1 
in the presence of C1q and antibodies and affect the persistence of virions in blood 
(Carlisle et al., 2009) (Figure 1-11). Incorporation of CAR-binding ablating mutations into 
HAdV-5 vectors successfully abolished agglutination of virions with human and rat 
erythrocytes (Nicol et al., 2004) but failed to prevent agglutination with erythrocytes in 
human plasma (Carlisle et al., 2009). Interestingly, it was recently reported that binding of 
HAdV-5 to erythrocytes is a reversible process and does not prevent extravasation and 
organ transduction after intravascular administration (Rojas et al., 2016). HAdV-5 has been 
consistently reported to cause transient thrombocytopenia between 5 and 24 h following 
intravenous administration of vectors that depends on vector dose (Lozier et al., 2002, 
Cichon et al., 1999, Varnavski et al., 2005, Othman et al., 2007). Thrombocytopenia was 
shown to take place as a consequence of HAdV-5 virions binding to and activating 
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platelets through interactions with CAR (Othman et al., 2007) (Figure 1-11). Activated 
platelets subsequently express cell adhesion molecule P-selectin, which binds its ligand P-
selectin glycoprotein ligand-1 (PSGL-1) on leukocytes to form platelet-leukocyte 
aggregates. Also, adenoviral vectors induce release of ultra-large molecular weight Von 
Willebrand factor (VWF), which can bind to platelets (Bernardo et al., 2005), from 
endothelial cells in vivo and expression of VCAM-1 in vitro (Othman et al., 2007), which 
potentially contributes to platelet-leukocyte aggregates rolling and transendothelial 
migration [reviewed by (Carlos and Harlan, 1994)]. As a consequence of these events, 
platelet-leukocyte aggregates are cleared from the circulation by scavenger macrophages in 
the liver (Stone et al., 2007, Bondanza et al., 2000). Also, adenovirus-induced 
thrombocytopenia was associated with factor B and C3 of the alternative complement 
pathway (Appledorn et al., 2008a, Kiang et al., 2006). 
In 2005 Shayakhmetov et al. used ldlr-/- mice together with the LRP and HSPG-binder 
lactoferrin, heparinase I and mutant HAdV-5 vectors with impaired binding to CAR, to 
demonstrate that LRP and HSPGs could serve as HAdV-5 receptors both in vitro and in 
vivo (Shayakhmetov et al., 2005b). Moreover, C4BP and coagulation factor IX (FIX) were 
identified as fiber knob domain-interacting blood proteins and were shown to confer CAR-
independent HAdV-5 transduction of HSPG and LRP-expressing cell lines and primary 
human hepatocytes. Thus, they proposed a novel pathway for HAdV-5 cell entry consisting 
of C4BP and FIX bridging HAdV-5 to cellular receptors such as LRP and HSPGs (Figure 
1-11). Interestingly, CAR-binding-ablated HAdV-5 exhibited similar liver transduction 
levels in FIX-/- mice than those of wild type HAdV-5, suggesting that C4BP and FIX were 
not the only blood proteins contributing to liver tropism (Shayakhmetov et al., 2005b). 
Further studies identified other vitamin K-dependent coagulation factors such as 
coagulation factor VII (FVII), coagulation factor X (FX) and protein C (PC) as able to 
enhance hepatocyte transduction in vitro (Parker et al., 2006) (Figure 1-11). Importantly, 
these coagulation factors share a common protein structure that comprises a non-catalytic 
glutamic acid (GLA) domain, two epidermal growth factor (EGF)-like domains and a 
serine protease (SP) domain: GLA-EGF1-EGF2-SP [reviewed by (Furie and Furie, 1988, 
Patthy, 1985)] (Figure 1-12A). Conversely, HAdV-5 transduction was not enhanced by 
vitamin K-dependent coagulation factors that do not have this structure such as coagulation 
factor XI (FXI) and coagulation factor XII (FXII) or by prothrombin/FII, which has 
“kringle” (KR) domains in place of the EGF-like domains [reviewed by (Furie and Furie, 
1988, Patthy, 1985)]. The same study also reported that treating mice with warfarin, which 
is an anticoagulant that inhibits the γ-carboxylation of GLA residues of vitamin K-
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dependent zymogens, prior to vector administration led to a substantially reduced liver 
transduction. Thus, they reported that the ability of vitamin K-dependent coagulation 
factors to enhance transduction was related to their particular protein domain structure 
(Parker et al., 2006). Further studies using surface plasmon resonance (SPR) confirmed 
interactions of HAdV-5 virions with FVII, FIX, FX and PC (Kalyuzhniy et al., 2008).  
 
Figure 1-11. HAdV-5 interactions with blood proteins. 1. FX-mediated transduction through heparan 
sulphate proteoglycans (HSPGs). 2. HAdV-5 interactions with erythrocytes via complement receptor (CR)1 
and coxsackie and adenovirus receptor (CAR). 3. HAdV-5:FVII complexes. 4. HAdV-5:complement-4 
binding protein (C4BP) complexes and proposed transduction via HSPGs or low-density lipoprotein 
receptor-related protein (LRP). 5. HAdV-5 interactions with platelets. 6. HAdV-5:FIXa complex and 
proposed transduction via HSPGs or LRP. FX; coagulation factor X, FVII; coagulation factor VII, FIXa; 
activated coagulation factor IX. Figure adapted from (Lopez-Gordo et al., 2014a). 
Later reports showed that HAdV-5 could not only make use of FX to facilitate liver 
transduction upon exposure to the bloodstream, but also for transduction of other tissues 
such as the adrenal glands, where there is absent expression of CAR (Tran et al., 2013). 
Similarly, FIX and FX mediated binding of HAdV-5 virions to human epithelial cells via 
HS (Jonsson et al., 2009). Importantly, other adenovirus serotypes can also exploit 
coagulation factors for host cell transduction. For instance, HAdV-31 can use FIX but not 
FX to transduce epithelial cells via HS-GAG (Jonsson et al., 2009), HAdV-18 transduction 
of epithelial cells from the airways or intestine is enhanced by FIX (Lenman et al., 2011) 
    Chapter 1 | Introduction 
48 
 
and FX can enhance HAdV-35 binding in SPR analysis and transduction in vivo in the 
absence of its primary receptor CD46 (Greig et al., 2009). However, these properties are 
not necessarily shared between serotypes belonging to the same adenovirus species. For 
instance, while FIX can enhance HAdV-18 and 31 transduction, it has no effect on HAdV-
12, another member of species A adenovirus (Lenman et al., 2011). Furthermore, binding 
affinities between adenovirus and coagulation factors or between adenovirus:coagulation 
factor complexes and host cell receptors can also differ among serotypes, as observed for 
HAdV-31 binding to FIX with a higher affinity than that of HAdV-5, and for HAdV-
31:FIX complex binding to less sulphated and more N-acetylated HS domains than the 
HAdV-5:FIX complex (Lenman et al., 2011). Finally, it was demonstrated that activation 
of FIX to FIXa exposes a binding site for LRP that allows FIXa:LRP binding in a heparin 
and calcium-dependent manner (Neels et al., 2000). 
1.3.4.2.1 FX-mediated HAdV-5 cell entry 
Interestingly, only recombinant human FX (hFX) fully rescued liver transduction of mice 
administered warfarin, highlighting a key role for FX in HAdV-5 hepatic tropism (Parker 
et al., 2006). Parker et al. reported that FX binds to HAdV-5 in a calcium-dependent 
manner since addition of EDTA was able to dissociate HAdV-5:FX interactions in SPR 
analysis (Parker et al., 2006). This finding also accounts for the fact that the γ-
carboxylation of GLA residues of vitamin K-dependent zymogens, which is inhibited by 
warfarin, is necessary for Ca2+ binding (Venkateswarlu et al., 2002). The affinity constant 
of HAdV-5:FX binding was determined to be 1.9x105 viral particles (vp)/ml (Parker et al., 
2006). Later studies reported an association rate constant (ka) of 1.2x106 M-1 s-1 and a 
dissociation rate constant (kd) of 2.23x10-3 s-1, with an overall equilibrium dissociation 
constant (KD) of 1.83x10-9 M (Waddington et al., 2008). Another group reported similar 
values: ka of 3.37x105 M-1 s-1, kd of 7.71x10-5 s-1 and KD of 228.7x10-9 M (Kalyuzhniy et 
al., 2008). 
To identify the adenovirus proteins involved in HAdV-5:FX interactions, mutant HAdV-5 
were generated. The use of fiberless HAdV-5 demonstrated that HAdV-5:FX interaction 
was not dependent on the fiber (Waddington et al., 2008). Three-dimensional 
reconstructions calculated from cryoelectron micrographs of HAdV-5:FX complexes 
revealed that one FX molecule binds to one hexon trimer at the central depression at the 
top of each trimer (Waddington et al., 2008) (Figure 1-12B-D). These data are in 
agreement with data obtained from affinity chromatography assays of HAdV-5:FX 
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complexes (Kalyuzhniy et al., 2008). Furthermore, studies on a range of 22 adenovirus 
serotypes with high, weak or no FX-binding indicated that the differences in HAdV-5 
binding affinity to FX depends on the hexon HVRs (Waddington et al., 2008) (Figure 
1-12E). Further studies suggested that HVR 5 was involved in hexon HAdV-5:FX 
interactions (Kalyuzhniy et al., 2008) and that disruption of HVR 5 by inserting a biotin 
acceptor peptide (BAP) or glycine-alanine residues could reduce hepatocyte transduction 
and liver damage or binding to FX and liver transduction, respectively (Shashkova et al., 
2009, Vigant et al., 2008). However, alignment of hexon amino acid sequences from FX-
binding and non-FX-binding adenoviruses revealed no correlation between the capacity to 
bind to FX and the presence of conserved amino acids within HVR 5 (Kalyuzhniy et al., 
2008). Instead, the amino acid residues TDT in HAdV-3 and 21 HVR 3 and amino acids 
423TET425 in HAdV-5 HVR 7 and TDT in HAdV-2, 4, 16 and 41 HVR 7 were associated 
with hexon binding to FX (Kalyuzhniy et al., 2008). In agreement, another study defined 
423TET425 in HVR 7 as the amino acid motif involved in hexon HAdV-5:FX interaction 
(Doronin et al., 2012) (Figure 1-12F). Further phylogenetic analysis together with high-
resolution models of HAdV-5:FX complexes identified the critical amino acid E451 in the 
HVR 7 of FX-binding adenoviruses, which was replaced by Q451 in non-FX-binders 
(Alba et al., 2009). Generation of a mutant HAdV-5 (hereafter referred to as AdT*) 
containing the mutations I421G, T423N, E424S, L426Y, E451Q in HVR 7 and T270P and 
E271G in HVR 5 was shown to reduce FX-binding to negligible levels (Alba et al., 2009). 
Importantly, AdT* exhibited extremely low liver transduction and induced lower levels of 
inflammatory cytokines and chemokines compared to those of HAdV-5 (Alba et al., 2010, 
Bradshaw et al., 2012, Alba et al., 2012, Alba et al., 2009). Successful abrogation of 
binding of HAdV-5 to FX was also achieved by introducing the point mutation T425A in 
HAdV-5 HVR 7 (Doronin et al., 2012).  
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Figure 1-12. HAdV-5:FX complexes and HAdV-5 amino acid residues involved in HAdV-5:FX 
interaction. A) Ribbon diagram of FX structure. Ca2+ is represented as green balls. B-C) HAdV-5:FX 
interaction. Hexon protein shown in magenta and FX in blue. D) HAdV-5 hexon:FX complex. Hexon protein 
shown in blue and FX in purple. E) HAdV-5 hexon hypervariable regions (HVRs). HVR 1 shown in red, 
HVR 2 in orange, HVR 3 in blue, HVR 4 in yellow, HVR 5 in pink, HVR 6 in green and HVR 7 in magenta. 
F) Top side view of HAdV-5 hexon. Amino acid residues that interact with FX are indicated in each of the 
three models calculated (Alba et al., 2009). Amino acid residues coloured correspond to those targeted for 
mutation in a mutant FX-binding deficient HAdV-5 (AdT*) (Alba et al., 2009). EGF; epidermal growth 
factor receptor, GLA; glutamic acid. Figure in (A) adapted from (Waddington et al., 2008), Figure in (B-C) 
reproduced with permission from (Lowenstein, 2008). Figure in (D) reproduced with permission from (Alba 
et al., 2009). Figures in (E) reproduced with permission from (Rux and Burnett, 2000). Figure in (F) 
reproduced with permission from (Alba et al., 2009). 
Regarding the domain from FX involved in HAdV-5:FX interaction, the use of GLA 
domainless recombinant hFX, hFXa lacking the GLA-EGF1 domains, and the FX GLA-
binder and FX inhibitor X-bp, which belongs to the C-type lectin superfamily (Atoda et al., 
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1998) (Figure 1-13F), showed that the FX GLA domain is required for FX binding to 
HAdV-5 hexon (Waddington et al., 2008, Kalyuzhniy et al., 2008, Corjon et al., 2011). 
MDFF simulations defined amino acid K10 in the GLA domain as the one responsible for 
interactions with the amino acid motif 423TET425 in HAdV-5 HVR 7 (Doronin et al., 
2012) (Figure 1-13A-D). The domain from FX involved in binding to HSPG was also 
investigated. The anticoagulants NAPc2 from the hematophagous nematode Ancylostoma 
caninum and Ixolaris from the tick salivary gland, which inhibit FX by binding to the 
heparin-binding exosite of FX (exosite II) with high affinity (Murakami et al., 2007, 
Monteiro et al., 2005), blocked FX-dependent HAdV-5 transduction in vitro and in vivo 
(Waddington et al., 2008). These data indicate that HAdV-5:FX complexes bind to HSPG 
through the FX exosite II, which is located in the SP domain (Rezaie, 2000). Other studies 
in vitro and ex vivo using FX containing mutations in the conserved amino acid residues 
within the FX exosite II [R424, K420, K351, R347, K276, R273, R306 of the mature 
peptide (Waddington et al., 2008)] confirmed that the FX SP domain interacts with HSPG 
(Duffy et al., 2011) (Figure 1-13E). HSPGs are glycoproteins composed of a core protein 
(proteoglycan) to which one or more HS-GAG side chains are covalently linked. HS-
GAGs are composed of units of N-acetylated or N-sulphated N-acetylglucosamine (GlcN) 
and D-glucuronic acid (GlcA) or the O-sulphated and epimerized GlcA that results in L-
iduronic acid (IdoA) (Hacker et al., 2005, Esko and Lindahl, 2001). Liver HS are 
characterized by having high levels of N and O-linked sulphate groups (Vongchan et al., 
2005) and in particular hepatocytes contain trisulphated disaccharides (Lawrence et al., 
2008). Competition experiments with highly sulphated heparins or HS in vitro and ex vivo, 
as well as experiments on cells lacking 2-O-sulphate groups, or cells treated with the 
chemical HSPG sulphation inhibitor sodium chlorate, demonstrated the role of N and O-
sulphation from HS side chains of HSPG in binding to FX (Bradshaw et al., 2010). In 
summary, coagulation FX mediates HAdV-5 liver transduction by binding to HAdV-5 
hexon HVRs via the FX GLA domain while simultaneously interacting with N and O-
linked sulphate groups of cellular HSPG through the FX SP domain.  
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Figure 1-13. FX interaction with HAdV-5 hexon and HSPG. A-D) Cryo-Electron Microscopy structure 
and molecular dynamic flexible fitting simulation of HAdV-5:FX complex. Amino acid residue K10 in FX 
(red ribbon) GLA domain interacts with the amino acids motif 423TET425 in HAdV-5 hexon hypervariable 
region (HVR) 7. Cryo-Electron Microscopy density for FX is shown in light pink in (A-B). 423TET425 side 
chains are shown in space-filling representation and coloured by element in (C-D). Ca2+ is represented as 
green balls in (C-D). E) Ribbon diagram of the FX serine protease (SP) and epidermal growth factor-like 
(EGF)2 domains. SP shown in blue and EGF2 in red. Amino acid residues that interact with heparan sulphate 
proteoglycans (HSPG) are indicated and shown in green. F) Ribbon diagram of the FX inhibitor X-bp and its 
binding to FX GLA domain. Subunits A and B of X-bp are shown and indicated. Figures in (A-D) 
reproduced with permission from (Doronin et al., 2012). Figure in (E) adapted from (Duffy et al., 2011). 
Figue in (F) reproduced with permission from (Mizuno et al., 2001). Copyright (2001) National Academy of 
Sciences, U.S.A. 
For the generation of safe HAdV-5-based vectors, in addition to de-targeting HAdV-5 
vectors from the liver (transductional de-targeting), it is essential to reduce off-target 
effects that can arise from transgene expression in off-target tissues or residual virion 
accumulation in the liver. With this aim, transcriptional de-targeting, which consists in 
decreasing transgene expression in a tissue-specific manner, can be achieved by using 
silencers of transcriptionally regulated tissue-specific markers (Kanai et al., 1996) or via 
tissue-specific miRNA-mediated post-transcriptional suppression (Bennett et al., 2012, 
Suzuki et al., 2008, Card et al., 2012). Thus, by the combination of both transductional and 
transcriptional de-targeting strategies, the availability of the adenoviral vector for the target 
tissue can be increased while reducing toxicity and off-target effects. 
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1.3.4.2.2 Implications for HAdV-5:FX interaction in immunity 
A role for FX in protecting HAdV-5 capsids against attack by the immune system in mice 
in vivo or after incubation of virions with mouse or human serum in vitro has been 
described (Xu et al., 2013, Ma et al., 2015, Duffy et al., 2016) (Figure 1-14). In the absence 
of FX, natural IgM antibodies recognize epitopes on the HAdV-5 capsid and activate the 
classical complement pathway, which via the opsonisation of HAdV-5 capsid by C3b 
complement protein leads to blockade of virion binding to host cells in vitro and thus cell 
transduction (Xu et al., 2013). In this process, complement protein C1q and complement 
component 4 (C4) were also identified as mediators of in vitro adenovirus neutralization 
(Xu et al., 2013). In contrast, IgM antibodies binding to virions is blocked in the presence 
of FX (Duffy et al., 2016) as well as covalent association of C3b with the adenoviral capsid 
(Xu et al., 2013), resulting in inhibition of in vitro adenovirus neutralization. Importantly, 
the HAdV-5 hexon HVRs, which are the capsid region targeted for FX-binding (Alba et 
al., 2009), were identified as the neutralization targeted epitopes (Ma et al., 2015). 
Interestingly, FX-binding deficient AdT* was able to bind to human IgM (hIgM) 
antibodies (Duffy et al., 2016), indicating that hIgM might not only recognize FX binding 
sites but also other hexon HVRs and thus suggesting that the mechanism by which FX 
blocks binding of hIgM antibodies to virions might be based on steric blocking rather than 
competition for binding sites. In contrast, FX did not block human IgG (hIgG) antibodies 
binding to HAdV-5 viral capsids (Duffy et al., 2016). Moreover, lack of binding to FX 
does not necessarily correlate with the presence of adenovirus neutralization as seen with 
the non-FX-binders HAdV-26 and 48, which despite not binding to FX are protected from 
in vitro neutralization in the presence of mouse serum (Ma et al., 2015). Furthermore, the 
ability of virions to bind to FX does not correlate with the presence of adenovirus 
neutralization in the absence of such binding. This is the case for the FX-binders HAdV-35 
and HAdV-50, which are not neutralized in vitro in the presence of mouse serum and 
absence of FX-binding (Ma et al., 2015). The effects of HAdV-5 neutralization were also 
observed in vivo. Transduction of liver, lung, kidney, heart and spleen was negligible with 
FX-binding deficient HAdV-5 mutants (Xu et al., 2013). Moreover, while IgM antibodies, 
C1q and C4 were found responsible for the suppression of liver transduction, HAdV-5 
neutralization in lung also required C3 (Xu et al., 2013). The exact mechanism by which 
FX protects HAdV-5 against in vitro and in vivo neutralization and the implications that 
binding to FX may have on different adenovirus serotypes have not been fully described 
yet. Also, whether FX also directly blocks interactions of C3b with viral capsids has not 
been investigated.  
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Figure 1-14. HAdV-5 interactions with the classical complement pathway in vivo. A) FX protects 
HAdV-5 from neutralization by the IgM antibody-mediated classical complement pathway and mediates 
transduction of hepatocytes. B) In the absence of FX or absence of HAdV-5 binding to FX, HAdV-5 is 
neutralized by natural IgM antibodies, which activate the classical complement pathway. Opsonization of 
HAdV-5 virions by C3b blocks HAdV-5 binding to host cells and thus cell transduction. FX; coagulation 
factor X, HSPG; heparan sulphate proteoglycan, C3; complement protein 3. Figure reproduced with 
permission from (Lopez-Gordo et al., 2014a). 
1.3.5 Strategies to circumvent immune responses to human 
adenoviral vectors 
The activation of immune responses against adenoviral vectors precludes efficient gene 
transfer and thus is still one of the main limitations for their use in gene therapy. In 
particular, several studies have reported toxicity and activation of anti-viral immune 
responses following intravascular delivery of HAdV-5 vectors, which has been mainly 
associated with their liver and spleen tropism (Lozier et al., 2002, Raper et al., 2002, 
Atencio et al., 2006, Morral et al., 2002, Bradshaw et al., 2012). Also, multiple interactions 
of adenoviral capsids or adenoviral DNA with DCs, NK cells, CD4+ and CD8+ T cells, 
NAbs and mechanisms of the innate immune response such as the complement system 
have also been reported (see sections 1.2.3 and 1.3.4.2.2). Thus, designing adenoviral 
vectors able to evade the immune response is key to increase their safety and gene transfer 
efficiency for their use in gene therapy. 
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NAbs can be directed to different components of the virion such as the hexon (Roberts et 
al., 2006, Abe et al., 2009, Shiratsuchi et al., 2010, Bradley et al., 2012b, Hong et al., 
2003), the fiber (Myhre et al., 2007, Bradley et al., 2012a, Yu et al., 2013, Hong et al., 
2003, Gahery-Segard et al., 1998, Parker et al., 2009) or the penton base (Yu et al., 2013, 
Hong et al., 2003, Gahery-Segard et al., 1998). Importantly, it was shown that the 
specificity of NAbs depends on the route of exposure to virions. While natural adenoviral 
infections result in antibodies mainly to the fiber protein, exposure to adenoviral vectors 
through vaccination results in antibodies that are largely directed to the hexon and/or 
penton base (Cheng et al., 2010, Sumida et al., 2005). The epitopes that are recognized by 
antibodies are primarily the hexon HVRs (Roberts et al., 2006, Abe et al., 2009, 
Shiratsuchi et al., 2010, Bradley et al., 2012a, Bradley et al., 2012b, Yu et al., 2013), the 
knob domain of the fiber (Myhre et al., 2007, Bradley et al., 2012a, Yu et al., 2013) and the 
RGD motif in the penton base (Hong et al., 2003). Several studies have either modified 
adenoviral capsid proteins or exchanged them with those of low-seroprevalent serotypes 
(pseudotyping) to remove neutralization epitopes and thus bypass the humoral immune 
response to adenoviral vectors (Figure 1-15). To achieve successful pseudotyping of 
adenoviral capsids, it is essential to first determine the viability of capsid protein 
replacements based on structural and biochemical constraints. Regarding the hexon, the 
exchange of only a subset of HAdV-5 hexon HVRs with those of HAdV-48 demonstrated 
that NAbs can recognize multiple HVRs and thus highlighted the importance of targeting 
all HVRs for genetic engineering to completely circumvent pre-existing immunity 
(Bradley et al., 2012b). Indeed, the exchange of all HAdV-5 hexon HVRs with those of 
HAdV-48 successfully evaded recognition of virions by NAbs in both mice and rhesus 
monkeys (Roberts et al., 2006). Other studies also reported evasion of pre-existing 
immunity in mice using HAdV-5 vectors with whole hexon or hexon HVRs replaced with 
those of serotypes 3, 4, 9, 12 or 43 (Roy et al., 1998, Ostapchuk and Hearing, 2001, Wu et 
al., 2002, Bruder et al., 2012). Importantly, a later study by Coughlan and colleagues 
showed that despite evading neutralizing antibodies, recombinant HAdV-5 vectors 
containing HAdV-48 hexon HVRs triggered a robust pro-inflammatory response that 
differed from that of HAdV-5 or HAdV-48 parental vectors (Coughlan et al., 2012). This 
study indicates that modification of capsid proteins can lead to unexpected effects that 
cannot be predicted from parental vectors. Given that anti-fiber NAbs represent a 
considerable proportion of the anti-adenovirus NAbs population and that seroprevalence is 
tightly associated with serotype, the design of chimeric adenoviral vectors by replacing the 
fiber of high-seroprevalent serotypes with that of low-seroprevalent serotypes is also a 
promising strategy to evade pre-existing immunity. Importantly, the high similarity of the 
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N-terminal region of the fiber (fiber tail) among serotypes facilitates fiber-pseudotyping 
strategies (Tarassishin et al., 2000). A study on the seroprevalence of a range of serotypes 
in the Belgian population reported a high number of NAbs to species A, C and E and a low 
number to species B and D, of which HAdV-11, 34, 35 and 50 (species B) and HAdV-43 
and 48 (species D) exhibited the lowest values (Vogels et al., 2003). These data indicate 
that such serotypes may be a good choice for fiber-pseudotyping strategies. Following this 
approach, chimeric vectors such as HAdV-5/F33 (Haviv et al., 2002, Kanerva et al., 2002, 
Volk et al., 2003, Ulasov et al., 2007), HAdV-5/F11 (Havenga et al., 2001, Stone et al., 
2005, Wang et al., 2011b), HAdV-5/F16 (Havenga et al., 2001) and HAdV-5/F35 
(Havenga et al., 2001) were generated. Despite HAdV-5/F11 and HAdV-5/F35 showing 
reduced toxicity and induction of inflammatory cytokines in mice and baboons (Ni et al., 
2005), HAdV-5/F35 exhibited tropism for CD34+ human hematopoietic stem cells 
(Shayakhmetov et al., 2000), monocytes, granulocytes and blast cells of human bone 
marrow (Rogozhin et al., 2011), and CD4+ and CD8+ T lymphocytes (Zhang et al., 2013) 
that while conferring unique targeting properties, might also trigger an unpredicted 
immune response. Thus, in-depth characterization of novel chimeric adenoviral vectors and 
the associated immune response in vivo should be done before conducting further studies 
in humans. Other strategies to bypass anti-fiber pre-existing immunity such as the 
truncation of the fiber knob domain or its replacement with foreign trimerization motifs 
fused to the fiber shaft (fiber deknobbing) [reviewed by (Coughlan et al., 2010)] have been 
also assessed and shown success in evading NAbs (Myhre et al., 2007, Gaden et al., 2004, 
Magnusson et al., 2001, Izumi et al., 2005) (Figure 1-15). Despite the promising results 
obtained by pseudotyping or deknobbing adenoviral vectors, these strategies are limited by 
the formation of nonviable virions and the generation of virions with a lower number of 
fiber copies that can result in lower vector titers and infectivity (Youil et al., 2002, Legrand 
et al., 1999, Falgout and Ketner, 1988, Von Seggern et al., 1999, Kupgan et al., 2014). To 
avoid infectivity issues associated with genetic engineering of viral capsid proteins, vectors 
have been developed from low-seroprevalent serotypes such as HAdV-6 (Capone et al., 
2006), HAdV-7 (Nan et al., 2003), HAdV-11 (Holterman et al., 2004, Stone et al., 2005), 
HAdV-35 (Gao et al., 2003, Sakurai et al., 2003, Seshidhar Reddy et al., 2003, Vogels et 
al., 2003, Barouch et al., 2004, McVey et al., 2010) or HAdV-49 (Lemckert et al., 2006) 
and have showed successful evasion of NAbs (Figure 1-15). Nevertheless, since 
seroprevalence to adenovirus serotypes is determined by exposure to virions (Thorner et 
al., 2006, Nwanegbo et al., 2004, Ludwig et al., 1998), seroprevalence should be assessed 
                                                 
3
“F” stands for adenovirus fiber and the preceeding number refers to the adenovirus serotype to which the 
fiber belongs.  
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by age and geographical location to allow smart choice of serotypes for the development of 
vectors able to evade pre-existing immunity. The use of NHAdVs such as simian (Roy et 
al., 2005, Belousova et al., 2010), canine (Lau et al., 2012, Ord et al., 2013), bovine 
(Sharma et al., 2009a, Tandon et al., 2012), porcine (Bangari et al., 2005, Sharma et al., 
2009a), fowl (Logunov et al., 2004, Shashkova et al., 2005), ovine (Hofmann et al., 1999, 
Voeks et al., 2002) or murine (Robinson et al., 2009) has also been proposed as an 
alternative to current strategies, since NHAdVs can circumvent NAbs targeted against 
HAdVs (Figure 1-15). Also, NHAdVs have other advantages over HAdVs such as having 
absent or very low pathogenicity, being unable to replicate in human cells and tolerate 
insertions of long transgenes [reviewed by (Lopez-Gordo et al., 2014b)]. However, many 
challenges such as potential cross-reactivity of NAbs against human antigens with non-
human antigens due to structural similarity between HAdVs and NHAdVs, or occurrence 
of interspecies adaptation have yet to be overcome for NHAdV to be safely used as gene 
therapy vectors [reviewed by (Lopez-Gordo et al., 2014b)].  
In addition to NAbs, CD4+ and CD8+ T cells can also limit efficiency of gene transfer with 
adenoviral vectors in vivo (see section 1.2.3). Since CD4+ and CD8+ T cells mainly 
recognize epitopes in the hexon (Leen et al., 2004, Olive et al., 2002, Tang et al., 2006, 
Onion et al., 2007), genetic engineering of hexon epitopes or hexon-pseudotyping might be 
an attractive approach to evade the anti-viral T cell response. Moreover, CTL-mediated 
killing of cells partially relies on the detection of antigenic peptides on transduced cells, 
which result from processing of capsid proteins of the incoming virions and from the leaky 
expression of adenoviral genes from the vector genome (Yang et al., 1994). To reduce the 
CTL response to transduced cells, third generation HD vectors, which are devoid of viral 
gene sequences in their genome, were generated (Kochanek et al., 1996). Importantly, their 
low immunogenicity allowed long-term transgene expression (Maione et al., 2001, 
Ehrhardt and Kay, 2002, Dudley et al., 2004). However, since these vectors are composed 
of stuffer DNA in place of viral gene sequences to maintain optimum vector size (Bett et 
al., 1993, Parks and Graham, 1997, Smith et al., 2009), the activation of innate immune 
mechanisms upon recognition of dsDNA has been observed. For instance, a TLR9-
dependent innate immune response, which is activated upon recognition of non-methylated 
CpG-containing viral DNA (Bauer et al., 2001), was observed both in vitro and in vivo to 
HD vectors (Cerullo et al., 2007). Also, one study reported that the nature of stuffer DNA 
has important effects on the T cell response against transduced cells (Parks et al., 1999). 
Importantly, despite the potential shown by HD vectors [reviewed by (Cots et al., 2013)], 
HD capsids can stimulate an immune response upon intravenous administration that is 
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equivalent to first and second generation adenoviral vectors and that is characterized by the 
production of pro-inflammatory cytokines such as IL-6 and TNF-α (Brunetti-Pierri et al., 
2004, Mane et al., 2006). Thus, other strategies aimed at blocking interactions between 
adenoviral capsid proteins and components of the immune system to further attenuate the 
anti-viral immune response might be essential to achieve efficient gene transfer with 
adenoviral vectors. Interestingly, blockade of interactions between HAdV-5 virions and 
SRs on KCs (Xu et al., 2008, Haisma et al., 2008, Khare et al., 2012) or between HAdV-5 
virions and complement proteins (Xu et al., 2008) blocked vector clearance by KCs in vitro 
and in vivo. Depletion of KCs with clodronate liposomes (van Rooijen and van Kesteren-
Hendrikx, 2003) or gadolinium chloride, which forms a colloidal precipitate that can be 
phagocytosed by macrophages and lead to cell death (Hardonk et al., 1992), are approaches 
that have been assessed in experimental models. Moreover, interaction of the RGD motif 
in the penton base with macrophage β3 integrin results in the secretion of IL-1α (Di Paolo 
et al., 2009a) and the RGD motif has also been proposed as the region targeted for binding 
to α-defensins (Flatt et al., 2013), which block capsid disassembly (Smith and Nemerow, 
2008, Smith et al., 2010, Snijder et al., 2013). Mutation of the HAdV-5 RGD motif to 
arginine-glycine-glutamic acid (RGE) achieved a reduction in spleen uptake following 
intravascular administration and in the associated immune response (Bradshaw et al., 
2012). Also, since DCs have been reported to interact with the adenovirus fiber shaft 
region via a heparin-sensitive receptor (Cheng et al., 2007), mutations in the fiber shaft 
region may help reducing DC-mediated immune responses.  
Other interactions between virions and non-immune cells have also been associated with 
the promotion of immune responses, limiting gene transfer efficiency. For instance, 
interactions between HAdV-5 fiber and CAR have been shown to stimulate an immune 
response in human respiratory cells, which is characterized by the activation of mitogen-
activated protein kinase 3 (MAPK3)/ERK1 MAPK, MAPK1/ERK2 MAPK, MAPK8/c-
Jun N-terminal kinase (JNK) MAPK and NF-κB and the induction of expression of 
chemokines IL-8, growth-related oncogene (GRO)-α and γ, C-C motif chemokine ligand 5 
(CCL5)/RANTES and CXCL10/IP-10 (Tamanini et al., 2006). HAdV-5 binding to CAR 
on platelets has also been associated with the formation of virion-platelet-leukocyte 
aggregates that are cleared from the circulation by macrophages in the liver (Stone et al., 
2007, Othman et al., 2007). CAR-binding ablating mutations might reduce CAR-mediated 
immune responses and virion clearance (Figure 1-15). Furthermore, immune recognition of 
virions can facilitate interactions of vectors with non-immune cells. This is the case for 
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human but not mouse erythrocytes, which can detect HAdV-5 virions via CR1 in the 
presence of C1q and antibodies (Carlisle et al., 2009).  
An alternative approach has been reported by several groups who have attempted to coat 
the adenoviral capsid with cationic polymers or lipid molecules, with the aim of preventing 
immune recognition of capsid proteins by IgG or IgM antibodies, complement proteins, α-
defensins or immune cells, and with the aim of hampering binding of virions to receptors 
on non-immune cells that may trigger the immune response and lead to toxicity 
(Wonganan and Croyle, 2010) (Figure 1-15). Initial studies performed chemical 
modifications of virions with polyethylene glycol (PEG) (Romanczuk et al., 1999), but 
later studies also showed promising results with multivalent copolymers of poly[N-(2-
hydroxypropyl)methacrylamide] (pHPMA) (Green et al., 2004). Both polymer coating 
approaches achieved protection of virions from NAbs in vitro (Romanczuk et al., 1999, 
Wang et al., 2011a, Eto et al., 2004) and led to lower production of NAbs in vivo (Eto et 
al., 2010). PEGylation of virions impaired virion-engulfment by macrophages in vitro or 
KCs in vivo, reducing the expression of IL-6 in both settings (Mok et al., 2005). 
PEGylation also prevented thrombocytopenia and abrogated neutrophil infiltration to the 
liver resulting in reduced toxicity, reduced spleen transduction, and decreased expression 
of pro-inflammatory cytokines (De Geest et al., 2005). Coating of HAdV-5 virions with 
pHPMA increased persistence of virions in the bloodstream and substantially reduced liver 
transduction and associated toxicity (Green et al., 2004). Interestingly, in addition to 
preventing immune recognition of virions and interactions of virions with host cell 
receptors (removal of native tropism), this strategy also offers retargeting possibilities, 
since targeting molecules can be chemically attached to polymer chains (Stevenson et al., 
2007, Morrison et al., 2008, Parker et al., 2005, Morrison et al., 2009). Nevertheless, it has 
to be taken into account that an IgM-mediated immune response is activated towards PEG 
molecules that depends on the length of PEG chains (Shimizu et al., 2012). Therefore, 
further characterization of the immune response elicited by polymer coated adenoviral 
vectors and the implications for gene transfer efficiency should be done for their safe use 
in gene therapy.   
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Figure 1-15. Strategies to circumvent the immune response to adenoviral vectors. Genetic pseudotyping 
of adenovirus capsid proteins (fiber or hexon) with those of low-seroprevalent serotypes, use of low-
seroprevalent adenovirus serotypes or non-human adenoviral vectors, fiber deknobbing or removal of fiber 
knob domain and replacement with foreign trimerization motifs, genetic engineering to remove epitopes in 
capsid proteins (fiber knob domain or penton base), and PEGylation of adenoviral virions, are illustrated. 
Blunt arrows indicate the interactions between adenoviral capsid proteins and host proteins that are inhibited 
due to each strategy. Adenovial capsid proteins represented in green indicate proteins from low-seroprevalent 
serotypes. Red stars indicate mutation sites on adenoviral capsid proteins. RGD; arginine-glycine-glutamic 
acid residues, CAR; coxsackie virus and adenovirus receptor, SR-A-II; scavenger receptor A-II, CR1; 
complement receptor 1. 
1.3.6 Adenoviral retargeting strategies  
Multiple strategies have been deployed to generate adenoviral vectors that selectively 
target the cell type where the gene therapy is required. These strategies are based on 
transcriptional or transductional re-targeting. Transcriptional retargeting is aimed at 
limiting adenovirus replication or transgene expression to the target tissue via genetic 
complementation (Fueyo et al., 2000) or through the use of tissue-specific 
promoters/enhancer systems (Rodriguez et al., 1997, Wu et al., 2001), respectively. 
Transductional retargeting is aimed at limiting adenovirus cell entry to a specific cell type 
and can be achieved by incorporating genetic mutations into the adenoviral capsid to 
modify tropism [e.g: fiber serotype swap (genetic pseudotyping) (Haviv et al., 2002, 
Kanerva et al., 2002, Ulasov et al., 2007, Volk et al., 2003, Havenga et al., 2001, Raki et 
al., 2008, Shayakhmetov et al., 2000, Ni et al., 2005); knobless fiber shaft fusions 
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(Magnusson et al., 2001, Belousova et al., 2003, Izumi et al., 2005, Li et al., 2006); adapter 
ligand complexes such as bispecific antibodies (Nettelbeck et al., 2001, Miller et al., 1998, 
Nettelbeck et al., 2004), conjugated antibody fragments (Korokhov et al., 2003, Li et al., 
2007) or recombinant bispecific fusion proteins (Harvey et al., 2010); or insertion of 
heterologous binding ligands into adenoviral proteins (Dmitriev et al., 1998)]. 
Transductional retargeting can also be achieved by modifying the adenoviral capsid via 
covalent or non-covalent fusion of adapter ligands with the capsid [reviewed by (Coughlan 
et al., 2010)]. The retargeting strategies used in adenoviral vectors that are currently 
undergoing clinical assessment are genetic pseudotyping [e.g: clinical trial with 21 patients 
using HAdV-5 with the fiber knob replaced with that of HAdV-3 and encoding GMCSF to 
stimulate an anti-tumor immune response (Koski et al., 2010)] and, predominantly, the 
insertion of heterologous binding ligands [e.g: clinical trial with 21 patients using HAdV-5 
with the RGD motif-containing CDCRGDCFC peptide inserted into the fiber knob HI loop 
for enhanced targeting of cancer cells in solid tumors (Nokisalmi et al., 2010)]. These 
studies showed anti-tumor activity with mild side effects including thrombocytopenia, 
transaminitis, hyponatremia, fever and fatigue (Koski et al., 2010, Nokisalmi et al., 2010), 
and thus highlight the potential of such strategies in the clinic. 
The insertion of heterologous binding ligands consists of selecting heterologous peptides 
that home to the in vivo target tissue and incorporating them into the adenoviral capsid. 
The selected peptide should not need any major post-translational modification in the ER 
to maintain binding to the target protein, since adenoviral proteins are translated in the 
cytosol under non-reducing conditions and they do not go to the ER before virus assembly 
in the nuclei. These peptides can be found by rational design or by technologies such as 
phage display (Figure 1-16), which allows the isolation of candidate peptides from peptide 
libraries as highly efficient and selective binders of specific proteins expressed on target 
cells [reviewed by (Azzazy and Highsmith, 2002, Pande et al., 2010)]. Heterologous 
peptides have been inserted into the C-terminal of the fiber (Kurachi et al., 2007b, Kurachi 
et al., 2007a, Wickham et al., 1997, Gonzalez et al., 1999, Ranki et al., 2007, Rein et al., 
2004, Staba et al., 2000), the penton base (Wickham et al., 1996, Einfeld et al., 1999), 
certain hexon HVRs (Vigne et al., 1999, Wu et al., 2005) or the capsid protein IX 
(Dmitriev et al., 2002, Campos et al., 2004, Vellinga et al., 2004). The insertion of 
heterologous peptides should not disrupt the interactions necessary for adenovirus 
assembly. The HAdV-5 knob domain at the C-terminal of the fiber is composed of an 
eight-stranded antiparallel β sandwich with interspersing exposed loop regions (Xia et al., 
1994). The loop regions comprise 8-55 amino acid residues (Xia et al., 1994) and are the 
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preferable location for peptide incorporation due to their flexibility, exposure and non-
conserved characteristics. The HI loop, which is not involved in fiber interactions with 
HAdV-5 native receptors, has been reported as the most suitable surface exposed loop for 
peptide incorporation (Figure 1-16) since fiber trimerization, capsid structure and viral titer 
is maintained after the introduction of peptides (Krasnykh et al., 1998). The first 
heterologous peptide that was successfully introduced into the HI loop was the RGD motif-
containing CDCRGDCFC peptide, which successfully targeted αvβ3,5 integrin-expressing 
primary ovarian cancer cells (Dmitriev et al., 1998), pancreatic carcinoma cells (Wesseling 
et al., 2001), non-hematopoietic human tumor cell lines and primary melanoma cells 
(Nagel et al., 2003). Also, the RGD motif-containing ACDCRGDCFCD peptide enhanced 
transduction of αvβ3,5 integrin-positive cells that do not express CAR (Kurachi et al., 
2007a). Interestingly, the targeting efficacy of RGD motif-containing peptides was 
demonstrated in vivo via increased transgene expression in liver, lung, spleen and kidney 
following intravenous delivery (Reynolds et al., 1999). Moreover, a HAdV-5 encoding the 
peptide motif NGR in the HI loop targeted aminopeptidase N-expressing 
rhabdomyosarcoma cells in vitro (Majhen et al., 2006). Another peptide successfully 
incorporated into the HI loop is A20FMDV2 (derived from VP1 of foot-and-mouth disease 
virus) to target αvβ6 integrin (Coughlan et al., 2009). A20FMDV2 peptide showed 
targeting and cytotoxicity on a panel of αvβ6 integrin-expressing human carcinoma cells 
and enhanced tumor virion uptake following systemic delivery (Coughlan et al., 2009). 
The incorporation of the YSA peptide into the HI loop achieved selective targeting of 
Ephrin A2 receptor (EphA2R)-positive cells and human pancreatic cancer cells in vitro but 
failed to show transduction of human pancreatic cells in vivo after intravascular 
administration (van Geer et al., 2009). In vitro phage display technology has made it 
possible to identify heterologous peptides that target human tracheal glandular cells 
(Gaden et al., 2004), endothelial cells (Nicklin et al., 2001), human transferrin receptor 
(hTfR) on brain microcapillary endothelium (Xia et al., 2000) or neuroglial cells (Joung et 
al., 2005), smooth muscle cells (Work et al., 2004) or gastric cancer tissues (Zhang et al., 
2012) in vitro. One study introduced an endothelial cell-targeting peptide that had been 
found by in vitro phage display, into the HI loop of the HAdV-5 fiber and showed 
selectivity for endothelial cells in vitro and for blood vessels following intravascular 
delivery into mice (Nicklin et al., 2004). Another study generated an HAdV-5 with an 
heterologous peptide found by in vitro phage display that selectively targeted human a 
colorectal cancer cell line in vitro, but failed to show selective targeting in mice (Rittner et 
al., 2007). In vivo phage display has also led to selection of peptides that home to mouse 
lung, skin, pancreas, intestine, uterus, adrenal gland or retina (Rajotte et al., 1998), mouse 
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brain or kidney blood vessels (Pasqualini and Ruoslahti, 1996), mouse white fat 
vasculature by targeting prohibitin (Kolonin et al., 2004), or rat kidney (Denby et al., 
2007). In the latter study, the identified kidney-targeting peptides were incorporated into 
the HI loop of HAdV-19p and the resultant vectors showed selectivity for rat kidney 
tubular epithelium or rat glomeruli (Denby et al., 2007). These studies show the potential 
of incorporating heterologous peptides into the HI loop of the fiber knob domain as a 
strategy to selectively retarget adenoviral vectors to tissues for gene therapy applications. 
 
Figure 1-16. Re-targeting of adenoviral vectors via the incorporation of heterologous peptides found by 
in vitro phage display, into the HI loop of the fiber knob domain. Candidate peptides for binding to a 
particular ligand are selected from in vitro phage display libraries and their corresponding DNA is sequenced. 
The DNA sequence is inserted into the adenoviral genome corresponding to the HI loop sequence in the fiber 
ORF. Recombinant adenoviral vectors are produced and tested in vitro for their specificity for cells 
expressing the targeted ligand. FK; fiber knob. Ribbon diagram of fiber and fiber knob images on the lower 
right square reproduced with permission from (Hall et al., 2010). 
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1.4 Aims of this thesis 
The studies presented in this thesis were conducted to gain further understanding of the 
mechanisms mediating HAdV-5 virion neutralization by the host innate immune response 
and hepatic and splenic tropism of HAdV-5-based vectors following intravascular delivery. 
To this end, the interactions of HAdV-5 virions with blood components and host cell 
receptors were investigated. The hypothesis of this thesis was that HAdV-5-based vectors 
can use FX for protection against neutralization and for liver transduction following 
administration of vectors through the vasculature, but that in the absence of FX-binding 
and neutralization, HAdV-5 can follow alternative pathways for liver and spleen 
transduction via CAR and αvβ3,5 integrins and via interactions with other blood proteins. It 
was also hypothesized that FX-binding deficient HAdV-5 vectors can be retargeted to 
specific tissues. Thus, this thesis is divided into three studies encompassing four questions: 
What are the mechanisms by which natural IgM antibodies, complement and FX 
mediate HAdV-5 virion neutralisation or protection from neutralisation in vitro and 
in vivo? Wild type and FX-binding deficient HAdV-5 vector transduction was assessed in 
mouse models lacking different components of the immune response, and in in vitro cell 
culture models in the presence of purified serum from individual mouse strains.  
Do FX, CAR and αvβ3,5 integrins mediate the hepatic and splenic tropism of HAdV-5 
following intravascular delivery? Do alternative transduction pathways exist for 
HAdV-5 in vitro and are they relevant in vivo? FX, CAR and αvβ3,5 integrin-binding 
deficient HAdV-5 vectors were administered through the vasculature to 
immunocompromised mice unable to neutralize FX-binding deficient virions and liver and 
spleen transduction was evaluated. HAdV-5 transduction of cell culture models was 
assessed after exposure of virions to purified mouse serum.  
Does FX binding to HAdV-5 influence the efficiency of cell uptake and endosomal 
membrane penetration of the virion? These processes were investigated in the presence 
of FX by microscopic assessment of fluorescently labelled virions at the single cell level.  
Can HAdV-5 vectors be selectively retargeted to relevant cells of the kidney by 
genetic modification of the capsid? HAdV-5 vectors were engineered to incorporate renal 
targeting peptides identified by in vitro phage display into the HI loop of the fiber knob 
domain, and assessed for their efficiency in mediating specific gene delivery in vitro.  
  
 
 
 
 
 
 
 
 
Chapter 2 Materials and Methods 
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2.1  Materials 
All chemicals were obtained from Sigma-Aldrich (Poole, UK) and of the highest quality 
available unless otherwise stated. All primers were purchased from Eurofins Genomics 
(Wolverhampton, UK) unless otherwise stated. All antibodies were purchased from 
Thermo Fisher Scientific (Renfrew, UK) unless otherwise stated. All cell culture reagents 
were obtained from GIBCO by Life Technologies (Paisley, UK) unless otherwise stated. 
The DNA plasmids used can be found in the appendix. 
2.1.1 Oligonucleotides 
The primers used in experimental procedures are summarised in Table 2-1.  
Table 2-1. Oligonucleotides used in experimental procedures. 
Name (probe type) DNA sequence (5’3’) Application 
Hexon-F CCCGCTTTCCAAGATGGCTA PCR 
Hexon-R GTTGGCGGGTATAGGGTAGA PCR 
Fiber-F ACTGCCACTGGTAGCTTGGG PCR 
Fiber-R TGGCCAGCTGGTTTAGGATG PCR 
Penton base-F ATGAGGAAGGTCCTCCTCCC PCR 
Penton base-R CCCCAGCCTGTGTTATTGCT PCR 
Hexon_HVR 5/HVR 7 CTCAGTGGTACGAAACTGAA Sequencing 
Hexon_HVR 7 CTATGTGGAATCAGGCTGTT Sequencing 
Fiber Knob_HI loop ACTGAAGGCACAGCC Sequencing 
Fiber Knob_AB loop_KO1 AATGCACCAAACACAAATCC Sequencing 
Penton base_RGE CATTCCCGCACTGTTGGATG Sequencing 
LacZ-F ATCTGACCACCAGCGAAATGG qPCR 
LacZ-R CATCAGCAGGTGTATCTGCCG qPCR 
Claudin 16_Mm00475025_m1 
(FAM_MGB probe) - TaqMan 
18s_Hs03928985_g1  
(VIC_MGB probe) - TaqMan 
Oligo_NotIASFPPAFNotI5-3 GCGGCCGCcGCGAGTTTTCCGCCGGCGTTTGCGGCCGC1 Cloning 
Oligo_NotIASFPPAFNotI3-5 GCGGCCGCAAACGCCGGCGGAAAACTCGCGGCGGCCGC Cloning 
Oligo_NotIYAAHRSHNotI5-3 GCGGCCGCcTATGCTGCGCATCGTTCTCATGCGGCCGC1 Cloning 
Oligo_NotIYAAHRSHNotI3-5 GCGGCCGCATGAGAACGATGCGCAGCATAGGCGGCCGC Cloning 
1NotI sites are shown in upper case, additional cytosine to maintain the fiber ORF in lower case, and 
nucleotides corresponding to ASFPPAF or YAAHRSH peptides, respectively, in upper case and underlined.  
All oligonucleotides were purchased from Eurofins MWG Operon by Eurofins Genomics with the exception 
of TaqMan® probes, which were purchased from Thermo Fisher Scientific. PCR; polymerase chain reaction, 
qPCR; quantitative Real-Time polymerase chain reaction. 
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2.1.2 DNA plasmids 
The DNA plasmids used in experimental procedures were based on the AdEasy, E1/E3 
deleted HAdV-5 adenoviral vector system (Stratagene by Agilent Technologies) (Luo et 
al., 2007) and are summarised in Table 2-2.  
 
Table 2-2. DNA plasmids used in experimental procedures. 
Name Encoded reporter 
and/or fiber genes 
Antibiotic 
resistance 
gene 
Source of reference 
pAdEasy1 wt HAdV-5 fiber AmpR Agilent Technologies 
pAdT* E.coli LacZ,  
wt HAdV-5 fiber Neo
R/KanR (Alba et al., 2009) 
pAdT*KO1 E.coli LacZ,  HAdV-5 fiber KO1 Neo
R/KanR Dr. Angela C. Bradshaw1 
pAdT*RGE E.coli LacZ  (Bradshaw et al., 2012) 
pShuttle-CMV-
LacZ E.coli LacZ Neo
R/KanR Agilent Technologies 
pShuttle-KO1-AAA HAdV-5 fiber KO1 AAA Sm
R
 Agilent Technologies 
pShuttle-KO1 HAdV-5 fiber KO1 SmR Generated in this study 
pShuttle-KO1-
AAA-AAASFPPAF 
HAdV-5 fiber KO1 
AAAASFPPAFAAA Sm
R
 Generated in this study 
pShuttle-KO1-
AAA-
AAAYAAHRSH 
HAdV-5 fiber KO1 
AAAYAAHRSHAAA Sm
R
 Generated in this study 
pAdEasy1-CMV-
LacZ 
E.coli LacZ,  
wt HAdV-5 fiber Neo
R/KanR Generated in this study 
pAdEasy1-CMV-
LacZ-KO1 
E.coli LacZ,  
HAdV-5 fiber KO1 Neo
R/KanR Generated in this study 
pAdT*KO1-AAA 
E.coli LacZ,  
HAdV-5 fiber KO1 
AAA 
NeoR/KanR Generated in this study 
pAdT*KO1-AAA-
AAAASFPPAF 
E.coli LacZ,  
HAdV-5 fiber KO1 
AAAASFPPAFAAA 
NeoR/KanR Generated in this study 
pAdT*KO1-AAA-
AAAYAAHRSH 
E.coli LacZ,  
HAdV-5 fiber KO1 
AAAYAAHRSHAAA 
NeoR/KanR Generated in this study 
Genetic maps of all the plasmids used in the studies presented in this thesis are shown in the appendix. 
HAdV-5; human adenovirus serotype 5, AmpR; ampicillin resistance, NeoR; neomycin resistance, KanR; 
kanamycin resistance, SmR; streptomycin resistance, wt; wild type.  
1pAdT*KO1 was a kind gift from Dr. Angela C. Bradshaw (University of Glasgow, UK). 
2.1.3 Antibodies  
The antibodies used in experimental procedures are summarised in Table 2-3 and Table 
2-4. Primary mouse anti-human Giantin IgG1 antibody was kindly provided by Professor 
Hans-Peter Hauri (Biocentre of the University of Basel, Switzerland). 
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Table 2-3. Primary antibodies used in experimental procedures.  
Antibody reactivity Host species Clonality 
Working 
concentration 
Application Provider (Catalogue number) 
Anti-adenovirus fiber IgG2a Mouse 
Monoclonal 
(Clone: 4D2) 0.2 µg/ml 
WB Abcam (ab3233) 
Anti-β-galactosidase-DIG 
Digoxigenin 
Mouse Monoclonal 0.5 µg/ml ELISA Roche (provided in the kit) 
Anti-CAR IgG1 Mouse 
Monoclonal 
(Clone: RmcB) 5 µg/ml 
FCM Upstate, NY (05-644) 
Anti-pericentrin  Rabbit Polyclonal 5 µg/ml ICC Abcam (ab4448) 
Anti-Alexa Fluor 488 Rabbit Polyclonal 1 µg/ml SLO Thermo Fisher Scientific (A-11094) 
Anti-human Giantin IgG1 Mouse 
Monoclonal 
(Clone: G1/133) 33.33 µg/ml 
SLO Enzo Life Sciences (ALX-804-600-C100) 
Anti-β-galactosidase Rabbit Polyclonal 5 µg/ml IHC MP Biomedicals LLC (08559761) 
Mouse IgG (isotype control) Mouse N/A Matched   Thermo Fisher Scientific (10400C) 
Rabbit IgG (isotype control) Rabbit N/A Matched  Thermo Fisher Scientific (10500C) 
WB; western blotting, FCM; flow cytometry, ICC; immunocytochemistry, IHC; immunohistochemistry, SLO; SLO penetration assay, N/A; not applicable. “Matched” refers to a 
concentration equivalent to that of the primary antibody used in each assay. 
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Table 2-4. Secondary antibodies used in experimental procedures.  
Antibody reactivity Host species Clonality 
Working 
concentration 
Application Provider (Catalogue number) 
Anti-mouse IgG HRP Rabbit Polyclonal 1.3 µg/ml WB Dako (P0260) 
Anti-DIG-POD Fab fragment 
Peroxidase 
Sheep Polyclonal 0.26 U/ml ELISA Roche (provided in the kit) 
Anti-mouse IgG Alexa Fluor 488  Goat Polyclonal 4 µg/ml FCM Thermo Fisher Scientific (A-11001) 
Anti-rabbit IgG Alexa Fluor 546  Goat Polyclonal 4 µg/ml ICC Thermo Fisher Scientific (A-11035) 
Anti-rabbit IgG Alexa Fluor 594  Goat Polyclonal 4 µg/ml SLO Thermo Fisher Scientific (A-11037) 
Anti-mouse IgG Alexa Fluor 680 Goat Polyclonal 4 µg/ml SLO Thermo Fisher Scientific (A-21058) 
Anti-rabbit IgG Alexa Fluor 488  Goat Polyclonal 4 µg/ml IHC Thermo Fisher Scientific (A-11008) 
HRP; horseradish peroxidase, Fab; fragment antigen-binding, WB; western blotting, FCM; flow cytometry, ICC; immunocytochemistry, IHC; immunohistochemistry, SLO; SLO 
penetration assay, N/A; not applicable. 
 
 
    Chapter 2 | Materials and methods 
70 
 
2.1.4 Bacterial cells 
The Escherichia coli (E. coli) strains used are summarised in Table 2-5.  
Table 2-5 Bacterial strains used.  
Bacterial 
strain 
Genotype Transformation 
characteristics 
JM109 
endA1, recA1, gyrA96, thi, hsdR17 (rk–
, mk+), relA1, supE44, Δ(lac-proAB), 
[F´ traD36, proAB, laqIqZΔM15] 
Chemically-competent 
BJ5183 endA1, sbcBC, recBC, galK, met, thi-1, bioT, hsdR. SmR. Electroporation-competent 
JM109 cells were purchased from Promega and BJ5183 from Stratagene by Agilent Technologies. SmR; 
streptomycin resistance. 
2.1.5 Immortalised cell lines 
The immortalised cell lines used, cell characteristics, medium used and culture 
requirements are described in Table 2-6. K562CLDN16 cells were kindly provided by 
Justin Roth (Case Western Reserve University, Cleveland, Ohio, USA). CHO-CAR cells 
were a kind gift from Dr. George Santis (King’s College London School of Medicine, 
London, UK) (Bergelson et al., 1997). SKOV3-CAR cells were generated by transfecting a 
RFP-hCAR plasmid that has been described before (Farmer et al., 2009). They were a kind 
gift from Dr. Katie White (University of Glasgow, UK).  
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Table 2-6. Immortalised cell lines used.  
Cell line Cellular origin and characteristics Cell culture medium and supplements 
HEK-293 Human Embryonic Kidney (Graham et al., 1977), 
adherent cell line. MEM supplemented with PCN, Sm, FCS, NaP and L-Gln. 
Per.C6 Human embryonic retina (HER) from Crucell (Leiden, The Netherlands) (Fallaux et al., 1998), adherent cell line. 
DMEM 5.55 mM D-Glucose, 4 mM L-Gln and 1 mM NaP supplemented 
with PCN, Sm, FCS and 0.01 M MgCl2. 
A549 Human lung carcinoma, adherent cell line.  RPMI-1640 supplemented with PCN, Sm, FCS, NaP and L-Gln. 
SKOV3 Human ovary adenocarcinoma, adherent cell line. RPMI-1640 supplemented with PCN, Sm, FCS, NaP and L-Gln. 
SKOV3-CAR SKOV3 cells stably overexpressing RFP-tagged hCAR 
and NeoR gene neo, adherent cell line. 
RPMI-1640 supplemented with PCN, Sm, FCS, NaP and L-Gln and 
geneticin. 
CHO-K1 Chinese hamster ovary, adherent cell line. Ham’s F-10 Nutrient Mixture medium 1 mM L-Gln and 1 mM NaP 
supplemented with PCN, Sm and FCS. 
CHO-CAR CHO cells stably expressing hCAR (Bergelson et al., 1997), adherent cell line. 
Ham’s F-10 Nutrient Mixture medium 1 mM L-Gln and 1 mM NaP 
supplemented with PCN, Sm and FCS. 
HeLa  Human cervix adenocarcinoma, adherent cell line. MEM supplemented with PCN, Sm, FCS, NaP and L-Gln. 
HepG2 Human liver hepatocellular carcinoma, adherent cell line. MEM supplemented with PCN, Sm, FCS, NaP and L-Gln. 
ACHN  Human kidney adenocarcinoma, adherent cell line. RPMI-1640 supplemented with PCN, Sm, FCS, NaP and L-Gln. 
MCF7 Human breast adenocarcinoma, adherent cell line. RPMI-1640 supplemented with PCN, Sm, FCS, NaP and L-Gln. 
K562 Human bone marrow chronic myelogenous leukemia, 
suspension cell line. 
DMEM 5.55 mM D-Glucose, 4 mM L-Gln and 1 mM NaP supplemented 
with PCN, Sm, and FCS. 
K562CLDN16 K562 cells stably expressing claudin 16 and PURO
R
 gene 
pac under the MND promoter, suspension cell line. 
DMEM 5.55 mM D-Glucose, 4 mM L-Gln and 1 mM NaP supplemented 
with PCN, Sm, FCS and puromycin. 
Supplements concentration used: PCN (100 U/ml), Sm (100 μg/ml), FCS (10% (v/v)), NaP (1 mM) and L-Gln (2 mM), geneticin (1000 ng/μL), puromycin (5 µg/ml). 
Abbreviations: MEM; Minimum Essential Medium, RPMI; Roswell Park Memorial Institute, DMEM; Dulbecco’s Modified Eagle Medium, FCS; foetal calf serum, PCN; penicillin, 
Sm; streptomycin, NaP; sodium pyruvate, Gln; glutamine, hCAR; human coxsackie and adenovirus receptor, RFP; red fluorescent protein, NeoR; neomycin resistance gene, PUROR; 
puromycin resistance gene.  
Supplier: MEM, DMEM, RPMI-1640, Ham’s F-10 Nutrient Mixture medium, PCN/Sm mix, geneticin and puromycin were purchased from GIBCO by Life Technologies, FCS was 
purchased from PAA Laboratories, NaP from Sigma-Aldrich and L-Gln from Invitrogen by Life Technologies. 
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2.1.6 Adenoviral vectors 
All adenoviral vectors used in experimental procedures are replication-deficient adenoviral 
vectors designed and generated in-house with the exception of Alexa Fluor 488 labelled 
HAdV-2 ts1, which was kindly provided by Professor Urs Greber (University of Zurich, 
Switzerland). Adenoviral vectors were based on the AdEasy, E1/E3 deleted HAdV-5 
adenoviral vector system (Stratagene by Agilent Technologies) (Luo et al., 2007) and 
encode the E.coli LacZ reporter gene for expression of the bacterial cytoplasmic β-
galactosidase, in place of the viral E1 early adenovirus gene under the cytomegalovirus 
immediate-early promoter (CMV-IEP). Adenoviral vectors’ genetic characteristics and 
mutations are specified in Table 2-7, Table 2-8 and Figure 2-1.  
Table 2-7. Adenoviral vectors’ genetic characteristics.  
Adenoviral vector 
Hexon 
mutation 
Penton 
base 
mutation 
Fiber 
mutation 
Targeting 
peptide into FK 
HI loop1 
HAdV-5  
(Waddington et al., 2008) - -  - 
AdT* (Alba et al., 2009) T* - - - 
HAdV-5 RGE  
(Bradshaw et al., 2012) - RGE  - 
HAdV-5 KO1 - - KO1 - 
AdT*RGE  
(Bradshaw et al., 2012) T* RGE - - 
AdT*KO1 AAA T* - KO1 544AAA546 
AdT*KO1 AAAASFPPAF T* - KO1 544AAAASFPPAFAAA556 
AdT*KO1 
AAAYAAHRSHAAA T* - KO1 
544AAAYAAH
RSHAAA556 
1Numbers refer to amino acid residue position in the protein. 
FK; fiber knob domain. 
Table 2-8. Genetic mutations in adenoviral capsid.  
Mutation Protein for 
ablated binding 
AdV protein targeted for 
mutation: region or 
domain mutated 
Genetic mutations on  
protein residues 
T* FX Hexon: HVR 5 and 7 
HVR 5: T270P, E271G  
HVR 7: I421G, T423N, 
E424S, L426Y, E451Q 
(Alba et al., 2009) 
RGE αvβ3,5 integrins Penton base D342E (Bai et al., 1993) 
KO1 CAR Fiber: AB loop region of the fiber knob domain 
S408E, P409A (Roelvink 
et al., 1999, Jakubczak et 
al., 2001) 
FX; coagulation factor X, HVR; hypervariable region, CAR; coxsackie and adenovirus receptor. 
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Figure 2-1. Genetic modifications introduced on adenoviral vectors. A-C) Nucleotide alignment between 
parental HAdV-5 genome and HAdV-5 genome with the T* mutations in the hexon HVRs (A), the RGE 
mutation in the penton base (B) or the KO1 mutation in the fiber knob domain (C). Mutated nucleotides are 
bolded capital letters and the corresponding mutated amino acid residues are boxed and indicated below each 
nucleotide triplet. D) Heterologous DNA sequences incorporated into the HI loop sequence of the fiber ORF 
are indicated below the parental HAdV-5 genome, with the corresponding heterologous peptide sequence 
indicated below. Candidate peptide sequences are bolded and restriction sites indicated. Numbers refer to 
amino acid residue position in the protein. 
2.1.7 Mouse strains and husbandry 
The mouse strains used were C57BL/6 (Harlan Laboratories, UK), Rag 2-/- (B6(Cg)-
Rag2tm1.1Cgn/J, on a C57BL/6 genetic background) kindly provided by Dr. Alison M. 
Michie (Glasgow University, UK) and NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) kindly 
provided by Professor James Brewer and Dr. Chris Hansell (Glasgow University, UK). 
Rag 2-/- mice are deficient in Rag-2 gene, which is necessary for the somatic DNA 
rearrangement V(D)J recombination (Shinkai et al., 1992, Alt et al., 1992). As a result, 
they are unable to differentiate B and T lymphocytes to a mature state, which leads to a 
lack of production of natural IgM antibodies (Shinkai et al., 1992, Alt et al., 1992). NSG 
mice have the severe combined immune deficiency (scid) mutation (Prkdcnull), a complete 
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null mutation in the IL2RG gene and 2 base pair (bp) deletion in the haemolytic 
complement (Hc) gene. They lack mature B and T lymphocytes [no IgM production 
(Shultz et al., 2005)], are defective in dendritic cell and macrophage cytokine production 
and haemolytic complement protein 5 (C5), and have extremely low NK cell cytotoxic 
activity (Shultz et al., 2005, Zhou et al., 2014, Ito et al., 2002, Shultz et al., 1995). A 
summary of the mouse strains characteristics can be found in Table 2-9. All animals were 
housed in the Central Research Facility (Glasgow, UK) under controlled environmental 
conditions maintained at ambient temperature with 12 h light/dark cycles. Mice were fed 
standard chow and water was provided ad libitum. Rag 2-/- and NSG mice were maintained 
in a pathogen-free environment in microisolator individually ventilated (PIV) caging. All 
animal experiments were approved by the University of Glasgow Animal Procedures and 
Ethics Committee and performed under UK Home Office licence (PPL 60/4429) in strict 
accordance with UK Home Office guidelines.  
Table 2-9. Summary of the immune system characteristics of mouse strains. 
Mouse strain Genotype Phenotype 
C57BL/6  Wild type Immunocompetent.  
Rag 2-/- Rag-2 null Immature B and T lymphocytes. 
NSG Prkdc null and IL2RG null 
Immature B and T lymphocytes. 
Deficient dendritic cell and 
macrophage cytokine production. 
Deficient complement protein 5. 
Low NK cell cytotoxic activity. 
 
2.2 Methods 
2.2.1 Cell culture 
Adherent cell lines were cultured at 37oC / 5% or 10% CO2 in the case of Per.C6® cells 
(Crucell) (Fallaux et al., 1998). Suspension cell lines were grown in tissue culture flasks 
siting in a vertical steady position at 37oC / 5% CO2. Adherent cells were passaged when 
80% confluence was reached to prevent overgrowth. Suspension cells were passaged 
approximately every 3 days and seeded again at a concentration of 3.3x103 cells/ml in 30 
ml of complete fresh medium. When passaging adherent cells, cells were washed once 
with Dulbecco’s calcium and magnesium free PBS (DPBS) and incubated with trypsin-
ethylenediamine tetra-acetic acid (trypsin-EDTA) 0.05% (Invitrogen by Life 
Technologies) at 37oC until cells detached from the flask surface. Next, cells were added to 
5 ml of complete medium, subjected to centrifugation at 480 g for 5 min and resuspended 
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into 10 ml of fresh complete culture medium. A total of 2 ml (1/5 dilution) of cell 
suspension was added to 13 ml of fresh medium and cultured at 37oC / 5% or 10% CO2. 
When seeding of a known number of cells per well was required, cells were counted from 
cell suspensions using a haemocytometer (Hausser Scientific, PA, USA). The volume of 
cell suspension containing that specific number of cells was calculated with the following 
formula ([Volume (ml) = N x n / (A x 1x104)], where N = number of wells to seed, n = 
number of cells required per well, A = average number of cells per block of squares in the 
haemocytometer) and topped with fresh complete medium up to the required volume 
(number of wells to seed x volume per well). When passaging suspension cells, cells were 
subjected to centrifugation at 480 g for 5 min, resuspended into 10 ml of fresh complete 
culture medium and counted using a haemocytometer. The volume of cell suspension 
containing 1x105 cells was calculated as described before, topped with fresh complete 
medium up to 30 ml, and transferred into a 150 cm2 tissue culture flask. 
2.2.2 Cryopreservation of cell lines 
A total of 1x106 cells were resuspended in 1 ml of fresh medium with 10% dimethyl 
sulphoxide (DMSO) (Fisher Scientific by Thermo Fisher Scientific), aliquoted into a 
cryopreservation vial, frozen down to -80oC in isopropanol to keep a cooling constant of -
1oC/min and stored in liquid nitrogen. For recovery of cryopreserved cells, vials were 
thawed at 37oC and cell suspensions added to 10 ml fresh medium in a universal container. 
After 5 min centrifugation at 480 g, pellets were resuspended in fresh medium, transferred 
to a 75 or 150 cm2 tissue culture flask and incubated at 37oC / 5% or 10% CO2. 
2.2.3 Cell lines testing 
2.2.3.1 RNA extraction from cultured cells 
Total RNA was extracted from K562 or K562CLDN16 suspension cells using the 
miRNeasy Mini kit (QIAGEN, Manchester, UK). Cells were subjected to centrifugation at 
480 g for 5 min, resuspended in 10 ml of PBS, and counted using a haemocytometer 
(Hausser Scientific, PA, USA). The volume of cell suspension containing 3x106 cells was 
calculated as described in section 2.2.1, subjected to centrifugation at 480 g for 5 min, and 
resuspended in 700 µl of QIAzol Lysis Reagent, a solution of phenol that contains 
guanidine thiocyanate used for cell lysis and inhibition of RNases. Samples were 
homogenized using a vortex and incubated for 5 min at room temperature. Next, proteins 
were removed from the lysate by organic extraction adding 140 µl of chloroform, shaking 
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the samples for 15 sec and incubating them at room temperature for 3 min, followed by 15 
min centrifugation at 12000 g at 4oC. The upper aqueous phase was transferred to a fresh 
tube and 1.5 volumes of absolute ethanol were added and mixed by pipetting to precipitate 
RNA. Samples were transferred into an RNeasy Mini silica-membrane column in a 2 ml 
collection tube and subjected to centrifugation at 8000 g for 15 sec at room temperature for 
RNA binding to the membrane. Next, 700 µl of buffer RWT, also containing guanidine 
thiocyanate, were added to the column and subjected to centrifugation for 15 sec at 8000 g. 
The column was washed with 500 µl of buffer RPE to remove salts and subjected to 
centrifugation as before. RNA was eluted in a new 1.5 ml microcentrifuge tube with 30 µl 
of RNase-free water by centrifugation at 8000 g for 1 min and elution was repeated using 
the same water to maximise RNA elution yield. RNA was stored at -80oC. 
2.2.3.2 Reverse transcription of RNA 
Complementary DNA was generated from total RNA that had been extracted from K562 
or K562CLDN16 suspension cells as described in section 2.2.3.1, using the Reverse 
Transcription kit (Applied Biosystems by Life Technologies, UK). A total of 1 µg of RNA 
was added to 2 µl 10X RT buffer, 5.5 mM MgCl2, 0.5 mM each deoxyribonucleotide 
triphosphates (dNTPs), 1 µl random hexamers, 0.4 µl RNase inhibitor and 0.5 µl 
Multiscribe Reverse Transcriptase, and topped up to 20 µl with RNase-free water, in a 96-
well plate. Thermal cycler conditions used as follows: 25oC for 10 min (DNA annealing); 
48oC for 30 min (cDNA extension); 95oC for 5 min (reverse transcriptase inactivation). 
Resultant cDNA was kept at -20oC for storage. 
2.2.3.3 TaqMan® Real-Time PCR 
Claudin 16 gene expression from K562 and K562CLDN16 suspension cells was quantified 
by TaqMan Real-Time PCR. This method consists in the use of a set of forward and 
reverse primers specific for the gene of interest and a TaqMan® oligonucleotide probe 
labelled with a reporter fluorophore at the 5’ end and a quencher at the 3’ end that prevents 
fluorescent emission by the fluorophore while both are attached to the probe. The 
TaqMan® probe recognizes and binds to a sequence on the cDNA downstream of the 
forward primer. The 5’3’ exonuclease activity of Taq polymerase allows cleavage of the 
TaqMan® probe upon product amplification, resulting in the separation of the fluorophore 
and the quencher and thus emission of fluorescence, the intensity of which is proportional 
to the amount of product generated. Fluorescence intensity is acquired during the 
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exponential PCR phase and the value it reaches when crossing an arbitrary threshold 
situated on the exponential phase [cycle threshold (CT)] is indicative of the amount of 
original cDNA in the samples, thus allowing comparative studies. Also, a housekeeping 
gene, the expression levels of which remain constant, is used for normalization of the 
reads, correcting for errors in cDNA content between samples.  
A total of 1.5 µl of cDNA, 5 µl 2X Universal TaqMan® mastermix II (containing buffer, 
dNTPs with dUTP, AmpliTaq Gold DNA Polymerase and ROXTM Passive Reference) 
(Applied Biosystems by Life Technologies, UK), 0.5 µl TaqMan® probe, and 8.5 µl 
nuclease-free water were added in triplicate to a 384-well plate. A negative control 
containing nuclease-free water instead of cDNA controled for DNA contaminations in any 
of the reagents. Claudin 16 mRNA probe (Table 2-1): Mm00475025_m1 conjugated to the 
fluorochrome FAM (Life Technologies by Thermo Fisher Scientific, UK); 18S ribosomal 
RNA probe as housekeeping gene (Table 2-1): Hs03928985_g1 conjugated to the 
fluorochrome VIC (Life Technologies by Thermo Fisher Scientific, UK). Thermal cycler 
conditions used as follows: 50oC for 2 min; 95oC for 10 min (DNA denaturation); 95oC for 
15 sec and 60oC for 1 min (DNA denaturation, annealing and extension) repeated 40 times. 
The 2(CT gene of interest – CT housekeeping gene) method (Livak and Schmittgen, 2001) was followed 
for graphical representation of results. The 7900HT Sequence Detection System v2.3 
(Applied Biosystems, California, USA) was used for analysis. 
2.2.3.4 Flow cytometry  
Expression levels of CAR protein on the plasma membrane were measured by flow 
cytometry. Flow cytometry allows the classification of cells in solution by measurement of 
size (FSC; forward scatter) and granularity or internal complexity (SSC; side scatter), 
which are determined by how the cell scatters incident laser light. Also, cells expressing a 
specific protein can be quantified by detection with a fluorescently labelled antibody.  
Cultured cells were washed with DPBS, dissociated with citric saline and resuspended in 
ice-cold serum-free (SF) medium to a concentration of 4x106 cells/ml. A total of 2x105 
cells (50 µl of cell suspension) were added to FACS tubes and incubated with an equal 
volume of mouse anti-CAR IgG1 primary antibody (clone: RmcB, Upstate, NY, Sigma-
Aldrich) or mouse IgG (Life Technologies by Thermo Fisher Scientific) as an isotype 
control (5 µg/ml in ice-cold SF medium) for 30 min at 4oC in triplicate. Next, cells were 
washed twice with SF medium, incubated with the secondary antibody (Alexa Fluor 488-
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conjugated goat anti-mouse IgG, Life Technologies by Thermo Fisher Scientific) for 30 
min at 4oC (4 µg/ml in ice-cold SF medium), washed twice with SF medium and 
resuspended in 150 µl of ice-cold SF medium for analysis. BD FACS Canto II flow 
cytometer and BD FACSDiva v6.1.3 software were used for analysis with 1-laser 
configuration (488 nm) and FlowJo single cell analysis v10.1 software for graphical 
representation. Cells were gated on the basis of forward and side light scatter profiles, with 
a minimum of 10,000 gated events analysed per sample. Results are shown as a percentage 
of the parental population and expressed as the mean of technical triplicates +/- standard 
error of the mean (SEM).  
2.2.4 Adenoviral vector genome cloning 
2.2.4.1 Growth and cryopreservation of Escherichia coli 
E. coli were grown in Luria Broth (LB) (Sigma-Aldrich, UK) at 37oC with shaking at 200 
rpm in an Innova 44 incubator shaker (Eppendorf, Hamburg, Germany) or spread on LB 
agar plates (Luria Agar Base, Miller, Sigma-Aldrich). When bacterial selection was 
required, ampicillin (50 µg/ml), kanamycin (50 µg/ml) or streptomycin (100 µg/ml) were 
added to LB or LB agar plates. Bacterial cultures, originating from single clones and 
carrying a particular DNA plasmid, were stored in 15% (v/v) glycerol LB at -80oC. 
2.2.4.2 Plasmid DNA transformation into chemically competent 
Escherichia coli 
To amplify plasmid DNA, a total of 50 ng plasmid DNA were added to 50 µl of JM109 
chemically competent bacteria cells (Table 2-5) (Promega, UK) on ice and samples were 
incubated on ice for 30 min. Next, samples were placed into a 42oC water bath for 30 sec 
to perform heat shock and, immediately after, placed on ice for 2 min. Next, samples were 
incubated in 450 µl super optimal broth with catabolite repression (S.O.C) medium 
(Invitrogen by Life Technologies, UK) in a 1.5 µl microcentrifuge tube for 60 min at 37oC 
with shaking at 200 rpm using an Innova 44 incubator shaker (Eppendorf). Following 
incubation, 100 µl of sample were spread on LB agar plates (see section 2.2.4.1) and 
incubated at 37oC overnight. 
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2.2.4.3 Plasmid DNA transformation into electrocompetent Escherichia 
coli 
To perform homologous recombination between two DNA plasmids (“transfer vector” and 
“plasmid vector”), 50 µl of BJ5183 electrocompetent bacteria cells (Table 2-5) (Stratagene 
by Agilent Technologies) were mixed with a (transfer vector):(plasmid vector) ratio of 1:0, 
1:3, 1:6 and 1:9 on ice, where 1 stands for 100 ng DNA. The ratio 1:0 was used as a 
background control. The mix was added to a chilled 2 mm electroporation cuvette (Cell 
Projects, UK), tapped gently to remove any air bubble and incubated on ice for 3 min. 
Next, the sample was subjected to a pulse at 200Ω 2.5kV 25µF, subsequently added to 500 
µl ice-cold S.O.C medium (Invitrogen by Life Technologies, UK) in a 1.5 µl 
microcentrifuge tube, and incubated for 60 min at 37oC with shaking at 200 rpm in an 
Innova 44 incubator shaker (Eppendorf). Cells were subjected to centrifugation at 400 g 
for 1 min, resuspended in 50 µl of S.O.C medium and spread on LB agar plates (see 
section 2.2.4.1) and incubated at 37oC overnight. 
2.2.4.4 Plasmid DNA isolation 
Plasmid DNA was isolated from bacteria grown in 3 ml of LB (Sigma-Aldrich, UK) using 
a PureLink Quick Plasmid Miniprep kit (Invitrogen by Life Technologies) if low 
amounts of DNA (≤ 30 µg DNA) were required (“miniprep”) or from bacteria grown in 
200 ml using a PureLink HiPure Plasmid Filter Purification kit (Invitrogen by Life 
Technologies) if high amounts of DNA (≤ 850 µg DNA) were required (“maxiprep”), 
following the manufacturer’s instructions. In both kits, cells are lysed using an 
alkaline/sodium dodecyl sulphate (SDS) procedure and DNA is bound to a silica 
membrane and eluted. For minipreps, the elution step was repeated using the same original 
volume of elution buffer to increase DNA elution yield. For maxipreps, 250 ml Nalgene 
centrifuge bottles (Sigma-Aldrich) in a JA-10 rotor (Beckman Coulter) with an Avanti J-
26XP centrifuge (Beckman Coulter) were used to subject the bacterial culture to 
centrifugation. DNA was eluted from the DNA Binding Column into a 50 ml Nalgene 
centrifuge tube and, to precipitate the eluted DNA, a JA-20 rotor (Beckman Coulter) with 
an Avanti J-26XP centrifuge (Beckman Coulter) were used. The concentration of plasmid 
DNA isolated from either kit was quantified using a NanoDrop 1000 Spectrophotometer 
(Thermo Scientific, Loughborough, UK) as described in section 2.2.4.5, and DNA was 
stored at -20oC. 
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2.2.4.5 Nucleic acid quantification 
The concentration of DNA and RNA from samples was quantified using a NanoDrop 1000 
Spectrophotometer (Thermo Scientific, Loughborough, UK). Samples were subjected to a 
260 nm UV light beam and absorbance was measured. DNA or RNA concentration was 
calculated using the Beer-Lambert law: A = ε x c x l, where A = absorbance of the sample, 
ε = molar absorptivity (constant for a given solution), c = nucleic acid concentration, l = 
path length of solution passed through by the light beam. Taking into account that proteins 
can absorb light at 280 nm, EDTA, guanidine HCl and other contaminants at 230 nm, and 
phenol at 230 nm and 270 nm, sample purity was examined by calculating the ratio A260 nm 
/ A280 nm and A260 nm / A230 nm. Samples with an A260 nm / A280 nm ratio higher than 1.8 for 
DNA or 2 for RNA, or with a A260 nm / A230 nm ratio higher than 2 were considered pure and 
used for further analysis. 
2.2.4.6 Restriction endonuclease digestion of plasmid DNA 
For screening of bacterial colonies carrying a specific DNA plasmid, DNA was extracted 
from single colonies (see section 2.2.4.4), digested with restriction endonucleases, and the 
amount and size of DNA bands were verified by agarose gel electrophoresis (see section 
2.2.4.7). With this purpose, 1 µg DNA was digested with 5 units of restriction 
endonuclease with the addition of buffer and bovine serum albumin (BSA), as per 
manufacturer’s instructions (New England Biolabs), in a final volume of 20 µl in nuclease-
free water, and incubated overnight at 37oC.  
When enzymatic digestion of plasmid DNA was required for subsequent cloning (e.g: 
homologous recombination of DNA plasmids or ligation of DNA plasmids) or transfection 
into eukaryotic cells, the required amount of plasmid DNA to be digested was chosen and 
digested in 50 µl final volume in nuclease-free water. A total of 5 units of restriction 
endonuclease per 1 µg DNA were used (volume of restriction endonuclease never 
exceeding 10% of final volume) along with buffer and BSA as indicated by the 
manufacturer (New England Biolabs). Samples were incubated overnight at 37oC. When 
enzymatic digestion was completed, restriction endonucleases were inactivated at 65oC for 
20 min or as indicated by the manufacturer.  
    Chapter 2 | Materials and methods 
81 
 
2.2.4.7 Agarose gel electrophoresis 
UltraPureTM Agarose (Invitrogen by Life Technologies) was dissolved in UltraPureTM TBE 
buffer [0.1 M Tris, 0.09 M boric acid, 0.001 M EDTA] (Life Technologies by Thermo 
Fisher Scientific) at 0.8% (w/v) by heating, with the addition of 0.5 µg/ml ethidium 
bromide (Sigma-Aldrich). DNA samples (≥1 µg) with the addition of Blue/Orange loading 
dye [0.4% orange G, 0.03% blomophenol blue, 0.03% xylene cyanol FF, 15% Ficoll 
400, 10 mM Tris-HCl pH 7.5, 50 mM EDTA pH 8.0] (Promega, UK) were loaded into the 
agarose wells along with 1 µg of 1 kb DNA ladder (Promega, UK), which was used as a 
marker of molecular weight. DNA fragments were separated by electrophoresis in TBE at 
a constant voltage of 100 V at room temperature, and visualized using a ChemiDocTM 
XRS+ System with Image LabTM software.  
2.2.4.8 Isolation and purification of DNA fragments from agarose gel 
DNA fragments were separated by agarose gel electrophoresis and extracted from the 
agarose gel using the Wizard SV Gel and PCR Clean-Up System (Promega, UK), which 
uses a silica membrane SV Minicolumn to bind the extracted DNA, following the 
manufacturer’s instructions. DNA bands were visualized using a transilluminator (UVP) 
and the elution step was repeated using the same original volume of nuclease-free water to 
increase DNA extraction yield. Isolated DNA was stored at -20oC until further use.  
2.2.4.9 Plasmid DNA 5’ end dephosphorylation 
To prevent self-ligation reactions of enzymatically digested DNA plasmids at a single site 
that would lead to recircularization, 5’ end of plasmids were dephosphorylated. The 
amount of enzymatically digested plasmid DNA to be dephosphorylated was chosen 
according to the amount of DNA required for subsequent cloning steps, and diluted up to 
30 µl in nuclease-free water. A total of 2 units of Antarctic Phosphatase (AP) (New 
England Biolabs, UK) were used per µg of digested plasmid DNA. The following formula 
was used to calculate the amount of buffer required for each reaction: Total reaction 
volume (Y) = 30 µl digested plasmid DNA + volume AP in µl (X) + volume of buffer in µl 
(Y/10), where X is a known value. Samples were incubated for 15 min at 37oC and AP was 
subsequently inactivated by incubation of samples at 65oC for 5 min. 
    Chapter 2 | Materials and methods 
82 
 
2.2.4.10 DNA precipitation 
DNA was mixed by vortexing with 3 M acetic acid pH 4.8 to a final concentration of 
2.44% (v/v) and with ethanol absolute (pre-cooled at -20oC) to a final concentration of 
73.17%, and incubated at -20oC for 60 min. Next, the sample was subjected to 
centrifugation at 16000 g for 5 min, the supernatant was removed, and DNA was air dried 
for 10 min and resuspended in DNase-free water. 
2.2.4.11 DNA ligation 
Backbone plasmid DNA and insert DNA were ligated at molar ratios 1:1 and 1:3, where 1 
stands for 50 ng backbone DNA. One µl T4 DNA ligase (New England Biolabs) was 
added to a total of 20 µl of 1X buffer in nuclease-free water containing both the backbone 
and the insert, and incubated overnight at 16oC. A background control was included, where 
the insert was replaced with nuclease-free water. When enzymatic ligation was completed, 
T4 DNA ligase was inactivated at 65oC for 10 min as indicated by the manufacturer, and 5 
µl of reaction was transformed into JM109 chemically competent bacteria cells (see 
section 2.2.4.2). 
2.2.4.12 DNA sequencing 
Specific DNA sequences within the adenoviral hexon, penton base or fiber ORFs were 
sequenced to verify the presence of mutations that had been introduced into the adenoviral 
vector’s genome by genetic engineering. The BigDye Terminator v3.1 Cycle Sequencing 
kit (Applied Biosystems by Life Technologies) was used to perform Sanger Sequencing. 
This method uses dNTPs and 2’,3’-dideoxyribonucleotide triphosphates (ddNTP), which 
lack a 3’-hydroxyl group and are labelled to a specific fluorescent dye depending on their 
nitrogenous base. Both nucleotides are incorporated into the nascent DNA, but when a 
ddNTP is incorporated, elongation is terminated. DNA products are separated by size by 
capillary electrophoresis and passed through a laser beam that allows the discrimination 
between the 4 different nitrogenous bases and, therefore, identification of DNA nucleotide 
sequence. 
A total of 200 ng of purified DNA amplicons (see section 2.2.5.16) or extracted plasmid 
DNA (see section 2.2.4.4), together with 4 µl of BigDye Terminator sequencing buffer 5X, 
1 µl Terminator Ready Reaction Mix and 2 µl of 2 µM sequencing primers (final 
concentration of 0.2 µM) (Table 2-1) were used per reaction in a 96-well plate as indicated 
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by the manufacturer. Sequencing reaction mix was adjusted to 20 µl with deionized water. 
Thermal cycler conditions used as follows: 96oC for 45 sec (DNA denaturation); 96oC for 
45 sec (DNA denaturation), 50oC for 25 sec (DNA annealing) and 60oC for 4 min (DNA 
extension) repeated 24 times. Samples were purified immediately after or stored at 4oC and 
purified on the next day. 
Purification of the DNA extension products was performed using Agencourt 
CleanSEQ (Beckman Coulter), which is based on Solid Phase Reversible Immobilization 
(SPRI) technology, where DNA is purified by binding to magnetic beads. The purification 
process was performed following the manufacturer’s instructions. A total of 40 µl 
nuclease-free water were used to resuspend DNA:magnetic bead complexes and, of those, 
20 µl were transferred to a MicroAmp Optical 96-well reaction plate (Applied Biosystems 
by Thermo Fisher Scientific). DNA extension products were separated by capillary 
electrophoresis in a 3730 DNA Analyzer (Applied Biosystems by Thermo Fisher 
Scientific) using 3730 Data collection v3.0 software. The obtained DNA sequences were 
analysed with Sequencing Analysis v5.2 software. 
2.2.5 Adenoviral vector amplification and quality control 
2.2.5.1 Adenoviral DNA transfection into HEK-293 cells 
Adenoviral vector genomes were linearized with PacI and the restriction endonuclease was 
subsequently heat-inactivated (65oC for 20 min) prior to transfection into eukaryotic cells 
(see section 2.2.4.6). A total of 4 µg of digested plasmid DNA were transfected per well 
into low passage HEK-293 packaging cells in a 6-well plate at 70% confluence (6x105 
cells/well) using Lipofectamine 2000 as per manufacturer’s instructions (Invitrogen by 
Life Technologies, USA). Since HEK-293 cells have the adenoviral E1 gene incorporated 
into their genome, they complement the E1 deficiency from adenoviral vectors and thus 
allow adenovirus propagation (Graham et al., 1977). After 5 h of incubation at 37oC / 5% 
CO2, 2 ml of fresh medium were added per well and, 24 h post-transfection, the medium 
was completely replaced with fresh medium. Medium was changed every 2-3 days and, 10 
days post-transfection, cells were collected and freeze-thawed to release the adenoviral 
vectors. Transfection of circular PD10-GFP plasmid was used as a control for transfection 
and as an indicator of transfection efficiency.  
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2.2.5.2 Adenoviral DNA transfection into Per.C6® cells 
Adenoviral vector genomes were linearized with PacI and restriction endonuclease was 
subsequently heat-inactivated prior to transfection into eukaryotic cells (see section 
2.2.4.6). A total of 8 µg were transfected into 3x106 cells Per.C6 (Crucell) packaging 
cells grown overnight in a T25 cm2 culture flask using Lipofectamine 2000 as per 
manufacturer’s instructions (Invitrogen by Life Technologies, USA). Per.C6 cells 
contain the adenoviral E1 gene into their genome to allow adenovirus propagation (Fallaux 
et al., 1998). After 5 h of incubation at 37oC / 5% CO2, 3 ml of fresh medium were added 
and, 24 h post-transfection, the medium was completely replaced with fresh medium. 
Medium was changed every 2-3 days and 8 days post-transfection cells were collected and 
freeze-thawed to release the adenoviral vectors.  
2.2.5.3 Generation of crude adenoviral vector stocks 
Rescued adenoviral vectors and pure adenoviral vector preparations were propagated in 
HEK-293 packaging cells or Per.C6® packaging cells (Crucell) (HAdV-5 KO1). When 
cytopathic effect (CPE) was observed, cells were detached from the culture flask by 
tapping, subjected to centrifugation at 480 g for 5 min, resuspended in DPBS (1 ml for 
early amplification steps and 6 ml when cells from 25 T150 cm2 culture flasks were pooled 
together), and lysed with 1,1,2-trichloro-1,2,2-trifluoroethane (ArkloneP) (Sigma-Aldrich) 
(see section 2.2.5.4). When 25 T150 cm2 culture flasks were used, one T150 cm2 culture 
flask was treated individually to generate a seed stock: cell resuspension in 1 ml of DPBS 
and lysis with ArkloneP. The seed stock was aliquoted into 100 µl aliquots and used for 
future adenovirus preparations.  
2.2.5.4 Adenoviral vector extraction from eukaryotic cells 
Adenoviral vectors were extracted from cellular suspensions using the organic dissolvent 
ArkloneP (Sigma-Aldrich) for cell lysis. An equal volume of ArkloneP was added to cells 
re-suspended in DPBS. The container was inverted for 30 sec followed by gentle shaking 
for 10 sec, and this process was repeated 4 times. After centrifugation at 750 g for 15 min 
at room temperature, the DPBS fraction containing the adenoviral vectors was collected 
and stored at -80oC.  
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2.2.5.5  Generation of pure adenoviral vector preparations by 
purification via double CsCl gradient ultracentrifugation 
Purification of adenovirus preparations allows concentration of the adenoviral vector and 
removal of empty adenovirus particles and contaminants such as cell debris or media 
components. Ultracentrifuge clear tubes (Beckman Coulter, UK) were rinsed with 70% 
ethanol and sterile water and a first CsCl gradient was generated by adding 2.5 ml of 1.25 
g/ml CsCl and 2.5 ml of 1.40 g/ml CsCl at the bottom. The crude adenoviral lysate from 
25X T150 cm2 culture flasks production was added gently on top of the CsCl gradient, 
topped up with DPBS and subjected to ultracentrifugation in a SW40 Ti rotor at 90000 g 
and 18oC for 1.5 h. On completion of the spin, two distinct white bands were observed 
between the two CsCl fractions: the upper band containing pure immature adenoviral 
vectors and the lower band pure mature adenoviral vectors (Figure 2-2A). The lower band 
was collected in the minimal volume possible by piercing the tube underneath the 
adenovirus layer with a 19 gauge needle. Extracted adenoviral vectors were added to a 
fresh ultracentrifuge tube containing 5 ml 1.34 g/ml CsCl solution and topped up with 
DPBS. After 18 h ultracentrifugation at 90000 g and 18oC in a SW40 Ti rotor, a unique 
adenovirus white band was obtained (Figure 2-2B) and collected with a 21 gauge needle in 
less than 1 ml and injected for dialysis into a Slide-A-Lyzer Dialysis Cassette G2 
(molecular weight cut-off of 10000 Da) (Perbio Science by Thermo Scientific, UK) that 
had been previously hydrated in TE buffer [0.01 M Tris pH 8, 0.001 M EDTA]. The 
adenoviral vector solution was dialysed by two rounds of 2 h in 2 litres TE followed by an 
overnight dialysis in 2 litres TE 10% (v/v) glycerol. The adenoviral vector solution (pure 
adenoviral vector preparation) was extracted from the cassette and stored at -80oC. 
 
Figure 2-2. Purification of a HAdV-5 preparation by double CsCl gradient ultracentrifugation. A) 
Crude adenoviral lysate after the first ultracentrifugation step. The upper band corresponds to immature 
adenovirus particles, the lower band to mature adenovirus particles, and cell debris is found on top of the 
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upper band. Arrow indicates the band that is collected for the second gradient. B) Mature adenovirus particles 
after the second ultracentrifugation step. 
2.2.5.6 X-Gal staining 
Expression of β-galactosidase reporter gene was detected from cells transduced with 
adenoviral vectors that encode the LacZ reporter gene, using 5-bromo-4-chloro-3-indolyl-
β-D-galactoside (X-Gal) as a substrate for β-galactosidase. X-Gal is a synthetic organic 
compound composed of a galactose and an indole that when hydrolysed generates an 
insoluble blue product, allowing the identification of active β-galactosidase (Horwitz et al., 
1964).  
Cells were washed once with DPBS, fixed in 2% (w/v) paraformaldehyde (PFA) (100 
µL/well for 96-well plates and 1 ml/well for 6-well plates) at room temperature for 10 min, 
washed with DPBS twice and stained with X-Gal staining solution [0.1 M phosphate 
buffer, pH 7.3, 1.3 mM MgCl2, 3 mM K3F3(CN)6, 3 mM K4Fe(CN6)6, 1 mg/ml X-gal] (200 
µL/well for 96-well plates and 3 ml/well for 6-well plates) at 37oC overnight.  
When staining for β-galactosidase expressed in whole mouse organs, organs (liver, spleen, 
lungs, intestine, kidney, heart and pancreas) that had been fixed in 2% (w/v) PFA 
overnight at 4oC were washed twice in 5 ml DPBS and stained with 5 ml X-Gal staining 
solution at 37oC overnight. Stained organs were stored in 70% ethanol at 4oC.  
2.2.5.7 Replication-competent adenovirus (RCA) assessment 
Replication-competent adenoviruses (RCA) are adenoviral particles that can replicate in 
non-permissive (E1-/-) cells and can result from the use of HEK-293 packaging cells for 
vector propagation (Lochmuller et al., 1994, Hehir et al., 1996). HEK-293 cells have an 
integrated 4344 bp fragment of the left end of the HAdV-5 genome containing the left 
inverted terminal repeat (LITR), the packaging signal and E1 and pIX genes (Louis et al., 
1997, Graham et al., 1977). Presence of HAdV-5 sequences flanking the E1 gene in the 
packaging cell line can result in homologous recombination events between HAdV-5-
based genomes and the cell genome and lead to the production of E1+ viral genomes and 
thus RCAs (Hehir et al., 1996, Lochmuller et al., 1994). In contrast, since Per.C6® cells 
contain only E1A and E1B-coding sequences (HAdV-5 nucleotides 459-3510), their use 
for vector propagation does not result in RCAs (Fallaux et al., 1998). A maximum of 1 
RCA per 3x1010 vp is accepted by FDA guidelines (FDA Gene Therapy Letter, 2000).  
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The presence of RCA was tested from pure adenoviral preparations by transducing non-
permissive HeLa cells at a density of 50-60% with 100 µl of the same adenovirus dilutions 
prepared for the titer determination of adenoviral plaque forming units (pfu) (see section 
2.2.5.9). Medium was changed to fresh complete medium every 2-3 days for a total of 8 
days. The presence of CPE or individual viral plaques was carefully checked during the 
process. 
2.2.5.8 Titre determination of physical adenoviral particles  
The concentration of physical adenoviral particles from pure adenovirus preparations was 
calculated using the micro bicinchoninic acid (BCA) Protein Assay (Pierce, Thermo Fisher 
Scientific, USA). This assay is based on the detection of Cu+1, generated when protein 
reduces Cu2+ in an alkaline environment. Two molecules of BCA chelate one molecule of 
Cu+1 producing a soluble purple product that absorbs light at 562 nm and thus can be 
quantified by colorimetric detection. The increase in absorbance directly correlates to the 
amount of protein present in the samples. The amount of protein present per unit volume is 
used as an indicative of the amount of adenovirus in the sample tested.  
BSA standards were prepared at concentrations ranging from 0.5 µg/ml to 200 µg/ml 
according to the manufacturer’s instructions. Adenovirus samples were diluted 1/150, 
3/150 and 5/150 in a final volume of 300 µl of DPBS and 150 µl of sample, BSA standards 
or DPBS (blank control) were added in duplicate in a 96-well culture plate. Next, an equal 
volume of BCA working reagent (solutions A, B and C in a ratio 25:24:1) was added to all 
wells and plate was incubated at 37oC for 2 h. Following incubation, the absorbance was 
assessed at 562 nm using a VICTORTM X3 Multilabel Plate Reader (PerkinElmer). Protein 
concentration was calculated by extrapolating from the standard curve after subtracting the 
absorbance from the blank control, and the number of adenoviral particles per unit volume 
(vp/ml) was determined using the formula: 1 µg protein = 4x109 vp, which is based on the 
HAdV-5 particle molecular weight of ~150 MDa (World WSM and Horwitz MS, 2007). 
2.2.5.9 Titre determination of infectious adenoviral particles by end-
point dilution assay 
The ratio vp/pfu is a quality control indicator of how infective an adenovirus preparation 
is, where a high ratio corresponds to lower quality and poorly infective preparations, which 
can be due to the presence of a high quantity of immature non-infective adenovirus 
particles [reviewed by (Vellinga et al., 2014)]. This value becomes essential when the 
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preparation is going to be administered in vivo in order to diminish toxicity. Also, the 
vp/pfu ratio is useful to detect possible propagation deficiency when producing novel 
mutant adenoviral vectors. However, vp/pfu values should be considered carefully since 
the intrinsic infectivity may vary between adenovirus serotypes or mutants. Thus, 
acceptable vp/pfu values should be determined for each particular adenoviral vector. For 
recombinant HAdV-5 vectors to be used in gene therapy and in particular in in vivo 
studies, the FDA Advisory Committee recommends a vp/pfu ratio of 30 (FDA Gene 
Therapy Letter, 2000) in order to diminish associated toxicity issues.  
Pure adenovirus preparations were diluted in complete medium in ten-fold serial dilutions 
and 100 µl were added to 50-60% confluent HEK-293 packaging cells or Per.C6 
packaging cells (Crucell) in the case of HAdV-5 KO1 in a 96-well plate with ten replicates 
of each dilution. Medium was changed after 16-18 h incubation at 37oC / 5% CO2 (HEK-
293 cells) or 10%CO2 (Per.C6 cells) and replaced with fresh complete medium every 2-3 
days until CPE was apparent. After 8 days, the number of wells with visible plaques for 
each dilution were counted and fitted into the following equations to determine the titre of 
the adenoviral vector preparation in pfu/ml: Proportionate distance = (% positive wells 
from dilution with above 50% positive wells - 50%) / (% positive wells from dilution with 
above 50% positive wells - % positive wells from dilution with below 50% positive wells). 
Log ID50 (infectivity dose) = [(-1) / (dilution above 50% positive wells)] - proportionate 
distance. Viral tissue culture ID50 (TCID50) / ml = 1 / [10(log ID50)] x 10 (conversion factor). 
Pfu/ml = 0.7 x TCID50/ml. 
Adenoviral plaques were not clearly visible when Per.C6 (Crucell) cells were used. 
Therefore, transduced cells (β-galactosidase-positive cells) were stained with X-Gal 
staining solution (see section 2.2.5.6) to ensure that all wells with plaques were considered 
for the calculations. In order to fairly compare adenoviral infectivity for the different pure 
adenoviral vector preparations, all titers of adenoviral pfu/ml were assessed both by eye 
and by X-Gal staining. Also, AdT*KO1 AAA and AdT*KO1 AAAASFPPAFAAA failed 
to form plaques. Thus, titers of these two vectors were determined in infectious units 
(IU)/ml by assessing the presence or absence of individual transduced cells in the wells by 
X-Gal staining following the same equations as above. 
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2.2.5.10 Nanoparticle Tracking Analysis (NTA) 
The laser-based Nanoparticle Tracking Analysis (NTA) by NanoSight is a technology that 
through individual visualization of nanoscale particles in solution in real-time, it allows the 
generation of high-resolution particle size distribution profiles (detection limit of 10 nm) 
and particles quantification (Figure 2-3). This technology was used to characterize the size 
of adenoviral particles from pure preparations, and identify the possible presence of 
aggregates.  
Pure adenoviral vector preparations were diluted 1/100 or 1/1000 in DPBS to a total of 700 
µl in order to have an approximate concentration of 1x107-1x1010 vp/ml as indicated by the 
manufacturer, and loaded into the instrument with a 1 ml syringe. Adenoviral particles in 
solution were recorded and analysed with Nanosight NTA v2.3 software.  
 
Figure 2-3. NanoSight output of a pure HAdV-5 preparation. A) Concentration (vp/ml) vs. particle size 
(nm). B) Nanoparticle Tracking Analysis (NTA) video frame of adenoviral particles. C) Intensity of the 
scattered light [arbitrary units (AU)] vs. particle size (nm). D) 3D representation of (C) where Z axis 
represents the amount of adenoviral particles for each (X,Y) coordenate. 
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2.2.5.11 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
A polyacrylamide gel composed of a 12% resolving gel [40% (v/v) Acrylamide/Bis 
Solution 30% (BIO-RAD, UK), 0.375 M Tris pH 8.8, 0.1% (w/v) sodium dodecyl sulphate 
(SDS) in ultrapure water] and a 4% stacker gel [13.3% (v/v) Acrylamide/Bis Solution 30% 
(BIO-RAD, UK), 0.125 M Tris pH 6.8, 0.1% (w/v) SDS in ultrapure water] was prepared. 
For polyacrylamide polymerization, 0.438 M ammonium persulphate (APS) (Thermo 
Fisher Scientific) was added to a final concentration of 1% (v/v) and N,N,N’,N’-
tetramethylethylenediamine (TEMED) (Sigma-Aldrich) was added to a final concentration 
of 0.1% (v/v). A total of 5x1010 adenoviral particles from pure adenoviral vector 
preparations were mixed with loading buffer 5X [10% (v/v) Tris-HCl pH 6.8, 10% (w/v) 
SDS, 30% (v/v) glycerol, 0.1% (w/v) bromophenol blue, 2% (v/v) β-mercaptoethanol] in a 
total volume of 100 μl in PBS. β-mercaptoethanol is used to reduce disulphide bonds in 
proteins and SDS to denature proteins and confer an overall negative charge to allow the 
separation of proteins uniquely by size (Laemmli, 1970). Samples were also heated to 95oC 
for 10 min to completely denature proteins. Samples, along with 20 μl of rainbow ladder 
(Amersham Bioscience UK Ltd, UK), which was used as a marker of molecular weight, 
were loaded into the polyacrylamide gel and electrophoresed at 100 V in running buffer 
[25 mM Tris-HCl, 0.2 M glycine, 0.1% (w/v) SDS pH 8.3] until the samples reached the 
resolving gel and then at 200 V until the dye front reached the bottom of the gel. 
2.2.5.12 Silver staining 
Adenoviral capsid composition and integrity of capsid structure of pure adenoviral vector 
preparations were confirmed by silver staining (Thermo Scientific by Life Technologies) 
performed on a polyacrylamide gel after electrophoretic separation of proteins (see section 
2.2.5.11), according to the manufacturer’s instructions. In this assay, proteins bind to silver 
ions that, when reduced, allow the visualization of such proteins. Gels were scanned using 
a ChemiDocTM XRS+ System with Image LabTM software.  
2.2.5.13 Western blotting analysis 
The presence of heterologous peptides into the HI loop of the adenovirus fiber knob 
domain was confirmed by western blotting. After electrophoretic separation of proteins on 
a polyacrylamide gel (see section 2.2.5.11), the gel was washed with Transfer buffer [0.2 
M glycine, 25 mM Tris, 20% methanol, 0.01% (w/v) SDS] for 10 min and protein bands 
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were transferred to a hydrophobic Amersham Hybond-P 0.45 µm polyvinylidene difluoride 
(PVDF) membrane (GE Healthcare Life Sciences, UK) at 90 mV overnight at 4oC. The 
membrane was pre-treated by incubation in methanol for 10 sec, followed by 5 min in 
ultrapure water and 10 min in Transfer buffer. After protein transfer, the membrane was 
blocked with TBS-Tween (TBST) [150 mM NaCl, 50 mM Tris, 0.1% (v/v) Tween-20] 
with the addition of 10% (w/v) fat-free milk powder for 3 h at 4oC. Next, the membrane 
was incubated with mouse anti-adenovirus fiber IgG2a primary antibody (clone: 4D2, 
Abcam) at 37oC for 60 min on an orbital shaker (0.2 µg/ml), washed twice with blocking 
buffer for 5 min each, incubated with secondary antibody (HRP-conjugated rabbit anti-
mouse IgG (Abcam)) for 60 min at room temperature with shaking (1 µg/ml), and 
washed 4 times with blocking buffer for 15 min each and twice with TBST for 15 min 
each. Protein bands were visualized using AmershamTM ECLTM Prime western blotting 
chemiluminescent detection reagent (GE Healthcare Life Sciences, UK), by which the 
membrane was incubated for 5 min at room temperature with a mix of Solution A (luminol 
as the chemiluminescent substrate) and Solution B (peroxide as the oxidizing agent) in 
equal proportions. Next, the membrane was drained from excess detection reagent, 
wrapped in clear cling film and placed on a Kodak Medical X-ray film General Purpose 
Blue/MXBE (Carestream, USA). The film was developed using a Kodak X-OMAT 1000 
developer and scanned using a ChemiDocTM XRS+ System with Image LabTM software. 
2.2.5.14 Adenoviral DNA extraction 
Adenoviral DNA was extracted from 1 µl pure adenoviral vector preparations or crude 
adenoviral vector stocks (see sections 2.2.5.5 and 2.2.5.3) using the QIAamp 
UltraSensTM Virus kit (QIAGEN, Manchester, UK) according to the manufacturer’s 
instructions. In this assay, samples are mixed with buffer containing a proprietary reagent 
that forms complexes with nucleic acids, which can then be sedimented by low-g-force 
centrifugation (QIAGEN, 2016). Next, DNA is bound to a silica-membrane QIAamp spin 
column, washed and eluted. The elution step was repeated using the same original volume 
of elution buffer to increase DNA extraction yield and isolated DNA was stored at -20oC 
until further use. 
2.2.5.15 Polymerase chain reaction (PCR) 
PCR was performed to amplify specific DNA sequences within the adenoviral hexon, 
penton base or fiber ORFs for their subsequent sequencing, using adenoviral DNA 
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extracted from pure adenoviral vector preparations or crude adenoviral vector stocks (see 
section 2.2.5.14) following the GoTaq G2 DNA Polymerase protocol provided by 
Promega. A total of 200 ng DNA, 10 µl colourless GoTaq reaction buffer (7.5 mM MgCl2) 
along with additional 2.5 µl of 1.25 mM MgCl2 for a final MgCl2 concentration of 2.75 
mM, 0.2 mM each dNTPs, 1.25 units GoTaq DNA polymerase, 5 µl of 2 µM forward and 
reverse primers (final concentration of 0.2 µM) (Table 2-1) and nuclease-free water up to a 
total reaction volume of 50 µL, were used per reaction in a 96-well plate. A negative 
control without the addition of DNA was done for each set of primers to assess for DNA 
contaminations in any of the reagents. Thermal cycler conditions used as follows: 95oC for 
2 min (DNA initial denaturation); 95oC for 1 min (DNA denaturation), 55oC for 1 min 
(DNA annealing) and 72oC for 3 min (DNA extension) repeated 30 times; 72oC for 5 min. 
Samples were subsequently purified and stored at 4oC. 
2.2.5.16 DNA purification of PCR amplicons 
PCR amplicons were purified prior to sequencing to eliminate primers, excess of dNTPs, 
salts, DNA polymerase and other components from the PCR reaction (see section 
2.2.5.15). Purification was performed using the Agencourt AMPure XP PCR 
purification system (Beckman Coulter, UK) following the manufacturer’s instructions. 
This system is based on the Agencourt’s solid-phase paramagnetic bead technology, by 
which DNA is purified by binding to magnetic beads. After DNA purification, samples 
were immediately sequenced (see section 2.2.4.12) or kept overnight at 4oC to be 
sequenced on the following day. 
2.2.6 Adenoviral vector experiments 
2.2.6.1 In vitro transduction assay with suspension cells  
K562 or K562CLDN16 suspension cells were seeded at 2x106 cells/well and incubated 
with 5000 vp/cell in SF medium in 6 well-plates at 37oC / 5% CO2 for 3 h on an orbital 
shaker at 90 rpm. Following incubation, cells were transferred to individual sterile 2 ml 
microcentrifuge tubes, subjected to centrifugation at 100 g for 5 min, resuspended in 2 ml 
fresh complete medium, transferred to new 6 well-plates and further incubated at 37oC for 
48 h. Following incubation, cells were transferred to individual 2 ml microcentrifuge tubes, 
subjected to centrifugation at 100 g for 5 min, resuspended in 2 ml DPBS, subjected to 
centrifugation again at 100 g for 5 min and resuspended in 200 µl of Reporter lysis buffer 
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[20 mM K3PO4 pH 7.8, 0.04% (v/v) Triton X-100] (Promega, USA). Wells were assessed 
for β-galactosidase activity (see section 2.2.6.5). 
2.2.6.2 In vitro coagulation factor X transduction assay 
A total of 1x104 cells/well seeded on a 96-well culture plate were incubated for 3 h at 37oC 
/ 5% CO2 with 1000 vp/cell in SF medium with or without recombinant hFX at a working 
concentration of 10 µg/ml (Haematologic Technologies). Next, the medium was replaced 
with fresh complete medium and cells incubated for further 48 h at 37oC / 5% CO2. When 
indicated, 50 µl SF medium containing 10 µg/ml of hFX was pre-incubated at 56oC for 30 
min before the addition of 2x1010 vp/ml adenoviral vector and incubation for 30 min at 
37oC. In that case, adenovirus suspensions were diluted 200-fold in SF medium following 
incubation, 1000 vp/cell were added onto cells (previously washed with SF medium) and 
cells incubated at 37oC / 5% CO2 for 2 h. After the 2 h incubation, medium was replaced 
with 2% fetal calf serum (FCS)-containing medium, and cells were further incubated for 
~20 h at 37oC / 5% CO2. In all conditions, cells were washed with DPBS following 
incubation and lysed with 100 µl of Reporter lysis buffer [20 mM K3PO4 pH 7.8, 0.04% 
Triton X-100] (Promega, USA), and wells were assessed for β-galactosidase activity (see 
section 2.2.6.5). 
2.2.6.3 In vitro adenovirus neutralization assay 
A total of 1x104 cells/well were plated on 96-well culture plates and incubated overnight at 
37oC / 5% CO2. As previously described (Xu et al., 2013), adenoviral vectors (2x1010 
vp/ml) were incubated for 30 min at 37oC with 50 µl SF medium, 90% fresh male mouse 
serum or serum pre-incubated with X-bp (40 µg/ml) at room temperature for 10 min to 
inhibit HAdV-5-based adenoviral vectors binding to FX. Pure mouse IgM antibodies were 
added to mouse serum when indicated [50, 150 or 300 µg/ml, as per previous reports (Xu 
et al., 2013)] and incubated for 10 min at room temperature prior to addition of X-bp. 
Where indicated, mouse serum was pre-incubated at 56oC for 30 min before the addition of 
X-bp to inhibit the complement system, as described previously (Xu et al., 2013). 
Following 30 min incubation at 37oC, adenoviral vector suspensions were diluted 200-fold 
in SF medium, 1000 vp/cell were added onto cells (previously washed with SF medium) 
and cells incubated at 37oC / 5% CO2 for 2 h. When IgM antibodies were used, volumes of 
all samples were equalized with SF medium to maintain adenovirus concentration constant 
across samples prior to diluting the samples by 200-fold. After the 2 h incubation at 37oC, 
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medium was replaced with 2% FCS-containing medium, and cells were further incubated 
for ~20 h at 37oC / 5% CO2. Cells were washed with DPBS and lysed with 100 µl of 
Reporter lysis buffer [20 mM K3PO4 pH 7.8, 0.04% Triton X-100] (Promega, USA), and 
wells were assessed for β-galactosidase activity (see section 2.2.6.5). 
2.2.6.4 In vitro fiber knob competition assay 
A total of 1x104 cells/well were plated on 96-well culture plates and incubated overnight at 
37oC / 5% CO2. Cells were washed with SF medium and incubated for 30 min at 4oC with 
1 µg/well (as per Lynda Coughlan’s unpublished observation) of recombinant fiber knob 
(FK) (Coughlan et al., 2009) or FK* [Y477A4 point mutation in the fiber DE loop to 
impair binding to CAR (Roelvink et al., 1999, Kirby et al., 2000, Alemany and Curiel, 
2001)] (kindly provided by Lynda Coughlan, University of Glasgow, UK) in 50 µl of SF 
medium per well. HAdV-5 (2x1010 vp/ml) was incubated for 30 min at 37oC with 50 µl SF 
medium, 90% fresh male mouse serum or serum pre-incubated with X-bp (40 µg/ml) at 
room temperature for 10 min to inhibit HAdV-5 binding to FX, as previously described 
(Xu et al., 2013). Where indicated, HAdV-5 was incubated in 50 µl SF medium with hFX 
at a working concentration of 10 µg/ml (Haematologic Technologies) for 30 min at 37oC. 
After the 30 min incubation at 37oC, adenoviral vector suspensions were diluted 100-fold 
in SF medium, 50 µl were added onto cells (1000 vp/cell) that had been pre-incubated with 
FK or FK* and cells were incubated for 2 h at 37oC / 5% CO2. In experiments where the 
only condition tested was HAdV-5 on FK or FK*-treated cells, 1000 vp/cell in 50 µl SF 
medium (2x108 vp/ml) were added onto cells that had been pre-incubated with FK or FK* 
as described before, and cells were incubated for 2 h at 37oC / 5% CO2. In all the 
conditions, medium was replaced with 2% FCS-containing medium after the 2 h 
incubation at 37oC, cells were further incubated for ~20 h at 37oC / 5% CO2, washed with 
DPBS and lysed with 100 µl of Reporter lysis buffer [20 mM K3PO4 pH 7.8, 0.04% Triton 
X-100] (Promega, USA), and wells were assessed for β-galactosidase activity (see section 
2.2.6.5).  
                                                 
4Numbers refer to amino acid residue position in the protein. 
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2.2.6.5 β-galactosidase transgene expression quantification for in vitro 
experiments 
β-galactosidase expression levels were quantified by Galacto-Light Plus β-galactosidase 
reporter gene assay (Life Technologies by Thermo Fisher Scientific, UK). This assay 
makes use of the enzymatic activity of β-galactosidase, which in the presence of Galacton-
Plus substrate releases chemiluminescence. The level of chemiluminescence is directly 
related to the amount of β-galactosidase in the sample.  
Cells were washed with DPBS, lysed with 100 or 200 µL/well (as indicated in each case) 
of 1X Reporter lysis buffer [20 mM K3PO4pH 7.8, 0.04% (v/v) Triton X-100] (Promega, 
USA) and plate was freeze-thawed to ensure intracellular content was completely released. 
A total of 20 µl of sample from each well was transferred to a white 96-well plate and 70 
µl of Tropix Galacton-Plus substrate (diluted 1/100 in 100 mM NaH2PO4, 1 mM MgCl2, 
pH 8) were added per well and incubated at room temperature in the dark for 60 min. Next, 
100 µl of Tropix Accelerator II were added per well and the chemiluminescence produced 
was immediately read using a VICTORTM X3 Multilabel Plate Reader (PerkinElmer). β-
galactosidase activity in relative light units (RLU) was normalized to the total amount of 
protein in 20 µl of sample, which was measured by the BCA Protein assay (see section 
2.2.6.6), thus obtaining β-galactosidase activity in RLU/mg protein. 
2.2.6.6 Bicinchoninic acid (BCA) Protein assay  
Total amount of protein from cellular extracts or purified protein samples was assessed 
using the BCA Protein Assay (Pierce, Thermo Scientific, USA). BSA standards were 
prepared at concentrations ranging from 25 µg/ml to 2000 µg/ml according to 
manufacturer’s instructions. A total of 20 µl of samples, BSA standards or DPBS as a 
blank control were added in duplicate in a 96-well culture plate. Next, 150 µl of BCA 
working reagent (solutions A and B in a ratio 50:1) was added to all wells and plate was 
incubated at 37oC for 30 min. Next, absorbance was read at 562 nm using a VICTORTM X3 
Multilabel Plate Reader (PerkinElmer). Protein concentration was calculated by 
extrapolating the blank-subtracted measurements from the standard curve and expressed as 
mg protein/ml. 
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2.2.6.7 Adenoviral vector labelling 
To label adenoviral vectors with Alexa Fluor 488 Dye, the Alexa Fluor® 488 Antibody 
Labeling kit (Molecular Probes by Thermo Fisher Scientific) was used. First, a volume 
corresponding to 500 µg of adenoviral vector (2x1012 vp, assuming 1 µg protein = 4x109 
vp) from pure preparations was loaded into a 10000 Da molecular weight cut-off (MWCO) 
Slide-A-Lyzer Dialysis Cassette G2 (Perbio Science by Thermo Scientific, UK) that had 
been previously hydrated in PBS [1.37 M NaCl, 27 mM KCl, 100 mM Na2HPO4, 18 mM 
KH2PO4]. Next, the adenoviral vector solution was dialysed by two rounds of 2 h in 2 litres 
PBS and then transferred to a 1.5 ml microcentrifuge tube, where 84 μg/ml sodium 
bicarbonate was added to a final concentration of 10% (v/v) in order to increase the pH for 
efficient labelling. The adenoviral vector mix was transferred to a vial containing Alexa 
Fluor 488 Dye as powder and a magnetic stir bar, and stirred on a magnetic stirrer for 15 
min at room temperature in the dark. Next, the adenoviral vector solution mix was injected 
into a new pre-wetted 10000 Da MWCO Slide-A-Lyzer Dialysis Cassette G2, dialysed in 5 
litres of TE [0.01 M Tris pH 8, 0.001 M EDTA] overnight, and dialysed in 2 litres of TE 
10% (v/v) glycerol for 4 h. The adenoviral vector solution was extracted from the cassette 
and stored at -80oC. 
2.2.6.8 Adenoviral vector trafficking assay 
The adenoviral vector trafficking assay allows the assessment of adenoviral vector 
internalization into host cells and trafficking towards the nucleus. In this assay, cells are 
incubated with labelled adenoviral vector and subsequently subjected to 
immunocytochemistry for colocalization analysis of adenoviral particles with cellular 
components. A549 and SKOV3 cells were plated in 8-well chamber slides at a density of 
5x104 cells/chamber in a total volume of 500 µL/chamber, and incubated overnight at 37oC 
/ 5% CO2. Cells were washed once with DPBS, 1 ml of ice-cold SF medium was added per 
well, and cells were incubated on ice at 4oC for 30 min. Following incubation, the medium 
was removed from wells and 150 µl of Alexa Fluor 488 labelled adenoviral vector (HAdV-
5 or AdT*) in SF medium (1x105 vp/cell) were added to each well with or without hFX 
(Haematologic Technologies) (10 µg/ml) while the culture plate was still on ice. Cells 
were incubated for 60 min on ice at 4oC in the dark. Next, to assess adenovirus binding to 
cell membrane (“0 min” condition), cells were washed once with DPBS, fixed with 4% 
(w/v) PFA for 10 min at room temperature, washed twice with DPBS and subjected to 
immunocytochemistry (see section 2.2.6.9). To assess adenovirus internalization into cells 
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(“60 min” condition), cells were washed once with DPBS after the cold incubation, 500 µl 
of SF medium was added to each well, and cells were incubated at 37oC / 5% CO2 for 60 
min. Next, cells were washed once with DPBS, fixed with 4% (w/v) PFA for 10 min at 
room temperature, washed twice with DPBS for 5 min each, and subjected to 
immunocytochemistry (see section 2.2.6.9). 
2.2.6.9 Immunocytochemistry (ICC) assay 
Following completion of the adenoviral vector trafficking assay (see section 2.2.6.8), cells 
were fixed with 4% (w/v) PFA, washed with DPBS, and permeabilized in PBST 0.1% 
(v/v) for 10 min at room temperature. Next, cells were rinsed three times in PBS for 5 min 
and blocked for 30 min in 10% normal goat serum (Vector Laboratories Inc., USA) in 
PBST 0.1% (v/v) to reduce nonspecific binding of secondary antibody. Sections were 
washed in PBST 0.1% (v/v) for 5 min at room temperature and incubated overnight at 4oC 
with rabbit anti-pericentrin (Abcam, USA) primary antibody or isotype control (rabbit 
IgG, Invitrogen by Thermo Fisher Scientific) to control for background noise (5 µg/ml in 
1% normal goat serum in PBST 0.01% (v/v)). Next, sections were rinsed three times with 
PBS for 5 min each and incubated with Alexa Fluor 546-conjugated goat anti-rabbit IgG 
secondary antibody (Life Technologies by Thermo Fisher Scientific) for 60 min at room 
temperature in the dark (4 µg/ml in PBS). Following incubation, sections were rinsed three 
times with PBS for 5 min each in the dark and slides were mounted with ProLong Gold 
Antifade Reagent with 4’,6-diamidino-2-penylindole (DAPI) (Molecular Probes by Life 
Technologies) for nuclei visualization. Immunofluorescence was captured using a Zeiss 
confocal imaging system LSM 510 META using LSM image acquisition software (Carl 
Zeiss, Welwyn Garden City, UK) with a 40x objective (water immersion, numerical 
aperture: 1) and excitations at 405 nm for DAPI, 488 nm for adenoviral vector and 543 nm 
for secondary antibody. Adjustments were applied equally to all acquired images. 
2.2.6.10 SLO penetration assay 
In this assay, the bacterial toxin streptolysin O (SLO) is used to generate pores in the 
plasma membrane, and these pores allow access of antibodies to the cytosol of the host cell 
(Suomalainen et al., 2013). For studies on the FX-mediated pathway of adenovirus 
transduction, 4x104 A549 cells were cultured per well for two days on Alcian blue-coated 
coverslips in 24-well plates, washed with serum-free RPMI-1640 medium without 
NaHCO3 (Sigma-Aldrich), and incubated with FK (Coughlan et al., 2009) at 0.4 µg/ml in 
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RPMI-BSA (RPMI-1640 medium without NaHCO3 supplemented with 0.2% BSA, 20mM 
HEPES, 100 U/ml penicillin and 100 μg/ml streptomycin) for 30 min at 4oC to avoid virus 
entry into host cells through the CAR-mediated pathway. Next, cells were incubated with 
Alexa Fluor 488 labelled HAdV-5 and hFX (10 µg/ml) on ice for 60 min in RPMI-BSA. A 
dose of 2.46x108 vp/well of Alexa Fluor 488 labelled HAdV-5 pre-determined from pilot 
experiments was used, resulting in 10 to 200 bound vp/cell and thus allowing single 
particle quantification. As a control, the CAR-pathway was also analysed using 7.04x109 
vp/well of Alexa Fluor 488 labelled HAdV-5 (10 to 200 bound vp/cell) without the 
addition of hFX or FK. When indicated, cells were incubated with Alexa Fluor 488 
labelled HAdV-2 ts1 in the presence of FK and hFX (3x108 vp/well) or in the absence of 
FK and hFX (2x109 vp/well). 
After the cold incubation, unbound virus was removed by washing the cells monolayer 
with RPMI-BSA. To verify that FX-coated Alexa Fluor 488 labelled HAdV-5 was 
efficiently detected by rabbit anti-Alexa Fluor 488 primary antibody (Life Technologies by 
Thermo Fisher Scientific), one well at “0 min” condition was incubated with rabbit anti-
Alexa Fluor 488 primary antibody (Life Technologies by Thermo Fisher Scientific) in 
RPMI-BSA for 60 min on ice (1 µg/ml) after unbound virus was washed away. Following 
incubation, cells were washed three times in RPMI-BSA and once with PBS [1.37 M 
NaCl, 27 mM KCl, 100 mM Na2HPO4, 18 mM KH2PO4] and fixed with 3% (w/v) PFA in 
PBS for 20 min at room temperature. For the rest of the conditions, after washing unbound 
virus away, cells were incubated for 45 min at 37oC in a water bath to allow virus 
internalization. When the FX-mediated pathway was studied, FK was added again (0.4 
µg/ml) prior to the incubation at 37oC.  
Next, to assess the percentage of viral particles remaining on the plasma membrane after 
the 45 min incubation (plasma membrane-associated viral particles), cells were 
subsequently incubated with rabbit anti-Alexa Fluor 488 primary antibody (Life 
Technologies by Thermo Fisher Scientific) in RPMI-BSA on ice for 60 min, washed three 
times with RPMI-BSA and once with PBS and fixed with 3% (w/v) PFA in PBS for 20 
min at room temperature. To assess the percentage of viral particles localized in the 
cytoplasm, cells that had been incubated for 45 min at 37oC were subsequently subjected to 
membrane permeabilization with SLO. First, cells were washed twice with SLO binding 
buffer (25 mM HEPES-KOH pH7.4, 110 mM potassium acetate, 2.5 mM magnesium 
acetate, 0.2 mM calcium chloride, 1 mM EGTA, 1mM dithiothreitol (DTT)) and SLO 
(2.48 µg per well, Sigma-Aldrich) was pre-activated by incubation in SLO binding buffer 
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at room temperature for 5 min just before use. Next, SLO was bound to the plasma 
membrane at 4oC for 10 min, unbound SLO was washed away and cells were covered in 
binding buffer and incubated at 37oC for 5 min to allow SLO oligomerization and pore 
formation. Next, cells were washed with SLO binding buffer once and twice with SLO 
internalization buffer (25 mM HEPES-KOH pH7.4, 110 mM potassium acetate, 2.5 mM 
magnesium acetate, 2 mM EGTA), and incubated with rabbit anti-Alexa Fluor 488 primary 
antibody (Life Technologies by Thermo Fisher Scientific) (1 µg/ml) in internalization 
buffer on ice for 60 min. When indicated, mouse anti-human Giantin IgG1 primary 
antibody [clone: G1/133; kindly provided by professor Hans-Peter Hauri, Biocentre of the 
University of Basel, Switzerland (Linstedt and Hauri, 1993)] was added to the antibody 
mix at 33.33 µg/ml to confirm correct SLO pore formation. Following incubation, cells 
were washed three times with internalization buffer and fixed with 3% (w/v) PFA in 
transport buffer (25 mM HEPES-KOH pH7.4, 110 mM potassium acetate, 2.5 mM 
magnesium acetate) for 20 min at room temperature. For all the conditions (“0 min”, “45 
min non-SLO-treated” and “45 min SLO-permeabilized”), cells were washed once in PBS 
after the fixation step, quenched with 25 mM ammonium chloride in PBS for 10 min, 
washed again in PBS, and permeabilized with 0.5% Triton X-100 in PBS for 5 min at room 
temperature. Next, cells were washed once in PBS, blocked in 10% goat serum for 5 min at 
room temperature and incubated for 30 min at room temperature with Alexa Fluor 594-
conjugated goat anti-rabbit IgG secondary antibody (Life Technologies by Thermo Fisher 
Scientific) at 4 µg/ml and DAPI for nuclear detection. Alexa Fluor 680-conjugated goat 
anti-mouse IgG secondary antibody (Life Technologies by Thermo Fisher Scientific) (4 
µg/ml) was also used along with Alexa Fluor 594-conjugated goat anti-rabbit IgG 
secondary antibody and DAPI for samples that had been previously incubated with mouse 
anti-human Giantin IgG1 primary antibody. Following incubation, cells were washed three 
times in PBS for 4 min each and fixed again in 3% (w/v) PFA in PBS, quenched as 
specified before, washed in PBS and washed in distilled water just before mounting.  
Samples were imaged with the Leica SP5 confocal laser scanning microscope with a 63x 
objective (oil immersion, numerical aperture: 1.4), excitations were at 405 nm for DAPI, 
488 nm for adenoviral vector and 561 nm, 594 nm or 633 nm for secondary antibody 
(excitation was at 561 nm or 594 nm when Alexa Fluor 594 was used and 633 nm when 
Alexa Fluor 680 was used), and stacks were recorded at 0.5 µm intervals using 4x 
averaging and sequential acquisition for the individual channels. Maximal projections of 
confocal stacks were analyzed by a custom-programmed MatLab (The Mathworks) routine 
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to score and quantify individual viral particles (Alexa Fluor 488-positive) and of those, 
whether they are antibody-positive (goat anti-rabbit IgG Alexa Fluor 594-positive) or 
antibody-negative (goat anti-rabbit IgG Alexa Fluor 594-negative), as well as quantify 
antibody signal on virus particles. The threshold value for positive antibody signal was 
determined by placing a virus image on an antibody image obtained from non-infected 
cells and taking the highest virus-associated antibody signal as a cutoff value. It has been 
previously reported that following this procedure less than 3.5% of particles have values 
within 20% of the threshold value indicating that errors due to data analysis are minimal 
(Suomalainen et al., 2013). Representative images were processed with ImageJ applying 
the same parameters of brightness and contrast to all images per group. 
The calculations applied to determine the number of plasma membrane-associated, 
cytosolic or endosomal viral particles as well as uptake and penetration efficiencies can be 
found in Table 2-10. 
Table 2-10. Calculations applied to classify adenoviral particles.  
Vp classification (%) or process Classification method / calculations 
Plasma membrane-associated vp [A] Alexa Fluor 488 and antibody-positive vp in intact cells 
Plasma membrane-associated plus 
cytosolic vp [B] 
Alexa Fluor 488 and antibody-positive vp in 
SLO-permeabilized cells 
Cytosolic vp [B] – [A] 
Endosomal vp 100 - [B] – [A] 
Uptake efficiency 100 – [A] 
Endosomal membrane penetration 
efficiency ([B] – [A]) / (100 – [A]) x 100 
“Intact cells” refers to non-permeabilized cells. “Antibody-positive” refers to viral particles positive for anti-
rabbit Alexa Fluor 594. Vp; viral particle. 
2.2.7 Animal experiments 
2.2.7.1 In vivo adenoviral vector delivery 
For the first adenoviral biodistribution study in C57BL/6 and Rag 2-/- mice, male mice 
aged 10-15 weeks were administered 150 µl of DPBS or 1x1011 vp/mouse of HAdV-5 
(Prep. 1), AdT* (Prep. 1), HAdV-5 RGE, AdT*RGE or HAdV-5 KO1 (Prep. 2) [C57BL/6 
mice] or HAdV-5 (Prep. 2), AdT* (Prep. 1), HAdV-5 RGE, AdT*RGE or HAdV-5 KO1 
(Prep. 1) [Rag 2-/- male] by intravascular tail vein injection in a total volume of 150 µl of 
DPBS. n = 5 C57BL/6 mice/group, n = 6 Rag 2-/- mice/group or 7 (AdT*).  
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For the second biodistribution experiment in Rag 2-/- and NSG mice mice, 9-13 weeks old 
male Rag 2-/- and NSG mice were administered 150 µl of DPBS or 1x1011 vp/mouse 
HAdV-5 (Prep. 3) or AdT* (Prep. 2) in 150 µl of DPBS by intravascular tail vein injection. 
n = 5 for adenoviral vectors groups or 6 (HAdV-5 in Rag 2-/- mice), n = 3 for the DPBS 
groups.  
For the third biodistribution experiment in Rag 2-/- and NSG mice, 19-21 weeks old male 
Rag 2-/- and NSG mice were administered 150 µl of DPBS or 1x1011 vp/mouse HAdV-5 
(Prep. 3), AdT* (Prep. 2) or AdT*RGE in 150 µl of DPBS by intravascular tail vein 
injection. n = 3 for all groups or 2 (AdT*RGE in Rag 2-/- mice). Blood was collected 6 h 
post adenoviral vector injections as described in section 2.2.7.2, to be used in cytokine 
profiling assays.  
Mice were sacrificed in all the experiments 48 h after adenoviral vector administration and 
perfused with DPBS. Organs (liver, spleen, lungs, intestine, kidney, heart and pancreas) 
were either collected and fixed in 2% (w/v) PFA overnight at 4oC, frozen in N2(l) or 
embedded in Optimal Cutting Temperature compound (O.C.T) in cryomolds (Tissue-Tek, 
USA) and frozen at -80oC.  
2.2.7.2 Preparation of mouse serum 
Male mouse blood was collected from C57BL/6, Rag2-/- or NSG mice by heart puncture 
post-mortem. Fresh serum was separated from whole blood by centrifugation at 6000 g for 
10 min at 4oC after formation of clot in a BD capillary blood collection microtainer tube 
(Fisher Scientific, UK) and stored at 4oC. Of note, only fresh serum from male mice was 
used since the mouse classical complement pathway is highly unstable (Goldman et al., 
1978) and there are sexual dimorphic differences in the titre of complement proteins (Baba 
et al., 1984, Hansen et al., 1974, Lachmann et al., 1975). 
When serum was required for cytokine profiling assays, blood was collected using a 
microvette CB 300 Z container (SARSTEDT, Germany) and subjected to centrifugation 
at 10000 g for 5 min at room temperature to separate serum from whole blood. Samples 
were stored at -80oC. 
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2.2.7.3 Protein extraction from mouse tissue 
When extracting protein from mouse tissue, approximately 25 mg of frozen liver or 10 mg 
of frozen spleen were placed in a 2 ml microcentrifuge tube containing 1 ml of lysis buffer 
provided in the anti-β-galactosidase enzyme-linked immunosorbent assay (ELISA) kit 
(Roche, Welwyn Garden City, UK) and 2 stainless steel beads (3 mm). Tissues were 
homogenized using a TissueLyser II (QIAGEN, Manchester, UK) for 1 min at 25 mHz 
twice, tissue lysates were subjected to centrifugation at 24000 g for 1 min at 4oC and 
supernatant was transferred to a clean 1.5 ml microcentrifuge tube for storage at -80oC. 
2.2.7.4 DNA extraction from mouse tissue 
DNA was extracted from mouse tissue samples (~25 or 10 mg of frozen liver or spleen, 
respectively) using QIAamp DNA Mini kit (QIAGEN, Manchester, UK), which is based 
on the use of QIAamp Spin Columns that bind DNA following lysis of tissue samples and 
protein degradation with proteinase K. The kit was used following the manufacturer’s 
instructions. DNA was eluted with 200 µl or 100 µl nuclease-free water for livers or 
spleens, respectively. A second elution step was done using the same water to maximize 
DNA elution yield and DNA samples were stored at -20oC until further use. 
2.2.7.5 SYBR Green based Quantitative Real-Time polymerase chain 
reaction (qPCR) 
Adenoviral genomes were extracted from frozen liver and spleen mouse tissue samples as 
described in section 2.2.7.4 and quantified by SYBR Green based qPCR. SYBR Green is 
an asymmetric cyanine dye that becomes brightly fluorescent when bound to dsDNA. 
Thus, when used in PCR, its fluorescence is proportional to the amount of DNA product 
generated. Fluorescence intensity is quantified during the exponential PCR phase and the 
value it reaches when crossing an arbitrary threshold situated on the exponential phase 
[cycle threshold (CT)] is indicative of the amount of original DNA in the sample. The 
comparison of CT values from samples with CT values from standards, which contain a 
known amount of adenoviral genomes, enables the determination of the amount of 
adenoviral genomes present in the samples. 
Adenoviral DNA standards were generated from pure HAdV-5 encoding LacZ reporter 
gene, ranging from 1.6 to 1.6x106 vp/µl in ten-fold serial dilutions in nuclease-free water, 
and DNA samples were diluted to 6 or 16 ng/µL, as indicated in each case, into a total of 
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25 µl nuclease-free water. A total of 6.25 µl of diluted samples (37.5 or 100 ng DNA, as 
indicated in each case) or adenoviral DNA standards (ranging from 10 vp to 1x107 vp in 
ten-fold serial dilutions) were added in triplicate to a 384-well plate. A volume of 6.25 µl 
of Power SYBR Green 2X (Applied Biosystems by Life Technologies) containing buffer, 
dNTPs, thermostable hot-start DNA polymerase and SYBR Green dye, was added per 
well, along with 0.05 µl of 100 µM forward and reverse LacZ primers (final concentration 
of 0.4 µM) (Table 2-1). A negative control containing nuclease-free water instead of DNA 
was performed to assess for non-specific DNA amplification such as primer-dimer 
formation and its possible impact on the analysis of data. Thermal cycler conditions used 
as follows: 50oC for 2 min; 95oC for 10 min (DNA denaturation); 95oC for 15 sec and 60oC 
for 1 min (DNA denaturation, annealing and extension) repeated 40 times; 95oC for 15 sec, 
60oC for 15 sec and 95oC for 15 sec (dissociation curve). The number of adenoviral 
genomes was calculated extrapolating CT values for each sample from the standard curve 
using SDS v2.3 software, assuming 1 adenoviral genome corresponds to 1 vp.  
2.2.7.6 Anti-β-galactosidase ELISA 
Protein homogenates were prepared from liver and spleen mouse tissue as described in 
section 2.2.7.3 and the amount of β-galactosidase present in the samples was determined 
by anti-β-galactosidase ELISA (Roche, Welwyn Garden City, UK) following the 
manufacturer’s instructions. In this assay, β-galactosidase specifically binds to anti-β-
galactosidase antibodies bound to a microplate surface and to a mouse anti-β-
galactosidase-DIG primary antibody conjugated to digoxigenin, following the sandwich 
ELISA principle. A sheep anti-DIG-POD Fab fragment secondary antibody conjugated to 
peroxidase recognizes digoxigenin from anti-β-galactosidase-DIG primary antibody and, 
upon addition of 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) 
substrate, a green coloured product is generated, allowing β-galactosidase quantification.  
Samples were diluted into sample buffer as appropriate to fit into the standard curve 
(concentrations ranging from 78 pg/ml to 1250 pg/ml). Absorbance was measured at 405 
nm using a VICTORTM X3 Multilabel Plate Reader (PerkinElmer). The concentration of β-
galactosidase present in the samples (pg/ml) was calculated by extrapolating the blank-
subtracted measurements from the standard curve, and corrected by the dilution performed 
to each protein sample. The values were then normalized by the protein concentration in 
the samples (mg/ml) measured by the BCA Protein assay (see section 2.2.6.6), obtaining 
pg β-galactosidase/mg protein. 
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2.2.7.7 Immunohistochemistry (IHC) assay 
Tissue sections were cut at 6 µm from frozen samples [embedded in O.C.T] using a 
Shandon CryotomeTM SME 77200227 Issue 4 Microtome Cryostat (Thermo Scientific). 
Sections were fixed for 10 min in 4% (w/v) PFA at room temperature, rinsed twice in PBS 
[1.37 M NaCl, 27 mM KCl, 100 mM Na2HPO4, 18 mM KH2PO4] for 5 min each, 
permeabilized in PBST 0.1% (v/v) for 10 min at room temperature, rinsed three times in 
PBS for 5 min and blocked for 30 min in PBST 0.1% (v/v) with 10% normal goat serum 
(Vector Laboratories Inc., USA) to reduce nonspecific binding of the secondary antibody. 
Next, sections were washed in PBST 0.1% (v/v) for 5 min at room temperature and 
incubated with rabbit anti-β-galactosidase primary antibody (MP Biomedicals LLC, USA) 
or isotype control (rabbit IgG, Invitrogen by Thermo Fisher Scientific) to control for 
background noise, overnight at 4oC (5 µg/ml in 1% normal goat serum in PBST 0.01% 
(v/v)). After the overnight incubation, sections were rinsed three times with PBS for 5 min 
and incubated with Alexa Fluor 488-conjugated goat anti-rabbit IgG secondary antibody 
(Life Technologies by Thermo Fisher Scientific) for 60 min at room temperature in the 
dark (4 µg/ml in PBS). Next, sections were rinsed three times with PBS for 5 min in the 
dark and slides were mounted with ProLong Gold Antifade Reagent with DAPI (Molecular 
Probes by Life Technologies) to counterstain the nuclei. Immunofluorescence was 
captured using a Zeiss confocal imaging system LSM 510 META using LSM image 
acquisition software (Carl Zeiss, Welwyn Garden City, UK) with a 40x objective (water 
immersion, numerical aperture: 1) and excitations at 405 nm for DAPI and 488 nm for 
secondary antibody. Adjustments were applied equally to all acquired images.  
2.2.7.8 Cytokine profiling 
Cytokine levels were quantified from serum samples from Rag 2-/- and NSG mice (see 
section 2.2.7.2) using the Cytokine mouse 20-Plez Panel for Luminex Platform assay (Life 
Technologies by Thermo Fisher Scientific, UK) following the manufacturer’s instructions. 
This cytokine panel is designed for the quantitative determination of FGF-basic, GM-CSF, 
IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p40/p70), IL-13, IL-17, 
CXCL10 (IP-10), KC, MCP-1, MIG, MIP-1α, TNF-α and VEGF in serum. In this assay, a 
range of cytokine-specific antibodies are conjugated to polystyrene beads, which are 
internally dyed with red and infrared fluorophores of differing intensities and assigned a 
bead region (unique number) that allows their differentiation. These antibodies are added 
to samples, standards and controls. Following the sandwich ELISA principle, cytokine-
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specific antibodies recognize cytokines from samples. These cytokines are also recognized 
by cytokine-specific biotinylated antibodies, which are in turn recognized by fluorescent 
R-Phycoerythrin (RPE)-conjugated streptavidin (streptavidin-RPE). The plate is analysed 
with the Luminex detection system (using a Bio-Rad Bio-Plex 100 Luminex analyser) that 
determines the concentration of the different cytokines by detecting the fluorescence of 
RPE and associating it with each bead region, which according to their spectral properties 
can be assigned to a particular cytokine. The concentration of each cytokine (pg 
protein/ml) in the samples was determined from the standard curve using curve fitting Bio-
Plex Manager v5.0 software. For values out of range (OOR) below the lowest standard, a 
zero value was assigned. 
2.2.8 Statistical analysis 
Data from experiments performed in vitro are either shown as the mean of values +/- SEM 
or shown as a percentage of one of the conditions (specified for each experiment) and 
expressed as the mean of the normalized values per experiment +/- SEM. n = 1-3 
biological replicates per condition with 3-4 technical replicates in experiments with 
adenoviral vectors in vitro. n = 1 biological replicate with 1 technical replicate in 
trafficking assays. n = 1-2 biological replicates (depending on condition) with 1 technical 
replicate in SLO penetration assays. n = 3 technical replicates in TaqMan Real-Time 
PCR and flow cytometry analysis.  
Data from in vivo experiments are represented as the mean +/- SEM. n = 2-7 mice in 
groups administered adenoviral vectors, n = 3-6 mice in groups administered DPBS. n = 3 
technical replicates in SYBR green based qPCR analysis. n = 1 technical replicate in the 
ELISA assay. n = 2-3 mice per group with one technical replicate in 
immunohistochemistry analysis. n = 2-3 mice per group with 1 technical replicate in 
cytokine profiling assays. 
Statistical analysis was performed in GraphPad Prism v5.0 (GraphPad Software, San 
Diego, CA, USA). Unpaired Student’s T-test, two-tailed Mann-Whitney U test, one-way 
ANOVA and Tukey’s range test for post hoc pairwise comparisons of groups, or repeated 
measures ANOVA and Tukey’s range test, were applied for significance assessment as 
specified for each analysis. p<0.05 was considered statistically significant.  
 
  
 
 
 
 
 
 
 
 
 
Chapter 3 HAdV-5 neutralization and tropism in 
vitro and in vivo in immunocompetent and 
immunocompromised mice 
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3.1 Introduction 
Intravascular delivery of vectors based on HAdV-5 leads to the sequestration of adenoviral 
particles in the liver as a result of the anatomical architecture of liver sinusoids and the 
presence of resident macrophages (Kupffer cells) (Di Paolo et al., 2009b, Shayakhmetov et 
al., 2004b, Alemany et al., 2000, Tao et al., 2001). Furthermore, intravascular delivery of 
HAdV-5 vectors leads to the transduction of hepatocytes via HAdV-5 interactions with 
cellular receptors. These processes result in high hepatic tropism, which cause toxicity and 
activation of immune responses (Lozier et al., 2002, Raper et al., 2002, Atencio et al., 
2006, Morral et al., 2002). Moreover, intravascular delivery of HAdV-5 results in high 
tropism for the spleen, which has also been associated with the activation of immune 
responses against adenoviral vectors (Bradshaw et al., 2012).  
CAR, αvβ3,5 integrins and HSPG were investigated as potential HAdV-5 receptors for liver 
and spleen transduction. Studies are, however, highly controversial. While the majority of 
studies reported that ablation of HAdV-5 interactions with CAR had no effect on liver 
transduction (Leissner et al., 2001, Alemany and Curiel, 2001, Martin et al., 2003, Smith et 
al., 2002, Smith et al., 2003a, Smith et al., 2003b, Zaiss et al., 2015), other studies 
sustained the opposite (Einfeld et al., 2001). Also, while some studies found that αvβ3,5 
integrins are not required for liver transduction (Smith et al., 2003a, Mizuguchi et al., 
2002, Bradshaw et al., 2012), others showed significantly reduced liver transduction with 
αvβ3,5 integrin-binding ablated vectors (Einfeld et al., 2001, Smith et al., 2003b). 
Furthermore, while ablation of CAR-binding failed to significantly reduce spleen 
transduction for the most part (Leissner et al., 2001, Alemany and Curiel, 2001, Martin et 
al., 2003, Smith et al., 2002, Smith et al., 2003a, Einfeld et al., 2001), other studies 
observed a moderate reduction on spleen transduction (Smith et al., 2003b). Also, some 
studies assessing the role of αvβ3,5 integrins in spleen transduction showed a significant 
reduction with αvβ3,5 integrin-binding ablated vectors (Smith et al., 2003a, Bradshaw et al., 
2012), while others found not significant effect (Einfeld et al., 2001, Mizuguchi et al., 
2002). The effect of simultaneous deletion of HAdV-5 interaction with CAR and αvβ3,5 
integrins on liver and spleen transduction was also assessed and despite some studies 
showed decreased liver and/or spleen transduction (Smith et al., 2003b, Einfeld et al., 
2001, Koizumi et al., 2003), others failed to find a significant effect (Martin et al., 2003). 
Mutation of the putative HSPG binding motif in the HAdV-5 fiber shaft (Smith et al., 
2003a, Nicol et al., 2004) or the combination of such mutations with CAR and αvβ3,5 
integrin-binding ablating mutations (Smith et al., 2003b, Koizumi et al., 2003) reduced 
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liver transduction in mice, rats and non-human primates, but the effects were subsequently 
shown to be likely due to defects in adenoviral particle trafficking associated with fiber 
shaft mutations (Bayo-Puxan et al., 2006, Kritz et al., 2007). In agreement, a recent study 
showed that HSPGs are dispensable for mouse liver transduction with HAdV-5 vectors 
(Zaiss et al., 2015). Interestingly, new mechanisms of HAdV-5 transduction consisting of 
blood factors bridging HAdV-5 to cellular receptors were identified (Shayakhmetov et al., 
2005b, Parker et al., 2006) and FX was shown to be the key factor responsible for liver but 
not spleen transduction (Parker et al., 2006, Alba et al., 2010, Alba et al., 2009, Xu et al., 
2013, Alba et al., 2012). 
In addition to the role that FX plays in HAdV-5 hepatic tropism, recent work revealed an 
alternative role for FX in protecting HAdV-5 virions against “immune attack” or 
adenovirus neutralization (Xu et al., 2013) (Figure 3-1). This study showed that HAdV-5 
neutralization in vitro is mediated by both natural IgM antibodies and the complement 
system, and that covalent modification of virions with C3b blocks binding of virions to 
host cells (Cichon et al., 2001, Xu et al., 2013). This data supports previous studies 
showing that activation of the classical complement pathway for adenovirus neutralization 
in vitro involves IgM antibodies (Tian et al., 2009). Conversely, other studies reported that 
both the classical and alternative complement pathways mediate adenovirus neutralization 
in vitro (Xu et al., 2008, Jiang et al., 2004). Moreover, it was discovered that HAdV-5 
neutralization in vivo involves natural IgM antibodies and the complement system and 
results in negligible liver and spleen transduction (Xu et al., 2013). These data are in 
agreement with another study, which reported that circulating IgM antibodies negatively 
correlate with liver transduction (Khare et al., 2013). Other reports, however, show that in 
vivo adenovirus neutralization involves both the classical and non-classical complement 
pathways, thus indicating that IgM antibodies may be dispensable for in vivo adenovirus 
neutralization (Tian et al., 2009). Binding of FX to HAdV-5 capsid prevented binding of 
IgM antibodies to virions and the activation of C3 convertase, thus inhibiting adenovirus 
opsonisation with C3b and allowing adenovirus transduction (Xu et al., 2013, Duffy et al., 
2016).  
Interestingly, mice lacking the mediators of adenovirus neutralization exhibited high liver 
transduction when FX-binding deficient adenoviral vectors were administered through the 
vasculature (Xu et al., 2013) indicating that FX is not required for liver transduction in 
immunocompromised mice and suggesting that other pathways of cell entry may be 
available. In agreement, mice lacking Ext1, an enzyme required for HS biosynthesis 
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(McCormick et al., 1998), exhibited high levels of HAdV-5 liver transduction indicating 
that alternative pathways of HAdV-5 transduction are present when the FX-mediated 
pathway is not available (Zaiss et al., 2015). Whether these alternative pathways involve 
HAdV-5 engaging with cellular receptors or serum proteins that bridge HAdV-5 to such 
receptors remains unknown. 
 
Figure 3-1. HAdV-5 in vivo neutralization and cell transduction following intravascular delivery. FX-
mediated host cell transduction and protection against neutralization by natural IgM antibodies and the 
complement system (left panel). Suggested role for CAR and αvβ3,5 integrins in liver and spleen transduction. 
Blockade of HAdV-5 cell transduction by neutralization of virions in the absence of FX-binding (right 
panel). Question marks indicate interactions yet to be confirmed. FX; coagulation factor X, CAR; coxsackie 
and adenovirus receptor, HSPG; heparan sulphate proteoglycan, C3; complement protein 3. Figure adapted 
from (Lopez-Gordo et al., 2014a). 
Here, the mechanisms dictating in vitro and in vivo HAdV-5 neutralization and the role of 
FX in protecting HAdV-5 from this process were investigated (Figure 3-1). The role of FX 
in HAdV-5 hepatic and splenic tropism in the absence of adenovirus neutralization 
following intravascular delivery was also assessed, and CAR and αvβ3,5 integrins were 
evaluated as possible receptors mediating FX-independent HAdV-5 liver and spleen 
transduction in this setting (Figure 3-1). Finally, the hypothesis that HAdV-5 can use 
alternative FX-independent pathways for cell transduction in vitro after exposure of virions 
to mouse serum that may be relevant in vivo, was also assessed.  
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3.2 Aims 
The aims of the present study were: 
• To describe the mechanisms mediating in vitro and in vivo HAdV-5 neutralization 
by the host innate immune response and the role of FX in this process. 
• To investigate the role of FX, CAR and αvβ3,5 integrins in HAdV-5 hepatic and 
splenic tropism in the absence of adenovirus neutralization following intravascular 
delivery. 
• To define alternative HAdV-5 FX-independent pathways for cell transduction in 
vitro after exposure of virions to mouse serum. 
3.3 Results 
3.3.1 Generation and validation of adenoviral vectors 
Adenoviral vectors used in this study were replication-deficient HAdV-5-based adenoviral 
vectors encoding the E.coli LacZ gene (β-galactosidase). A summary of the adenoviral 
vectors’ genetic and receptor recognition characteristics is shown in section 2.1.6. 
3.3.1.1 Cloning strategy to generate HAdV-5 KO1 adenoviral vector 
The genome of HAdV-5 KO1 (pAdEasy1-CMV-LacZ-KO1) was engineered in order to 
incorporate specific genetic modifications in the fiber knob domain to alter receptor 
recognition characteristics (Figure 3-2). Briefly, pAdEasy1-CMV-LacZ-KO1 was 
generated by the homologous recombination of pAdEasy1-CMV-LacZ with pShuttle-KO1. 
pAdEasy1-CMV-LacZ was the resultant of the homologous DNA recombination between 
pAdEasy1 and pShuttle-CMV-LacZ. pShuttle-KO1 was the resultant of the enzymatic 
ligation of pShuttle-KO1-AAA with pAdT*KO1. 
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Figure 3-2. Cloning strategy to generate HAdV-5 KO1 genome (pAdEasy1-CMV-LacZ KO1). 1. First 
cloning step where pAdEasy1 and pShuttle-CMV-LacZ are subjected to homologous DNA recombination to 
generate pAdEasy1-CMV-LacZ. 2. Second cloning step involving enzymatic ligation between the fiber ORF 
from AdT*KO1 with the backbone from pShuttle-KO1-AAA, to obtain pShuttle-KO1. 3. Third cloning step 
to generate pAdEasy1-CMV-LacZ-KO1 by homologous DNA recombination between pShuttle-KO1 and 
pAdEasy1-CMV-LacZ. Features in green represent LacZ, features in purple represent the fiber ORF, and 
stars in red represent genetic mutations (AAA peptide and KO1 mutation in pShuttle-KO1-AAA or only 
KO1 mutation in the other plasmids). AmpR; ampicillin resistance, KmR; kanamycin resistance, SmR; 
streptomycin resistance. 
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The first cloning step involved generating pAdEasy1-CMV-LacZ by introducing the 
reporter gene LacZ under the control of the CMV-IEP promoter (from pShuttle-CMV-
LacZ) into pAdEasy1 genome. pShuttle-CMV-LacZ was transformed into chemically 
competent E. coli for plasmid amplification. Plasmid DNA (pDNA) was extracted from 
single kanamycin resistant colonies, enzymatically digested with PacI and subsequently 
electrophoresed for plasmid confirmation (Figure 3-3A). To prepare pShuttle-CMV-LacZ 
for homologous DNA recombination, the plasmid was linearized with PmeI, the 5’ ends 
were de-phosphorylated, and PmeI-digested pDNA was electrophoresed (Figure 3-3B) and 
subsequently extracted from the agarose gel for DNA purification. Homologous DNA 
recombination was performed by transforming purified PmeI-digested pShuttle-CMV-
LacZ into electrocompetent recA+ E. coli together with the transfer circular vector 
pAdEasy1 (amplified in bacteria as before and verified by digestion with PacI or AscI 
(Figure 3-3C). pAdEasy1-CMV-LacZ was extracted from single ampicillin resistant 
colonies, confirmed by enzymatic digestion with PacI (Figure 3-3D), and transformed into 
chemically competent E. coli to amplify pDNA in a recA1 system unable to recombine 
DNA, thus conferring stability to the plasmid. A large-scale preparation of pAdEasy1-
CMV-LacZ was obtained from a single positive colony and confirmed by enzymatic 
digestion with PacI or SpeI (Figure 3-3E-F). 
 
Figure 3-3. pAdEasy1-CMV-LacZ KO1 first cloning step. A) PacI-digested pShuttle-CMV-LacZ 
maxiprep (7730 bp, 2930 bp). B) PmeI-digested pShuttle-CMV-LacZ (10660 bp). C) PacI-digested (1) or 
AscI-digested (2) pAdEasy1 maxiprep. Bands 37126 bp (1) or 27506 bp and 9620 bp (2). D) PacI-digested 
pAdEasy1-CMV-LacZ miniprep from recA+ bacteria (34196 bp, 2930 bp). E) PacI-digested pAdEasy1-
CMV-LacZ maxiprep (34196 bp, 2930 bp). F) SpeI-digested pAdEasy1-CMV-LacZ maxiprep. Arrow 
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indicates the DNA band extracted from the agarose gel. 1 kb DNA ladder (Invitrogen, UK) used in (A) and 1 
kb DNA ladder (Promega, UK) used in (B-F). 
In the second cloning step, pShuttle-KO1 was obtained by enzymatic ligation of the fiber 
ORF from pAdT*KO1 (containing the KO1 mutation) with the backbone pShuttle-KO1-
AAA, from which the fiber ORF [containing the KO1 mutation and an extra NotI site + 
cytosine (AAA peptide)] had been removed. See section 5.3.1.1 for more details on the 
latter plasmid. To prepare pAdT*KO1 and pShuttle-KO1-AAA for ligation, the fiber ORF 
from both plasmids was extracted by enzymatic digestion with MfeI and SpeI. The digests 
were electrophoresed and the DNA bands corresponding to the pAdT*KO1 fiber ORF and 
the pShuttle-KO1-AAA backbone were extracted from the agarose gel (Figure 3-4A-B). 
Enzymatic ligation was performed between both DNA fragments and the ligation product 
was transformed into chemically competent E. coli. A large-scale preparation of pShuttle-
KO1 was obtained from a single positive streptomycin resistant colony and confirmed by 
enzymatic digestion with MfeI and SpeI (Figure 3-4C). Absence of the extra NotI site in the 
fiber knob HI loop sequence was confirmed by sequencing. 
 
Figure 3-4. pAdEasy1-CMV-LacZ KO1 second cloning step. A) MfeI and SpeI-digested pAdT*KO1 
maxiprep (16412 bp, 10359 bp, 4091 bp, 3088 bp, 1615 bp, 1038 bp, 529 bp). B) MfeI and SpeI-digested 
pShuttle-KO1-AAA maxiprep (3440 bp, 3097 bp). C) MfeI and SpeI-digested pShuttle-KO1 maxiprep (3440 
bp, 3088 bp). Arrows indicates the DNA bands extracted from the agarose gel. 1 kb DNA ladder (Invitrogen, 
UK) used in (A) and 1 kb DNA ladder (Promega, UK) used in (B-C). 
The third cloning step involved generating the final HAdV-5 KO1 genome (pAdEasy1-
CMV-LacZ-KO1). Homologous DNA recombination was performed between pAdEasy1-
CMV-LacZ and pShuttle-KO1 to exchange the pAdEasy1-CMV-LacZ fiber ORF with the 
fiber ORF from pShuttle-KO1, which contained the KO1 mutation. To prepare the 
plasmids, pAdEasy1-CMV-LacZ was linearized with SpeI (Figure 3-5A), the 5’ ends were 
de-phosphorylated and pDNA was purified by DNA precipitation. pShuttle-KO1 was 
enzymatically digested with AscI and PacI, electrophoresed, and the band containing the 
“fiber KO1” was extracted from the agarose gel (Figure 3-5B). Homologous DNA 
recombination was performed as before and positive ampicillin resistant colonies were 
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confirmed by sequencing. pDNA from one of the positive colonies was transformed into 
chemically competent recA1 E. coli as before and a large-scale preparation for pAdEasy1-
CMV-LacZ-KO1 was obtained from positive clones which were sequenced to confirm 
presence of the KO1 mutation in the fiber ORF. To confirm homologous recombination 
had taken place only via the left homology arm of the DNA plasmids (see section 5.3.1.1 
for detailed principle explanation), the final pAdEasy1-CMV-LacZ-KO1 was confirmed by 
enzymatic digestion with XhoI (Figure 3-5D). As a further quality control, pAdEasy1-
CMV-LacZ-KO1 was enzymatically digested with a range of restriction endonucleases as 
shown in Figure 3-5C-D.  
 
Figure 3-5. pAdEasy1-CMV-LacZ KO1 third cloning step. A) SpeI-digested pAdEasy1-CMV-LacZ 
maxiprep. B) AscI and PacI-digested pShuttle-KO1 maxiprep (3440 bp, 3088 bp). C) uncut pAdEasy1-
CMV-LacZ-KO1 maxiprep (1), pAdEasy1-CMV-LacZ-KO1 maxiprep digested with SpeI, (2), PacI (3), AscI 
(4), EcoRI (5), BamHI (6) or SalI (7). Bands 37126 bp (2), 34196 bp, 2930 bp (3), 27506 bp, 9620 bp (4), 
24282 bp, 12844 bp (5), 18456 bp, 11734 bp, 6936 bp (6), or 20413 bp, 9431 bp, 6903 bp, 379 bp (7). D) 
pAdEasy1-CMV-LacZ-KO1 maxiprep digested with SmaI (1), BglII (2), XhoI (3). Bands 8370 bp, 6478 bp, 
4456 bp, 3540 bp, 3386 bp, 2463 bp, 2278 bp, 2262 bp, 1455 bp, 1398 bp, 630 bp, 230 bp, 180 bp (1), 8895 
bp, 6180 bp, 5415 bp, 5178 bp, 4645 bp, 2151 bp, 1625 bp, 1497 bp, 1268 bp, 272 bp (2), 14500 bp, 12376 
bp, 5744 bp 2466 bp, 1445 bp, 595 bp (3). Arrows indicates the DNA bands extracted from the agarose gel. 1 
kb DNA ladder (Promega, UK) used. Bolded and in italics DNA band sizes in figure legend correspond to 
bands that are not visible in the image but that were visible in the agarose gel using a transilluminator (UVP). 
3.3.1.2 Adenoviral vectors amplification and quality control  
HAdV-5, AdT* and HAdV-5 RGE were amplified from pure adenoviral vector 
preparations originated from a single plaque. Due to a lack of available pure adenoviral 
vector preparations, AdT*RGE was produced by transfecting the PacI-linearized 
adenoviral genome pAdT*RGE into eukaryotic permissive HEK-293 cells for vector 
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amplification and generation of crude adenoviral vector stocks. Since HAdV-5 KO1 
exhibited propagation difficulties in HEK-293 cells, the genome of HAdV-5 KO1 
(pAdEasy1-CMV-LacZ-KO1) was linearized with PacI and transfected into eukaryotic 
permissive Per.C6® cells (Crucell), which allow higher levels of adenovirus production 
than those from HEK-293 cells (Fallaux et al., 1998), and rescued HAdV-5 KO1 were 
subsequently propagated in Per.C6® cells. Pure adenoviral vector preparations were 
generated for all adenoviral vectors above and tested for their quality (safety, genetic 
stability, concentration and infectivity, transgene expression, and adenovirus particles 
aggregation, protein composition and integrity) as indicated below.  
The absence of RCAs was confirmed for the pure adenoviral vector preparations generated 
in this study, ensuring safety of adenoviral preparations. Vector genetic stability was 
confirmed by sequencing the adenoviral vectors’ genome for each amplification step. With 
this aim, adenoviral DNA was extracted from adenovirus particles and sequences 
corresponding to the hexon, penton base or fiber ORFs were amplified by PCR. PCR 
amplicons were purified and analysed by sequencing to confirm the presence of the 
introduced genetic modifications. The concentration of adenovirus particles (vp/ml) and 
infectivity (pfu/ml) of pure adenoviral vector preparations were also assessed. The 
expected vp/ml and vp/pfu ratios for wild type and mutant HAdV-5 vectors according to 
historical values following the manufacturing process available in our laboratory facilities 
were obtained (from around 40 to 150, with the exception of HAdV-5 KO1 that exhibited 
high vp/pfu ratios, being those higher than 6000) (Table 3-1). Of note, adenoviral vectors 
presented vp/pfu ratios that slightly differed from the recommended values by the FDA 
(see section 2.2.5.9). Since a high ratio for HAdV-5 KO1 might merely result from the lack 
of binding to CAR due to the KO1 mutation (Leissner et al., 2001, Jakubczak et al., 2001, 
Roelvink et al., 1999) and not be associated with impaired adenovirus propagation, vp/pfu 
ratios obtained were considered acceptable for a safe use of the adenoviral vectors in in 
vivo studies. 
Table 3-1. Adenoviral vectors quality control.  
Adenoviral vector Titre  (vp/ml) 
Titer  
(pfu/ml) Vp/pfu 
Vp 
diameter 
(nm) 
HAdV-5 (Prep. 1) 1.55x1012 1.88x1010 82.45 91 
HAdV-5 (Prep. 2) 1.66x1012 1.11x1010 149.55 95 
HAdV-5 (Prep. 3) 3.27x1012 2.61x1010 125.29 103 
AdT* (Prep. 1) 2.55x1012 1.76x1010 144.89 86 
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AdT* (Prep. 2) 3.85x1012 8.81x1010 43.70 88 
HAdV-5 RGE 1.60x1012 3.20x1010 50 94 
HAdV-5 KO1 (Prep. 1) 8.75x1011 1.40x108 6250 100 
HAdV-5 KO1 (Prep. 2) 7.73x1012 1.16x109 6663.79 90 
AdT*RGE 5.34x1012 3.62x1010 147.51 109 
Plaque forming units (pfu/ml) values shown were obtained with the pfu observed after performing X-Gal 
staining. Values of viral particle (vp) diameter by Nanoparticle Tracking Analysis (NanoSight) are the mean 
of technical triplicates. “Prep.” followed by a number refers to the individual pure adenovirus preparations 
generated. HAdV-5; human adenoviral vector serotype 5. 
The absence of virion aggregates in pure adenoviral vector preparations was confirmed by 
assessing the adenovirus capsid size. Adenovirus capsid diameter values were similar to 
the historical values for HAdV-5-based vectors [90-100 nm (Norrby, 1969, Goosney and 
Nemerow, 2003)] (Table 3-1). HAdV-5 KO1 capsid protein composition and integrity of 
capsid structure was confirmed by silver staining (Figure 3-6), indicating that the KO1 
mutation did not interfere with capsid assembly and maturation. Silver staining of HAdV-
5, AdT*, HAdV-5 RGE and AdT*RGE have been previously demonstrated (Alba et al., 
2009, Bradshaw et al., 2012).  
 
Figure 3-6. Adenovirus capsid protein composition of HAdV-5 KO1. A total of 5x1010 denatured HAdV-
5 or HAdV-5 KO1 particles were loaded in a 12% SDS-polyacrylamide gel and proteins were visualized by 
silver staining (Life Technologies). Rainbow ladder (Amersham Bioscience UK Ltd, UK) was used as a 
marker for molecular weight. Numbers on the right indicate polypeptides of viral particles and their 
designations. Mw (kDa): 109 (protein II/hexon), 63.3 (protein III/penton base and IIIa), 62 (protein IV/fiber), 
41.6 (protein V) and 23.4 (protein VI) (San Martin and Burnett, 2003).  
Next, the ability of FX to enhance cell transduction of HAdV-5 but not FX-binding 
deficient AdT*-based vectors was confirmed by assessing adenoviral transduction of 
CARhigh A549 or CARlow SKOV3 cells in the presence or absence of hFX. As expected, 
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transduction with HAdV-5-based vectors was significantly enhanced by hFX in both cell 
lines while transduction with AdT*-based vectors remained unaffected or minimally 
enhanced (Figure 3-7). As previously reported (Bradshaw et al., 2012), HAdV-5 RGE and 
AdT*RGE were able to transduce A549 and SKOV3 cells in the absence of hFX despite 
lacking αvβ3,5 integrin-binding (Figure 3-7). HAdV-5 KO1 exhibited extremely low 
transduction levels of A549 cells in the absence of hFX (Figure 3-7) in agreement with 
previous reports (Jakubczak et al., 2001, Smith et al., 2003b, Smith et al., 2002). In 
contrast, HAdV-5 KO1 showed similar transduction levels to HAdV-5 in CARlow SKOV3 
cells (Figure 3-7). 
 
Figure 3-7. Sensitivity to FX on adenoviral transduction. A549 or SKOV3 cells were incubated with pure 
adenoviral vector preparations (1000 vp/cell) at 37oC for 3 h in the presence or absence of human 
recombinant FX (10 µg/ml), washed with 10% FCS RPMI-1640 medium and incubated at 37oC for further 
48 h. β-galactosidase expression levels were quantified as relative light units (RLU) and normalized to total 
mg of protein. n = 4 technical replicates per condition. Data from a single adenoviral preparation for each 
wild type or mutant adenoviral vector is shown as a representative. Values are shown as the mean of values 
+/- SEM. Unpaired Student’s T-test applied. *p<0.05 vs. matched controls. 
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3.3.2 Validation of mouse models 
Since immunocompromised Rag 2-/- (Shinkai et al., 1992, Alt et al., 1992) and NSG (Zhou 
et al., 2014, Shultz et al., 2005, Shultz et al., 1995, Ito et al., 2002) mice lack IgM 
antibodies (section 2.1.7), one of the reported mediators of in vitro and in vivo adenovirus 
neutralization (Xu et al., 2013), these mice were used in in vivo studies to bypass the 
adenovirus neutralization associated with FX-binding deficient adenoviral vectors and thus 
allow tropism studies with such vectors. To confirm Rag 2-/- and NSG mice are unable to 
neutralize HAdV-5 virions, HAdV-5 transduction of A549 cells was assessed following 
pre-incubation of HAdV-5 with Rag 2-/- or NSG serum. Serum from immunocompetent 
C57BL/6 mice was used as a control. Transduction occurred at low levels in the presence 
of SF medium alone due to the low MOI (adenoviral particles/cell) used in the assay 
(Figure 3-8). The presence of C57BL/6 serum produced a significant enhancement in 
HAdV-5 transduction (2.4-fold) indicating the presence of a factor(s) in the serum able to 
contribute to HAdV-5 transduction (Figure 3-8A). Pre-incubation of C57BL/6 serum with 
X-bp, a molecule that binds to FX GLA domain impairing HAdV-5:FX interaction (Atoda 
et al., 1998), resulted in the inhibition of HAdV-5 transduction (Figure 3-8A), suggesting 
the presence of adenovirus neutralization in the absence of FX-binding. Both Rag 2-/- and 
NSG sera significantly enhanced HAdV-5 transduction by 3.5-fold and 3.2-fold, 
respectively (Figure 3-8A). In contrast to C57BL/6 serum, Rag 2-/- and NSG serum pre-
incubated with X-bp did not reduce HAdV-5 transduction in comparison to the SF media 
condition (Figure 3-8A) suggesting an absence of adenovirus neutralization and thus 
validating the immunocompromised mouse models chosen for in vivo experiments. 
Interestingly, Rag 2-/- and NSG serum pre-incubated with X-bp enhanced HAdV-5 
transduction to levels similar to those observed in the absence of X-bp (Figure 3-8A). 
These results suggest that HAdV-5 transduces A549 cells predominantly via a FX-
independent mechanism in the presence of immunocompromised mouse serum. Next, FX-
binding deficient AdT* was used to confirm results. C57BL/6 serum inhibited AdT* 
transduction both in the presence and absence of X-bp (Figure 3-8B), again supporting a 
role for FX in protecting HAdV-5 from neutralization. However, both Rag 2-/- and NSG 
sera enhanced AdT* transduction by 2.4-fold and 1.8-fold, respectively (Figure 3-8B), 
although this was only significant for Rag 2-/- serum, confirming lack of adenovirus 
neutralization and FX-independency in mouse serum-enhanced transduction in the 
presence of immunocompromised mouse serum.  
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Figure 3-8. Effect of mouse serum on adenoviral transduction. HAdV-5 (A) or AdT* (B) (2x1010 vp/ml) 
were incubated for 30 min at 37oC with serum-free (SF) RPMI-1640 media or 90% C57BL/6, Rag 2-/- or 
NSG serum in the presence or absence of X-bp (40 µg/ml). Adenovirus suspensions were diluted 200-fold in 
SF media and added to A549 cells (1000 vp/cell) and incubated at 37oC for 2 h. Then, media was replaced 
with 2% FCS RPMI and cells incubated for further 20 h. β-galactosidase expression levels were quantified as 
relative light units (RLU) and normalized to total mg of protein. n = 7 (C57 BL/6), n = 6 (Rag 2-/-), n = 3 
(NSG) biological replicates per condition with 4 technical replicates. Values are shown as a percentage of the 
SF media alone condition and expressed as the mean of the normalized values per experiment +/- SEM. 
Repeated measures ANOVA and post hoc Tukey’s range test applied. *p<0.05 vs. matched controls, $p<0.05 
vs. matched serum. 
These data indicate that while FX is critical in protecting HAdV-5 from neutralization, FX 
may only partially mediate HAdV-5 transduction in vitro in the presence of 
immunocompromised Rag 2-/- or NSG serum, suggesting that other mechanisms of HAdV-
5 transduction might be present in this setting. 
3.3.2.1 Role of IgM antibodies on HAdV-5 neutralization by mouse serum in 
vitro 
To assess the specific role of IgM antibodies on HAdV-5 neutralization in vitro, A549 cells 
were incubated with HAdV-5 in the presence of immunocompromised Rag 2-/- serum with 
the addition of pure mouse IgM antibodies. X-bp was added when indicated to inhibit 
HAdV-5:FX interaction and thus expose HAdV-5 to neutralization. C57BL/6 serum was 
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used as a control. C57BL/6 serum significantly enhanced HAdV-5 transduction 2.5-fold 
and pre-incubation of C57BL/6 serum with X-bp decreased transduction (Figure 3-9) as 
previously observed (Figure 3-8). In contrast, Rag 2-/- serum pre-incubated with X-bp 
enhanced HAdV-5 transduction 2.5-fold confirming the lack of adenovirus neutralization 
(Figure 3-9). A range of three different concentrations of IgM were used according to 
previous reports (Xu et al., 2013). Addition of IgM to Rag 2-/- serum that had been pre-
incubated with X-bp to expose HAdV-5 to possible neutralization, had no effect on HAdV-
5 serum-enhanced transduction (Figure 3-9). These data suggest that IgM may not be 
involved in adenovirus neutralization by Rag 2-/- serum but is in disagreement with 
previous reports (Xu et al., 2013). 
 
Figure 3-9. Role of IgM antibodies on adenovirus neutralization. HAdV-5 (2x1010 vp/ml) was incubated 
for 30 min at 37oC with serum-free (SF) RPMI-1640 media or 90% C57 BL/6 or Rag 2-/- serum in the 
presence or absence of X-bp (40 µg/ml) or IgM antibodies (low: 50, medium: 150 or high: 300 µg/ml). 
Adenovirus suspensions were diluted 200-fold in SF media and added to A549 cells (1000 vp/cell) and 
incubated at 37oC for 2 h. Then, media was replaced with 2% FCS RPMI and cells incubated for further 20 h. 
β-galactosidase expression levels were quantified as relative light units (RLU) and normalized to total mg of 
protein. n = 3 biological replicates per condition with 4 technical replicates. Values are shown as a 
percentage of the SF media alone condition and expressed as the mean of the normalized values per 
experiment +/- SEM. Repeated measures ANOVA and post hoc Tukey’s range test applied. *p<0.05 vs. 
media, $p<0.05 vs. matched serum. 
3.3.2.2 Role of complement on HAdV-5 neutralization by mouse serum in 
vitro 
Next, the role of complement on adenovirus neutralization in vitro in the presence of 
mouse serum was studied by performing transduction assays with HAdV-5 on A549 cells 
using immunocompetent C57BL/6 serum that had been pre-incubated at 56oC to inhibit the 
complement system. Immunocompromised Rag 2-/- serum was used as a non-neutralizing 
control serum. Unheated C57BL/6 and Rag 2-/- serum significantly enhanced HAdV-5 
transduction (2.2-fold and 3.3-fold, respectively) and X-bp inhibited HAdV-5 transduction 
when added to unheated C57BL/6 serum (Figure 3-10) as observed before (Figure 3-8). 
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Interestingly, heat-treated C57BL/6 and heat-treated Rag 2-/- sera were unable to enhance 
HAdV-5 transduction (Figure 3-10), suggesting that the factors in serum involved in such 
enhancement may be heat-labile and thus unable to enhance HAdV-5 transduction after 
exposure to high temperatures. Furthermore, heated C57BL/6 serum pre-incubated with X-
bp failed to inhibit HAdV-5 transduction (Figure 3-10A), similar to that observed with 
heated Rag 2-/- serum with X-bp (Figure 3-10B). 
 
Figure 3-10. Effect of heat-treated serum on adenoviral transduction. HAdV-5 (2x1010 vp/ml) was 
incubated for 30 min at 37oC with serum-free (SF) RPMI-1640 media or 90% C57 BL/6 (A) or Rag 2-/- (B) 
serum in the presence or absence of X-bp (40 µg/ml). When indicated, mouse serum was pre-incubated at 
56oC for 30 min before the addition of X-bp. Adenovirus suspensions were diluted 200-fold in SF media and 
added to A549 cells (1000 vp/cell) and incubated at 37oC for 2 h. Then, media was replaced with 2% FCS 
RPMI and cells incubated for further 20 h. β-galactosidase expression levels were quantified as relative light 
units (RLU) and normalized to total mg of protein. n = 3 biological replicates per condition with 4 technical 
replicates. Values are shown as a percentage of the SF media alone condition and expressed as the mean of 
the normalized values per experiment +/- SEM. Repeated measures ANOVA and post hoc Tukey’s range test 
applied. *p<0.05 vs. media, $p<0.05 vs. serum, #p<0.05 vs. serum+X-bp. 
These results indicate that exposing C57BL/6 serum to high temperatures (56oC) impairs 
the adenovirus neutralizing properties of C57BL/6 serum in the absence of FX-binding and 
the transduction enhancing properties of mouse serum, suggesting a role for heat-labile 
factors in adenovirus neutralization and transduction. 
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3.3.3 HAdV-5 neutralization and role of FX, αvβ3,5 integrins and 
CAR in tropism in C57BL/6 and Rag 2-/- mice 
Next, the role of FX, CAR and αvβ3,5 integrins as possible receptors for HAdV-5 
transduction in vivo was evaluated. To study receptor usage for HAdV-5 transduction in 
vivo a series of HAdV-5 mutants were used with impaired binding to FX (AdT*) (Alba et 
al., 2009), αvβ3,5 integrins (HAdV-5 RGE) (Bradshaw et al., 2012) or CAR (HAdV-5 
KO1), and a mutant lacking binding to both FX and αvβ3,5 integrins (AdT*RGE) 
(Bradshaw et al., 2012) to dismiss the possibility of FX being sufficient for HAdV-5 RGE 
to transduce cells despite lacking αvβ3,5 integrin-binding. A total of 1x1011 vp of HAdV-5, 
AdT*, HAdV-5 RGE, AdT*RGE or HAdV-5 KO1 vectors were administered to C57BL/6 
and IgM antibody-deficient Rag 2-/- mice via intravascular delivery and accumulation of 
viral genomes and transduction levels were quantified in liver and spleen 48 h post-
administration (Figure 3-11). 
 
Figure 3-11. Timeline diagram of in vivo experiments. Mice were administered 1x1011 vp of adenoviral 
vector per animal via tail vein injection. Mice were sacrificed 48 h post-injections and organs were analysed 
for adenovirus genome content and transduction levels. 
In agreement with the X-Gal staining (Figure 3-12A), quantification of viral genomes and 
adenoviral transduction levels in C57BL/6 mice liver revealed that AdT*-based vectors 
(AdT* or AdT*RGE) were at significantly lower levels (191-fold and 6774-fold for AdT* 
and 10.5-fold and 25-fold for AdT*RGE, respectively) than those of HAdV-5 or HAdV-5 
RGE controls (Figure 3-12C-D), confirming a role for FX in protecting HAdV-5 from 
neutralization. Also, AdT*RGE genomes were at statistically significant higher levels (8-
fold) than those of AdT* (Figure 3-12C). Levels of HAdV-5 RGE genomes and 
transduction in C57BL/6 liver were significantly decreased (2-fold and 12-fold, 
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respectively) compared to those of HAdV-5 (Figure 3-12C-D), suggesting a role for αvβ3,5 
integrins in liver transduction. Whilst significantly lower levels of HAdV-5 KO1 
transduction were also detected in the liver (4-fold) (Figure 3-12D), suggesting a role for 
CAR in liver transduction of C57BL/6 mice, HAdV-5 KO1 genomes were found at similar 
levels to those of HAdV-5 (Figure 3-12C). Analysis of C57BL/6 spleens revealed that 
AdT* genomes and transduction levels were significantly lower than those of HAdV-5 (6-
fold and 5-fold, respectively) (Figure 3-12E-F) supporting again the presence of 
adenovirus neutralization of FX-binding deficient AdT* vectors. Surprisingly, despite the 
lack of FX-binding, AdT*RGE genome and transduction levels in C57BL/6 spleen were 
found comparable to those of HAdV-5 RGE (Figure 3-12E-F). Also, AdT*RGE genome 
and transduction levels in C57BL/6 spleen were significantly higher (8.9-fold and 6.2-fold, 
respectively) than those of AdT* (Figure 3-12E-F). HAdV-5 RGE and HAdV-5 KO1 
genomes and transduction levels in C57BL/6 spleen were comparable to those of HAdV-5 
(Figure 3-12E-F), indicating no involvement of αvβ3,5 integrins or CAR in spleen 
transduction. Similar levels of X-Gal staining were observed in spleens of C57BL/6 mice 
for all administered vectors (Figure 3-12B). The pattern of liver and spleen transduction 
following immunohistochemistry analysis for β-galactosidase was similar to that of 
genome and transduction levels for all vectors (Figure 3-13). Interestingly, both HAdV-5 
RGE and AdT*RGE localized in the spleen marginal zone (MZ) (Figure 3-13B), the area 
between the red and the white pulp. Together with previous reports, these results indicate 
that AdT*-based vectors are neutralized by the immune system of C57BL/6 mice. The data 
also shows that αvβ3,5 integrins and CAR might be involved in liver but not spleen 
transduction of C57BL/6 mice, and that lack of binding to αvβ3,5 integrins seems to 
increase localization of adenoviral vectors to the spleen MZ and liver and spleen 
transduction in FX-binding deficient vectors.  
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Figure 3-12. Adenoviral genomes accumulation and transduction in C57BL/6 mice. C57BL/6 mice were 
administered DPBS or 1x1011 vp/mouse HAdV-5, AdT*, HAdV-5 RGE, AdT*RGE or HAdV-5 KO1 (n = 5 
mice/group) by intravascular delivery and sacrificed and perfused 48 h post-injection. A-B) β-galactosidase 
expression in C57BL/6 mice by X-Gal staining following organ fixation in 2% paraformaldehyde. 
Representative images of liver (A) and spleen (B) are shown. Scale bar 1 cm (A) or 0.25 cm (B). C-F) Viral 
genome content was quantified by SYBR green based qPCR analysis in liver (C) and spleen (E). β-
galactosidase expression was quantified by ELISA in liver (D) and spleen (F) and normalised to total mg of 
protein. Values are expressed as the mean +/- SEM. Unpaired Student’s T-test applied. *p<0.05 vs. HAdV-5, 
#p<0.05 vs. AdT*, $p<0.05 vs. HAdV-5 RGE.  
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Figure 3-13. Immunohistochemistry analysis of β-galactosidase in C57BL/6 mice. Representative merged 
images of 6 μm frozen liver (A) and spleen (B) sections from C57BL/6 mice 48 h following intravascular 
administration of DPBS or 1x1011 vp/mouse HAdV-5, AdT*, HAdV-5 RGE, AdT*RGE or HAdV-5 KO1 (n 
= 5 mice/group). Rabbit anti-β-galactosidase primary antibody and Alexa Fluor 488-conjugated goat anti-
rabbit IgG secondary antibody (green) were used. Nuclei were counterstained with DAPI (blue). n = 3 mice 
analysed per group with 1 technical replicate. Magnification 40x or 25x for the lower AdT*RGE image in 
(B). Scale bars 50 μm. 
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Next, liver and spleen transduction of immunocompromised Rag 2-/- mice was evaluated. 
Accumulation of genomes in Rag 2-/- liver was lower for AdT* compared to HAdV-5 (6-
fold) (Figure 3-14C) but it did not reach statistical significance. AdT* liver transduction 
levels were significantly lower (23-fold) than those of HAdV-5 (Figure 3-14D), in 
agreement with immunohistochemistry analysis on liver sections (Figure 3-15A). 
Moreover, AdT*RGE genome and transduction levels in Rag 2-/- liver were significantly 
lower (2.3-fold and 2.6-fold, respectively) than those of HAdV-5 RGE (Figure 3-14C-D), 
as observed in immunohistochemistry analysis on liver sections (Figure 3-15A). Since Rag 
2-/- mice are unable to neutralize adenovirus in vitro (section 3.3.2), these results suggest a 
role for FX in liver transduction of these mice. HAdV-5 RGE and HAdV-5 KO1 showed 
levels of accumulated genomes and liver transduction similar to those of HAdV-5 (Figure 
3-14C-D), suggesting αvβ3,5 integrins and CAR are not involved in liver tropism in Rag 2-/- 
mice. No differences in β-galactosidase activity were detected in livers subjected to X-Gal 
staining (Figure 3-14A). Interestingly, immunohistochemistry analysis on liver sections 
revealed lower levels of β-galactosidase detection in Rag 2-/- mice administered HAdV-5 
RGE and HAdV-5 KO1 than those of HAdV-5 (Figure 3-15A). Regarding the spleen, 
significantly higher levels of AdT*RGE transduction were detected in comparison to those 
of AdT* or HAdV-5 RGE (293-fold and 82-fold, respectively) (Figure 3-14F), in 
agreement with X-Gal staining (Figure 3-14B) and immunohistochemistry analysis on 
spleen sections (Figure 3-15B). Together, these data suggest that in contrast to αvβ3,5 
integrins and CAR, FX might be involved in liver transduction of immunocompromised 
Rag 2-/- mice, and that lack of αvβ3,5 integrins binding on a FX-binding deficient vector 
might increase liver and spleen transduction. 
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Figure 3-14. Adenoviral genomes accumulation and transduction in Rag 2-/- mice. Rag 2-/- mice were 
administered DPBS (n = 6) or 1x1011 vp/mouse HAdV-5 (n = 6), AdT* (n = 7), HAdV-5 RGE (n = 6), 
AdT*RGE (n = 6) or HAdV-5 KO1 (n = 6) by intravascular delivery and sacrificed and perfused 48 h post-
injection. A-B) β-galactosidase expression in Rag 2-/- mice by X-Gal staining following organ fixation in 2% 
paraformaldehyde. Representative images of liver (A) and spleen (B) are shown. Scale bar 1 cm (A) or 0.25 
cm (B). C-F) Viral genome content was quantified by SYBR green based qPCR analysis in liver (C) and 
spleen (E). β-galactosidase expression was quantified by ELISA in liver (D) and spleen (F) and normalised to 
total mg of protein. Values are expressed as the mean +/- SEM. Unpaired Student’s T-test applied. *p<0.05 
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vs. HAdV-5, #p<0.05 vs. AdT*, $p<0.05 vs. HAdV-5 RGE. Values ≤ 1 have been omitted from the graphical 
representation but considered for statistical analysis. 
 
Figure 3-15. Immunohistochemistry analysis of β-galactosidase in Rag 2-/- mice. Representative merged 
images of 6 μm frozen liver (A) and spleen (B) sections from Rag 2-/- mice 48 h following intravascular 
administration of DPBS (n = 6) or 1x1011 vp/mouse HAdV-5 (n = 6), AdT* (n = 7), HAdV-5 RGE (n = 6), 
AdT*RGE (n = 6) or HAdV-5 KO1 (n = 6). Rabbit anti-β-galactosidase primary antibody and Alexa Fluor 
488-conjugated goat anti-rabbit IgG secondary antibody (green) were used. Nuclei were counterstained with 
DAPI (blue). n = 3 mice analysed per group with 1 technical replicate. Magnification 40x. Scale bars 50 μm. 
3.3.4 Role of FX in tropism in NSG mice 
To confirm a role of FX in liver transduction in immunocompromised mice, HAdV-5 and 
AdT* vectors were administered to NSG mice as before (Figure 3-11) and Rag 2-/- mice 
were used as a control. 
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Quantification of viral genomes and adenoviral transduction in Rag 2-/- mice liver revealed 
significantly lower levels of AdT* than those of HAdV-5 (4-fold and 7-fold, respectively) 
(Figure 3-16A-B) in agreement with immunohistochemistry analysis of β-galactosidase on 
liver sections (Figure 3-17B), and thus confirming previous results (Figure 3-14C-D and 
Figure 3-15A). X-Gal staining in Rag 2-/- mice livers showed no visual differences between 
vectors (Figure 3-17A). Slightly higher levels of AdT* genomes and transduction were 
found in Rag 2-/- spleen (4-fold and 6-fold, respectively) (Figure 3-16C-D), consistent with 
X-Gal staining of spleen (Figure 3-17A) and immunohistochemistry analysis of β-
galactosidase on spleen sections (Figure 3-17B), but they did not reach statistical 
significance. 
 
Figure 3-16. Adenoviral transduction and genomes accumulation in Rag 2-/- mice. Rag 2-/- mice were 
administered 1x1011 vp/mouse HAdV-5 (n = 6) or AdT* (n = 5) by intravascular delivery and sacrificed and 
perfused 48 h post-injection. Viral genome content was quantified by SYBR green based qPCR analysis in 
liver (A) and spleen (C). β-galactosidase expression was quantified by ELISA in liver (B) and spleen (D) and 
normalised to total mg of protein. Values are expressed as the mean +/- SEM. Unpaired Student’s T-test 
applied. *p<0.05 vs. HAdV-5. 
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Figure 3-17. β-galactosidase expression in Rag 2-/- mice liver and spleen. Rag 2-/- mice were administered 
DPBS (n = 3) or 1x1011 vp/mouse HAdV-5 (n = 6) or AdT* (n = 5) by intravascular delivery and sacrificed 
and perfused 48 h post-injection. A) Representative images of X-Gal staining of liver (top panel) and spleen 
(bottom panel) fixed in 2% paraformaldehyde are shown. Scale bar 1 cm (upper panel) or 0.25 cm (lower 
panel). B) Immunohistochemistry analysis of β-galactosidase on 6 μm frozen liver and spleen sections from 
Rag 2-/- mice. Rabbit anti-β-galactosidase primary antibody and Alexa Fluor 488-conjugated goat anti-rabbit 
IgG secondary antibody (green) were used. Nuclei were counterstained with DAPI (blue). n = 3 mice 
analysed per group with 1 technical replicate. Representative merged images are shown. Magnification 40x. 
Scale bars 50 μm. 
In NSG mice, AdT* genome and transduction levels in liver were similar to those of 
HAdV-5 (Figure 3-18A-B), suggesting FX is not involved in liver tropism in NSG mice, 
which is in sharp contrast to Rag 2-/- mice (Figure 3-14C-D and Figure 3-16A-B). Also, no 
differences were found in X-Gal staining of liver or immunohistochemistry analysis for β-
galactosidase in liver sections (Figure 3-19). Quantification of genomes and transduction in 
spleen showed statistically significant higher levels of AdT* than those of HAdV-5 (5-fold 
and 13-fold, respectively) (Figure 3-18C-D), in agreement with X-Gal staining of spleen 
(Figure 3-19A), suggesting that lack of binding to FX results in a change in HAdV-5 
biodistribution towards the spleen in these mice. No differences were found in 
immunohistochemistry analysis for β-galactosidase in spleen sections (Figure 3-19B). 
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Figure 3-18. Adenoviral genomes accumulation and transduction in NSG mice. NSG mice were 
administered 1x1011 vp/mouse HAdV-5 (n = 5) or AdT* (n = 5) by intravascular delivery and sacrificed and 
perfused 48 h post-injection. Viral genome content was quantified by SYBR green based qPCR analysis in 
liver (A) and spleen (C). β-galactosidase expression was quantified by ELISA in liver (B) and spleen (D) and 
normalised to total mg of protein. Values are expressed as the mean +/- SEM. Unpaired Student’s T-test 
applied. *p<0.05 vs. HAdV-5. 
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Figure 3-19. β-galactosidase expression in NSG mice liver and spleen. NSG mice were administered 
DPBS (n = 3) or 1x1011 vp/mouse HAdV-5 (n = 5) or AdT* (n = 5) by intravascular delivery and sacrificed 
and perfused 48 h post-injection. A) Representative images of X-Gal staining of liver (top panel) and spleen 
(bottom panel) fixed in 2% paraformaldehyde are shown. Scale bar 1 cm (upper panel) or 0.25 cm (lower 
panel). B) Immunohistochemistry analysis of β-galactosidase on 6 μm frozen liver and spleen sections from 
NSG mice. Rabbit anti-β-galactosidase primary antibody and Alexa Fluor 488-conjugated goat anti-rabbit 
IgG secondary antibody (green) were used. Nuclei were counterstained with DAPI (blue). n = 3 mice 
analysed per group with 1 technical replicate. Representative merged images are shown. Magnification 40x. 
Scale bars 50 μm. 
3.3.5 Role of αvβ3,5 integrins in tropism in NSG mice 
The lack of αvβ3,5 integrins-binding in a FX-binding deficient vector (AdT*RGE) resulted 
in an increase in liver and spleen transduction in both immunocompetent C57BL/6 and 
immunocompromised Rag 2-/- mice (see section 3.3.3). Whether this effect was also 
present in other immunocompromised mouse strains and whether the increased 
transduction would result in an immune response against the adenoviral vector was 
investigated. HAdV-5, AdT* and AdT*RGE vectors were administered to NSG mice as 
before, Rag 2-/- mice were used as a control, and cytokine production was evaluated from 
mouse serum 6 h post adenovirus injections (Figure 3-20). Of note, one Rag 2-/- mouse 
administered AdT*RGE was excluded from data analysis due to technical reasons (n = 2). 
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Figure 3-20. Timeline diagram of in vivo experiment. Mice were administered 1x1011 vp of adenoviral 
vector per animal via tail vein injection and, after 6 h, blood was collected for cytokine profiling assays. Mice 
were sacrificed 48 h post-injections and organs were analysed for adenovirus genome content and 
transduction levels.  
The analysis of livers and spleens of Rag 2-/- mice administered HAdV-5, AdT* or 
AdT*RGE (Figure 3-21 and Figure 3-22) showed results consistent with those described 
previously (section 3.3.3). AdT* genome and transduction levels in liver were significantly 
lower than those of HAdV-5 (4-fold and 97-fold, respectively) (Figure 3-21A-B). Despite 
the low number of animals administered AdT*RGE (n = 2) did not allow statistical 
significance assessment, AdT*RGE genome and transduction levels in liver and spleen 
were found higher than those of AdT* (Figure 3-21 and Figure 3-22), as observed 
previously (Figure 3-14 and Figure 3-15). 
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Figure 3-21. Adenoviral genomes accumulation and transduction in Rag 2-/- mice. Rag 2-/- mice were 
administered 1x1011 vp/mouse HAdV-5 (n = 3), AdT* (n = 3) or AdT*RGE (n = 2) by intravascular delivery 
and sacrificed and perfused 48 h post-injection. Viral genome content was quantified by SYBR green based 
qPCR analysis in liver (A) and spleen (C). β-galactosidase expression was quantified by ELISA in liver (B) 
and spleen (D) and normalised to total mg of protein. Values are expressed as the mean +/- SEM. Unpaired 
Student’s T-test applied. *p<0.05 vs. HAdV-5. Values ≤ 1 have been omitted from the graphical 
representation but considered for statistical analysis. 
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Figure 3-22. β-galactosidase expression in Rag 2-/- mice liver and spleen. Rag 2-/- mice were administered 
DPBS (n = 3) or 1x1011 vp/mouse HAdV-5 (n = 3), AdT* (n = 3) or AdT*RGE (n = 2) by intravascular 
delivery and sacrificed and perfused 48 h post-injection. A) Representative images of X-Gal staining of liver 
(A) and spleen (B) fixed in 2% paraformaldehyde are shown. Scale bar 1 cm (A) or 0.25 cm (B). C-D) 
Immunohistochemistry analysis of β-galactosidase on 6 μm frozen liver (C) and spleen (D) sections from 
Rag 2-/- mice. Rabbit anti-β-galactosidase primary antibody and Alexa Fluor 488-conjugated goat anti-rabbit 
IgG secondary antibody (green) were used. Nuclei were counterstained with DAPI (blue). n = 3 mice 
analysed per group with 1 technical replicate, with the exception of AdT*RGE samples (n = 2). 
Representative merged images are shown. Magnification 40x. Scale bars 50 μm. 
In the NSG mice, genome and transduction levels (Figure 3-23A-B), X-Gal staining 
(Figure 3-24A) and immunohistochemistry analysis for β-galactosidase in liver (Figure 
3-24C) showed no differences between the administered vectors, as observed previously 
(Figure 3-18A-B and Figure 3-19), and thus confirming FX is not involved in liver tropism 
in NSG mice and suggesting αvβ3,5 integrins do not serve as receptors for liver transduction 
in the absence of FX-binding. In the spleen, AdT* exhibited slightly higher levels of 
transduction than those of HAdV-5 (18-fold) (Figure 3-23D) as observed previously 
(Figure 3-18D). Also, higher genome and transduction levels (122–fold and 14-fold, 
respectively) (Figure 3-23C-D), X-Gal staining (Figure 3-24B) and β-galactosidase 
detection in immunohistochemistry analysis (Figure 3-24D) were found for AdT*RGE in 
comparison to AdT* in spleen. These data suggest that lack of binding to αvβ3,5 integrins in 
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a non-FX-binding vector has an enhancing effect on NSG mice spleen transduction, as 
observed in C57BL/6 and Rag 2-/- mice (section 3.3.3).  
 
Figure 3-23. Adenoviral genomes accumulation and transduction in NSG mice. NSG mice were 
administered 1x1011 vp/mouse HAdV-5, AdT* or AdT*RGE (n = 3 mice/group) by intravascular delivery 
and sacrificed and perfused 48 h post-injection. Viral genome content was quantified by SYBR green based 
qPCR analysis in liver (A) and spleen (C). β-galactosidase expression was quantified by ELISA in liver (B) 
and spleen (D) and normalised to total mg of protein. Values are expressed as the mean +/- SEM. Unpaired 
Student’s T-test applied. Values ≤ 1 have been omitted from the graphical representation but considered for 
statistical analysis. 
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Figure 3-24. β-galactosidase expression in NSG mice liver and spleen. NSG mice were administered 
DPBS or 1x1011 vp/mouse HAdV-5, AdT* or AdT*RGE (n = 3 mice/group) by intravascular delivery and 
sacrificed and perfused 48 h post-injection. A) Representative images of X-Gal staining of liver (A) and 
spleen (B) fixed in 2% paraformaldehyde are shown. Scale bar 1 cm (A) or 0.25 cm (B). C-D) 
Immunohistochemistry analysis of β-galactosidase on 6 μm frozen liver (C) and spleen (D) sections from 
NSG mice. Rabbit anti-β-galactosidase primary antibody and Alexa Fluor 488-conjugated goat anti-rabbit 
IgG secondary antibody (green) were used. Nuclei were counterstained with DAPI (blue). n = 3 mice 
analysed per group with 1 technical replicate. Representative merged images are shown. Magnification 40x. 
Scale bars 50 μm. 
3.3.5.1 Cytokine profiling of FX and αvβ3,5 integrin-binding deficient HAdV-5 
vectors in Rag 2-/- and NSG mice 
To assess the immune response to HAdV-5, AdT* and AdT*RGE vectors in Rag 2-/- and 
NSG mice, cytokine production was evaluated from blood 6 h post administration of 
vectors using a Mouse Cytokine 20-Plex Panel for Luminex® Platform which includes 
FGF-basic, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p40/p70), 
IL-13, IL-17, CXCL10 (IP-10), KC, MCP-1, MIG, MIP-1α, TNF-α and VEGF.  
Of the analysed cytokines, only NSG mice administered AdT*RGE showed statistically 
significant lower levels of IL-4 in comparison to those administered AdT* (Figure 3-25B). 
However, the values detected for this cytokine were negligible for all the animals and 
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AdT*RGE showed lower levels than control NSG mice administered DPBS (Figure 
3-25B).  
 
Figure 3-25. Cytokine profiling of Rag 2-/- and NSG mice serum after adenoviral vector administration. 
Cytokine concentrations detected in Rag 2-/- (A) and NSG (B) serum 6 h following intravascular 
administration of DPBS (n = 3) or 1x1011 vp/mouse HAdV-5 (n = 3), AdT* (n = 3) or AdT*RGE (n = 2) (A) 
or DPBS or 1x1011 vp/mouse HAdV-5, AdT* or AdT*RGE (n = 3 mice/group) (B). Values are shown as the 
mean of values (pg cytokine/ml) +/- SEM. n = 2-3 mice analysed per group with one measurement per 
sample with a readout of n = 1-3 (Rag 2-/- serum samples) or n = 2-3 (NSG serum samples). One-way 
ANOVA and post hoc Tukey’s range test applied. *p<0.05 vs. AdT*. This assay was performed by Dr. Julio 
Alonso Padilla (University of Glasgow, UK) with the assistance of Dr. Ashley Miller (University of 
Glasgow, UK), who helped in data analysis and interpretation of results.  
3.3.6 Identification of FX-independent pathways of HAdV-5 
transduction in the presence of mouse serum in vitro 
Experiments in vivo indicate that FX-independent pathways for transduction of 
immunocompromised NSG mice liver are present (see section 3.3.4). Moreover, 
transduction experiments in vitro suggest the existence of FX-independent mechanisms 
driving transduction after exposure of HAdV-5 to immunocompromised Rag 2-/- or NSG 
serum (see section 3.3.2). Here, alternative FX-independent pathways for HAdV-5 
transduction in vitro that might be relevant in vivo were investigated. 
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3.3.6.1 Role of CAR in FX-independent HAdV-5 transduction in the presence 
of mouse serum in vitro 
To assess the role of CAR in mouse serum-enhanced HAdV-5 transduction, HAdV-5 
transduction of CARnegative CHO-K1 and CHO cells stably expressing hCAR (CHO-CAR 
cells) (Bergelson et al., 1997) was assessed in the presence of immunocompromised Rag 2-
/-
 serum with or without X-bp. 
First, flow cytometry was performed on CHO-K1 and CHO-CAR cells to assess CAR-
expression. 91.3±3.8% of CHO-CAR cells expressed CAR in contrast to only 0.6±0.05% 
of CHO-K1 cells (Figure 3-26A). Transduction of CHO-K1 cells with HAdV-5 or AdT* in 
SF media alone was negligible (Figure 3-26B) as previously reported (Di et al., 2012). Rag 
2-/- serum did not enhance HAdV-5 or AdT* transduction of CHO-K1 cells (Figure 
3-26B), suggesting that the cell receptor(s) involved in the enhancement of transduction 
produced by serum is not present in this cell line. These results are in agreement with 
previous reports showing no enhancement of HAdV-5 transduction of CHO cells in the 
presence of mouse FX (mFX), which is consistent with the presence of low levels of HSPG 
on these cells (Zaiss et al., 2011). Conversely, CHO-CAR cells exhibited higher levels of 
basal HAdV-5 transduction than those of CHO-K1 cells in the presence of SF media alone, 
Rag 2-/- serum significantly enhanced HAdV-5 transduction by 3-fold and pre-incubation 
of serum with X-bp had no effect on the enhanced transduction (Figure 3-26C). Also, Rag 
2-/- serum significantly enhanced AdT* transduction by 2.7-fold (Figure 3-26C) despite the 
lack of FX-binding. These data suggests that, in similarity to A549 cells, a FX-independent 
pathway for HAdV-5 transduction is present in CHO cells expressing hCAR, suggesting a 
possible role for CAR in this setting. 
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Figure 3-26. Adenoviral transduction in the presence of immunocompromised mouse serum in CHO 
cells engineered to express CAR. A) CAR expression levels on cell plasma membrane were tested by flow 
cytometry in CHO-K1 and CHO-CAR cells. Mouse anti-CAR IgG1 primary antibody and Alexa Fluor 488-
conjugated goat anti-mouse IgG secondary antibody were used. CAR-positive cells are shown as a 
percentage of the parental population and expressed as the mean of technical triplicates +/- SEM. A 
representative image is shown. B-C) HAdV-5 or AdT* (2x1010 vp/ml) were incubated for 30 min at 37oC 
with serum-free (SF) F-10 media or 90% Rag 2-/- serum in the presence or absence of X-bp (40 µg/ml). 
Adenovirus suspensions were diluted 200-fold in SF media and added to CHO-K1 (B) or CHO-CAR (C) 
cells (1000 vp/cell) and incubated at 37oC for 2 h. Then, media was replaced with 2% FCS F-10 media and 
cells incubated for further 20 h. β-galactosidase expression levels were quantified as relative light units 
(RLU) and normalized to total mg of protein. n = 3 biological replicates per condition with 4 technical 
replicates. Values are shown as a percentage of the SF media alone condition and expressed as the mean of 
the normalized values per experiment +/- SEM. Repeated measures ANOVA and post hoc Tukey’s range test 
applied. *p<0.05 vs. matched controls.  
To further assess the role of CAR in the observed mouse serum-enhanced transduction, 
transduction experiments in the presence of Rag 2-/- serum were performed in CARlow 
SKOV3 cells and SKOV3 cells stably expressing hCAR (SKOV3-CAR). 
Via flow cytometry only 1.3±0.05% of SKOV3 cells expressed CAR, while 63.9±0.3% of 
SKOV3-CAR cells was positive for CAR (Figure 3-27A). Rag 2-/- serum significantly 
enhanced HAdV-5 transduction of SKOV3 cells by 8-fold and addition of X-bp inhibited 
the transduction enhancing properties of Rag 2-/- serum (Figure 3-27B). These data 
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indicates that serum-enhanced transduction in SKOV3 cells is predominantly mediated by 
FX, as previously reported (Ma et al., 2015). Moreover, Rag 2-/- serum enhanced AdT* 
transduction minimally (Figure 3-27B), confirming that HAdV-5 transduction of SKOV3 
cells in the presence of immunocompromised Rag 2-/- serum is mainly dependent on FX. 
Similar to that seen in A549 cells, Rag 2-/- serum significantly enhanced SKOV3-CAR cell 
transduction by 3.5-fold, and addition of X-bp had minimal effect on the enhanced 
transduction (Figure 3-27C). Furthermore, AdT* transduction was significantly enhanced 
by 3.1-fold in the presence of Rag 2-/- serum in SKOV3-CAR cells (Figure 3-27C), 
showing that a FX-independent transduction mechanism is also present in SKOV3-CAR 
cells as observed for A549 and CHO-CAR cells.  
 
Figure 3-27. Adenoviral transduction in the presence of immunocompromised mouse serum in SKOV3 
cells engineered to express CAR. A) CAR expression levels on cell plasma membrane were tested by flow 
cytometry in SKOV3 and SKOV3-CAR cells. Mouse anti-CAR IgG1 primary antibody and Alexa Fluor 488-
conjugated goat anti-mouse IgG secondary antibody were used. CAR-positive cells are shown as a 
percentage of the parental population and expressed as the mean of technical triplicates +/- SEM. A 
representative image is shown. B-C) HAdV-5 or AdT* (2x1010 vp/ml) were incubated for 30 min at 37oC 
with serum-free (SF) RPMI-1640 media or 90% Rag 2-/- serum in the presence or absence of X-bp (40 
µg/ml). Adenovirus suspensions were diluted 200-fold in SF media and added to SKOV3 (B) or SKOV3-
CAR (C) cells (1000 vp/cell) and incubated at 37oC for 2 h. Then, media was replaced with 2% FCS RPMI-
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1640 (B) or 2% FCS 1000 ng/μl geneticin RPMI-1640 (C) media and cells incubated for further 20 h. β-
galactosidase expression levels were quantified as relative light units (RLU) and normalized to total mg of 
protein. n = 4 (B), n = 3 (C) biological replicates per condition with 4 technical replicates. Values are shown 
as a percentage of the SF media alone condition and expressed as the mean of the normalized values per 
experiment +/- SEM. Repeated measures ANOVA and post hoc Tukey’s range test applied. *p<0.05 vs. 
matched controls, $p<0.05 vs. matched serum. 
To further interrogate HAdV-5 receptor usage in the presence of mouse serum, the 
availability of CAR during cell transduction was blocked using soluble recombinant 
HAdV-5 fiber knob (FK) (Coughlan et al., 2009). FK*, which has the point mutation 
Y477A in the fiber DE loop to impair CAR-binding (Roelvink et al., 1999, Kirby et al., 
2000, Alemany and Curiel, 2001), was used as a control. First, the ability of FK to block 
CAR was confirmed by assessing HAdV-5 transduction of A549 cells pre-incubated with 
FK or FK* (Figure 3-28). Pre-incubation of A549 cells with FK significantly decreased 
HAdV-5 transduction 12-fold compared to the FK* control (Figure 3-28). Of note, FK* 
significantly increased HAdV-5 transduction of A549 cells (Figure 3-28). Next, A549 cells 
were incubated with HAdV-5 in the presence of C57BL/6 (Figure 3-29A) or Rag 2-/- 
(Figure 3-29B) serum. Pre-incubation of A549 cells with FK decreased basal HAdV-5 
transduction in the presence of SF media alone, while FK* had no effect (Figure 3-29A-B). 
Both C57BL/6 and Rag 2-/- sera enhanced HAdV-5 transduction (Figure 3-29A-B) as 
observed before, and while pre-incubation of C57BL/6 serum with X-bp resulted in a 
decrease in transduction (Figure 3-29A), it had minimal effect on Rag 2-/- serum-enhanced 
transduction (Figure 3-29B). Importantly, pre-incubation of cells with FK significantly 
reduced the enhancing properties of C57BL/6 serum from 6.9–fold (+FK*) to 2.9–fold 
(+FK) and of Rag 2-/- serum from 7.4–fold (+FK*) to 1.5–fold (+FK) (Figure 3-29A-B). 
These results show that blockade of CAR on A549 cells has a direct impact on HAdV-5 
transduction in the presence of mouse serum, confirming a role for CAR in this context.  
 
Figure 3-28. Effect of soluble recombinant HAdV-5 fiber knob (FK) on adenoviral transduction. 
HAdV-5 (1000 vp/cell) was added on A549 or SKOV3 cells that had been pre-incubated with SF media, FK 
or FK* (Y477A point mutation to impair binding to CAR) at 1 μg/well. After 2 h incubation at 37oC, media 
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was replaced with 2% FCS RPMI media and cells were incubated for further 20 h. β-galactosidase 
expression levels were quantified as relative light units (RLU) and normalized to total mg of protein. 
Background chemoluminescence was subtracted from all values. n = 4 technical replicates per condition. 
Values are shown as the mean of values +/- SEM. One-way ANOVA and post hoc Tukey’s range test 
applied. *p<0.05 vs. matched controls, #p<0.05 vs. “+FK*” condition. 
 
Figure 3-29. CAR-dependency of adenoviral transduction in the presence of mouse serum. HAdV-5 
(2x1010 vp/ml) was incubated for 30 min at 37oC with serum-free (SF) RPMI-1640 media, 90% C57BL/6 (A) 
or Rag 2-/- (B-C) mouse serum in the presence or absence of X-bp (40 µg/ml). Adenovirus suspensions were 
diluted 100-fold in SF media and added to A549 (A-B) or SKOV3 (C) cells (1000 vp/cell) that had been pre-
incubated with an equal volume of SF media, soluble recombinant fiber knob (FK) or FK* (Y477A point 
mutation to impair binding to CAR) at 1 μg/well. After 2 h incubation at 37oC, media was replaced with 2% 
FCS RPMI and cells were incubated for further 20 h. β-galactosidase expression levels were quantified as 
relative light units (RLU) and normalized to total mg of protein. n = 3 biological replicates per condition with 
4 technical replicates. Values are shown as a percentage of the SF media alone condition and expressed as the 
mean of the normalized values per experiment +/- SEM. Repeated measures ANOVA and post hoc Tukey’s 
range test applied. *p<0.05 vs. matched controls, $p<0.05 vs. matched serum, #p<0.05 vs. serum + FK*. 
Statistical significance was reached between the fold-change enhancement produced by serum in the 
presence of FK vs. that in the presence of FK* in (A-C) (paired Student’s T-test, p<0.05). 
Surprisingly, despite the presence of FX in mouse serum, C57BL/6 and Rag 2-/- serum 
failed to significantly enhance HAdV-5 transduction in the presence of FK (Figure 3-29A-
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B), suggesting that HAdV-5 might not follow the FX-mediated pathway in the presence of 
mouse serum when the FX-independent and CAR-mediated pathway is unavailable. To 
evaluate whether the FX-mediated pathway of HAdV-5 transduction in the presence of 
mouse serum is affected by the presence of soluble FK, HAdV-5 transduction experiments 
with Rag 2-/- serum and FK were performed in SKOV3 cells, which are transduced 
predominantly in a FX-dependent manner in the presence of Rag 2-/- serum. First, FK was 
confirmed to have no effect on basal HAdV-5 transduction of CARlow SKOV3 cells in the 
presence of SF media alone (Figure 3-28). As observed in A549 cells (Figure 3-28), FK* 
significantly increased HAdV-5 transduction in SKOV3 cells (Figure 3-28). Next, HAdV-5 
transduction of SKOV3 cells was assessed in the presence of Rag 2-/- serum and FK or 
FK* (Figure 3-29C). Rag 2-/- serum produced a significant enhancement in HAdV-5 
transduction in the presence of FK (4.3-fold) that was inhibited by X-bp (Figure 3-29C), 
indicating HAdV-5 was able to transduce SKOV3 cells via the FX-mediated pathway. 
However, this enhancement was significantly lower than that in the presence of FK*, 
which was 10.6-fold (Figure 3-29C). Since only 1.3±0.05% of SKOV3 cells were shown to 
express CAR in flow cytometry assays (Figure 3-27A), these results suggest that presence 
of FK might affect the use of the FX-mediated pathway in the presence of Rag 2-/- serum. 
To further investigate whether the observed effects of FK on the FX-mediated pathway of 
HAdV-5 transduction are evident only in the presence of Rag 2-/- serum, HAdV-5 
transduction of A549 cells was assessed in the presence of FK or FK* with or without the 
addition of hFX in the absence of mouse serum. Addition of hFX enhanced HAdV-5 
transduction by 3-fold but, unexpectedly, it did not reach statistical significance (Figure 
3-30). Presence of FK slightly reduced FX-enhanced transduction and FK* slightly 
increased FX-enhanced transduction but did not reach statistical significance (Figure 3-30). 
Together, these data show a trend for FK but not FK* to negatively affect HAdV-5 
transduction via the FX-mediated pathway. 
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Figure 3-30. Effect of soluble recombinant fiber knob (FK) and FX on adenoviral transduction. HAdV-
5 (2x1010 vp/ml) was incubated for 30 min at 37oC with serum-free (SF) RPMI-1640 media in the absence or 
presence of recombinant human FX (10 µg/ml). Adenovirus suspensions were diluted 100-fold in SF media 
and added to A549 cells (1000 vp/cell) that had been pre-incubated with an equal volume of SF media, FK or 
FK* (Y477A point mutation to impair binding to CAR) at 1 μg/well. After 2 h incubation at 37oC, media was 
replaced with 2% RPMI media and cells were incubated for further 20 h. β-galactosidase expression levels 
were quantified as relative light units (RLU) and normalized to total mg of protein. n = 3 biological replicates 
per condition with 4 technical replicates. Values are shown as a percentage of the SF media alone condition 
and expressed as the mean of the normalized values per experiment +/- SEM. Repeated measures ANOVA 
and post hoc Tukey’s range test applied (p<0.05). 
Together, these data support a role for CAR in HAdV-5 transduction in vitro in the 
presence of immunocompetent or immunocompromised mouse serum. Moreover, the data 
suggests that HAdV-5 may not transduce A549 cells via alternative pathways such as the 
FX-mediated pathway when the FX-independent and CAR-mediated pathway is 
unavailable. 
3.3.6.2 Direct HAdV-5 fiber knob interaction with CAR is not required for 
transduction in the presence of immunocompromised mouse serum 
The presence of mouse serum is required to enhance HAdV-5 transduction via a CAR-
mediated pathway. The mechanisms behind this effect might involve a mouse serum 
protein either able to bridge HAdV-5 to CAR on the plasma membrane or to enhance 
transduction by stabilizing HAdV-5:CAR interactions. To assess whether the CAR-
mediated pathway of HAdV-5 transduction in the presence of mouse serum occurs via a 
direct interaction between the HAdV-5 fiber knob and CAR, transduction assays were 
performed in the presence of Rag 2-/- serum using the CAR-binding deficient HAdV-5 
KO1. HAdV-5 was used as a control. 
HAdV-5 KO1 transduction of A549 cells was enhanced 2.8–fold in the presence of Rag 2-/- 
serum (Figure 3-31), and pre-incubation of Rag 2-/- serum with X-bp had no effect on the 
enhanced transduction (Figure 3-31), indicating that HAdV-5 KO1 transduced A549 cells 
in a FX-independent manner, as observed for HAdV-5 (Figure 3-31). These results suggest 
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that a direct interaction of HAdV-5 fiber knob with CAR is not required for transduction in 
the presence of Rag 2-/- serum, suggesting the CAR-mediated pathway might involve a 
serum protein bridging HAdV-5 to CAR. 
 
Figure 3-31. Effect of immunocompromised mouse serum on CAR-binding deficient HAdV-5 
transduction. HAdV-5 or HAdV-5 KO1 (2x1010 vp/ml) were incubated for 30 min at 37oC with serum-free 
(SF) RPMI-1640 media or 90% Rag 2-/- mouse serum in the presence or absence of X-bp (40 µg/ml). 
Adenovirus suspensions were diluted 200-fold in SF media and added to A549 cells (1000 vp/cell) and 
incubated at 37oC for 2 h. Then, media was replaced with 2% FCS RPMI and cells incubated for further 20 h. 
β-galactosidase expression levels were quantified as relative light units (RLU) and normalized to total mg of 
protein. n = 4 biological replicates per condition with 4 technical replicates. Values are shown as a 
percentage of the SF media alone condition and expressed as the mean of the normalized values per 
experiment +/- SEM. Repeated measures ANOVA and post hoc Tukey’s range test applied. *p<0.05 vs. 
matched controls, $p<0.05 vs. matched serum. 
3.3.6.3 Effect of heat on the FX-mediated pathway for HAdV-5 transduction 
Next, the mouse serum proteins that might be involved in the observed enhancement on 
HAdV-5 transduction in the presence of mouse serum were investigated. As discussed in 
section 3.3.2.2, exposure of C57BL/6 or Rag 2-/- serum to high temperatures (56oC) 
inhibited the transduction enhancing properties of mouse serum, suggesting that the factors 
involved in both FX-mediated and FX-independent HAdV-5 transduction in the presence 
of mouse serum are heat-labile. To confirm that FX is heat-labile, transduction experiments 
were performed with HAdV-5 on A549 cells in the presence or absence of hFX that had 
been pre-exposed to 56oC. As expected, HAdV-5 transduction was significantly enhanced 
in the presence of hFX by 2.9-fold (Figure 3-32). However, heat-exposed hFX failed to 
enhance HAdV-5 transduction (Figure 3-32), confirming that heat inhibits the enhancing 
properties of hFX. 
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Figure 3-32. Effect of heat on the HAdV-5 transduction enhancing properties of FX in vitro. HAdV-5 
(2x1010 vp/ml) was incubated for 30 min at 37oC with recombinant human FX (hFX) or heat-treated hFX (10 
µg/ml) in serum-free (SF) RPMI-1640 media. Adenovirus suspensions were diluted 200-fold in SF media 
and added to A549 cells (1000 vp/cell) and incubated at 37oC for 2 h. Then, media was replaced with 2% 
FCS RPMI media and cells incubated for further 20 h. β-galactosidase expression levels were quantified as 
relative light units (RLU) and normalized to total mg of protein. n = 3 biological replicates per condition with 
4 technical replicates. Values are shown as a percentage of the SF media alone condition and expressed as the 
mean of values +/- SEM. Repeated measures ANOVA and post hoc Tukey’s range test applied. *p<0.05 vs. 
“Media” condition.  
3.3.6.4 HAdV-5 transduction in the presence of immunocompromised mouse 
serum in a series of high and low CAR-expressing cell lines 
To investigate whether the CAR-mediated pathway in the presence of mouse serum is also 
present in other high CAR-expressing cell lines (determined from NCI60 database, 
retrieved from http://biogps.org/#goto=welcome), transduction experiments were 
performed in the presence of immunocompromised Rag 2-/- serum with or without X-bp in 
HeLa and HepG2 cells. Flow cytometry assays confirmed a high percentage of HeLa and 
HepG2 cells expressing CAR on the cell plasma membrane, 79.9±4.6% and 71±0.3% 
respectively (Figure 3-33A). Both cell lines exhibited an HAdV-5 transduction profile 
similar to that observed in A549 cells, where Rag 2-/- serum significantly enhanced HAdV-
5 transduction (4.7-fold in HeLa cells and 2.2-fold in HepG2 cells) and X-bp had minimal 
or inexistent effect on the enhanced transduction (Figure 3-33B-C). AdT* transduction was 
significantly enhanced by Rag 2-/- serum in HeLa cells both in the presence or absence of 
X-bp by 4.7-fold and 3.3-fold, respectively (Figure 3-33B). However, despite a 2-fold 
transduction enhancement was observed for AdT* in HepG2 cells with and without X-bp, 
it did not reach statistical significance (Figure 3-33C). These results indicate that FX-
independent pathways of HAdV-5 transduction in the presence of Rag 2-/- serum are also 
present in other CARhigh cell lines such as HeLa and HepG2 cells. 
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Figure 3-33. Adenoviral transduction in the presence of immunocompromised mouse serum in high 
CAR-expressing cell lines. A) CAR expression levels on cell plasma membrane were tested by flow 
cytometry in HeLa and HepG2 cells. Mouse anti-CAR IgG1 primary antibody and Alexa Fluor 488-
conjugated goat anti-mouse IgG secondary antibody were used. CAR-positive cells are shown as a 
percentage of the parental population and expressed as the mean of technical triplicates +/- SEM. A 
representative image is shown. B-C) HAdV-5 or AdT* (2x1010 vp/ml) were incubated for 30 min at 37oC 
with serum-free (SF) MEM media or 90% Rag 2-/- serum in the presence or absence of X-bp (40 µg/ml). 
Adenovirus suspensions were diluted 200-fold in SF media and added to HeLa (B) or HepG2 (C) cells (1000 
vp/cell) and incubated at 37oC for 2 h. Then, media was replaced with 2% FCS MEM media and cells 
incubated for further 20 h. β-galactosidase expression levels were quantified as relative light units (RLU) and 
normalized to total mg of protein. n = 6 (B), n = 3 (C) biological replicates per condition with 4 technical 
replicates. Values are shown as a percentage of the SF media alone condition and expressed as the mean of 
the normalized values per experiment +/- SEM. Repeated measures ANOVA and post hoc Tukey’s range test 
applied. *p<0.05 vs. matched controls, $p<0.05 vs. matched serum.  
Next, whether other low CAR-expressing cell lines (determined from NCI60 database, 
retrieved from http://biogps.org/#goto=welcome) such as ACHN or MCF7 are transduced 
by HAdV-5 via the FX-mediated pathway in the presence of Rag 2-/- serum, as observed in 
SKOV3 cells, was assessed. The levels of CAR on the cell plasma membrane were 
assessed by flow cytometry, and only 3.5±0.5% of ACHN and 0.3±0.08% of MCF7 cells 
were positive for CAR (Figure 3-34A). Rag 2-/- serum significantly enhanced HAdV-5 
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transduction by 3.6-fold in ACHN and 2.9-fold in MCF7 cells (Figure 3-34B-C). The 
presence of X-bp reduced serum-enhanced HAdV-5 transduction in ACHN cells but 
unexpectedly this reduction did not reach statistical significance (Figure 3-34B). X-bp had 
minimal effect on the enhanced transduction in MCF7 cells (Figure 3-34C). Moreover, Rag 
2-/- serum significantly enhanced AdT* transduction by 2.1-fold in ACHN and 2.5-fold in 
MCF7 in the presence and absence of X-bp (Figure 3-34B-C). These data indicate that FX-
independent pathways of HAdV-5 transduction in the presence of Rag 2-/- serum are also 
present in CARlow ACHN and CARnegative MCF7 cells.  
 
Figure 3-34. Adenoviral transduction in the presence of immunocompromised mouse serum in low 
CAR-expressing cell lines. A) CAR expression levels on cell plasma membrane were tested by flow 
cytometry in ACHN and MCF7 cells. Mouse anti-CAR IgG1 primary antibody and Alexa Fluor 488-
conjugated goat anti-mouse IgG secondary antibody were used. CAR-positive cells are shown as a 
percentage of the parental population and expressed as the mean of technical triplicates +/- SEM. A 
representative image is shown. B-C) HAdV-5 or AdT* (2x1010 vp/ml) were incubated for 30 min at 37oC 
with serum-free (SF) RPMI-1640 media or 90% Rag 2-/- serum in the presence or absence of X-bp (40 
µg/ml). Adenovirus suspensions were diluted 200-fold in SF media and added to ACHN (B) or MCF7 (C) 
cells (1000 vp/cell) and incubated at 37oC for 2 h. Then, media was replaced with 2% FCS RPMI media and 
cells incubated for further 20 h. β-galactosidase expression levels were quantified as relative light units 
(RLU) and normalized to total mg of protein. n = 3 biological replicates per condition with 4 technical 
replicates. Values are shown as a percentage of the SF media alone condition and expressed as the mean of 
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the normalized values per experiment +/- SEM. Repeated measures ANOVA and post hoc Tukey’s range test 
applied. *p<0.05 vs. matched controls.  
Together, these results suggest that HAdV-5 can transduce different cell lines in a FX-
independent manner in the presence of immunocompromised Rag 2-/- serum, independently 
of CAR expression levels.   
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3.4 Discussion 
Here, the mechanisms mediating in vitro and in vivo HAdV-5 neutralization were assessed. 
Moreover, the use of FX-independent pathways for HAdV-5 liver and spleen transduction 
following intravascular delivery were investigated and novel pathways of HAdV-5 
transduction in vitro after exposure of virions to mouse serum were defined. The data 
indicate that while natural IgM antibodies and the complement system are required for 
adenovirus neutralization in vitro after exposure to mouse serum, innate immunity alone 
might be sufficient to mediate neutralization in vivo. FX was identified as critical in 
protecting HAdV-5 from neutralization by mouse serum both in vitro and in vivo but 
dispensable for liver and spleen transduction in immunocompromised NSG mice. CAR and 
αvβ3,5 integrins were shown to have no role in liver or spleen tropism in 
immunocompromised Rag 2-/- and αvβ3,5 integrins in immunocompromised NSG mice 
(CAR not assessed), while CAR and αvβ3,5 integrins appeared to be involved in 
immunocompetent C57BL/6 mice liver transduction. Both immunocompetent and 
immunocompromised mouse serum enhanced HAdV-5 transduction in vitro in a FX-
independent manner on high CAR-expressing cell lines via a mechanism involving a blood 
factor bridging HAdV-5 to CAR. In contrast, HAdV-5 transduction of low CAR-
expressing cell lines in the presence of immunocompromised mouse serum was either FX-
dependent or via other FX and CAR-independent pathways, depending on cell type. 
Therefore, Figure 3-35 summarizes our suggested model of HAdV-5 in vitro neutralization 
and cell transduction in the presence of mouse serum. 
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Figure 3-35. Suggested model of HAdV-5 in vitro neutralization and cell transduction in the presence 
of mouse serum. HAdV-5 can use FX for protection against neutralization in the presence of 
immunocompetent mouse serum. In the absence of adenovirus neutralization and presence of mouse serum, 
HAdV-5 can transduce host cells via a FX-mediated pathway or through a FX-independent mechanism that 
involves an unidentified blood protein bridging HAdV-5 to CAR. FX; coagulation factor X, CAR; coxsackie 
and adenovirus receptor, HSPG; heparan sulphate proteoglycan, C3; complement protein 3. Figure adapted 
from (Lopez-Gordo et al., 2014a). 
3.4.1 In vitro and in vivo adenovirus neutralization 
First, immunocompromised Rag 2-/- mice (IgM antibodies-deficient) (Shinkai et al., 1992, 
Alt et al., 1992) and NSG mice (IgM antibodies and C5-deficient) (Zhou et al., 2014, 
Shultz et al., 2005, Ito et al., 2002, Shultz et al., 1995) were confirmed to lack the ability to 
neutralize HAdV-5 in vitro in the absence of FX-binding, in contrast to immunocompetent 
C57BL/6 mice, revealing a role for IgM antibodies in in vitro HAdV-5 neutralization and a 
role for FX in protecting HAdV-5 from it. However, complementation of IgM antibodies 
in Rag 2-/- serum failed to rescue in vitro HAdV-5 neutralization. The finding that IgM 
antibodies might not be involved in HAdV-5 in vitro neutralization in the presence of Rag 
2-/- serum is in contrast with a previous report (Xu et al., 2013). This study showed that 
complementation of Rag 1-/- serum with mouse IgM antibodies purified from BALB/c 
mice rescued HAdV-5 neutralization in vitro. Here, Rag 2-/- serum was complemented with 
pure mouse IgM antibodies that had been isolated from BALB/c serum. Rag 1-/- and Rag 2-
/-
 mice are both strains derived from C57BL/6 mice by mutation of Rag-1 or Rag-2 genes 
respectively (Mombaerts et al., 1992, Shinkai et al., 1992), which are involved in the 
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somatic DNA rearrangement V(D)J recombination (Alt et al., 1992). Since these two 
mouse strains have a very similar phenotype (Mombaerts et al., 1992, Shinkai et al., 1992), 
it was presumed the mechanisms of adenovirus neutralization might also be closely related. 
Furthermore, Rag 2-/- mice only lack IgM production in comparison to its background 
strain C57BL/6 mice, which can neutralize HAdV-5 in vitro when not bound to FX (Xu et 
al., 2013). Thus, lack of adenovirus neutralization by IgM-complemented Rag 2-/- serum 
might be due to strain incompatibilities, where the complement system from Rag 2-/- serum 
is unable to bind BALB/c IgM antibodies to initiate the classical complement cascade on 
the HAdV-5 capsid. Also, BALB/c IgM antibodies were not tested for binding to HAdV-5 
vectors neither in the absence nor the presence of Rag 2-/- serum. Confirmation of these 
interactions by techniques such as NanoSight, ELISA or SPR would help in assessing the 
reason behind the controversial results. To further dissect the underlying mechanisms of 
adenovirus neutralization by mouse serum in vitro, the role of complement was assessed. 
Transduction assays in the presence of C57BL/6 serum that had been heat-treated resulted 
in the impairment of HAdV-5 neutralization when not bound to FX, indicating that a heat-
labile protein is involved in HAdV-5 neutralization. Based on previous data (Xu et al., 
2013), it was presumed this was the complement system. However, further experiments 
should be performed to draw definite conclusions since other heat-labile proteins might be 
present in C57BL/6 serum and be the ones involved in HAdV-5 in vitro neutralization. 
Next, liver transduction was assessed in C57BL/6, Rag 2-/- and NSG mice. FX-binding 
deficient AdT* exhibited a significantly lower liver transduction than that of HAdV-5 in 
C57BL/6 mice in contrast to NSG mice, which had equivalent levels of liver transduction 
with these two vectors. Interestingly, Rag 2-/- mice had a significantly lower AdT* liver 
transduction compared to that of HAdV-5, albeit this reduction was less pronounced than 
in C57BL/6 mice. These results suggest that while FX might play a role in protecting 
HAdV-5 against neutralization in C57BL/6 mice, its role in liver tropism in 
immunocompromised NSG mice is minimal, which is in agreement with previous data 
suggesting that FX-independent pathways can mediate liver transduction (Zaiss et al., 
2015). Interestingly, FX might be involved in liver tropism in immunocompromised Rag 2-
/-
 mice, indicating that strain-specific processes may dictate adenovirus liver tropism. For 
instance, the effect of both CAR and integrin-binding ablating mutations on HAdV-5 
vectors on liver transduction was highly variable between mouse and rat and between 
different rat strains (Nicol et al., 2004), suggesting that indeed intrinsic differences in the 
use of adenoviral receptors for liver transduction may be present between strains. 
However, the lower liver transduction found in Rag 2-/- mice could be the result of 
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adenovirus neutralization, albeit at lower levels than those found in C57BL/6 mice. Here, it 
was suggest that the mechanisms for adenovirus neutralization in vivo may differ from 
those in vitro: IgM antibodies may be required for in vitro neutralization but dispensable in 
vivo. Thus, while neither Rag 2-/- or NSG mice serum can neutralize HAdV-5 in vitro in 
the absence of FX-binding because they lack IgM antibodies, the intact innate immunity of 
Rag 2-/- mice might be sufficient to mediate adenovirus neutralization in vivo. Under this 
hypothesis, since NSG mice are defective in both the adaptive and innate immune 
response, they would not be able to mediate adenovirus neutralization in vivo. Supporting 
our hypothesis, one study demonstrated that while in vitro neutralization requires IgM 
antibodies and the classical complement pathway, both the classical and non-classical 
pathways are apparent in vivo (Tian et al., 2009), indicating that in vitro and in vivo 
adenovirus neutralization is mediated by different mechanisms. Furthermore, this study 
showed that C3 is activated in vivo in Rag 1-/- mice following adenovirus administration 
but not in vitro after exposure of HAdV-5 to Rag 1-/- serum, in agreement with our 
findings. Also, a more recent study using Rag 1-/- mice showed lower levels of liver 
transduction after administration of FX-binding deficient HAdV-5 or HAdV-5 with X-bp, 
in contrast to C57BL/6 mice (Xu et al., 2013). However, although these data might suggest 
that HAdV-5 can be neutralized in mice lacking IgM antibodies, they suggested the lower 
transduction might be due to FX being involved in liver tropism to some extent in Rag 1-/- 
mice (Xu et al., 2013). Nevertheless, data from other studies assessing in vitro adenovirus 
neutralization are highly controversial. For instance, one report showed that although 
HAdV-5 is mainly opsonized by the IgM-mediated classical complement pathway in vitro, 
there are other antibody-independent pathways that can opsonize HAdV-5 in vitro (Xu et 
al., 2008). In particular, this study showed that HAdV-5 was opsonized by C3b when 
incubated with Rag 1-/- serum despite lacking IgM antibodies (Xu et al., 2008), which is in 
agreement with another study showing that in the absence of IgM antibodies the alternative 
complement pathway can be activated in vitro (Jiang et al., 2004). These findings are 
however in contrast with our data showing that in vitro HAdV-5 neutralization requires the 
presence of IgM antibodies and with more recent reports showing similar results (Xu et al., 
2013). Thus, further studies should be done to describe the mechanisms behind in vitro and 
in vivo adenovirus neutralization and confirm the involvement or dispensability of IgM 
antibodies in this process. In any case, if the innate immunity alone is sufficient to 
neutralize adenovirus in vivo, differences in the presence of proteins from the innate 
immune response in NSG and Rag 2-/- mice may dictate the capacity or incapacity to 
neutralize adenovirus in the bloodstream and thus account for the differences observed in 
liver transduction with HAdV-5 and AdT* vectors in these mouse strains. For instance, 
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while both NSG and Rag 2-/- mice can produce C1q and C4, complement proteins that have 
been associated with adenovirus neutralization in vitro and in vivo (Xu et al., 2013), NSG 
mice lack C5 (Baxter and Cooke, 1993), which is a downstream mediator of both the 
classical and non-classical complement pathways. Thus, absence of C5 might impair NSG 
mice from neutralizing FX-binding deficient vectors. Also, the levels of C4 differ between 
mouse strains (Hansen et al., 1974, Lachmann et al., 1975) and, interestingly, the levels of 
C4 have been shown to be elevated in the intestine of Rag 1-/- mice although unaffected in 
the liver (Jima et al., 2009). Since C4 is a mediator of adenovirus neutralization (Xu et al., 
2013), the levels of C4 might directly affect adenovirus neutralization. More studies would 
be required to investigate whether the differences observed in liver transduction between 
immunocompromised Rag 2-/- and NSG mice with FX-binding deficient vectors are due to 
strain-specific mechanisms dictating tropism or differences in HAdV-5 neutralization due 
to intrinsic strain-specific differences in the components of the innate immune system. 
Regarding the spleen, AdT* exhibited a higher transduction than that of HAdV-5 in NSG 
mice. Taking into account that NSG mice are defective in macrophage response (Ito et al., 
2002, Shultz et al., 1995), these observations are in agreement with previous work showing 
that macrophage depletion in MF1 mice results in higher spleen transduction with AdT* 
compared to HAdV-5 vectors (Alba et al., 2010, Bradshaw et al., 2012). Further 
experiments are needed to investigate the reason behind this observation. NSG mice are a 
well stablished highly immunocompromised mouse model that supports engraftment with a 
functional human immune system (Brehm et al., 2010, Pearson et al., 2008) and thus 
allows investigation of the in vivo function of the human immune system (Shultz et al., 
2007). Here, NSG mice were used to study adenovirus tropism in the absence of 
adenovirus neutralization. However, it should be taken into account that neutrophils and 
monocytes remain functional in NSG mice and, therefore, they could have an effect on the 
biodistribution of adenoviral vectors. 
3.4.2 Cellular receptors mediating liver and spleen transduction 
In the assessment of receptors for HAdV-5 liver and spleen transduction, it was found that 
both CAR and αvβ3,5 integrins seem to play a role in liver tropism in C57BL/6 mice but not 
in Rag 2-/- mice or NSG mice in the case of αvβ3,5 integrins (CAR not assessed). CAR and 
αvβ3,5 integrins did not seem to be involved in spleen transduction in neither C57BL/6 or 
Rag 2-/- mice and αvβ3,5 integrins were not involved in NSG mice spleen transduction 
(CAR not assessed). Previous studies using HAdV-5 with mutations in the fiber knob 
domain such as S408E, P409A, Y491D, A494D, A503D, Y477A or K417A successfully 
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impaired interactions with CAR but did not achieve liver de-targeting in C57BL/6, 
BALB/c and CD-1 mice or non-human primates (Leissner et al., 2001, Alemany and 
Curiel, 2001, Smith et al., 2002, Smith et al., 2003b, Martin et al., 2003, Zaiss et al., 2015, 
Smith et al., 2003a), suggesting that CAR is not involved in liver transduction. The effect 
of mutations impairing interaction of HAdV-5 with αvβ3,5 integrins on liver and spleen 
transduction have also been studied. The substitution of the RGD motif in the penton base 
with an influenza HA epitope to impair binding to αvβ3,5 integrins had little effect on liver 
or spleen transduction in BALB/c mice (Einfeld et al., 2001). Deletion of RGD motif in the 
penton base was also tested but resulted in no differences on liver or spleen transduction in 
C57BL/6 mice (Mizuguchi et al., 2002, Martin et al., 2003). The PD1 mutation, which 
consists of a substitution of amino acids 337HAIRGDTF3445 with amino acids 
SRGYPYDVPDYAGTS in the penton base, significantly reduced liver transduction in 
C57BL/6 mice and also decreased spleen transduction (Smith et al., 2003b). In non-human 
primates, the PD1 mutation produced levels of liver transduction similar to HAdV-5 but 
lower levels of transduction in the spleen (Smith et al., 2003a). Moreover, a previous study 
using HAdV-5 RGE revealed no role of αvβ3,5 integrins on MF1 mice liver transduction in 
contrast to the spleen, where it produced a 5-fold reduction in transduction (Bradshaw et 
al., 2012). The impact of simultaneously ablating CAR-binding and αvβ3,5 integrins on 
liver and spleen transduction has also been assessed. Incorporation of an influenza HA 
epitope into the HI loop of the fiber knob domain and in place of the penton base RGD 
motif to simultaneously ablate interactions with CAR and αvβ3,5 integrins, respectively, 
reduced liver transduction 700-fold in BALB/c mice (Einfeld et al., 2001). Also, the 
combination of PD1 and KO1 mutations produced a moderate effect on liver and spleen 
transduction in C57BL/6 mice (Smith et al., 2003b) and the deletion of amino acids 
489TAYT492 in the FG loop of the fiber knob to ablate binding to CAR together with a 
deletion of the RGD motif produced a 270-fold lower liver transduction (Koizumi et al., 
2003). However, liver transduction of C57BL/6 mice was not altered by the combination 
of K417A in the fiber knob and the deletion of RGD in the penton base (Martin et al., 
2003). Despite the moderate effect that CAR and αvβ3,5 integrin-binding ablating mutations 
produced in liver transduction in some of the studies above, ablation of HAdV-5 
interactions with CAR or αvβ3,5 integrins for the most par failed to significantly reduce 
liver transduction. This is in agreement with our data from Rag 2-/- mice but in contrast to 
our observations in C57BL/6 mice. The reason behind these differences should be further 
investigated. Nevertheless, it is important to bear in mind that when assessing CAR or 
                                                 
5Numbers refer to amino acid residue position in the protein. 
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αvβ3,5 integrin-binding ablating mutations it might be necessary to simultaneously ablate 
interactions with FX or block the use of HSPGs to prevent HAdV-5 from using 
compensatory pathways for transduction, such as the FX-mediated pathway, when CAR or 
αvβ3,5 integrins are unavailable. Studies on spleen transduction are more controversial, but a 
tendency for αvβ3,5 integrins to be involved in spleen transduction has been reported in 
several studies. This is in contrast with our data, where neither C57BL/6 nor Rag 2-/- mice 
spleen transduction levels were reduced by the αvβ3,5 integrin-binding ablating mutation 
RGE. Interestingly, this mutation enhanced localization of vectors to the spleen MZ, where 
phagocytic cells such as MARCO-positive scavenging macrophages and Moma-1 
(CD169)-positive marginal metallophilic macrophages have been shown to trap HAdV-5 
particles at early time-points following adenovirus administration (Di Paolo et al., 2009a). 
Also, it was found that the presence of the RGE mutation in FX-binding deficient vectors 
(AdT*RGE) enhanced liver and spleen transduction in C57BL/6, Rag 2-/- and NSG mice. 
These data is in contrast with one study using the same vector that showed no differences 
on liver or spleen transduction in MF1 mice compared to the control vector (Bradshaw et 
al., 2012). However, these differences might be due to strain-specific processes. Previous 
studies reported that macrophage β3 integrins can interact with the adenovirus RGD motif 
and induce an innate antiviral immune response via production of IL-1β (Di Paolo et al., 
2009a). The lack of binding to β3 integrins in RGD-mutated vectors might impair 
adenovirus recognition and engulfment by macrophages via the β3 integrin-mediated 
pathway, resulting in an increase in the amount of adenovirus available to transduce non-
immune cells in tissues such as liver and spleen. However, although this effect might be 
more evident when using low viral doses (1 to 3x1010 vp/mouse), which are completely 
taken up by immune cells (Tao et al., 2001), the use of a high viral dose (1x1011 vp/mouse) 
in our studies that saturates resident macrophages in the liver (Tao et al., 2001) would have 
been expected to attenuate the effects associated with macrophage sequestration. 
Nevertheless, the immune response against AdT*RGE was investigated in Rag 2-/- and 
NSG mice. No significant differences were found in any of the cytokines analysed. 
However, since the innate immune response decreases with age (Grolleau-Julius et al., 
2006, Wong et al., 2010, Pereira et al., 2011, Wong and Goldstein, 2013, Zacca et al., 
2015) and the mice used in this experiment were 19-21 weeks old, the response might have 
been slightly attenuated. Assessment of cytokine levels in liver and spleen tissue could 
help in detecting subtle changes between groups that might not be detectable in serum. 
Also, increasing the sample size of the experimental groups would help in increasing the 
experimental power and confirming results. Finally, further experiments would be 
necessary to draw conclusions on the involvement of CAR and αvβ3,5 integrins on mouse 
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liver and spleen transduction and to determine the influence of the αvβ3,5 integrin-binding 
ablating RGE mutation on AdT* vectors and the resulting effects on liver and spleen 
transduction.  
3.4.3 Pathways of in vitro HAdV-5 transduction after exposure of 
virions to mouse serum 
Together with previous reports (Xu et al., 2013, Zaiss et al., 2015, Martin et al., 2003), 
evidence that FX, CAR and αvβ3,5 integrins might be dispensable for liver transduction in 
immunocompetent and immunocompromised mice suggests that alternative pathways of 
adenovirus transduction are present in vivo. Moreover, transduction experiments in vitro 
revealed that HAdV-5 can follow FX-independent pathways for cell transduction after 
exposure to immunocompetent and immunocompromised mice serum. Interestingly, 
evidence of such pathways in the presence of serum from different strains of 
immunocompromised mice suggests that these pathways might be conserved across mouse 
strains. Also, the use of FX-independent pathways in this setting was confirmed for several 
cell lines, suggesting that these pathways might be widely used. Interestingly, they were 
also observed in hepatocyte-derived HepG2 cells, indicating that HAdV-5 might 
potentially use these pathways for hepatocyte transduction in vivo. Here, it was found that 
in this setting HAdV-5 can use CAR via an indirect mechanism that involves a mouse 
serum protein able to bridge HAdV-5 to CAR (Figure 3-35). The biological relevance of 
CAR as a receptor for HAdV-5 transduction has historically been quite controversial. CAR 
has been reported as a receptor for adenovirus species A, C, D, E, F and G (Roelvink et al., 
1998, Lenman et al., 2015). However, the localization of CAR on the basolateral side of 
the plasma membrane (Walters et al., 1999, Cohen et al., 2001) hinders its use as a receptor 
for replicating adenovirus infecting intact epithelium and for non-replicating adenoviruses. 
The CAR amino acid sequence is highly conserved, with a 83% homology and 
conservative amino acid substitutions in differing positions between human and mouse 
CAR (Tomko et al., 1997, Bergelson et al., 1998). hCAR is a 46 kDa transmembrane 
glycoprotein that belongs to the immunoglobulin (Ig) superfamily and is composed of a 
leader sequence (LS), two Ig-like domains (D1 and D2), a transmembrane domain and a 
cytoplasmic domain containing a class I PSD95/DlgA/ZO-1 (PDZ)-binding domain 
involved in interactions with several proteins (Bergelson et al., 1997, Cohen et al., 2001, 
Excoffon et al., 2010). The D1 distal domain is involved in direct binding to adenovirus 
(Roelvink et al., 1999, Lortat-Jacob et al., 2001, Freimuth et al., 1999, Kirby et al., 2000, 
Bewley et al., 1999), while D2 domain facilitates D1:HAdV-5 interaction (Excoffon et al., 
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2005). hCAR is encoded by the highly conserved gene CXADR composed of 8 exons 
(Bowles et al., 1999), which via alternative splicing results in three soluble isoforms and 
two transmembrane isoforms (Thoelen et al., 2001, Dorner et al., 2004). The 
transmembrane isoforms (CAREx7 and CAREx8) are both composed of LS, D1, D2 and 
transmembrane domains but they differ in the last 26 (CAREx7) or 13 (CAREx8) amino 
acids of the cytoplasmic domain (Excoffon et al., 2010). Recent studies show that the 
isoform that localizes to the basolateral side of polarized epithelia with a role in cell-cell 
adhesion corresponds to CAREx7, the most abundant isoform. Interestingly, CAREx8 
isoform has been reported to localize to the apical membrane and be negatively regulated 
by basolateral hCAR (CAREx7) through interactions with the membrane-associated 
guanylate kinase inverted 1 (MAGI-1)b (Excoffon et al., 2010). Also, the expression of 
apical hCAR (CAREx8) is stimulated by the pro-inflammatory cytokine and neutrophil 
chemoattractant IL-8, which is in turn induced by HAdV-5 fiber binding to CAR 
(Tamanini et al., 2006), through activation of AKT/S6K and inhibition of GSK3β (Kotha 
et al., 2015). Apical hCAR enhances the adhesion of transmigrating neutrophils at the 
apical surface of polarized epithelium and the presence of neutrophils on the apical surface 
has been associated with the promotion of adenovirus entry to host cells (Kotha et al., 
2015). Of note, IL-8 also induces re-localization of αvβ3 integrin to the apical side of 
polarized cells via activation of Src-family tyrosine kinases enabling HAdV-5 transduction 
(Lutschg et al., 2011). These studies suggest that adenovirus evolved to stimulate the 
expression of its own receptors to allow infection of intact epithelium from the apical side 
and support a possible role for the apical hCAR isoform on adenovirus transduction. 
Moreover, it was reported that the intrinsic expression levels of basolateral and apical 
hCAR can vary between tissues (Shaw et al., 2004) and, in particular, while basolateral 
hCAR was poorly expressed in liver, apical hCAR was mainly expressed in liver over 
heart, brain and lung (Excoffon et al., 2010). Evidence that apical hCAR is highly 
expressed in liver and that HAdV-5 can follow a CAR-mediated mechanism for in vitro 
transduction after exposure to mouse serum might begin to unravel the high liver tropism 
found when administering HAdV-5 through the vasculature. Furthermore, since the use of 
CAR as a receptor for cell transduction by HAdV-5 has been shown to stimulate the 
immune response by inducing transcription of inflammatory genes (Tamanini et al., 2006), 
future studies should address whether this response is also promoted upon HAdV-5 
following the CAR-mediated pathway in the presence of mouse serum. 
Interestingly, while the CAR-mediated pathway was found as the predominant route for 
HAdV-5 transduction in the presence of immunocompromised mouse serum in high CAR-
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expressing cell lines, a partial response to the FX-inhibitor X-bp was also observed, 
suggesting that the FX-mediated and the CAR-mediated HAdV-5 transduction pathways 
may be available simultaneously. These results suggest that availability of cellular 
receptors such as CAR or HSPG might determine which transduction pathway is followed 
in the presence of mouse serum. This observation is in agreement with previous studies 
showing that other receptors such as CD46 might compete with FX for binding to other 
adenovirus serotypes such as HAdV-35 (Greig et al., 2009). Moreover, it was unexpectedly 
found that blockade of CAR decreased FX-mediated transduction, suggesting that HAdV-5 
attachment to CAR might also facilitate the use of the FX-mediated pathway at some level. 
A previous report showed that while optimal adenovirus transport to the MTOC via FX-
mediated cell uptake requires the post-attachment internalisation signal provided by 
integrins, it does not require CAR (Bradshaw et al., 2010). However, the influence of CAR 
on other processes such as adenovirus binding to host cells in the presence of FX was not 
assessed. Alternatively, when the CAR-mediated pathway is unavailable due to limited 
access to CAR on the plasma membrane, our data indicates that HAdV-5 can use other 
pathways for cell entry. Here, HAdV-5 transduced CARlow SKOV3 cells via the FX-
mediated pathway in the presence of Rag 2-/- serum, as previously reported (Ma et al., 
2015). Furthermore, other mechanisms of HAdV-5 cell transduction in the presence of 
mouse serum might be present. For instance, HAdV-5 transduced CARlow ACHN and 
CARnegative MCF7 cells in the presence of Rag 2-/- serum via a mechanism independent of 
FX and CAR. These mechanisms might involve other receptors that have been described to 
interact with species C adenovirus such as αvβ3,5 integrins, VCAM-1 (Chu et al., 2001), 
MHC-I-α2 (Hong et al., 1997, Davison et al., 1999), SR (Khare et al., 2012), LRP 
(Shayakhmetov et al., 2005b) or CR1 (Carlisle et al., 2009). The potential existence of 
several FX-independent pathways for HAdV-5 transduction in vitro in the presence of 
mouse serum brings into discussion how many mechanisms of HAdV-5 transduction are 
yet to be identified and whether they might be relevant in vivo. It remains unclear what 
factors determine which pathway of HAdV-5 transduction is followed after exposure to 
mouse serum. Previous work suggested that the levels of expression of specific cellular 
receptors or their relative abundance on susceptible cells might dictate which transduction 
pathway is used for adenoviral transduction (Zaiss et al., 2011). Also, the affinity of the 
adenoviral capsid for individual components of the different transduction pathways (e.g: 
receptors, bridging molecules, etc.) might also determine the route of entry. For instance, a 
previous report showed that the ability of HAdV-5:hFX or HAdV-5:mFX complexes to 
enhance transduction in vitro was determined by their affinity for HSPG (Zaiss et al., 
2011). Evidence that several FX-independent transduction pathways exist in the presence 
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of mouse serum and that HAdV-5 can potentially use different pathways to transduce a 
single cell line has direct implications on our study. For instance, it highlights the need for 
further experiments to confirm that HAdV-5 KO1 is able to use the CAR-mediated 
pathway in the presence of mouse serum and it does not use other FX-independent 
pathways in this setting, which is key to confirm the existence of a bridging mechanism for 
CAR-mediated transduction. 
3.4.4 Mouse serum factor(s) mediating in vitro HAdV-5 
transduction after exposure of virions to mouse serum 
The mouse serum factor involved in CAR-mediated HAdV-5 transduction in the presence 
of mouse serum (Figure 3-35) has not been identified yet. However, several mouse serum 
proteins have been reported to interact with HAdV-5 and potentially enhance transduction. 
These include FVII (Parker et al., 2006), FIX (Parker et al., 2006, Shayakhmetov et al., 
2005b, Kalyuzhniy et al., 2008), C4BP (Shayakhmetov et al., 2005b) and PC (Parker et al., 
2006, Kalyuzhniy et al., 2008). One study shows that FVII might slightly enhance HAdV-5 
transduction (Parker et al., 2006). As found for HAdV-5:FX interaction, FVII can bind to 
HAdV-5 amino acid motif 423TET425 in the HVR 7 through the residue R28 in FVII 
GLA domain (Irons et al., 2013). However, despite FVII contains a heparin-binding 
exosite (Martinez-Martinez et al., 2011, Irons et al., 2013), another study shows that FVII 
is unable to interact with HSPG due to the formation of dimers between the SP domains 
(Irons et al., 2013). FIX was reported to bind to HAdV-5 (Kalyuzhniy et al., 2008) and to 
contain a heparin-binding exosite in similarity to that in FVII that could potentially be used 
for binding to HS on the plasma membrane (Yang et al., 2002, Johnson et al., 2010). FIX 
enhanced HAdV-18 binding to and infection of epithelial cells (Lenman et al., 2011) and 
HAdV-31 binding to and infection of epithelial cells via HS-GAG (Jonsson et al., 2009, 
Lenman et al., 2011). Interestingly, FIX enhanced HAdV-5 transduction of mouse 
hepatocytes and Kupffer cells in vitro and in vivo, and human hepatocytes in vitro 
(Shayakhmetov et al., 2005b). C4BP allowed primary human hepatocyte transduction in 
vitro in a CAR-independent manner (Shayakhmetov et al., 2005b), and PC mediated CAR-
independent HAdV-5 transduction of HepG2 cells (Parker et al., 2006). Moreover, it would 
be interesting to investigate other vitamin K-dependent coagulation factors such as 
prothrombin or protein S, which contain GLA domains that might potentially bind to 
HAdV-5 and mediate cell transduction in the presence of mouse serum. Here, it was found 
that both hFX and the factor(s) involved in FX-independent mouse serum-enhanced 
HAdV-5 transduction are heat-labile. Transduction assays in the presence of heat-treated 
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recombinant mFX should be done to confirm results. Also, pull-down assays such as 
tandem affinity purification (TAP), co-immunoprecipitation using an anti-adenovirus 
antibody, SPR, cross-linking or mass spectrometry performed on HAdV-5 after incubation 
with mouse serum would help in identifying the mouse blood factor involved in the CAR-
mediated pathway.  
Finally, future experiments using more translationally relevant animal models would 
provide valuable information on the interplay between adenovirus immune recognition and 
cellular uptake mechanisms and how the data obtained from mouse experimentation may 
translate into humans. A recent study showed high variability on the effect of human serum 
(with no pre-existing neutralising hIgG antibodies) on HAdV-5 neutralization and 
transduction in vitro (Duffy et al., 2016). This study demonstrated a protective role for FX 
binding to HAdV-5 capsids against neutralization in 56% of human serum samples 
analysed and of the remaining 44% that did not neutralize HAdV-5 in the absence of FX-
binding some enhanced transduction in a complete FX-dependent manner and others in a 
partial FX-dependent manner (Duffy et al., 2016). Understanding of the complex 
adenovirus biology is essential for the optimization and development of adenoviral vectors 
for gene therapy. 
 
  
 
 
 
 
 
 
 
 
 
Chapter 4 Investigating the effect of FX:HAdV-5 
interaction on virion uptake and endosomal 
membrane penetration  
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4.1 Introduction 
HAdV-5 exploits interactions with blood components such as FX for host cell transduction 
and protection against virion neutralization (Parker et al., 2006, Xu et al., 2013). In 
particular, binding of HAdV-5 hexon to FX facilitates access to HSPG on the plasma 
membrane of host cells (Parker et al., 2006, Kalyuzhniy et al., 2008, Waddington et al., 
2008, Alba et al., 2009, Bradshaw et al., 2010). The interactions that take place between 
HAdV-5 and FX have been carefully described both in vitro and in vivo, as well as the 
interactions between FX and HSPG (Waddington et al., 2008, Alba et al., 2009, Bradshaw 
et al., 2010, Duffy et al., 2011, Doronin et al., 2012). However, the effect of FX on the 
different stages of the HAdV-5 cell entry pathway (virion binding to plasma membrane, 
uptake, escape from endosomal vesicles, trafficking towards the nucleus and nuclear 
import) and whether interaction of virions with additional co-receptors is required for FX-
mediated transduction has not been defined in detail yet (Figure 4-1). FX was reported to 
increase binding of virions to host cells (Alba et al., 2009, Bradshaw et al., 2012). Another 
study addressed whether the presence of CAR or αv integrins might be necessary for FX-
mediated cell entry in vitro and reported that HAdV-5 vectors ablated for αv integrin-
binding had a delayed cell entry in contrast to CAR-binding deficient HAdV-5 vectors 
(Bradshaw et al., 2010). This suggests that an efficient post-attachment internalisation 
signal might be necessary for HAdV-5 optimal transport to the nucleus following FX-
mediated cell surface attachment. No other studies have assessed whether FX remains 
bound to HAdV-5 capsids during viral cell entry or the influence that the presence of FX 
might have on capsid disassembly, uptake of virions, escape from endosomal vesicles, 
transport of nucleocapsids along the microtubule network and docking onto the NPC. 
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Figure 4-1. Species C adenovirus in vitro transduction pathways. 1. Adenovirus attaches to the plasma 
membrane via CAR and αvβ1, αMβ2, αvβ3 and αvβ5 integrins. 2. Adenovirus binding to integrins promotes 
integrins clustering. 3. Adenoviral binding to αvβ1, αvβ3 and αvβ5 integrins promotes internalization of viral 
particles via clathrin-mediated endocytosis. 4. Viral capsids traffic in the endosomes. 5. Adenoviral capsids 
escape from early endosomes in a process mediated by pre-protein VI (pVI). 6. Viral capsids travel along the 
microtubule network towards the nucleus. 7. A percentage of incoming adenoviruses get degraded in the 
lysosomes. 8. Adenoviral DNA is imported into the nucleus. CAR; coxsackie and adenovirus receptor, 
HSPG; heparan sulphate proteoglycan, FX; coagulation factor X, MTOC; microtubule-organizing centre, TP; 
terminal protein, NPC; nuclear pore complex. 
With the aim of studying these processes at the single cell level, new methods such as the 
SLO penetration assay emerged (Suomalainen et al., 2013). The SLO penetration assay 
was developed to allow the study of adenovirus uptake and endosomal membrane 
penetration (Figure 4-2A). In this assay, cells are incubated with Alexa Fluor 488-labelled 
viral vectors and pores are subsequently generated in the plasma membrane of transduced 
cells using the bacterial toxin SLO. This protein is a thiol-activated cholesterol-dependent 
cytolysin toxin from Streptococcus pyogenes (Tweten, 2005, Hotze and Tweten, 2012) that 
binds as a monomer to cholesterol in the plasma membrane and via oligomerization of 50-
80 subunits can form pores of variables sizes (up to ~30 nm diameter) (Bhakdi et al., 1985, 
Palmer et al., 1998, Niedermeyer, 1985, Hugo et al., 1986, Sekiya et al., 1993). A 
representation of a SLO monomer is shown in Figure 4-2B. The formation of SLO pores 
on the plasma membrane allows access of antibodies into the cell cytosol that recognize 
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Alexa Fluor 488 dye on cytosolic viral particles. In contrast, viral particles located in the 
endosomes remain inaccessible to antibody recognition. Thus, viral particles can be 
classified into plasma membrane-associated plus cytosolic viral particles (Alexa Fluor 488 
and antibody-positive) or endosomal viral particles (Alexa Fluor 488-positive and 
antibody-negative). Via the classification and quantification of viral particles, virus uptake 
and endosomal membrane penetration efficiencies can be determined. Furthermore, the use 
of penetration-deficient HAdV-2 ts1 allows the assessment of endosome integrity within 
the experimental conditions. HAdV-2 ts1 is a HAdV-2 vector belonging to species C that 
has the P137L mutation in the AVP (Rancourt et al., 1995), which is located in a surface-
exposed loop in proximity to 3 cysteine residues (C104, C122 and C126) that are important 
for enzyme activity (Rancourt et al., 1994). This point mutation prevents correct protein 
folding and incorporation of the AVP into the adenoviral capsid (Rancourt et al., 1995). 
Since AVP is involved in degradation of the capsid-stabilizing pVI (Rancourt et al., 1995, 
Weber, 1976, Greber et al., 1996, Ruzindana-Umunyana et al., 2002) to allow penetration 
from endosomes (Maier et al., 2010, Moyer et al., 2011, Wiethoff et al., 2005), HAdV-2 
ts1 gets trapped in the endosomes and degraded in lysosomes (Greber et al., 1996, Imelli et 
al., 2009, Gastaldelli et al., 2008). 
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Figure 4-2. SLO penetration assay. A) Graphical representation of the SLO penetration assay that allows 
measurement of virus uptake and endosomal membrane penetration into the cytosol of host cells. Viral 
particles are classified as plasma membrane‐associated plus cytosolic (Alexa Fluor 488 and antibody-
positive) or endosomal (Alexa Fluor 488-positive and antibody-negative). Alexa Fluor 488 (green), primary 
antibody (black) and secondary antibody (red). B) Ribbon diagram of the crystal structure of SLO [with 
permission from (Feil et al., 2014)]. Domain 1 (red), domain 2 (cyan), domain 3 (yellow), domain 4 (dark 
blue), and TMH1 and TMH2 regions (magenta). N; NH2-terminal, AdV; adenovirus. 
Here, the effect of FX binding to HAdV-5 capsid on adenovirus uptake and endosomal 
membrane penetration was investigated by performing the SLO penetration assay. This 
work was undertaken in the Institute of Molecular Life Sciences at the University of Zurich 
under the supervision of Professor Urs Greber and Dr. Maarit Suomalainen as part of the 
Marie Curie ITN ADVance programme. 
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4.2 Aims 
The aims of the present study were: 
• To investigate the effect of FX binding to HAdV-5 capsid on adenovirus uptake. 
• To investigate the effect of FX binding to HAdV-5 capsid on adenovirus 
endosomal membrane penetration.  
4.3 Results 
4.3.1 Generation and validation of adenoviral vectors 
Adenoviral vectors used in this study were replication-deficient HAdV-5-based adenoviral 
vectors encoding the E.coli LacZ gene (β-galactosidase). A summary of the adenoviral 
vectors’ genetic and receptor recognition characteristics is shown in section 2.1.6. 
Adenoviral vectors were amplified from pure adenoviral vector preparations originated 
from a single plaque and the resultant pure adenoviral vector preparations were confirmed 
for the absence of RCAs, presence of genetic modifications and absence of virion 
aggregates (Table 4-1), as before (see section 3.3.1.2).  
Table 4-1. Quality control of adenoviral vectors.  
Adenoviral vector Titre  (vp/ml) 
Titer  
(pfu/ml) Vp/pfu 
Vp 
diameter 
(nm) 
HAdV-5  4.33x1012 N/T N/T 102 
HAdV-5-Alexa Fluor 488 7.04x1011 1.39x109 506.47 106 
AdT*  5.90x1012 N/T N/T 99 
AdT*-Alexa Fluor 488 3.25x1012 1.35x1010 240.74 113 
HAdV-2 ts1-Alexa Fluor 488 2x1012 N/A N/A N/T 
Plaque forming units (pfu/ml) values shown were obtained with the pfu observed after performing X-Gal 
staining. Values of viral particle (vp) diameter by Nanoparticle Tracking Analysis (NanoSight) are the mean 
of technical triplicates. HAdV-5; human adenoviral vector serotype 5, N/T; not tested, N/A; not applicable. 
In order to perform the SLO penetration assay to study HAdV-5 uptake and endosomal 
membrane penetration in the presence of FX, HAdV-5 was fluorescently-labelled with 
Alexa Fluor 488 dye (Figure 4-3), which reacts with primary amines on the adenoviral 
capsid proteins. The FX-binding deficient control vector AdT* was also fluorescently-
labelled with Alexa Fluor 488 dye. Alexa Fluor 488 labelled HAdV-2 ts1 was kindly 
provided by Professor Urs Greber (University of Zurich, Switzerland). Pure Alexa Fluor 
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488-labelled adenoviral vector preparations were assessed for their viral particle 
concentration (vp/ml) and infectivity (pfu/ml), and vp/pfu ratios of 506.47 and 240.74 were 
obtained for Alexa Fluor 488-labelled HAdV-5 and AdT*, respectively (Table 4-1). 
 
Figure 4-3. Alexa Fluor 488 dye. A) Chemical structure of Alexa Fluor 488 fluorophore. B) Fluorescence 
spectra of Alexa Fluor 488 dye. Absorption spectral profile (dotted line) and emission spectral profile (green 
filled area). Image reproduced from BD Biosciences. 
4.3.1.1 Effect of FX on Alexa Fluor 488-labelled HAdV-5 
To confirm that the ability of FX to bind to HAdV-5 and enhance cell binding and 
transduction was preserved on Alexa Fluor 488-labelled HAdV-5, CARhigh A549 or 
CARlow SKOV3 cells were incubated with Alexa Fluor 488-labelled HAdV-5 in the 
presence or absence of hFX at 0oC for 60 min (“0 min” condition) to assess cell binding or 
subsequently incubated at 37oC for 60 min (“60 min” condition) to allow virion 
internalization and transport along the microtubules towards the MTOC and the nucleus, a 
process that takes around 45 min to be completed (Greber et al., 1993). Alexa Fluor 488-
labelled AdT* was used as a negative control, since it lacks binding to FX and thus cell 
binding and transduction is not affected by the presence of FX. After the incubation time, 
cells were subjected to immunocytochemistry using antibodies that specifically recognize 
pericentrin, which is an integral component of the MTOC, to enable colocalization 
analysis. As expected, both HAdV-5 and AdT* colocalized with the MTOC in A549 and 
SKOV3 cells in the “60 min” condition both in the presence or absence of FX (Figure 4-4). 
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In contrast, colocalization was not observed in cells in the “0 min” condition with or 
without FX (Figure 4-4). Presence of FX increased HAdV-5 binding and transduction of 
A549 cells (Figure 4-4A) and SKOV3 cells (Figure 4-4B). As expected, AdT* binding and 
transduction of A549 (Figure 4-4A) and SKOV3 (Figure 4-4B) cells was unaffected in the 
presence of FX. IgG isotype controls for antibodies confirmed specificity (Figure 4-4C).  
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Figure 4-4. Effect of FX on adenoviral cell binding and transduction. A549 (A) or SKOV3 (B) cells were 
incubated with Alexa Fluor 488-labelled HAdV-5 or AdT* (1x105 vp/cell) for 60 min at 0oC (“0 min” 
condition) or further incubated for 60 min at 37oC (“60 min” condition) in the presence or absence of 
recombinant human FX (10 μg/ml). Alexa Fluor 488-labelled HAdV‐5 (green). Rabbit anti-pericentrin 
primary antibody and Alexa Fluor 546-conjugated goat anti-rabbit IgG secondary antibody were used to stain 
the microtubule-organizing centre (MTOC) (red). Nuclei were counterstained with DAPI (blue). n = 1 
biological replicate with 1 technical replicate. Representative merge images are shown. Yellow indicates 
viral particles colocalizing with MTOC. Scale bar 10 μm. AdV; adenovirus, FX; coagulation factor X. 
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4.3.2 HAdV-5 uptake and endosomal membrane penetration via 
the CAR-mediated pathway in vitro 
4.3.2.1 Assessment of correct pore formation by SLO on the cell surface 
First, it was confirmed that SLO pores can be successfully formed on the surface of A549 
cells under the experimental conditions, resulting in plasma membrane permeabilization 
and thus allowing access of antibodies into the cytosol for adenovirus recognition. A549 
cells were incubated with Alexa Fluor 488-labelled HAdV-5 on ice for 60 min to 
synchronize adenovirus internalization and subsequently at 37oC for 45 min, permeabilized 
with SLO and stained for Giantin, a Golgi membrane protein conserved in several 
mammalian cell types (Linstedt and Hauri, 1993). Giantin was successfully stained in 
SLO-treated cells in the presence of HAdV-5 (Figure 4-5A left panel) in similarity to SLO-
treated cells in the absence of adenovirus, which were used as a control (Figure 4-5C), 
indicating that the primary antibody was able to access the cytosol and thus confirming 
A549 cells can be SLO-permeabilized.  
 
Figure 4-5. SLO pores formation in A549 cells. Cells were incubated with Alexa Fluor 488-labelled 
HAdV‐5 (A), Alexa Fluor 488-labelled HAdV‐2 ts1 (B) or serum-free media (C) for 45 min at 37oC in the 
presence or absence of soluble recombinant HAdV-5 fiber knob (FK) (0.4 μg/ml) and recombinant human 
FX (10 μg/ml) and permeabilized with SLO (2.48 µg/well). Mouse anti-human Giantin IgG1 primary 
antibody and Alexa Fluor 680-conjugated goat anti-mouse IgG secondary antibody were used to stain 
Giantin (red). Nuclei were counterstained with DAPI (blue). n = 1 biological replicate with 1 technical 
replicate. Representative images of maximum projections of individual confocal stacks are shown. Scale bar 
10 μm.  
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4.3.2.2 HAdV-5 uptake and endosomal membrane penetration in vitro 
Once the correct formation of SLO pores on A549 cells was confirmed, uptake and 
endosomal membrane penetration of HAdV-5 particles following the CAR-mediated 
pathway was investigated. A549 cells were incubated with Alexa Fluor 488-labelled 
HAdV-5 for 45 min at 37oC and intact (non-permeabilized) or SLO-permeabilized cells 
were incubated with rabbit anti-Alexa Fluor 488 antibody to detect adenoviral particles.  
To study HAdV-5 uptake, antibody-positive viral particles on intact A549 cells after 45 
min incubation (plasma membrane-associated viral particles) were imaged (Figure 4-6) and 
quantified (Figure 4-7). For the first independent experiment performed, 4.2% of viral 
particles were detected by the antibody (Figure 4-7A), indicating that 4.2% of viral 
particles remained on the surface after virus internalization. These results indicate that 
HAdV-5 uptake efficiency via the CAR-mediated pathway was 95.8%. For the second 
independent experiment performed, it was found that 4.8% of viral particles were 
membrane-associated viral particles (Figure 4-7B), resulting in a HAdV-5 uptake 
efficiency via the CAR-mediated pathway of 95.2%. 
 
Figure 4-6. HAdV‐5 internalization via the CAR-mediated pathway in vitro. Cells were incubated with 
Alexa Fluor 488-labelled HAdV‐5 for 45 min at 37oC and permeabilized or not with SLO (2.48 µg/well). 
Rabbit anti-Alexa Fluor 488 primary antibody and Alexa Fluor 594-conjugated goat anti-rabbit IgG 
secondary antibody were used. Alexa Fluor 488-labelled HAdV‐5 (green). Alexa Fluor 594-conjugated goat 
anti-rabbit IgG secondary antibody puncta (red) correspond to plasma membrane‐associated (-SLO) or 
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plasma membrane‐associated plus cytosolic (+SLO) viral particles. Nuclei were counterstained with DAPI 
(blue). n = 2 biological replicates with 1 technical replicate. Representative images of maximum projections 
of individual confocal stacks are shown. In the merge image, yellow indicates viral particles double‐positive 
for Alexa Fluor 488 and Alexa Fluor 594-conjugated goat anti-rabbit IgG antibody. Scale bar 10 μm. AdV; 
adenovirus, CAR; coxsackie and adenovirus receptor.  
 
Figure 4-7. Quantification of antibody-positive HAdV‐5 particles following the CAR or the FX-
mediated pathway in vitro. Cells were incubated with Alexa Fluor 488-labelled HAdV‐5 or Alexa Fluor 
488-labelled HAdV‐2 ts1 for 45 min at 37oC with or without soluble recombinant fiber knob (FK) (0.4 
μg/ml) and recombinant human FX (10 μg/ml) and permeabilized or not with SLO (2.48 µg/well). Rabbit 
anti-Alexa Fluor 488 primary antibody and Alexa Fluor 594-conjugated goat anti-rabbit IgG secondary 
antibody were used for viral particles detection. Maximal projections of confocal stacks were analysed by a 
custom-programmed MatLab (The Mathworks) routine to score and quantify individual virus particles (vp). 
The plots show the percentages of Alexa Fluor 594-conjugated goat anti-rabbit IgG secondary antibody-
positive vp in two independent experiments [first independent experiment (A), second independent 
experiment (B)] with 1 technical replicate per condition. Each dot represents one cell and numbers of cells 
and viruses analysed per condition are indicated. Values are expressed as the mean +/- SEM. Two‐tailed 
Mann‐Whitney U test applied. *p<0.05. pi; post-start of incubation of cells with adenovirus at 37oC (time of 
internalization). 
    Chapter 4 | Results 
175 
 
To study HAdV-5 endosomal membrane penetration, viral particles were classified as 
plasma membrane-associated plus cytosol-associated (Alexa Fluor 488 and antibody-
positive) or endosomal (Alexa Fluor 488-positive but antibody-negative) in SLO-
permeabilized cells after 45 min incubation at 37oC and imaged (Figure 4-6) and quantified 
(Figure 4-7). Following the CAR-mediated pathway, 63.7% of viral particles were plasma 
membrane-associated plus cytosolic viral particles for the first independent experiment 
(Figure 4-7A). Since 4.2% of viral particles remained on the surface after virus 
internalization (Figure 4-7A), 59.5% of viral particles were classified as cytosolic. The 
remaining 36.3% of viral particles were classified as endosomal. These results indicate that 
of 95.8% of viral particles that were internalized into A549 cells, 62.1% penetrated the 
endosomes into the cytosol (penetration efficiency of 62.1%). For the second independent 
experiment, it was found that 78.4% of viral particles were plasma membrane-associated 
plus cytosolic viral particles (Figure 4-7B). Since 4.8% were plasma membrane-associated 
viral particles (Figure 4-7B), 73.6% of viral particles were classified as cytosolic and the 
remaining 21.6% as endosomal. These results indicate the endosomal membrane 
penetration efficiency was 77.3%. Table 4-2 contains a summary of the obtained results. 
Table 4-2. Uptake and endosomal membrane penetration efficiencies for HAdV-5 following the CAR-
mediated or the FX-mediated pathway in vitro.  
Cell entry 
pathway 
Plasma 
membrane-
associated 
vp (%) 
Cytosolic 
vp (%) 
Endosomal 
vp (%) 
Uptake 
efficiency 
(%) 
Endosomal 
membrane 
penetration 
efficiency 
(%) 
CAR-mediated 
(Exp. 1) 4.2 59.5 36.3 95.8 62.1 
CAR-mediated 
(Exp. 2) 4.8 73.6 21.6 95.2 77.3 
FX-mediated 
(Exp. 1) 9.7 51.2 39.1 90.3 56.7 
FX-mediated 
(Exp. 2) 2.9 45.8 51.3 97.1 47.2 
“Exp.” followed by a number refers to the individual independent experiment performed. Vp; viral particles. 
4.3.3 HAdV-5 uptake and endosomal membrane penetration 
following the FX-mediated pathway in vitro 
4.3.3.1 Assessment of Alexa Fluor 488 dye signal intensity 
Since the fluorescence emitted by Alexa Fluor 488 fluorophore is used to detect adenoviral 
particles for quantitative and comparative analysis, it was first confirmed that the different 
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Alexa Fluor 488-labelled adenoviral preparations to be used in the experiments (HAdV-5 
and HAdV-2 ts1) emitted a similar level of fluorescence intensity. The fluorescence signal 
from Alexa Fluor 488 dye was assessed after detection of viral particles with the antibodies 
in intact (non-permeabilized) A549 cells that had been incubated for 45 min at 37oC with 
Alexa Fluor 488-labelled HAdV-5 or Alexa Fluor 488-labelled HAdV-2 ts1. Since the 
antibodies cannot access the inside of intact cells, they only recognize the few viral 
particles remaining on the plasma membrane after the incubation time. Thus, the majority 
of viral particles, which have been internalized into cells, are Alexa Fluor 488-positive but 
antibody-negative, enabling quantification of Alexa Fluor 488 fluorescence signal intensity 
with no interference from the antibody fluorophore. The peak of fluorescence was around 
3x104 relative fluorescence units (RFU) for Alexa Fluor 488-labelled HAdV-5, slightly 
lower than that of Alexa Fluor 488-labelled HAdV-2 ts1, which was around 4.2x104 RFU 
(Figure 4-8). However, it was considered they were within acceptable levels of similarity 
to perform comparative uptake and endosomal membrane penetration assays. 
 
Figure 4-8. Level of Alexa Fluor 488 emitted fluorescence from Alexa Fluor 488-labelled adenoviral 
particles. Histograms show the intensity of emitted fluorescence for Alexa Fluor 488 fluorophore on labelled 
HAdV-5 (A) or HAdV-2 ts1 (B) in the absence of Alexa Fluor 488 recognition by rabbit anti-Alexa Fluor 
488 primary antibody. Signal of emitted fluorescence was analysed by a custom-programmed MatLab (the 
Mathworks) routine. n = 1 biological replicate with 1 technical replicate per virus. RFU; relative fluorescence 
units. 
4.3.3.2 Blockade of CAR for HAdV-5 transduction with soluble recombinant 
HAdV-5 fiber knob 
For experiments assessing the FX-mediated pathway for HAdV-5 transduction, FK was 
used to block access to CAR on the cell surface and thus prevent virus from using the 
CAR-mediated pathway. Therefore, under this condition, quantification analysis for uptake 
and endosomal membrane penetration studies only reflects HAdV-5 using the FX-
mediated pathway. To confirm a concentration of 0.4 µg/ml of FK (based on previous 
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dose-finding experiments) can successfully block the use of CAR by HAdV-5 within the 
experimental conditions, A549 cells that had been pre-incubated with FK were incubated 
with Alexa Fluor 488-labelled HAdV-5 for 45 min at 37oC to allow virus internalization. 
Of note, the same dose of Alexa Fluor 488-labelled HAdV-5 than that used for 
quantification studies on the FX-mediated pathway was used in this assay. Adenoviral 
particles were detected in intact or SLO-permeabilized A549 cells with the antibodies as 
before and classified as membrane-associated viral particles (intact cells) or membrane-
associated plus cytosolic viral particles (SLO-permeabilized cells). Only few HAdV-5 
particles (Alexa Fluor 488-positive) were detected in intact and SLO-permeabilized cells 
(Figure 4-9). Of those, very few viral particles were antibody-positive in intact A549 cells 
(Figure 4-9 upper panel), indicating that only few viral particles remained on the plasma 
membrane. In SLO-permeabilized A549 cells there were also only few viral particles either 
antibody-positive or negative, indicating that only few were internalized (Figure 4-9 lower 
panel), and thus confirming that FK successfully blocked the use of CAR for adenovirus 
transduction within the experimental conditions.  
 
Figure 4-9. Blockade of in vitro HAdV-5 transduction with soluble recombinant HAdV-5 fiber knob 
(FK). Cells were incubated with Alexa Fluor 488-labelled HAdV‐5 for 45 min at 37oC in the presence of FK 
(0.4 μg/ml) and permeabilized or not with SLO (2.48 µg/well). Rabbit anti-Alexa Fluor 488 primary antibody 
and Alexa Fluor 594-conjugated goat anti-rabbit IgG secondary antibody were used. Alexa Fluor 488-
labelled HAdV‐5 (green). Alexa Fluor 594-conjugated goat anti-rabbit IgG secondary antibody puncta (red) 
correspond to plasma membrane‐associated (-SLO) or plasma membrane‐associated plus cytosolic (+SLO) 
viral particles. Nuclei were counterstained with DAPI (blue). n = 1 biological replicate with 1 technical 
replicate. Representative images of maximum projections of individual confocal stacks are shown. In the 
merge image, yellow indicates viral particles double‐positive for Alexa Fluor 488 and Alexa Fluor 594-
conjugated goat anti-rabbit IgG antibody. Scale bar 10 μm. AdV; adenovirus. 
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4.3.3.3 Assessment of correct pore formation by SLO on cell surface in the 
presence of FX 
Next, it was confirmed that A549 cells are successfully SLO-permeabilized in the presence 
of FX, allowing access of antibodies into the cytosol for adenovirus recognition. A549 
cells were incubated with the different Alexa Fluor 488-labelled adenovirus to be used in 
the experiments (HAdV-5 and HAdV-2 ts1) for 45 min at 37oC in the presence of FK and 
hFX. Then, cells were permeabilized with SLO and stained for Giantin. Giantin was 
successfully stained in SLO-treated cells in the presence of either virus under the 
experimental conditions (Figure 4-5A-B right panel) in similarity to SLO-treated control 
cells (absence of adenovirus, FK or FX) (Figure 4-5C), indicating that the primary 
antibody was able to access the cytosol and thus confirming that SLO can form functional 
pores on the plasma membrane in the presence of FX.  
4.3.3.4 Assessment of FX-coated HAdV-5 recognition by anti-Alexa Fluor 488 
antibody 
To confirm that Alexa Fluor 488-labelled HAdV-5 is efficiently recognized by rabbit anti-
Alexa Fluor 488 primary antibody in the presence of FX, A549 cells that had been pre-
incubated with FK were incubated with Alexa Fluor 488-labelled HAdV-5 for 60 min on 
ice in the presence of FK and hFX. After the incubation time, viral particles attached to the 
plasma membrane were detected on intact A549 cells with the antibodies as before. Cells 
were imaged (Figure 4-10) and antibody-positive viral particles quantified (Figure 4-7). 
One hundred per cent of viral particles was detected by the antibody (Figure 4-7), 
indicating that FX binding to viral capsids does not interfere with antibody detection of 
viral capsids.  
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Figure 4-10. HAdV-5 in vitro cell binding in the presence of FX. Cells were incubated with Alexa Fluor 
488-labelled HAdV‐5 on ice for 60 min in the presence of soluble recombinant HAdV-5 fiber knob (FK) (0.4 
μg/ml) and recombinant human FX (10 μg/ml). Rabbit anti-Alexa Fluor 488 primary antibody and Alexa 
Fluor 594-conjugated goat anti-rabbit IgG secondary antibody were used. Alexa Fluor 488-labelled HAdV‐5 
(green). Alexa Fluor 594-conjugated goat anti-rabbit IgG secondary antibody puncta (red) correspond to 
plasma membrane‐associated viral particles. Nuclei were counterstained with DAPI (blue). n = 1 biological 
replicate with 1 technical replicate. Representative images of maximum projections of individual confocal 
stacks are shown. In the merge image, yellow indicates viral particles double‐positive for Alexa Fluor 488 
and Alexa Fluor 594-conjugated goat anti-rabbit IgG antibody. Scale bar 10 μm. AdV; adenovirus. 
4.3.3.5 Assessment of endosome integrity in the presence of FX 
To investigate HAdV-5 endosomal membrane penetration in the presence of FX, it is 
essential to ensure that the endosomes remain intact under the experimental conditions. 
Thus, to assess whether adenovirus-bound FX may increase endosomal permeability itself, 
lack of endosomal membrane penetration was confirmed for the penetration-deficient and 
FX-binding HAdV-2 ts1 (Rancourt et al., 1995, Waddington et al., 2008) in the presence of 
hFX. A549 cells were incubated with Alexa Fluor 488-labelled HAdV-2 ts1 for 45 min at 
37oC in the presence of FK and hFX and viral particles were detected in intact or SLO-
permeabilized cells with the antibodies as before. As a control, endosomal membrane 
penetration was also assessed in intact and SLO-permeabilized A549 cells for Alexa Fluor 
488-labelled HAdV-2 ts1 in the absence of FK and hFX. Antibody-positive viral particles 
were imaged (Figure 4-11) and quantified (Figure 4-7).  
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Figure 4-11. Endosome integrity in the presence of FX. Cells were incubated with Alexa Fluor 488-
labelled HAdV‐2 ts1 for 45 min at 37oC in the presence (B) or absence (A) of soluble recombinant HAdV-5 
fiber knob (FK) (0.4 μg/ml) with (B) or without (A) recombinant human FX (10 μg/ml) and permeabilized or 
not with SLO (2.48 µg/well). Rabbit anti-Alexa Fluor 488 primary antibody and Alexa Fluor 594-conjugated 
goat anti-rabbit IgG secondary antibody were used. Alexa Fluor 488-labelled HAdV‐5 (green). Alexa Fluor 
594-conjugated goat anti-rabbit IgG secondary antibody puncta (red) correspond to plasma membrane‐
associated (-SLO) or plasma membrane‐associated plus cytosolic (+SLO) viral particles. Nuclei were 
counterstained with DAPI (blue). n = 1 (A) or 2 (B) biological replicates with 1 technical replicate. 
Representative images of maximum projections of individual confocal stacks are shown. In the merge image, 
yellow indicates viral particles double‐positive for Alexa Fluor 488 and Alexa Fluor 594-conjugated goat 
anti-rabbit IgG antibody. Scale bar 10 μm. AdV; adenovirus. 
Following the CAR-mediated pathway (in the absence of FK and FX), 18% of viral 
particles were found at the plasma membrane in intact cells (uptake efficiency of 82%) and 
17.2% of viral particles were antibody-positive in SLO-permeabilized cells (plasma 
membrane-associated plus cytosolic viral particles) (Figure 4-7A). These results indicate 
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that the majority of antibody-positive particles in SLO-permeabilized cells corresponded to 
plasma membrane-associated viral particles. Thus, internalized HAdV-2 ts1 particles were 
mainly located in the endosomes (82% of incoming viruses), resulting in an endosomal 
membrane penetration efficiency of 0%. These results confirm that endosomes remain 
intact during the assay in the absence of FK and FX.  
Following the FX-mediated pathway (in the presence of FK and FX), 6.5% of viral 
particles were associated with the plasma membrane of intact cells for the first independent 
experiment (Figure 4-7A), resulting in an uptake efficiency of 93.5%. In SLO-
permeabilized cells, the percentage of plasma membrane-associated plus cytosolic viral 
particles was 10.4% (Figure 4-7A). Since 6.5% of viral particles were on the plasma 
membrane after the 45 min incubation (Figure 4-7A), 3.9% of viral particles were 
classified as cytosolic and the remaining 89.6% as endosomal. These results indicate the 
endosomal membrane penetration efficiency for HAdV-2 ts1 in the presence of FK and FX 
was 4.2%. For the second independent experiment, it was found that 5.7% of viral particles 
associated with the plasma membrane of intact cells (Figure 4-7B) in the presence of FK 
and FX (uptake efficiency of 94.3%). In SLO-permeabilized cells, the percentage of 
plasma membrane-associated plus cytosolic viral particles was 16% (Figure 4-7B). Since 
5.7% were plasma membrane-associated viral particles (Figure 4-7B), 10.3% of viral 
particles were classified as cytosolic and the remaining 84% as endosomal, resulting in an 
endosomal membrane penetration efficiency of 11%. Table 4-3 contains a summary of the 
obtained results. 
Table 4-3. Uptake and endosomal membrane penetration efficiencies for HAdV-2 ts1 following the 
CAR-mediated or the FX-mediated pathway in vitro.  
Cell entry 
pathway 
Plasma 
membrane-
associated vp 
(%) 
Cytosolic 
vp  
(%) 
Endosomal 
vp 
(%) 
Uptake 
efficiency 
(%) 
Endosomal 
membrane 
penetration 
efficiency 
(%) 
CAR-mediated 
(Exp. 1) 18 0 82 82 0 
FX-mediated 
(Exp. 1) 6.5 3.9 89.6 93.5 4.2 
FX-mediated 
(Exp. 2) 5.7 10.3 84 94.3 11 
“Exp.” followed by a number refers to the individual independent experiment performed. Vp; viral particles. 
Statistical analysis was performed on the percentage of HAdV-2 ts1 particles that remained 
bound to the plasma membrane of intact cells after the 45 min incubation following the 
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CAR or FX-mediated pathway, to assess statistical significance of the uptake efficiency via 
these transduction pathways. Uptake efficiency of HAdV-2 ts1 following the FX-mediated 
pathway was significantly higher than that following the CAR-mediated pathway (Figure 
4-7A), indicating that binding to FX might facilitate HAdV-2 ts1 internalization into A549 
cells. As expected, viral particles did not penetrate the endosomal membrane following the 
CAR-mediated pathway (Figure 4-7A). In contrast, few viral particles penetrated the 
endosomes into the cytosol following the FX-mediated pathway (Figure 4-7), suggesting 
that the integrity of endosomes could have been slightly compromised in the presence of 
FX. Figure 4-12 shows a summary of the mean values for the data obtained from the two 
independent experiments. 
 
Figure 4-12. Classification of HAdV-2 ts1 particles by localization in host cells, and uptake and 
endosomal membrane penetration efficiencies. The mean of values +/- SEM from two independent 
experiments is shown for the FX-mediated pathway. Vp; viral particles. 
4.3.3.6 HAdV-5 uptake and endosomal membrane penetration in vitro 
Once the correct formation of SLO pores and endosome integrity on A549 cells in the 
presence of FX was confirmed, as well as the correct detection of FX-coated HAdV-5 with 
anti-Alexa Fluor 488 antibody, HAdV-5 uptake and endosomal membrane penetration 
following the FX-mediated pathway was investigated. A549 cells that had been pre-
incubated with FK were incubated with Alexa Fluor 488-labelled HAdV-5 for 45 min at 
37oC in the presence of FK and hFX to allow virus internalization. Intact or SLO-
permeabilized A549 cells were incubated with the antibodies to detect adenoviral particles 
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as before and antibody-positive viral particles were imaged (Figure 4-13) and quantified 
(Figure 4-7). 
For the first independent experiment, a total of 9.7% (Figure 4-7A) of viral particles 
remained on the surface of intact cells after the 45 min incubation, indicating that HAdV-5 
uptake efficiency via the FX-mediated pathway was 90.3%. In SLO-permeabilized cells, 
60.9% (Figure 4-7A) of viral particles were either plasma membrane-associated or 
cytosolic. Since 9.7% (Figure 4-7A) of viral particles were on the plasma membrane after 
the 45 min incubation, 51.2% were classified as cytosolic and the remaining 39.1% as 
endosomal. These data indicate that the endosomal membrane penetration efficiency was 
56.7%. For the second independent experiment, it was found that 2.9% of viral particles 
were plasma membrane-associated viral particles (Figure 4-7B) (uptake efficiency of 
97.1%). In SLO-permeabilized cells, 45.8% of viral particles were plasma membrane-
associated plus cytosolic viral particles (Figure 4-7B). Since 2.9% were plasma membrane-
associated viral particles (Figure 4-7B), 45.8% of viral particles were classified as 
cytosolic and the remaining 51.3% as endosomal, resulting in an endosomal membrane 
penetration efficiency of 47.2%. Table 4-2 contains a summary of the results obtained. 
 
Figure 4-13. HAdV‐5 internalization via the FX-mediated pathway in vitro. Cells were incubated with 
Alexa Fluor 488-labelled HAdV‐5 for 45 min at 37oC in the presence of soluble recombinant HAdV-5 fiber 
knob (FK) (0.4 μg/ml) and recombinant human FX (10 μg/ml) and permeabilized or not with SLO (2.48 
µg/well). Rabbit anti-Alexa Fluor 488 primary antibody and Alexa Fluor 594-conjugated goat anti-rabbit IgG 
secondary antibody were used. Alexa Fluor 488-labelled HAdV‐5 (green). Alexa Fluor 594-conjugated goat 
anti-rabbit IgG secondary antibody puncta (red) correspond to plasma membrane‐associated (-SLO) or 
plasma membrane‐associated plus cytosolic (+SLO) viral particles. Nuclei were counterstained with DAPI 
(blue). n = 2 biological replicates with 1 technical replicate. Representative images of maximum projections 
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of individual confocal stacks are shown. In the merge image, yellow indicates viral particles double‐positive 
for Alexa Fluor 488 and Alexa Fluor 594-conjugated goat anti-rabbit IgG antibody. Scale bar 10 μm. AdV; 
adenovirus. 
Unexpectedly, a lower level of fluorescence intensity was detected for Alexa Fluor 594-
conjugated goat anti-rabbit IgG secondary antibody in SLO-permeabilized cells in the 
presence of FK and FX for the second independent experiment performed in comparison 
with the rest of the conditions tested (representative images shown in Figure 4-13). A 
lower intensity signal can lead to the underestimation of the percentage of antibody-
positive viral particles and have an impact on data quantification analysis. To assess 
whether this observed effect was a single isolated case or the result of treating the cells 
with SLO in the presence of FK and FX, Alexa Fluor 594 fluorescence signal intensity was 
assessed in SLO-permeabilized cells incubated with HAdV-5 in the presence of FK and 
FX for both independent experiments and compared to a positive and a negative control 
(Figure 4-14). Alexa Fluor 594 fluorescence signal intensity from SLO-permeabilized cells 
after 45 min incubation with HAdV-5 in the absence of FK and FX were used as a positive 
control, since a high percentage of HAdV-5 (59.5% or 73.6% from two independent 
experiments) is located in the cytosol and thus recognized by the antibody (Figure 4-7). 
SLO-permeabilized cells incubated with HAdV-2 ts1 in the presence of FK and FX was 
used as a negative control, since the majority of HAdV-2 ts1 (89.6% or 84% from two 
independent experiments) localizes in the endosomes and thus is not recognized by the 
antibody. For the first independent experiment, the peak of Alexa Fluor 594 fluorescence 
intensity in the negative control was found around 100 RFU and around 300 RFU for the 
positive control (Figure 4-14A). The peak of Alexa Fluor 594 fluorescence intensity in the 
test sample (SLO-permeabilized cells incubated with HAdV-5 in the presence of FK and 
FX) was found within acceptable levels of similarity to the positive control, at 
approximately 250 RFU (Figure 4-14A). In the second experiment however, while the 
negative control showed a fluorescence intensity of approximately 0 RFU and the positive 
control ~1.5x104 RFU (Figure 4-14B), fluorescence intensity in the test sample was found 
at approximately 3x103 RFU (Figure 4-14B), slightly lower than that in the positive control 
and in agreement with the images shown in Figure 4-13.  
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Figure 4-14. Level of Alexa Fluor 594 emitted fluorescence. Cells were incubated with Alexa Fluor 488-
labelled HAdV‐5 for 45 min at 37oC in the presence or absence of soluble recombinant HAdV-5 fiber knob 
(FK) (0.4 μg/ml) and recombinant human FX (10 μg/ml) and permeabilized with SLO (2.48 µg/well). Rabbit 
anti-Alexa Fluor 488 primary antibody and Alexa Fluor 594-conjugated goat anti-rabbit IgG secondary 
antibody were used. Histograms show the intensity of emitted fluorescence for Alexa Fluor 594 fluorophore 
on Alexa Fluor 594-conjugated goat anti-rabbit IgG antibody for two independent experiments [first 
independent experiment (A), second independent experiment (B)] with 1 technical replicate per condition. 
Positive control (left panel), negative control (right panel) and test sample (centre panel). Signal of emitted 
fluorescence was analysed by a custom-programmed MatLab (the Mathworks) routine. RFU; relative 
fluorescence units, FK; soluble recombinant fiber knob, FX; coagulation factor X. 
4.3.4 Comparison of HAdV-5 uptake and endosomal membrane 
penetration efficiencies following the CAR or FX-mediated 
pathways in vitro 
Statistical analysis was performed on the percentage of HAdV-5 particles that remained 
bound to the plasma membrane and thus not internalized in intact cells after 45 min 
incubation at 37oC, following the CAR or FX-mediated pathway. For the first independent 
experiment, uptake efficiency of HAdV-5 following the FX-mediated pathway was 
significantly lower than that via the CAR-mediated pathway (Figure 4-7A). In contrast, 
uptake efficiency via the FX-mediated pathway was significantly higher in the second 
independent experiment (Figure 4-7B). Figure 4-15 shows a summary of the mean values 
for the data obtained from the two independent experiments. 
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To analyse statistical significance for endosomal membrane penetration efficiencies for 
HAdV-5 following the FX or CAR-mediated pathways, the statistical test is applied on the 
percentage of antibody-positive viral particles in SLO-permeabilized cells (plasma 
membrane-associated plus cytosolic viral particles). The test is applied with the assumption 
that the percentage of antibody-positive viral particles that are located at the plasma 
membrane of SLO-permeabilized cells after 45 min incubation at 37oC in the presence of 
FK and FX (FX-mediated pathway) is very similar to that in the absence of FK and FX 
(CAR-mediated pathway). In this study, these percentages were 4.2% following the CAR-
mediated pathway and 9.7% via the FX-mediated pathway for the first independent 
experiment and 4.8% following the CAR-mediated pathway and 2.9% via the FX-mediated 
pathway for the second independent experiment (Figure 4-7). Thus, since the percentage of 
membrane-associated viral particles were very similar in both conditions, the percentage of 
membrane-associated plus cytosolic viral particles was compared to determine statistical 
significance on the endosomal membrane penetration efficiencies via the CAR or FX-
mediated pathway. This comparison was done in each independent experiment, and both 
experiments showed significantly lower penetration efficiency following the FX-mediated 
pathway compared to that via the CAR-mediated pathway (Figure 4-7). Figure 4-15 shows 
a summary of the mean values for the data obtained from the two independent 
experiments.  
 
Figure 4-15. Classification of HAdV-5 particles by localization in host cells, and uptake and endosomal 
membrane penetration efficiencies. The mean of values +/- SEM from two independent experiments is 
shown. Vp; viral particles. 
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4.4 Discussion 
Here, the effect of FX binding to the HAdV-5 capsid on HAdV-5 uptake and endosomal 
membrane penetration was investigated at the single cell level performing the SLO 
penetration assay (Suomalainen et al., 2013). Our results indicate that binding of FX to 
certain adenovirus serotypes might facilitate virion internalization into host cells, as seen 
for the penetration-deficient HAdV-2 ts1. However, uptake efficiency for HAdV-5 
following the FX-mediated pathway was very similar to that via the CAR-mediated 
pathway. Moreover, the presence of FX itself slightly affected the integrity of endosomes, 
increasing membrane permeability and thus virion leakage into the cytosol. Interestingly, 
however, it decreased HAdV-5 endosomal membrane penetration efficiency, restricting the 
amount of HAdV-5 virions able to access the cytosol. 
4.4.1 FX-mediated HAdV-5 cell binding  
The most evident finding was related to the viral dose required for quantification of 
individual viral particles. The optimal MOI to allow imaging of individual viral particles is 
approximately 10 to 200 viral particles bound per cell. Also, it is important to use a similar 
MOI for the different conditions tested to avoid any additional effects merely related to the 
amount of virus transducing the host cells at a given time. In this study, a similar number 
of viral particles bound per cell were present in each of the conditions tested; however, to 
obtain these MOIs, the viral dose used for studies of the FX-mediated pathway (2.46x108 
vp/well) was 28.6 times lower than that when assessing the CAR-mediated pathway 
(7.04x109 vp/well) (see section 2.2.6.10). This suggests that the main advantage of 
following the FX-mediated pathway for cell transduction might be an increase in binding 
to host cells, which is in agreement with our data assessing cell binding and with previous 
reports (Alba et al., 2009, Bradshaw et al., 2012). This increase in HAdV-5 binding in the 
presence of FX indicates that the FX-mediated pathway may involve higher affinity or 
stable interactions compared to those between HAdV-5 and CAR. Therefore, in the 
presence of CAR and FX, viral particles might predominantly use the FX-mediated 
pathway. 
4.4.2 HAdV-5 uptake following the FX-mediated pathway 
Analysis of HAdV-5 uptake revealed similar efficiencies via the CAR-mediated and FX-
mediated pathways, indicating that internalization of HAdV-5 particles after binding to 
HSPG via FX might be as efficient as after binding to CAR. HSPG has multiple roles on 
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cellular processes such as ligand-receptor clustering and signalling, basement membrane 
organization and provision of a matrix for cell migration, cell adhesion and packing of 
granular content for secretion, and it can also bind to cytokines, chemokines and growth 
factors to protect them against proteolysis, or bind to proteases and protease inhibitors for 
their spatial distribution and activity [reviewed by (Christianson and Belting, 2014, 
Sarrazin et al., 2011, Lin, 2004, Dreyfuss et al., 2009)]. Whether HAdV-5 uses HSPG only 
for attachment to host cells or whether HAdV-5 is also internalized via an HSPG-
dependent mechanism is still unknown. Interestingly, HSPGs have been associated with 
ligand-induced endocytosis of molecules for clearance [(Wittrup et al., 2009) and reviewed 
by (Christianson and Belting, 2014, Belting, 2003)]. Also, it has been observed that HSPGs 
cluster during endocytosis via a conserved GxxxG dimerization motif in the 
transmembrane domain (Dews and Mackenzie, 2007, Chen and Williams, 2013). 
Moreover, depending on the cellular context and type of extracellular ligand, HSPG-
mediated internalization can take place in a lipid-raft-dependent or independent manner 
(Fuki et al., 2000, Tkachenko et al., 2004, Zimmermann et al., 2005, Wittrup et al., 2010, 
Payne et al., 2007, Fuki et al., 1997, Chen and Williams, 2013, Capurro et al., 2012) and 
can end up with the degradation of HSPG and its cargo in the lysosomes (Fuki et al., 2000, 
Burbach et al., 2003, Sarrazin et al., 2010). Alternatively, HSPG can work in conjunction 
with integrins, which can be used for adenovirus internalization into host cells (Wickham 
et al., 1993, Wickham et al., 1994, Mathias et al., 1998, Salone et al., 2003, Shayakhmetov 
et al., 2005a, Patterson and Russell, 1983, Meier et al., 2002, Wang et al., 1998, 
Chardonnet and Dales, 1970a). According to previous reports, extracellular matrix 
components can bind to HSPG and simultaneously to αvβ3, αvβ5, α2β1 or α6β4 integrins via 
RGD motifs to mediate intracellular signalling (Saoncella et al., 1999, Woods et al., 2000, 
Beauvais et al., 2004, McQuade et al., 2006, Hozumi et al., 2006). Importantly, it was 
shown that after HAdV-5 attachment to HSPG via FX, virus engagement with αv integrins 
is necessary for efficient viral trafficking towards the MTOC (Bradshaw et al., 2010), 
suggesting that while FX allows adenovirus attachment to HSPG, viral particles might 
need to interact with co-receptors such as αv integrins to facilitate virus internalization. 
Future studies should address whether adenovirus endocytosis is mediated by HSPG or if, 
on the contrary, HSPG only serve as attachment receptors and virus endocytosis is 
mediated by integrins. Also, studies to describe the exact mechanism mediating virus 
endocytosis (clathrin or caveolin-dependent or clathrin and caveolin-independent) after 
attachment to HSPG should be performed.  
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4.4.3 HAdV-5 endosomal membrane penetration following the FX-
mediated pathway 
Regarding HAdV-5 endosomal membrane penetration efficiency, differences were found 
between the CAR-mediated and FX-mediated pathways. The use of HAdV-2 ts1 (Rancourt 
et al., 1995) revealed that FX might slightly affect the integrity of endosomes by increasing 
membrane permeability. However, when analysing HAdV-5 endosomal membrane 
penetration after attachment to HSPG, the penetration efficiency was found significantly 
reduced in both independent experiments compared to that after attachment to CAR. These 
results suggest that the presence of FX might negatively affect the capacity of HAdV-5 to 
penetrate the endosomes and access the cytosol. Although no further studies were 
performed to elucidate the reason behind this observation, it was hypothesized FX might 
remain bound to HAdV-5 hexon, be internalized along with the incoming virions, and 
hamper capsid disassembly by increasing capsid stability. Alternatively, since FK was used 
in our experimental setting to block CAR-mediated HAdV-5 uptake when studying the 
FX-mediated pathway, decreased endosomal membrane penetration efficiency via the FX-
mediated pathway could have been associated, not with the presence of FX itself, but with 
the lack of binding to CAR. Since binding to CAR is required for capsid disassembly, 
which starts with the loss of fiber from viral capsids and thus exposure of pVI (Nakano et 
al., 2000, Burckhardt et al., 2011) for penetration from endosomes (Wiethoff et al., 2005, 
Moyer et al., 2011, Maier et al., 2010), lack of binding to CAR might have increased 
capsid stability and thus hindered penetration from endosomes. As an alternative, 
assessment of endosomal membrane penetration via the FX-mediated pathway could be 
done using CAR-binding deficient HAdV-5 vectors instead of FK. In either case, an 
increase in capsid stability may result in a delay of capsid disassembly to late endosomes, 
where a lower pH could facilitate this process. Importantly, delayed capsid disassembly 
could lead to retrograde transport of viral capsids to the cell surface, as observed 
previously for HAdV-5 vectors carrying species B HAdV-35 fiber knob (Shayakhmetov et 
al., 2003), which would result in a lower endosomal membrane penetration efficiency and 
delivery of viral genomes to the nucleus. However, delayed capsid disassembly might still 
result in efficient nuclear delivery of viral genomes, in similarity to species A, B and D 
adenoviruses, which access the nucleus from late endosomes and lysosomes in a fiber 
knob-dependent manner (Defer et al., 1990, Miyazawa et al., 2001, Miyazawa et al., 1999, 
Chardonnet and Dales, 1970b, Shayakhmetov et al., 2003, Teigler et al., 2014). It should 
however be taken into account that although these adenovirus species successfully reach 
the nucleus via a lysosomal trafficking pathway following endocytosis, this process takes 
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longer than the classical species C adenovirus trafficking pathway via early endosomes 
after endocytosis and it can stimulate endosomal acidification-dependent anti-viral immune 
mechanisms (Teigler et al., 2014). In particular, one study reported that species B HAdV-7 
DNA accumulated in the nucleus at 220 min post-receptor attachment in comparison with 
HAdV-5, which only took 40 min (Miyazawa et al., 2001). Therefore, while analysis of 
antibody-positive and negative viral particles in SLO penetration assays 45 min post-
receptor attachment may allow studies on HAdV-5 penetration from early endosomes, 
studies on HAdV-5 penetration from late endosomes might require to be done at later time 
points, since at 45 min viral capsids may still locate to the endosomes and not have 
accessed the cytosol. Future experiments assessing HAdV-5 intracellular localization at 
different time points (kinetic assays) would allow determination of how long 
internalization, penetration from endosomes, trafficking and access to the nucleus may take 
when HAdV-5 follows the FX-mediated pathway. Also, further studies assessing whether 
FX remains bound to HSPG or the adenoviral capsid during virus endocytosis and 
vesicular trafficking would help in studying the possible implications FX-binding may 
have on virus internalization and endosomal membrane penetration. Moreover, further 
studies on whether the absence of binding to CAR affects viral capsid stability and thus 
endosomal membrane penetration could be done, for instance, by assessing the exposure 
efficiency of pVI from CAR-binding deficient HAdV-5 vectors using antibodies specific 
for pVI. Finally, the lower endosomal membrane penetration efficiency observed when 
HAdV-5 follows the FX-mediated pathway may not be associated with increased capsid 
stability but instead with the mechanism mediating uptake of viral particles. As stated 
above, viral particles may be internalized in a HSPG-dependent manner via a clathrin-
independent mechanism, which might result in lower endosomal membrane penetration 
efficiency due to slower vesicular trafficking kinetics compared to that of clathrin-
mediated endocytosis. For instance, a study reported that while non-HSPG-binding mutant 
AAV2 was internalized via clathrin-mediated endocytosis, HSPG-binding AAV2 was 
internalized in a clathrin- and caveolin-independent manner that resulted in less efficient 
nuclear delivery of viral genomes (Uhrig et al., 2012). The observation that binding or lack 
of binding to HSPG on other viruses such as AAV can lead to the use of different 
internalization pathways with different efficiencies of nuclear delivery of viral genomes 
suggests that different mechanisms might also mediate CAR-dependent or HSPG-
dependent adenovirus internalization. Again, if attachment to HSPG promotes clathrin-
independent adenoviral endocytosis that takes longer to deliver viral capsids to the nucleus 
than the described clathrin-mediated endocytosis following the CAR-mediated pathway, 
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studies of endosomal membrane penetration might require to be done at later time points, 
when viral particles have had sufficient time to access the cytosol. 
4.4.4 Implications of the FX-mediated pathway on cell signalling 
and immunity 
Adenoviral vectors might also exploit interactions with HSPG to activate signalling 
pathways within the host cell that may indirectly facilitate adenovirus transduction. A role 
for HSPG in the activation of signalling pathways by retaining and stabilizing ligands, 
transporting ligands or facilitating ligand-receptor interactions has been described 
[reviewed by (Christianson and Belting, 2014, Sarrazin et al., 2011, Lin, 2004, Dreyfuss et 
al., 2009, Hacker et al., 2005)]. Although HSPG has not yet been associated with 
promotion of signalling pathways after binding to the FX:HAdV-5 complex, this 
possibility should be investigated. Also, it would be interesting to address whether the 
presence of FX may also have additional effects on viral transduction aside from mediating 
attachment of viral capsids to HSPG, such as activation or inhibition of particular cellular 
processes within the cell that facilitate adenovirus transduction. To investigate these 
possibilities, uptake and endosomal membrane penetration could be assessed in cells 
incubated with the FX-binding deficient AdT* vector, which follows the CAR-mediated 
pathway in the presence of FX. This would allow assessment of additional effects that the 
presence of FX itself or FX binding to HSPG could have on adenoviral internalization of 
HAdV-5 based vectors. Moreover, FX might prevent the activation of intracellular immune 
responses to adenoviral capsids. Since FX blocks viral capsid recognition and binding to 
IgM antibodies (Duffy et al., 2016), intracellular defence mechanisms such as the 
TRIM21-dependent dismantling of viral capsids and degradation in the proteasome that 
depends on the association of viral capsids with IgG or IgM antibodies (Mallery et al., 
2010, Hauler et al., 2012) might not take place in the presence of FX and absence of IgG 
antibodies. Furthermore, if FX remains bound to viral capsids during virus internalization 
and transport to the nucleus, it might also protect the virus against host cell presentation of 
viral peptides via MHC-I to immune cells or recognition via TLRs. Further studies should 
address these questions. 
4.4.5 Limitations of the study 
It is important to note that the high scatter of data in the quantification of antibody-positive 
viral particles in SLO-permeabilized cells both in the presence and absence of FX reflects a 
high cell-to-cell variability in the assay. This observation indicates that the stability of cells 
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could have been slightly compromised during the assay. Analysis on a higher number of 
cells might reduce the observed variability. Also, to score and quantify the amount of 
antibody-positive viral particles from imaged samples with the custom-programmed 
MatLab (The Mathworks) routine, it is essential to choose the threshold signal intensity 
value that discriminates between antibody-positive and antibody-negative viral particles 
(background intensity). To assess whether the thresholding procedure efficiently detects 
most of the antibody-positive viruses within the cell, a control sample can be done, where 
all internalized adenoviruses are also antibody-positive. This control sample can be SLO-
permeabilized cells incubated with HAdV-5 and treated with Triton X-100 before addition 
of antibodies. Triton permeabilizes cell membranes leaving endosomal viral particles 
accessible for the antibody and thus ensuring recognition of all viral particles 
(Suomalainen et al., 2013). The threshold signal intensity value chosen should be lower 
than the antibody fluorescence intensity to allow detection of all viral particles in the 
control sample, since they are all antibody-positive viral particles. If the threshold does not 
allow classification of 100% of viral particles as antibody-positive in the control sample, 
the threshold should be adjusted. Moreover, the main limitation on analysing statistical 
significance on endosomal membrane penetration efficiencies is that it is done based on the 
percentage of total antibody-positive viral particles in SLO-permeabilized cells 45 min 
post-receptor attachment, which not only includes cytosolic but also membrane-associated 
viral particles. Thus, comparisons between endosomal membrane penetration efficiencies 
via the CAR or FX-mediated pathways require a similar number of particles remaining on 
the plasma membrane following one or the other pathway after 45 min incubation. This 
allows comparability and reduction of the error associated with the method applied 
(custom-programmed MatLab (The Mathworks) routine) for analysis and quantification of 
individual viral particles. Since only two independent experiments were done, the 
experiments from this study should be repeated for confirmation of initial results. 
Furthermore, while HAdV-2 ts1 is often used as a penetration-deficient vector, studies 
show that HAdV-2 ts1 capsids still contain 2 to 3 copies of the AVP, which despite being a 
lower number of copies than in wild type HAdV-2 [~7 copies (Benevento et al., 2014)], 
can still result in HAdV-2 ts1 particles being able to penetrate from endosomes (Anderson, 
1990). Moreover, HAdV-5 capsids have been reported to associate with the MTOC during 
cell transduction and accumulate at high viral doses (Bailey et al., 2003, Bradshaw et al., 
2010). No visible accumulation of viral particles at the MTOC was observed when using 
low HAdV-5 MOIs in the SLO penetration assays regardless of the presence of FX. 
However, addition of FX to a higher input viral dose in HAdV-5 trafficking assays resulted 
in a clear accumulation of viral particles in the MTOC. These results indicate that the 
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behaviour of viral particles during cell transduction might also depend on the viral dose 
used, highlighting the importance of studies using different MOIs for more translational 
conclusions.  
Finally, different adenovirus trafficking patterns have been associated with cell type (e.g: 
due to different expression of adenoviral receptors), the environment around the host cell 
or the physiologic state within the host cell, as well as different trafficking patterns based 
on adenovirus serotype [reviewed by (Leopold and Crystal, 2007)]. Thus, study of the FX-
mediated pathway of adenovirus transduction should not be limited to one specific 
adenovirus serotype or host cell type. Assessment of this pathway for FX-binding 
serotypes with different affinities for FX belonging to different adenovirus species such as 
HAdV-2, 7, 16, 18, 49 or 50 (Waddington et al., 2008) would provide useful mechanistic 
data, increasing our knowledge on the biological processes mediating the different 
pathways for adenovirus transduction of host cells, and thus helping in the optimization of 
adenoviral vectors for gene therapy with increased transgene transfer efficiencies.   
 
    
 
 
 
 
 
 
 
 
 
Chapter 5 Designing adenoviral vectors for 
kidney-specific gene therapy  
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5.1 Introduction 
A wide range of heritable or acquired kidney diseases are incurable to date and require 
renal replacement therapy by dialysis or transplantation as they progress to an advanced 
stage. For instance, chronic kidney disease (CKD), which is defined as a gradual loss of 
kidney function (decreased glomerular filtration rate (GFR) and increased proteinuria) over 
time (National Kidney, 2002, Levey et al., 2005), is recognised as a global public health 
problem with an increasing prevalence of end-stage renal failure (ESRF) in the more 
developed countries [(Foley and Collins, 2007, Rutkowski, 2000, Coresh et al., 2007) and 
reviewed by (Jha et al., 2013)]. Furthermore, there is a tight association between a low 
GFR and raised albuminuria with an increased risk of cardiovascular disease and a 
reduction in life expectancy (Go et al., 2004, Chronic Kidney Disease Prognosis et al., 
2010, van der Velde et al., 2011, Kottgen et al., 2007, Wattanakit et al., 2007, Astor et al., 
2006, Alonso et al., 2011, Kokubo et al., 2009). The main described causes of CKD are 
hypertension and diabetes mellitus (DM) (Coresh et al., 2007, Marumo et al., 2015, 
Guyton et al., 1972, Wadei and Textor, 2012, Fox et al., 2012, de Boer et al., 2011, 
Berhane et al., 2011a), which are also risk factors for cardiovascular disease (Franco et al., 
2007, Loukine et al., 2011, Franco et al., 2005). Moreover, CKD has been reported to 
cause hypertension (Kokubo et al., 2009), which can also lead to cardiovascular diseases. 
However, other conditions such as glomerulonephritis (GN), inherited diseases affecting 
the kidneys (e.g: polycystic kidney disease, autosomal dominant tubulointerstitial kidney 
disease ADTKD, etc), immune diseases such as lupus, kidney infections or malformations 
can also cause CKD [reviewed by (Jha et al., 2013, Eckardt et al., 2013)]. Importantly, the 
incidence of diabetic nephropathy (DN) has dramatically increased in the past decade in 
the more developed Asian countries, and GN is the leading cause of ESRF for the less 
developed countries (Couser et al., 2011). Current therapy to retard progression of renal 
damage is based on lifestyle interventions such as controlling the diet (high sodium and 
restricted protein intake to reduce blood pressure or cardiovascular events, respectively) 
and increasing physical activity to reduce albuminuria, and on pharmacological 
interventions such as using hypertensive agents to treat high blood pressure (e.g: 
angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers 
(ARBs) to inhibit the renin-angiotensin-aldosterone system (RAAS), which also lowers 
albuminuria), lowering lipid content to reduce cardiovascular events or administering oral 
glucose-lowering drugs in CKD patients with DM [(Fouque and Aparicio, 2007) and 
reviewed by (Gansevoort et al., 2013, Wiggins and Kelly, 2009)]. However, despite the 
success of current therapy for preventing progression of kidney disease (Ruggenenti et al., 
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2008), there are limitations yet to be overcome such as the high costs associated with 
dialysis or the insufficient supply of renal allografts for transplantation in the most 
advanced cases. Also, due to the high diversity of causes and risk factors that can lead to 
kidney disease as well as the heterogeneity of mechanisms mediating specific subgroups or 
stages of kidney disease [reviewed by (Gansevoort et al., 2013)], there is a lack of 
subgroup-directed therapeutic interventions. Thus, the use of a gene therapy approach such 
as adenoviral vectors that can target specific renal cell subsets in the kidney to deliver a 
therapeutic drug or restore genetic deficiencies might help in reducing morbidity and 
mortality associated with particular subtypes of kidney disease. Several studies in swine, 
rat or dog using ex vivo or in vivo approaches with delivery to the kidney via the renal 
artery or aorta successfully achieved adenovirus-mediated gene transfer to the renal cortex 
and inner and outer medulla, renal vasculature, glomerular cells, proximal tubular cells, 
distal tubular and pyelic epithelial cells, tubular cells from the papilla and medulla, 
epithelial cysts, interstitial fibroblasts, mesangial cells, podocytes or parietal epithelial cells 
of the Bowman’s capsule of the glomerulus (Heikkila et al., 1996, Heikkila et al., 2001, 
Moullier et al., 1994, Zhu et al., 1996, Fujishiro et al., 2005, Chetboul et al., 2001, Nahman 
et al., 2000, Bhatt et al., 2002, Sandovici et al., 2006, Denby et al., 2007). Importantly, 
therapeutic effect was observed in a model of salt-induced renal damage where 
systemically administered adenoviral vectors expressing kallikrein partially reversed salt-
induced glomerular hypertrophy, reduced urinary protein and blood urea nitrogen levels, 
reduced collagen and reticular deposition, supressed superoxide generation and restored 
nitric oxide production. (Bledsoe et al., 2006). 
In the last decade, several de-targeting and re-targeting strategies have been developed to 
generate adenoviral vectors that selectively target the cell type where the gene therapy is 
required, while having minimal off-target effects (see sections 1.3.4 and 1.3.6). Targeting 
of specific renal cell subsets in the kidney with adenoviral vectors requires the 
identification of particular proteins selectively expressed on those cell subsets. Here, I 
focused on claudin 16 and nephrin. Claudin 16 is a tight junction protein located in the 
thick ascending limb of loop of Henle (Figure 5-1) with a major role in the regulation of 
magnesium reabsorption [reviewed by (Hou and Goodenough, 2010)]. Nephrin is located 
at the slit diaphragm area of the glomerular podocyte (Ruotsalainen et al., 1999, Mundel 
and Shankland, 2002) (Figure 5-1) and it has been associated with cell adhesion and 
signalling [reviewed by (Ristola and Lehtonen, 2014)]. Targeting of the thick ascending 
limb of loop of Henle or the nephron is of special interest for the treatment of diseases 
affecting those areas. These include diseases associated with the thick ascending limb of 
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loop of Henle such as ADTKD-UMOD (Bleyer and Hart, 1993) or medullary cystic kidney 
disease type 1 (MCKD1) (Kirby et al., 2013) or diseases affecting the glomerulus such as 
diffuse mesangial sclerosis (DMS), congenital nephrotic syndrome of the Finnish type 
(CNSF), Alport’s syndrome and variants, minimal change disease (MCD), focal segmental 
glomerulosclerosis (FSGS) and collapsing glomerulonephropathy, immune and 
inflammatory glomerulonephropathies, hypertensive nephropathy, diabetic 
glomerulonephropathy and age-associated glomerulonephropathy [reviewed by (Wiggins, 
2007)]. 
 
Figure 5-1. Nephrin and claudin 16 location in the kidney. Nephrons are the functional units of the kidney 
and locate within the renal cortex and renal medulla. Nephrons are composed of a renal corpuscle and a renal 
tubule and are involved in blood filtration and reabsorption. They are connected to blood vessels and to the 
collecting tubule, which collects urine for excretion. The renal corpuscle is composed of different cell types 
such as endothelial cells, mesengial cells and podocytes. Nephrin is located in the slit diaphragm area of 
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podocytes. Claudin 16 is a tight junction protein located in the thick ascending limb of loop of Henle (TAL), 
which is a component of the renal tubule. 
In this study, HAdV-5-based vectors were engineered by introducing heterologous 
peptides found by in vitro phage display into the HI loop of the fiber knob domain with the 
aim of targeting distinct marker proteins in the kidney such as claudin 16 or nephrin. Also, 
specific genetic mutations were added to the engineered adenoviral vectors to reduce liver 
transduction and thus possible off-target effects and toxicity problems as well as the 
activation of immune responses, which have been associated with intravascular 
administration of HAdV-5-based vectors (Lozier et al., 2002, Raper et al., 2002, Atencio et 
al., 2006, Morral et al., 2002). 
5.2 Aims 
The aim of the present study was: 
• To generate liver de-targeted adenoviral vectors with specific targeting of claudin 
16 or nephrin-expressing cells for kidney-specific gene therapy. 
5.3 Results 
5.3.1 Generation of adenoviral vectors 
Adenoviral vectors used in this study (AdT*KO1 AAA, AdT*KO1 AAAASFPPAFAAA 
and AdT*KO1 AAAYAAHRSHAAA) are replication-deficient HAdV-5-based adenoviral 
vectors encoding the E.coli LacZ gene (β-galactosidase). These vectors have FX-binding 
ablating mutations in the hexon HVR 5 and 7 (Alba et al., 2009), the CAR-binding ablating 
KO1 mutation into the fiber knob domain (Leissner et al., 2001, Jakubczak et al., 2001, 
Roelvink et al., 1999) and AAA, AAAASFPPAFAAA or AAAYAAHRSHAAA 
heterologous peptides (found by in vitro phage display), respectively, into the HI loop of 
the fiber knob domain. A summary of the adenoviral vectors’ genetic and receptor 
recognition characteristics is shown in section 2.1.6.  
5.3.1.1 Cloning strategy to generate kidney-specific adenoviral vectors 
The genomes of AdT*KO1 AAA, AdT*KO1 AAAASFPPAFAAA and AdT*KO1 
AAAYAAHRSHAAA (pAdT*KO1-AAA, pAdT*KO1-AAA-AAAASFPPAF and 
pAdT*KO1-AAA-AAAYAAHRSH, respectively) were engineered to incorporate specific 
genetic modifications in the hexon and fiber knob domain to alter receptor recognition 
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characteristics (Figure 5-2). Briefly, ASFPPAF and YAAHRSH peptides were identified 
after 4 rounds of in vitro phage display [7-mer linear peptide library fused to pIII N-
terminal on bacteriophage M13KE (Noren and Noren, 2001)] as binders to claudin 16 on 
K562CLDN16 suspension cells (K562 cells stably expressing claudin 16) or nephrin on 
K562NPHN suspension cells (K562 cells stably expressing nephrin), respectively. The 
DNA sequences corresponding to ASFPPAF and YAAHRSH peptides flanked by NotI 
sites were cloned into the NotI site from pShuttle-KO1-AAA, which has the KO1 mutation 
(Leissner et al., 2001, Jakubczak et al., 2001, Roelvink et al., 1999) in the fiber ORF and 
an additional AAA peptide (NotI site + cytosine at NotI site 3’ end) incorporated into the 
HI loop of the fiber knob domain. Of note, the additional cytosine was added to maintain 
the fiber ORF after the addition of the NotI site. The 5’3’ and complementary 3’5’ 
ssDNA oligonucleotides for ASFPPAF or YAAHRSH peptides 
(Oligo_NotIASFPPAFNotI5-3 and Oligo_NotIASFPPAFNotI3-5 or 
Oligo_NotIYAAHRSHNotI5-3 and Oligo_NotIYAAHRSHNotI3-5, respectively) were 
mixed at a 1:1 ratio in nuclear-free water to generate dsDNA. Of note, as a result of the 
enzymatic ligation, a new NotI site is generated in the plasmid. Again, to avoid disruption 
of the fiber ORF, an additional cytosine was added at the 3’ end of the first NotI site in 
Oligo_NotIASFPPAFNotI5-3 and Oligo_NotIYAAHRSHNotI5-3 oligonucleotides, thus 
resulting in a new AAA peptide. Next, the dsDNA sequences were enzymatically digested 
with NotI restriction enzyme and enzymatically ligated into NotI-digested pShuttle-KO1-
AAA. As a result, pShuttle-KO1-AAA-AAAASFPPAF and pShuttle-KO1-AAA-
AAAYAAHRSH were generated, which encode the KO1 mutation and 
AAAASFPPAFAAA or AAAYAAHRSHAAA peptides, respectively. This work was 
performed by Dr. Laura Denby (University of Glasgow, UK) and funded by Myrovylitis 
Trust. pShuttle-KO1-AAA-AAAASFPPAF, pShuttle-KO1-AAA-AAAYAAHRSH or 
pShuttle-KO1-AAA were then recombined by homologous DNA recombination with 
pAdT* (Alba et al., 2009) to generate pAdT*KO1-AAA-AAAASFPPAF, pAdT*KO1-
AAA-AAAYAAHRSH or pAdT*KO1-AAA (control vector), respectively. 
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Figure 5-2. Cloning strategy to generate AdT*KO1 AAAASFPPAFAAA genome (pAdT*KO1-AAA-
AAAASFPPAF). 1. First cloning step consisting in the insertion of the DNA sequence corresponding to the 
heterologous peptide into the HI loop sequence of the fiber ORF from pShuttle-KO1-AAA. 2. Second 
cloning step where pAdT* and pShuttle-KO1-AAA-AAAASFPPAF are subjected to homologous DNA 
recombination to generate pAdT*KO1-AAA-AAAASFPPAF. The cloning strategy to generate AdT*KO1 
AAA and AdT*KO1 AAAYAAHRSHAAA genomes (pAdT*KO1-AAA and pAdT*-KO1-
AAAYAAHRSH, respectively) are identical to the represented one with the exception of the DNA sequence 
corresponding to the heterologous peptide. Features in green represent LacZ, features in purple represent the 
fiber ORF, and stars in red represent genetic mutations (AAA peptide and KO1 mutation in pShuttle-KO1-
AAA, or AAAASFPPAFAAA peptide and KO1 mutation in pShuttle-KO1-AAA-AAAASFPPAF and 
pAdT*KO1-AAA-AAAASFPPAF). SmR; streptomycin resistance, KmR; kanamycin resistance.    
To perform the homologous recombination, pShuttle-KO1-AAA-AAAASFPPAF, 
pShuttle-KO1-AAA-AAAYAAHRSH and pShuttle-KO1-AAA were transformed into 
chemically competent E. coli for plasmid amplification and a pDNA large-scale 
preparation was generated from one of the streptomycin resistant positive colonies. To 
prepare the plasmids for recombination, pAdT* was linearized with SpeI (Figure 5-3A), 
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the 5’ ends were de-phosphorylated and pDNA was purified by DNA precipitation. 
pShuttle-KO1-AAA, pShuttle-KO1-AAA-AAAASFPPAF and pShuttle-KO1-AAA-
AAAYAAHRSH were enzymatically digested with AscI and PacI, electrophoresed, and 
the band containing the “fiber KO1 with the peptide sequence” was extracted from the 
agarose gel for each of the plasmids (Figure 5-3B). 
 
Figure 5-3. pAdT*KO1-AAA, pAdT*KO1-AAA-AAAASFPPAF and AdT*KO1-AAA-
AAAYAAHRSH second cloning step. A) Circular pAdT* (1) and SpeI-digested pAdT* (2) (37132 bp). B) 
Circular pShuttle-KO1-AAA (1), AscI and PacI-digested pShuttle-KO1-AAA (2), AscI and PacI-digested 
pShuttle-KO1-AAA-AAAASFPPAF (3) and AscI and PacI-digested pShuttle-KO1-AAA-AAAYAAHRSH 
(4). Bands 4038 bp and 2499 bp (2) or 4068 bp and 2499 bp (3 and 4). C) XhoI-digested pAdT*KO1-AAA 
(1), pAdT*KO1-AAA-AAAASFPPAF (2) and pAdT*KO1-AAA-AAAYAAHRSH (3). Bands 14500 bp, 
12391 bp, 5744 bp, 2466 bp, 1445 bp and 595 bp (1) or 14500 bp, 12421 bp, 5744 bp, 2466 bp, 1445 bp and 
595 bp (2 and 3). Arrow indicates the DNA band extracted from the agarose gel. 1 kb DNA ladder 
(Invitrogen, UK) used. 
Of note, pAdT* and pShuttle-KO1-based plasmids share two homologous DNA regions 
(Figure 5-4A). However, homologous DNA recombination between pAdT* and pShuttle-
KO1-based plasmids must happen via only the left homology arm in order to exclusively 
mutate pAdT* fiber ORF by introducing the mutated fiber ORF from pShuttle-KO1-based 
plasmids. Homologous DNA recombination via both the left and right homology arms 
would result in a deletion of 2717 base pairs from pAdT* genome in the resultant plasmid 
(exchange of a 2899 bp DNA fragment from pAdT* with a 182 bp DNA fragment from 
pShuttle-KO1-based plasmids) (Figure 5-4A). Thus, digestion of pShuttle-KO1-based 
plasmids with AscI and PacI removed the right homology arm.  
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Figure 5-4. Homologous recombination between pAdT* and pShuttle-KO1-AAA-AAAASFPPAF. 
pShuttle-KO1-AAA-AAAASFPPAF has been used in this representation as an example of the pShuttle-KO1 
plasmids used in this study. A) DNA sequence homology between pAdT* and pShuttle-KO1-AAA-
AAAASFPPAF. Left homology arm (LHR) in blue and right homology arm (RHA) in orange. Numbers 
indicate the base pair position in the genome for each feature. B) pAdT*KO1-AAA-AAAASFPPAF resultant 
from the homologous recombination between pAdT* and pShuttle-KO1-AAA-AAAASFPPAF via the LHA 
(left panel), and pAdT*KO1-AAA-AAAASFPPAF* resultant from the homologous recombination via the 
LHA and the RHA (right panel). The red square corresponds to the DNA region between the LHR and RHA 
(A) or the non-homologous DNA region between pAdT*KO1-AAA-AAAASFPPAF and pAdT*KO1-AAA-
AAAASFPPAF* (B). SmR; streptomycin resistance gene, KmR; kanamycin resistance gene. 
Homologous DNA recombination was performed by transforming purified AscI and PacI-
digested pShuttle-KO1-AAA, AscI and PacI-digested pShuttle-KO1-AAA-
AAAASFPPAF, or AscI and PacI-digested pShuttle-KO1-AAA-AAAYAAHRSH into 
electrocompetent recA+ E. coli together with purified SpeI-digested pAdT*. The resultant 
pAdT* KO1-AAA, pAdT*KO1-AAA-AAAASFPPAF or pAdT*KO1-AAA-
AAAYAAHRSH were extracted from single kanamycin resistant colonies, confirmed by 
enzymatic digestion with XhoI, and transformed into chemically competent E. coli to 
amplify pDNA in a recA1 system unable to recombine DNA, thus conferring stability to 
the plasmid. Large-scale preparations of pAdT* KO1-AAA, pAdT*KO1-AAA-
AAAASFPPAF or pAdT*KO1-AAA-AAAYAAHRSH were obtained from single positive 
colonies. Plasmids were confirmed by enzymatic digestion with XhoI (Figure 5-3C) to 
ensure that homologous DNA recombination had taken place between SpeI-digested 
pAdT* and AscI and PacI-digested pShuttle-KO1-based plasmids via only the left 
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homology arm. XhoI was chosen since there is a XhoI restriction site in the region between 
the left and right homology arms in pShuttle-KO1-based plasmids (region removed from 
pShuttle-KO1-based plasmids by digestion with AscI and PacI) that is not present in 
pAdT* genome (Figure 5-4B). This quality control was performed in case partially 
digested or non-digested molecules of pShuttle-KO1-based plasmids remained in the 
sample used for plasmid recombination. As a further quality control, the resultant plasmids 
(pAdT*KO1-AAA, pAdT*KO1-AAA-AAAASFPPAF and pAdT*KO1-AAA-
AAAYAAHRSH) were sequenced to confirm the presence of the genetic mutations in the 
hexon HVRs, the KO1 mutation in the fiber knob domain, and the AAA, AAAASFPPAF 
or AAAYAAHRSHAAA peptides in the fiber HI loop, respectively. 
5.3.2 Adenoviral vectors amplification and quality control 
AdT*KO1 AAA, AdT*KO1 AAAASFPPAFAAA and AdT*KO1 AAAYAAHRSHAAA 
genomes were linearized with PacI and transfected into eukaryotic permissive HEK-293 
cells and PD10-GFP plasmid was used as a control of transfection (Figure 5-5A). Rescued 
adenoviral vectors were collected from cells and propagated in HEK-293 packaging cells. 
Four rounds of amplification (T25, T150, 4 T150, 25 T150) were required for obtaining 
sufficient amount of virus to generate pure adenoviral vector preparations. Of note, 
amplification of AdT*KO1 AAA, AdT*KO1 AAAASFPPAFAAA and AdT*KO1 
AAAYAAHRSHAAA was done simultaneously and cells were collected when CPE was 
observed in the control AdT*KO1 AAA vector. Unfortunately, in contrast to AdT*KO1 
AAAASFPPAFAAA vector that produced CPE in similarity to AdT*KO1 AAA at 
collection time points, AdT*KO1 AAAYAAHRSHAAA did not show CPE in any round 
of amplification. To assess whether AdT*KO1 AAAYAAHRSHAAA had propagation 
deficiencies, an arbitrary volume of 50 µl of the collected virus from each round of 
amplification (virus from each round collected in an equal volume of DPBS) was 
incubated with HEK-293 cells. A dramatic decrease in the number of transduced cells (β-
galactosidase-positive) was observed with each round of amplification (Figure 5-5B), 
suggesting a loss of AdT*KO1 AAAYAAHRSHAAA infectivity during propagation. 
Therefore, amplification of AdT*KO1 AAAYAAHRSHAAA was not continued. Pure 
adenoviral vector preparations were generated for AdT*KO1 AAA and AdT*KO1 
AAAASFPPAFAAA. 
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Figure 5-5. Amplification of kidney-targeted AdT*KO1-based vectors. A) Kidney-targeted AdT*KO1 
AAA, AdT*KO1 AAAASFPPAFAAA or AdT*KO1 AAAYAAHRSHAAA genomes (pAdT*KO1-AAA, 
pAdT*KO1-AAA-AAAASFPPAF or pAdT*KO1-AAA-AAAYAAHRSH, respectively) were transfected 
into HEK-293 cells. GFP-positive cells (green) 24 h after transfection of PD10-GFP control plasmid into 
HEK-293 cells. β-galactosidase expression by X-Gal staining of HEK-293 cells after fixation with 2% 
paraformaldehyde 10 days post-transfection. B) β-galactosidase expression by X-Gal staining of HEK-293 
cells incubated for 20 h with 50 μl of AdT*KO1 AAAYAAHRSHAAA from three different rounds of 
amplification (T25, T150 or 4 T150). Representative images are shown. β-galactosidase-positive cells are 
highlighted with a red circle in images corresponding to T150 and 4 T150 to facilitate their visualization. 
Scale bars = 250 μM. 
The absence of RCAs was confirmed for the pure adenoviral vector preparations generated 
in this study, ensuring safety of adenoviral preparations. Also, adenoviral DNA was 
sequenced after each amplification step to verify vector genetic stability and confirm the 
presence of the T* mutations in the hexon HVRs, the KO1 mutation in the fiber knob 
domain and the heterologous peptides in the HI loop of the fiber knob domain.  
The concentration of adenovirus particles (vp/ml) and infectivity (pfu/ml) of pure 
adenoviral vector preparations were also tested (Table 5-1). In this study, no visual 
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presence of plaques was found when assessing infectivity of AdT*KO1 AAA or 
AdT*KO1 AAAASFPPAFAAA preparations, thus making it impossible to determine the 
infectivity by detection of pfu. Thus, HEK-293 cells from infectivity assays were subjected 
to X-Gal staining at completion of the assay and visual detection of individual β-
galactosidase-positive cells was used to determine the infectivity in IU/ml. AdT*KO1 
AAA and AdT*KO1 AAAASFPPAFAAA preparations exhibited extremely high vp/IU 
ratios (1924554 vp/IU and 2237205 vp/IU, respectively) (Table 5-1).  
Table 5-1. Kidney-targeted adenoviral vectors quality control.  
Adenoviral vector Adenovirus titre (vp/ml) 
Adenovirus 
titer (IU/ml) Vp/IU 
Vp diameter 
(nm) 
AdT*KO1 AAA 6.91x1011 3.59x105 1924554 109 
AdT*KO1 
AAAASFPPAFAAA 8.03x10
11
 3.59x105 2237205 114 
Infectious units (IU)/ml values shown were obtained from β-galactosidase-positive cells observed by X-Gal 
staining. Values of vp diameter by Nanoparticle Tracking Analysis (NanoSight) are the mean of technical 
triplicates. Vp; viral particle. 
To assess whether the low infectivity of AdT*KO1 AAA or AdT*KO1 
AAAASFPPAFAAA preparations was the result of adenovirus aggregation, pure 
adenovirus preparations were tested for the presence of adenovirus aggregates using the 
laser-based NTA by NanoSight, a technology that allows visualization and size 
determination of adenovirus particles. HAdV-5 capsids are around 90-100 nm in diameter 
(Norrby, 1969, Goosney and Nemerow, 2003). AdT*KO1 AAA and AdT*KO1 
AAAASFPPAFAAA capsids were found to be 109 nm and 114 nm, respectively, 
confirming the absence of adenovirus aggregates (Table 5-1).  
Next, whether the genetic modification incorporated in these vectors might interfere with 
capsid assembly and maturation and thus infectivity of vectors was investigated by 
performing silver staining on AdT*KO1 AAA and AdT*KO1 AAAASFPPAFAAA 
preparations electrophoresed in a polyacrylamide gel. AdT* was used as a control in this 
assay. Despite the presence of the major adenovirus capsid proteins (hexon, penton base 
and fiber) was confirmed for AdT*KO1 AAA and AdT*KO1 AAAASFPPAFAAA, a 
slightly different pattern of bands was observed for these vectors in comparison to AdT* 
control vector (Figure 5-6). These results suggest that adenovirus capsid protein 
composition and integrity might be affected in these vectors.  
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Figure 5-6. Adenovirus capsid composition of kidney-targeted AdT*KO1-based vectors analysed by 
silver staining. A total of 5x1010 denatured AdT*, AdT*KO1 AAA or AdT*KO1 AAAASFPPAFAAA 
particles were loaded in a 12% SDS-polyacrylamide gel and proteins were visualized by silver staining (Life 
Technologies). Rainbow ladder (Amersham Bioscience UK Ltd, UK) was used as a marker for molecular 
weight. Numbers on the right indicate polypeptides of viral particles and their designations. Mw (kDa): 109 
(protein II/hexon), 63.3 (protein III/penton base and IIIa), 62 (protein IV/fiber) and 41.6 (protein V) (San 
Martin and Burnett, 2003). 
Finally, whether the difference in fiber mass between AdT*KO1 AAA and AdT*KO1 
AAAASFPPAFAAA associated with the incorporation of the heterologous peptide into the 
HI loop of the fiber knob domain could be detected as a shift in fiber mobility in a 
polyacrylamide gel was investigated, using HAdV-5 and AdT* as controls. HAdV-5 fiber 
monomer has a mass of 62 kDa (San Martin and Burnett, 2003), the AAA peptide of 
231.25 Da and the AAAASFPPAFAAA peptide of 1.1623 kDa. Thus, the expected fiber 
monomer mass from AdT*KO1 AAA is 62.23125 kDa and from AdT*KO1 
AAAASFPPAFAAA is 63.1623 kDa. A similar mobility was observed for HAdV-5, AdT* 
and AdT*KO1 AAA fiber monomers (Figure 5-7). A slight shift in fiber monomer 
mobility was observed for AdT*KO1 AAAASFPPAFAAA in comparison to the control 
vectors (Figure 5-7).  
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Figure 5-7. Western blotting analysis of adenovirus fiber monomers from kidney-targeted AdT*KO1-
based vectors. Fiber monomers from 5x1010 denatured HAdV-5, AdT*, AdT*KO1 AAA or AdT*KO1 
AAAASFPPAFAAA particles visualized on a 12% SDS-polyacrylamide gel. Mouse anti-adenovirus fiber 
IgG2a primary antibody and HRP-conjugated rabbit anti-mouse IgG secondary antibody were used. Rainbow 
ladder (Amersham Bioscience UK Ltd, UK) was used as a marker for molecular weight. Fiber monomer 
mass: 62 kDa (HAdV-5 or AdT*), 62.23 kDa (AdT*KO1 AAA) and 63.16 (AdT*KO1 
AAAASFPPAFAAA). 
5.3.3 Specificity of claudin16-targeted AdT*KO1 AAAASFPPAFAAA 
for claudin16-expressing cells in vitro 
Since ASFPPAF peptide was selected by in vitro phage display as a specific binder to 
claudin 16 expressed on K562CLDN16 suspension cells, the specificity of AdT*KO1 
AAAASFPPAFAAA for K562CLDN16 cells was investigated. To confirm that 
K562CLDN16 cells express claudin 16 in contrast to K562 cells, total RNA was extracted 
from K562CLDN16, complementary DNA (cDNA) was generated, and the amount of 
claudin 16 mRNA was quantified by TaqMan Real-Time PCR. K562CLDN16 cells 
showed expression of claudin 16 mRNA in contrast to K562 cells (Figure 5-8A).  
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Figure 5-8. Specificity of claudin 16-targeted adenoviral vector for claudin 16-expressing cells in vitro. 
A) Claudin 16 mRNA expression in K562CLDN16 and K562 cells was determined by TaqMan® Real-Time 
PCR. Data represented as the mean of technical triplicates +/- SEM following the 2ΔCT method (Livak and 
Schmittgen, 2001) and normalized to 18S rRNA expression. B) K562CLDN16 and K562 cells were 
incubated with AdT*, AdT*KO1 AAA or AdT*KO1 AAAASFPPAFAAA (5000 vp/cell) at 37oC for 3 h, 
washed with 10% FCS DMEM media and incubated for further 48 h. β-galactosidase expression levels were 
quantified as relative light units (RLU) and normalized to total mg of protein. n = 2 biological replicates per 
condition with 3 technical replicates. Values corresponding to one representative experiment are shown and 
expressed as the mean of values +/- SEM. Unpaired Student’s T-test applied.  
Next, K562CLDN16 cells were incubated with AdT*, AdT*KO1 AAA or AdT*KO1 
AAAASFPPAFAAA and K562 cells were used as a control. AdT*KO1 AAA and 
AdT*KO1 AAAASFPPAFAAA transduction of control K562 cells was 103-fold or 455-
fold lower than that of AdT*, respectively (Figure 5-8B). Transduction of K562CLDN16 
cells was comparable to that of K562 cells for all the adenoviral vectors tested (Figure 
5-8B).  
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5.4 Discussion 
With the aim of developing novel adenoviral vectors that specifically target the kidney for 
gene therapy applications, two mutant adenoviral vectors (AdT*KO1 AAAASFPPAFAAA 
and AdT*KO1 AAAYAAHRSHAAA) that lack binding to CAR and FX and have 
candidate heterologous peptides into the HI loop of the fiber knob domain for targeting of 
the kidney were designed. Also, a control vector (AdT*KO1 AAA) was designed in this 
study. AdT*KO1 AAAYAAHRSHAAA was successfully produced after transfection of 
adenoviral genomes into packaging cells; however, viral particles were not able to 
propagate. AdT*KO1 AAA and AdT*KO1 AAAASFPPAFAAA were successfully 
generated and showed reporter gene expression, lack of RCAs, presence of genetic 
mutations and lack of adenovirus aggregates. However, both vectors exhibited extremely 
low infectivity and a slightly different pattern of protein bands on silver staining performed 
on adenoviral capsids compared to the control adenoviral vector. Moreover, AdT*KO1 
AAAASFPPAFAAA failed to specifically target K562 cells expressing claudin 16, the 
target for ASFPPAF.  
5.4.1 Limitations of the engineered adenoviral vectors  
The lack of AdT*KO1 AAAYAAHRSHAAA propagation suggests that the genetic 
modifications incorporated in this vector might have interfered with capsid assembly and 
maturation processes affecting capsid protein composition and integrity and thus infectivity 
of vectors. The low infectivity of AdT*KO1 AAA and AdT*KO1 AAAASFPPAFAAA 
vectors in HEK-293 cells is in agreement with the requirement of several rounds of 
amplification to produce sufficient adenovirus for the generation of pure adenoviral vector 
preparations and with the relatively low vp/ml titers obtained after adenovirus purification. 
The low infectivity of these vectors could be partly associated with their deficiency in 
CAR-binding as previously reported for CAR-positive cells transduced with adenoviral 
vectors with the KO1 mutation (Jakubczak et al., 2001, Smith et al., 2003b, Smith et al., 
2002). However, these vectors also exhibited low transduction levels of low CAR-
expressing K562 cells (Ebbinghaus et al., 2001, Shayakhmetov et al., 2000) and a slightly 
different pattern of protein bands on silver staining of adenovirus capsids. Moreover, 
previous reports have successfully generated adenoviral vectors that combine the KO1 
mutation with the introduction of heterologous peptides (Nicklin et al., 2001, Nicklin et al., 
2004, Uusi-Kerttula et al., 2016). Also, despite a negative correlation between the 
introduced peptide size and viral infectivity has been reported, peptides of up to 83 amino-
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acids in length have been successfully incorporated (Belousova et al., 2002), suggesting 
that the 13 amino-acid AAAASFPPAFAAA peptide used in our study is within an 
appropriate length. Together, the data suggests that the incorporation of AAA or 
AAAASFPPAFAAA peptides in particular into the fiber knob of these mutant vectors 
might have affected the formation of mature capsids at a certain degree and led to low 
infective adenoviral particles, which could have been due to a hampered internalization 
into host cells or trafficking towards the nucleus, or even to the presence of virus 
degradation in the endosomes or lysosomal recycling of viral particles. Nevertheless, the 
presence of immature non-infective viral particles as a result of the adenovirus purification 
process cannot be dismissed. On the other hand, the lack of AdT*KO1 
AAAASFPPAFAAA specificity for the target cells suggests that ASFPPAF peptide might 
have lost its binding properties to claudin 16 once incorporated into the adenoviral capsid. 
It is important to consider that there might be several reasons behind this observation. For 
instance, the specificity of AAAASFPPAFAAA peptide for claudin 16 might differ from 
that of ASFPPAF. Also, the loss of specificity of ASFPPAF peptide might be due to 
changes in its spatial conformation as a result of it being constrained when fused with the 
fiber. Moreover, even if the peptide spatial conformation is maintained after fusion with 
the fiber, binding of ASFPPAF peptide to claudin 16 might be influenced by fiber residues 
in close proximity. To confirm whether the lack of AdT*KO1 AAAASFPPAFAAA 
specificity for claudin 16positive K562CLDN16 cells results from an impaired binding of 
AAAASFPPAFAAA-containing fiber to claudin 16, binding of AdT*KO1 
AAAASFPPAFAAA to K562CLDN16 cells should be assessed at low temperatures, 
which only allow virus binding but not virus internalization. Also, it is to notice that a 
better control adenoviral vector in this study would be an AdT*KO1 with an AAAAAA 
peptide incorporated into the HI loop instead of the AAA peptide it was designed with, 
since the mutant kidney-targeted AdT*KO1 vectors have a total of 6 additional alanine 
residues in the HI loop (3 alanine residues flanking each end of the candidate peptide). 
Furthermore, it would also be advisable to confirm whether claudin 16 mRNA is 
successfully translated into protein and whether it successfully locates to the plasma 
membrane on K562CLDN16 cells. 
5.4.2 Alternative re-targeting strategies 
Despite incorporation of heterologous peptides into the HI loop of the fiber knob domain 
being a very promising strategy and proven very useful for adenoviral vectors’ selective 
targeting, problems associated with the conservation of peptide conformation and target-
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binding properties once inserted into the fiber knob domain can limit its success. Strategies 
to bypass these problems have been developed. For instance, one study performed in vitro 
phage display employing a functional HAdV-5 fiber knob domain with a collection of 
ligands in the HI loop as a peptide library and screened for candidates on a mouse 
fibroblast cell line, successfully resulting in three candidate peptides (Fontana et al., 2003). 
The main advantage is that following this strategy the candidate peptides are screened 
based on the conformation and binding properties they have once into the HI loop. In our 
setting, the construction of custom phage display libraries using the fiber knob with 
random heterologous peptides into the HI loop flanked by AAA peptides might help in 
better screening for candidates for specific targeting. Other strategies to bypass these 
problems include the use of affibody libraries. Affibodies are engineered proteins based on 
the Z-domain derived from the immunoglobulin-binding region of staphylococcal protein 
A, a 58 amino acids-peptide that folds into a three-helical bundle structure (Uhlen et al., 
1984). Affibody libraries are constructed by the combinatorial randomization of 13 amino 
acid positions from the molecule and can be employed for phage display (Nord et al., 1995, 
Nord et al., 1997). Next, affibodies can be inserted into the HI loop (Magnusson et al., 
2007, Myhre et al., 2009). As before, following this strategy the spatial conformation of 
candidate peptides is maintained throughout the whole process. Alternatively, other 
locations are available for insertion of candidate peptides such as other loops in the C-
terminal of the fiber, the fiber shaft, the penton base, the hexon HVRs or protein IX, which 
also allow correct viral assembly and effective targeting (Kurachi et al., 2007b, Kurachi et 
al., 2007a, Wickham et al., 1997, Gonzalez et al., 1999, Ranki et al., 2007, Rein et al., 
2004, Staba et al., 2000, Wickham et al., 1996, Einfeld et al., 1999, Vigne et al., 1999, Wu 
et al., 2005, Dmitriev et al., 2002, Campos et al., 2004, Vellinga et al., 2004, Li et al., 
2006). Nonetheless, peptide sequence could also influence whether the candidate peptide 
maintains its targeting properties once inserted into the adenoviral protein. For instance, 
incorporation of certain peptides into the hexon HVR 5 achieved target-binding in contrast 
to other peptides (Vigne et al., 1999, Kurachi et al., 2007a). If the targeting peptides are not 
functional as fiber insertions, adapter ligand complexes can be generated, which are 
comprised of a protein that binds to the adenoviral vector (soluble ectodomain of CAR 
(sCAR), FX GLA domain, antibody fragments (Fab) specific for adenoviral proteins etc.) 
and a protein that specifically binds to the therapeutic target (peptide ligand, protein 
domain, single-chain variable fragment (scFv) antibody, etc.) [reviewed by (Barnett et al., 
2002, Coughlan et al., 2010)]. Once the adapter ligand complexes are generated, they are 
used to coat the adenoviral vector prior to its use. Finally, other re-targeting strategies not 
involving heterologous peptides might be particularly useful for kidney-targeting with 
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adenoviral vectors such as genetic pseudotyping, which consists of modifying tropism by 
exchanging adenoviral proteins from the adenoviral vector with those from a different 
adenovirus serotype to generate a chimeric vector. Human adenovirus serotypes 7, 11, 21, 
34, 35 and 37 have been associated with acute haemorrhagic cystitis and nephritis in 
humans (Asim et al., 2003, Shields et al., 1985, Ambinder et al., 1986, Harnett et al., 1982, 
Liles et al., 1993, Murphy et al., 1993). Thus, these serotypes could be used for 
development of chimeric adenoviral vectors for kidney targeting. Also, some of these 
serotypes (e.g: HAdV-11, 34, 35) have low seroprevalence of neutralizing antibodies in the 
human population (Thorner et al., 2006, Vogels et al., 2003) making them particularly 
attractive for gene therapy since they evade pre-existing immunity. Since the fiber N-
terminal region or fiber tail, which is bound to penton base protein, presents high 
homology amongst diverse adenovirus species (Tarassishin et al., 2000), the fiber has been 
the main target for pseudotyping. However, chimeric adenovirus should be carefully 
designed, since capsid proteins other than fiber have been shown to influence tropism. For 
instance, HAdV-11 kidney tropism in mice was shown to be independent of the fiber 
(Stone et al., 2005). Thus, the generation of kidney-targeted chimeric adenovirus is a 
promising strategy as an alternative to the incorporation of heterologous peptides into 
adenoviral proteins.  
Increasing knowledge on adenovirus biodistribution and emerging strategies for vector re-
targeting and de-targeting together with the identification of disease-specific biomarkers 
will potentially allow the development of tissue-specific adenoviral vectors with improved 
efficacy able to bypass toxicity and host immune responses when administered 
systemically for gene therapy. 
 
    
 
 
 
 
 
 
 
 
 
Chapter 6 General discussion and future 
perspectives  
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The studies presented in this thesis were focused on investigating the interactions of 
HAdV-5-based vectors with host cell receptors and blood components following 
intravascular administration, and defining their role in hepatic and splenic tropism in vivo 
as well as in the immune response against virions. Moreover, the generation of kidney-
specific adenoviral vectors for gene therapy was assessed.  
The success of gene therapy to treat human diseases relies on the use of delivery vectors 
able to efficiently introduce genetic material into affected host cells. The ideal vector 
should be specific for the target tissue, able to deliver short or large therapeutic transgenes 
into the host cell, enable transient or sustained transgene expression as required without 
causing insertional mutagenesis, be non-immunogenic or able to evade immune responses, 
be easily produced and manufactured, and have sufficient storage stability for distribution 
to clinics (Somia and Verma, 2000). Through time, adenoviruses have evolved to become 
very efficient biological machines able to deliver genetic material into susceptible 
eukaryotic cells in a very elegant manner via complex but, at the same time, simple 
mechanisms that have been optimized and adapted to different environments to ensure 
their survival and endurance. Interestingly, not only have they developed mechanisms to 
evade deleterious interactions with host cells such as those with components of the anti-
viral immune response but also they have developed mechanisms to benefit from certain 
interactions and enhance infectious events. A clear example is FX, which by binding to the 
HAdV-5 capsid is exploited to facilitate interactions with host cell receptors for cell 
transduction as well as to protect virions against attack by the immune system (Parker et 
al., 2006, Waddington et al., 2008, Xu et al., 2013). Moreover, given that one of the routes 
of entry of HAdV-5 into susceptible hosts is via the respiratory tract and that respiratory 
epithelial cells can produce FVII and FX upon tissue damage (Perrio et al., 2007), it makes 
evolutionary sense for HAdV-5 to use coagulation factors to facilitate infection of host 
cells and subsequent virus spread. In particular, FX binds to the HAdV-5 hexon protein 
and mediates transduction through cellular HSPG (Parker et al., 2006, Kalyuzhniy et al., 
2008, Waddington et al., 2008, Alba et al., 2009, Bradshaw et al., 2010, Duffy et al., 2011, 
Doronin et al., 2012). Simultaneously, FX prevents binding of natural IgM antibodies to 
HAdV-5 capsids thus blocking the activation of the classical complement pathway on 
virions that would otherwise lead to virion neutralization (Xu et al., 2013, Ma et al., 2015). 
The use of HAdV-5-based vectors in gene therapy following intravascular delivery, which 
is the preferable administration route for many diseases such as cardiovascular disease or 
metastatic cancer, is limited by the high hepatic tropism these vectors exhibit that has been 
associated with toxicity and the activation of immune responses (Lozier et al., 2002, Raper 
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et al., 2002, Atencio et al., 2006, Morral et al., 2002). The ability of FX to bridge HAdV-5 
virions to HSPG on the surface of hepatocytes and thus drive liver transduction has 
become a clear target to fully define the responsible capsid regions to allow ablation of this 
interaction and thus reduce liver transduction and associated toxicity. Genetic manipulation 
of key amino acid residues in the HAdV-5 hexon led to the generation of HAV-5-based 
adenoviral vectors unable to bind to FX that consequently exhibited substantially reduced 
liver transduction in immunocompetent mice (Alba et al., 2010, Alba et al., 2009, 
Bradshaw et al., 2012). Unfortunately, recent studies using FX-binding deficient HAdV-5 
vectors in immunocompromised mice lacking the mediators for adenovirus neutralization 
(Xu et al., 2013) or mice lacking HS biosynthesis (Zaiss et al., 2015) revealed the dual 
function of FX in protecting virions from neutralization and that alternative pathways of 
HAdV-5 liver transduction are present when the FX-mediated pathway is not available. 
Moreover, these studies also highlighted the need of further research to unravel the 
mechanisms mediating liver transduction and immune attack and their implications for the 
use of HAdV-5 vectors in gene therapy.  
Here, assessment of liver transduction in immunocompetent and immunocompromised 
mice intravenously administered wild type or FX-binding deficient HAdV-5-based vectors 
confirmed the role of FX in protecting HAdV-5 from in vitro and in vivo neutralization. 
Interestingly, it was found that IgM antibodies might not be required for in vivo adenovirus 
neutralization. Conversely, assessment of HAdV-5 neutralization in vitro following 
exposure of virions to immunocompetent or immunocompromised mouse serum revealed 
that IgM antibodies are essential for in vitro HAdV-5 neutralization, suggesting that in 
vitro and in vivo adenovirus neutralization is mediated by different mechanisms. 
Neutralization of virions has been poorly characterized and data from studies both in vitro 
and in vivo is controversial. While some authors have reported adenovirus neutralization 
via the classical and alternative pathways in vitro (Xu et al., 2008, Jiang et al., 2004), 
others have only detected activation of the IgM-mediated classical pathway (Xu et al., 
2013). Moreover, while some authors report lack of HAdV-5 neutralization by the 
complement system in the absence of IgM antibodies in vivo (Xu et al., 2013), others 
sustain the opposite (Tian et al., 2009). Unfortunately, in the time frame imposed by this 
study these controversies could not be resolved. Further studies to clarify the mechanisms 
mediating in vitro and in vivo neutralization of virions are required and are fundamental for 
the development of adenoviral vectors able to evade immune responses when administered 
intravascularly. For instance, the use of mouse models lacking different components of the 
immune response, including complement proteins [e.g: C1q-/- (Botto, 1998), C3-/- (Wessels 
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et al., 1995), C4-/- (Fischer et al., 1996), Bf/C2-/- (Taylor et al., 1998)], T and/or B cell 
response [e.g: B and T cell deficient SCID (reviewed by (Bosma and Carroll, 1991)) or 
Rag 1-/- (Mombaerts et al., 1992); B cell deficient Igh-6-/- (Kitamura et al., 1991) or JHD 
mice (Chen et al., 1993a) ; T cell deficient athymic nude mice (Flanagan, 1966, Groscurth 
and Kistler, 1975); secreted immunoglobulins deficient “mIg Tg” mice (Hannum et al., 
2000)] or other components of the innate immune response including macrophage and 
natural killer-associated responses [e.g: NSG mice (Zhou et al., 2014, Shultz et al., 2005, 
Shultz et al., 1995, Ito et al., 2002)], and the development of novel immunocompromised 
mouse models lacking other key components of the anti-viral immune response would help 
in addressing these questions. Furthermore, the use of inhibitors for specific components of 
the complement system such as “C1 inhibitor”, which affects C1r and C1s proteases of the 
C1 complex and can be used in vitro and in vivo (Rossi et al., 2010, Patston et al., 1991, 
Landsem et al., 2013, Tradtrantip et al., 2014, Tillou et al., 2010), among others [reviewed 
by (Wouters and Zeerleder, 2015)], would provide valuable information in defining the 
mechanism mediating neutralization. Also, soluble recombinant CR1 can be employed to 
inhibit both the classical and alternative complement pathways (Yazdanbakhsh and 
Scaradavou, 2004, Yazdanbakhsh et al., 2003), and thus further confirm the role of the 
complement system in adenovirus neutralization. Since FX has been identified as essential 
to protect HAdV-5 vectors from neutralization (Xu et al., 2013, Ma et al., 2015, Duffy et 
al., 2016), it might be advisable to maintain HAdV-5:FX interactions when designing 
HAdV-5-based adenoviral vectors for gene therapy. In this scenario, however, additional 
strategies to block HAdV-5:FX complexes from binding to HSPG might be required to 
reduce liver tropism and associated toxicity as well as FX-mediated transduction of tissues 
or cells where the gene therapy is not required (Jonsson et al., 2009, Tran et al., 2013). 
Alternatively, HAdV-5-based vectors could be genetically engineered by mutating only the 
key amino acid residues involved in neutralization and thus protect virions against immune 
attack regardless of FX-binding, as has been observed for HAdV-26 and 48, which despite 
not binding to FX are intrinsically protected from in vitro neutralization in the presence of 
mouse serum (Ma et al., 2015). Alternative approaches to prevent FX from facilitating 
HAdV-5 liver transduction while also protecting HAdV-5 virions from neutralization and 
simultaneously exploiting FX-binding as a retargeting strategy have also been explored. 
For instance, a study coating HAdV-5 capsids with the FX GLA domain fused to scFv 
antibodies specific for receptors such as Her2, EGFR or the stem cell marker ATP-binding 
cassette protein G2 (ABCG2) demonstrated retargeting to cells expressing these receptors 
both in vitro and in vivo (Chen et al., 2010). However, these vectors still showed high 
levels of liver transduction due to binding to endogenous FX. Importantly, while pre-
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treatment of mice with warfarin resulted in substantially reduced liver transduction, it still 
partially maintained the retargeting characteristics of these vectors, indicating that coating 
of capsids with FX GLA domain may partially protect virions against neutralization and 
allow retargeting of vectors. A recent study showed that position-specific PEGylation of 
HAdV-5 hexon HVR1 protected virions from IgM antibody and complement-mediated 
neutralization and scavenging of virions by macrophages in vitro, and prolonged 
circulation of virions in blood (Krutzke et al., 2016). However, this study also reported 
high liver transduction with a HVR1 PEGylated and FX and CAR-binding deficient 
HAdV-5 vector. Nevertheless, other studies demonstrated that tissue-specific targeting 
with FX-binding deficient HAdV-5 vectors can still be achieved in the absence of 
additional strategies to protect virions against the detrimental consequences of 
neutralization (Vigant et al., 2008, Shashkova et al., 2009, Alba et al., 2010). Collectively, 
these studies suggest that neutralization of virions might not be as crucial when using 
HAdV-5 vectors provided with mechanisms to target specific cell types, when the required 
therapeutic transgene levels can be achieved with low amount of vector reaching the target 
tissue or when using oncolytic vectors able to replicate in the target cell and amplify the 
therapeutic effect. Finally, only one study has assessed both adenovirus neutralization by 
human serum with no pre-existing neutralising hIgG antibodies and the role of FX in this 
process (Duffy et al., 2016). This study showed high heterogeneity across samples, where 
some individual serums neutralized HAdV-5 in the absence of FX-binding (56%) while 
others failed to neutralize regardless of FX (44%). These results differ from those obtained 
from studies performed in mice and presented in this thesis, where all serum samples from 
immunocompetent mice led to HAdV-5 virion neutralization in the absence of FX-binding. 
These differences between humans and animal models represents one of the main 
limitations of vector development, causing failure of a high number of clinical trials, since 
on some occasions the observations from pre-clinical studies in animal models do not 
translate into the clinical setting. Thus, the use of human primary cell cultures, ex vivo 
approaches with human tissue or the development of appropriate in vitro systems using 
human samples and translationally relevant animal models might be essential to determine 
the effects of HAdV-5 binding to blood components upon systemic delivery of vectors in 
humans. 
The in vivo studies presented in this thesis with FX-binding deficient HAdV-5 in 
immunocompromised mice confirmed the existence of alternative FX-independent 
pathways of liver transduction in the absence of FX-binding, supporting previous reports 
(Zaiss et al., 2015, Xu et al., 2013). This finding was also corroborated by performing 
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transduction experiments in vitro in the presence of immunocompromised mouse serum 
and absence of FX-binding, either using FX-binding deficient HAdV-5-based vectors or 
the FX inhibitor X-bp (Atoda et al., 1998). These studies confirmed the existence of FX-
independent mechanisms able to enhance HAdV-5 cell transduction in this setting. These 
data are also consistent with previous reports showing that HAdV-5 can use mouse serum 
proteins such as FVII, FIX or C4BP to access host cell receptors such as LRP or HSPGs 
both in vitro and in vivo (Shayakhmetov et al., 2005b). Together, these findings support the 
assertion that FX is not the only bridging molecule that can facilitate HAdV-5 cell 
transduction in vivo or in the presence of mouse serum in vitro. Importantly, several studies 
have investigated the role of CAR and αvβ3,5 integrins as possible host cell receptors for 
liver transduction in mice following intravascular administration of HAdV-5-based vectors 
(Leissner et al., 2001, Alemany and Curiel, 2001, Smith et al., 2002, Smith et al., 2003b, 
Martin et al., 2003, Einfeld et al., 2001, Mizuguchi et al., 2002, Smith et al., 2003a, 
Bradshaw et al., 2012, Koizumi et al., 2003). Despite some differences between the 
individual studies, ablation of HAdV-5 binding to CAR or αvβ3,5 integrins for the most part 
failed to reduce liver transduction in immunocompetent mice. Here, it was hypothesised 
that this might have been the result of HAdV-5 using FX as a compensatory pathway for 
liver transduction in the absence of CAR or αvβ3,5 integrin-binding. To date, only one study 
investigated the role of CAR in HAdV-5 liver tropism when the FX-mediated pathway was 
unavailable for cell transduction, which was performed by depleting mice of HSPG 
expression as opposed to using FX-binding ablated mutant HAdV-5 (Zaiss et al., 2015). 
This strategy allowed the study of the role of FX in tropism in immunocompetent mice 
while still maintaining its function in protecting virions from neutralization. This study 
reported that CAR does not serve as a receptor for hepatocyte transduction in 
immunocompetent mice following intravascular administration of vectors. Currently, no 
studies have been done to assess the role of αvβ3,5 integrins in HAdV-5 liver tropism in a 
setting where the FX-mediated pathway of cell transduction is not available and HAdV-5 
virions cannot be neutralized. Here, liver tropism of HAdV-5 vectors simultaneously 
ablated for FX and αvβ3,5 integrin-binding to prevent HAdV-5 from using compensatory 
pathways for transduction was assessed in immunocompromised NSG mice lacking the 
mediators for neutralization (Zhou et al., 2014, Shultz et al., 2005, Shultz et al., 1995, Ito et 
al., 2002) and thus bypassing the associated virion neutralization in the absence of FX-
binding. In similarity to findings for CAR (Zaiss et al., 2015), the data in this thesis suggest 
that αvβ3,5 integrins do not serve as receptors for hepatocyte transduction in 
immunocompromised mice following intravascular administration of vectors. Future 
experiments delivering αvβ3,5 integrin-binding deficient HAdV-5-based vectors to 
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immunocompetent HSPG-deficient mice (Zaiss et al., 2015) would help in confirming 
results. In an attempt to identify the reported FX-independent mechanisms driving liver 
transduction, the existence of alternative transduction pathways in vitro was investigated 
following exposure of virions to immunocompromised mouse serum. The use of a range of 
immortalized cell lines expressing high, low or absent levels of CAR together with the use 
of engineered cell lines stably expressing hCAR, soluble recombinant HAdV-5 fiber knob 
to block access to CAR for cell binding and CAR-binding deficient HAdV-5 vector, 
demonstrated the existence of a FX-independent cell transduction mechanism in the 
presence of mouse serum involving the use of CAR as a host cell receptor but not relying 
on direct interactions between HAdV-5 virions and CAR. Importantly, the presence of FX-
independent transduction pathways in this setting was also confirmed for hepatocyte-
derived HepG2 cells, indicating that HAdV-5 might potentially use this pathway for 
hepatocyte transduction in vivo. Whether CAR is involved in HepG2 cell transduction in 
the presence of mouse serum is yet to be investigated. To my knowledge, this is the first 
study describing a specific FX-independent pathway for adenovirus cell transduction 
following pre-incubation of virions with mouse serum involving CAR as a cellular 
receptor. Future experiments should focus on identifying the mouse blood factor(s) 
responsible for CAR-mediated HAdV-5 transduction in vitro in the presence of mouse 
serum as well as the adenovirus capsid protein(s) and the amino acid residues involved in 
interactions with such blood factor(s). To address these questions, several strategies can be 
employed such as pull-down assays or co-immunoprecipitation, competition assays with 
recombinant HAdV-5 capsid proteins, SPR, cross-linking or mass spectrometry performed 
on HAdV-5 after incubation with mouse serum. 
Interestingly, it was observed that when CAR is available, the CAR-mediated pathway is 
the predominant route for cell transduction in the presence of mouse serum, suggesting that 
the use of CAR as a host cell receptor might be particularly beneficial over other available 
receptors, including HSPGs. However, a partial response to the FX-inhibitor X-bp was also 
observed in the presence of immunocompromised mouse serum, indicating that HAdV-5 
might also be able to simultaneously use the FX-mediated pathway in this setting. 
Furthermore, transduction assays on immortalised cell lines with low or absent levels of 
CAR on the plasma membrane revealed two different patterns of HAdV-5 transduction in 
the presence of mouse serum when CAR is unavailable. HAdV-5 either transduced cells 
via the FX-mediated pathway or via yet unknown FX and CAR-independent mechanisms. 
These results highlight the high versatility of viruses in transducing cells within different 
environments and bring into question how many pathways HAdV-5 vectors can use for 
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cell entry in the presence of mouse serum and whether they are relevant in vivo. With the 
aim of further investigating the beneficial effect of the different transduction pathways on 
HAdV-5 cell entry, HAdV-5 cell binding, uptake and endosomal membrane penetration in 
the presence of FX was assessed at the single cell level. Here, FX-binding was found to 
minimally affect HAdV-5 virion uptake into host cells and the main advantage for HAdV-
5 following the FX-mediated pathway for cell entry was increased binding to host cells, 
confirming previous reports (Alba et al., 2009, Bradshaw et al., 2012). Interestingly, 
HAdV-5 endosomal membrane penetration efficiency was decreased in the presence of FX 
within the experimental conditions, restricting virions from accessing the cytosol for 
trafficking towards the cell nucleus. Therefore, the use of certain pathways for cell 
transduction might present both advantages and disadvantages for HAdV-5 and it might 
depend on the cellular context, the differential affinity of the adenoviral capsid for 
individual components of the transduction pathway, and/or the type of cellular receptor 
available which determines the transduction pathway used in a particular setting. Further 
experiments assessing the reason behind these observations, as well as investigating the 
benefits of using the CAR-mediated pathway in the presence of mouse serum at the single 
cell level would provide valuable data to gain a greater depth of understanding of the 
complex adenovirus biology, as well as contribute to the development of liver de-targeted 
adenoviral vectors. Also, it is important to bear in mind that in vitro studies or studies in 
vivo with animal models do not always translate to humans. For instance, differences have 
been found in the capability of HAdV-5 to bind to mouse, rhesus macaque or human 
erythrocytes that can result from differential expression of HAdV-5 receptors on these cells 
(Seiradake et al., 2009, Carlisle et al., 2009). Similarly, while the species B receptor CD46 
is expressed ubiquitously in humans [(Johnstone et al., 1993) and reviewed by (Liszewski 
et al., 1991)], its expression in mice, rat and guinea pig is predominantly located in the 
testes (Miwa et al., 1998, Tsujimura et al., 1998, Hosokawa et al., 1996) and in leukocytes, 
erythrocytes and endothelial and epithelial cells in pigs (Toyomura et al., 1997). Also, 
assessment of HAdV-5 transduction of cultured cells in the presence of human serum 
samples with no pre-existing neutralising hIgG antibodies revealed that of those samples 
unable to neutralize HAdV-5, some enhanced HAdV-5 transduction of CAR-expressing 
A549 cells in a FX-dependent and some in a FX-independent manner, showing high 
heterogeneity between samples (Duffy et al., 2016). These results differ from those 
obtained in the studies presented in this thesis, where incubation of HAdV-5 with A549 
cells in the presence of immunocompromised mouse serum resulted in FX-independent 
cell transduction regardless of the mouse sample used. Thus, these studies highlight the 
limitations of using animal models and the need of better systems to investigate the effects 
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of HAdV-5 binding to blood components and host cell receptors upon intravascular 
delivery in humans. Nevertheless, our findings further increase the knowledge of the 
interactions of HAdV-5 vectors with host proteins and their implications for systemic gene 
therapy and provide a model for a novel mechanism of HAdV-5 transduction in the 
presence of mouse serum that may be relevant in vivo, putting researchers one step closer 
towards achieving generation of efficient and safe tissue-specific HAdV-5 vectors.  
6.1 Concluding remarks 
The studies presented in this thesis highlight the complexity of adenovirus biology and the 
capacity of adenovirus to adapt to different environments by binding to host factors and 
cell receptors to achieve efficient cell transduction. Despite evidence showing that CAR 
and αvβ3,5 integrins might not be essential for liver tropism following intravascular 
administration and instead interactions with host factors might represent the main 
mechanisms of liver transduction, it might still be beneficial to engineer CAR-binding 
deficient vectors given that CAR is highly expressed in a wide range of mouse and human 
tissues (Shaw et al., 2004, Excoffon et al., 2010, Tomko et al., 1997). Furthermore, it has 
also been reported that thrombocytopenia is caused by interaction between CAR on 
platelets and virions (Othman et al., 2007), and that sequestration of virions by 
erythrocytes in the bloodstream, which greatly reduces the circulating half-life of the 
vector, is mediated by CAR (Nicol et al., 2004). Moreover, the results presented in this 
thesis investigating the existence and implications of as yet unidentified interactions 
together with previous work indicate that avoiding HAdV-5 interaction with proteins 
present in the bloodstream that enhance undesired tropism should be the next focus in 
generating safe HAdV-5-based vectors for gene therapy with limited adenovirus-associated 
toxicity. With this aim, de-targeting strategies combined with additional strategies to 
reduce the anti-viral immune response should be developed and assessed in a relevant pre-
clinical setting. Once de-targeting and evasion of immune responses to virions is achieved, 
the next step would be to develop re-targeting strategies to design tissue-specific vectors 
able to efficiently target the desired tissue with minimal side effects. Here, the design of 
liver de-targeted and kidney-specific HAdV-5-based vectors for gene therapy was 
assessed, but unfortunately it did not achieve specificity for the target cells or preserve 
virus functionality. In particular, these vectors exhibited very low infectivity and capsid 
integrity problems, highlighting the limitations of current re-targeting strategies and the 
importance of performing detailed studies on the viability of capsid protein replacements 
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or mutations and extensive quality control assays on engineered vectors before pre-clinical 
testing.  
In summary, the discovery of the role of FX in liver tropism and immune protection for 
HAdV-5 was a major advance in the generation of adenoviral vectors for gene therapy and 
changed the view from simple viral capsid protein:cell receptor interactions to a more 
complex system where multiple interactions can take place simultaneously to mediate 
adenoviral transduction. The work presented in this thesis confirms previous findings on 
the role of FX in protecting HAdV-5 virions against attack from the immune system while 
also contributing to tropism and provides a novel model of FX-independent HAdV-5 
transduction involving as yet unidentified mouse serum proteins. 
Together, adenoviral vectors based on HAdV-5 still present pitfalls that need to be further 
addressed for their use in gene therapy. However, refinement in the resolution of existing 
techniques such as X-ray crystallography and electron microscopy that allows detailed 
study of adenoviral capsid proteins and their interactions within the capsid, emergence of 
new technologies such as single cell based assays that enable precise characterization of 
cellular processes, and improved genome editing strategies and analytical techniques for 
in-depth characterization of protein:protein interactions, gene expression and in vivo 
immune responses, has certainly expanded current knowledge and allowed major recent 
advances that will hopefully translate into successful development of safe, efficient, 
specific, potent, long-lasting and economically and socially accessible adenoviral-based 
gene therapy products in the coming years. 
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Appendix 
Plasmid DNA genetic maps 
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Figure A-1. pAdEasy1. Genetic elements are shown as coloured boxes or arrows. AmpR, ampicillin 
resistance gene. The genetic map was generated with SnapGene v2.8.3. 
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Figure A-2. pShuttle-CMV-LacZ. Genetic elements are shown as coloured boxes or arrows. Right and left 
homology arms represent homologous DNA sequences with pAdEasy1. Restriction enzyme used for cloning 
is indicated on the map. ITR; inverted terminal repeat, NeoR; neomycin resistance gene, KanR; kanamycin 
resistance gene. The genetic map was generated with SnapGene v2.8.3. 
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Figure A-3. pAdT*KO1. Genetic elements are shown as coloured boxes or arrows. DNA sequence in red 
represent the region removed from the plasmid for ligation with enzymatically digested pShuttle-KO1-AAA. 
Restriction enzymes used for cloning are indicated on the map. ITR; inverted terminal repeat, NeoR; 
neomycin resistance gene, KanR; kanamycin resistance gene. The genetic map was generated with SnapGene 
v2.8.3. 
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Figure A-4. pShuttle-KO1-AAA. Genetic elements are shown as coloured boxes or arrows. DNA sequence 
in red represent the region removed from the plasmid for ligation with enzymatically digested pAdT*KO1. 
DNA sequence in brown represent the region removed from the plasmid for homologous DNA 
recombination with pAdT*. Restriction enzymes used for cloning are indicated on the map. SmR; 
streptomycin resistance gene. The genetic map was generated with SnapGene v2.8.3. 
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Figure A-5. pShuttle-KO1. Genetic elements are shown as coloured boxes or arrows. Right and left 
homology arms represent homologous DNA sequences with pAdEasy1-CMV-LacZ. DNA sequence in red 
represent the region removed from the plasmid for homologous DNA recombination with pAdEasy1-CMV-
LacZ. Restriction enzymes used for cloning are indicated on the map. SmR; streptomycin resistance gene. 
The genetic map was generated with SnapGene v2.8.3. 
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Figure A-6. pAdEasy1-CMV-LacZ. Genetic elements are shown as coloured boxes or arrows. Right and 
left homology arms represent homologous DNA sequences with pShuttle-KO1. Restriction enzyme used for 
cloning is indicated on the map. ITR; inverted terminal repeat, NeoR; neomycin resistance gene, KanR; 
kanamycin resistance gene. The genetic map was generated with SnapGene v2.8.3. 
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Figure A-7. pAdEasy1-CMV-LacZ-KO1. Genetic elements are shown as coloured boxes or arrows. ITR; 
inverted terminal repeat, NeoR; neomycin resistance gene, KanR; kanamycin resistance gene. The genetic 
map was generated with SnapGene v2.8.3. 
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Figure A-8. pShuttle-KO1-AAA-AAAASFPPAF. Genetic elements are shown as coloured boxes or 
arrows. DNA sequence in red represent the region removed from the plasmid for homologous DNA 
recombination with pAdT*. Restriction enzymes used for cloning are indicated on the map. SmR; 
streptomycin resistance gene. The genetic map was generated with SnapGene v2.8.3. 
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Figure A-9. pShuttle-KO1-AAA-AAAYAAHRSH. Genetic elements are shown as coloured boxes or 
arrows. DNA sequence in red represent the region removed from the plasmid for homologous DNA 
recombination with pAdT*. Restriction enzymes used for cloning are indicated on the map. SmR; 
streptomycin resistance gene. The genetic map was generated with SnapGene v2.8.3. 
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Figure A-10. pAdT*. Genetic elements are shown as coloured boxes or arrows. Restriction enzymes used 
for cloning are indicated on the map. ITR; inverted terminal repeat, NeoR; neomycin resistance gene, KanR; 
kanamycin resistance gene. The genetic map was generated with SnapGene v2.8.3. 
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Figure A-11. pAdT*KO1-AAA. Genetic elements are shown as coloured boxes or arrows. ITR; inverted 
terminal repeat, NeoR; neomycin resistance gene, KanR; kanamycin resistance gene. The genetic map was 
generated with SnapGene v2.8.3. 
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Figure A-12. pAdT*KO1-AAA-AAAASFPPAF. Genetic elements are shown as coloured boxes or arrows. 
ITR; inverted terminal repeat, NeoR; neomycin resistance gene, KanR; kanamycin resistance gene. The 
genetic map was generated with SnapGene v2.8.3. 
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Figure A-13. pAdT*KO1-AAA-AAAYAAHRSH. Genetic elements are shown as coloured boxes or 
arrows. ITR; inverted terminal repeat, NeoR; neomycin resistance gene, KanR; kanamycin resistance gene. 
The genetic map was generated with SnapGene v2.8.3. 
  
 
 
 
